{"bf942766e5690450c1c6e5278e8062526367f4c4": [["IntroductionPorcine reproductive and respiratory syndrome (PRRS), caused by a small RNA virus, member of the Arteriviridae family [1] , is one of the most costly diseases in swine production world-wide [2, 3] .", [["IntroductionPorcine reproductive and respiratory syndrome", "DISEASE", 0, 57], ["PRRS", "DISEASE", 59, 63], ["swine", "SPECIES", 174, 179], ["PRRS", "SPECIES", 59, 63], ["swine", "SPECIES", 174, 179], ["IntroductionPorcine reproductive", "PROBLEM", 0, 32], ["respiratory syndrome", "PROBLEM", 37, 57], ["a small RNA virus", "PROBLEM", 76, 93], ["respiratory syndrome", "OBSERVATION", 37, 57]]], ["In Western Europe, PRRS virus 1 (PRRSV-1) is the main circulating PRRSV species.", [["PRRS virus 1", "ORGANISM", 19, 31], ["PRRSV-1", "ORGANISM", 33, 40], ["PRRSV", "ORGANISM", 66, 71], ["PRRS virus 1", "SPECIES", 19, 31], ["PRRSV-1", "SPECIES", 33, 40], ["PRRS virus 1", "SPECIES", 19, 31], ["PRRSV-1", "SPECIES", 33, 40], ["PRRS virus", "TEST", 19, 29], ["PRRSV", "TEST", 33, 38], ["PRRSV species", "OBSERVATION", 66, 79]]], ["PRRSV infection is characterized by reproductive failure in sows and by respiratory disorders, growth retardation and increased mortality in growing pigs.", [["respiratory", "ANATOMY", 72, 83], ["PRRSV infection", "DISEASE", 0, 15], ["reproductive failure", "DISEASE", 36, 56], ["respiratory disorders", "DISEASE", 72, 93], ["growth retardation", "DISEASE", 95, 113], ["PRRSV", "ORGANISM", 0, 5], ["sows", "ORGANISM", 60, 64], ["pigs", "ORGANISM", 149, 153], ["PRRSV", "SPECIES", 0, 5], ["pigs", "SPECIES", 149, 153], ["PRRSV", "SPECIES", 0, 5], ["pigs", "SPECIES", 149, 153], ["PRRSV infection", "PROBLEM", 0, 15], ["reproductive failure", "PROBLEM", 36, 56], ["respiratory disorders", "PROBLEM", 72, 93], ["growth retardation", "PROBLEM", 95, 113], ["increased mortality", "PROBLEM", 118, 137], ["infection", "OBSERVATION", 6, 15], ["reproductive", "OBSERVATION_MODIFIER", 36, 48], ["failure", "OBSERVATION", 49, 56], ["respiratory disorders", "OBSERVATION", 72, 93], ["increased", "OBSERVATION_MODIFIER", 118, 127], ["mortality", "OBSERVATION_MODIFIER", 128, 137]]], ["PRRSV predis-poses pigs to secondary infections associated with the porcine respiratory disease complex [4] .", [["respiratory", "ANATOMY", 76, 87], ["infections", "DISEASE", 37, 47], ["porcine respiratory disease", "DISEASE", 68, 95], ["PRRSV predis", "ORGANISM", 0, 12], ["pigs", "ORGANISM", 19, 23], ["PRRSV predis", "SPECIES", 0, 12], ["pigs", "SPECIES", 19, 23], ["porcine", "SPECIES", 68, 75], ["PRRSV predis", "SPECIES", 0, 12], ["pigs", "SPECIES", 19, 23], ["PRRSV predis", "TREATMENT", 0, 12], ["secondary infections", "PROBLEM", 27, 47], ["the porcine respiratory disease complex", "PROBLEM", 64, 103], ["secondary", "OBSERVATION_MODIFIER", 27, 36], ["infections", "OBSERVATION", 37, 47], ["respiratory disease", "OBSERVATION", 76, 95]]], ["To limit the impact of PRRS, modified live virus (MLV) vaccines based on cell culture attenuated PRRSV strains are routinely used in gilts, sows and growing pigs, but control of PRRS in the field is still a challenge.", [["cell", "ANATOMY", 73, 77], ["PRRS", "DISEASE", 23, 27], ["PRRS", "DISEASE", 178, 182], ["PRRS", "ORGANISM", 23, 27], ["live virus", "ORGANISM", 38, 48], ["MLV", "ORGANISM", 50, 53], ["cell", "CELL", 73, 77], ["PRRSV", "ORGANISM", 97, 102], ["gilts", "ORGANISM", 133, 138], ["sows", "ORGANISM", 140, 144], ["pigs", "ORGANISM", 157, 161], ["PRRS", "ORGANISM", 178, 182], ["PRRSV", "SPECIES", 97, 102], ["pigs", "SPECIES", 157, 161], ["PRRS", "SPECIES", 23, 27], ["MLV", "SPECIES", 50, 53], ["PRRSV", "SPECIES", 97, 102], ["pigs", "SPECIES", 157, 161], ["PRRS", "SPECIES", 178, 182], ["PRRS", "TREATMENT", 23, 27], ["modified live virus (MLV) vaccines", "TREATMENT", 29, 63], ["cell culture attenuated PRRSV strains", "TREATMENT", 73, 110]]], ["Only partial protection is achieved, mainly limiting the clinical signs and lesions [5] [6] [7] .", [["lesions", "ANATOMY", 76, 83], ["the clinical signs", "TEST", 53, 71], ["lesions", "PROBLEM", 76, 83], ["partial", "OBSERVATION_MODIFIER", 5, 12], ["protection", "OBSERVATION", 13, 23]]], ["However, in experimental conditions, these vaccines provide good protection against PRRSV challenge in piglets, controlling the viremia in infected pigs and decreasing transmission to contact pigs [8, 9] .", [["viremia", "DISEASE", 128, 135], ["PRRSV", "ORGANISM", 84, 89], ["piglets", "ORGANISM", 103, 110], ["pigs", "ORGANISM", 148, 152], ["pigs", "ORGANISM", 192, 196], ["PRRSV", "SPECIES", 84, 89], ["piglets", "SPECIES", 103, 110], ["pigs", "SPECIES", 148, 152], ["pigs", "SPECIES", 192, 196], ["PRRSV", "SPECIES", 84, 89], ["piglets", "SPECIES", 103, 110], ["pigs", "SPECIES", 148, 152], ["these vaccines", "TREATMENT", 37, 51], ["PRRSV challenge", "TREATMENT", 84, 99], ["the viremia", "PROBLEM", 124, 135], ["viremia", "OBSERVATION", 128, 135]]], ["Unlike to experimental conditions, in field conditions, vaccinated piglets are generally born to PRRSV infected, exposed or vaccinated sows since they are commonly vaccinated against PRRSV to prevent PRRSV circulation in farrowing units and improve farrowing https://doi.org/10.1016/j.vaccine.2019.06.045 0264-410X/\u00d3 2019 Elsevier Ltd.", [["PRRSV infected", "DISEASE", 97, 111], ["piglets", "ORGANISM", 67, 74], ["PRRSV", "ORGANISM", 97, 102], ["sows", "ORGANISM", 135, 139], ["PRRSV", "ORGANISM", 183, 188], ["PRRSV", "ORGANISM", 200, 205], ["piglets", "SPECIES", 67, 74], ["PRRSV", "SPECIES", 97, 102], ["PRRSV", "SPECIES", 183, 188], ["piglets", "SPECIES", 67, 74], ["PRRSV", "SPECIES", 97, 102], ["PRRSV", "SPECIES", 183, 188], ["PRRSV", "SPECIES", 200, 205], ["experimental conditions", "PROBLEM", 10, 33], ["vaccinated piglets", "PROBLEM", 56, 74], ["PRRSV infected", "PROBLEM", 97, 111], ["PRRSV", "PROBLEM", 183, 188], ["PRRSV circulation", "PROBLEM", 200, 217]]], ["Consequently, high levels of maternally-derived antibodies (MDAs) against PRRSV are frequently detected in piglets vaccinated at weaning [11] .", [["maternally-derived antibodies", "GENE_OR_GENE_PRODUCT", 29, 58], ["MDAs", "GENE_OR_GENE_PRODUCT", 60, 64], ["PRRSV", "ORGANISM", 74, 79], ["piglets", "ORGANISM", 107, 114], ["maternally-derived antibodies", "PROTEIN", 29, 58], ["MDAs", "PROTEIN", 60, 64], ["PRRSV", "SPECIES", 74, 79], ["piglets", "SPECIES", 107, 114], ["PRRSV", "SPECIES", 74, 79], ["piglets", "SPECIES", 107, 114], ["maternally-derived antibodies (MDAs)", "PROBLEM", 29, 65], ["PRRSV", "PROBLEM", 74, 79]]], ["Among MDAs, maternally-derived neutralizing antibodies (MDNAs) can protect suckling piglets against PRRSV infection during their first weeks of life and prevent viremia in weaned piglets [12, 13] .", [["PRRSV infection", "DISEASE", 100, 115], ["viremia", "DISEASE", 161, 168], ["MDAs", "SIMPLE_CHEMICAL", 6, 10], ["suckling piglets", "ORGANISM", 75, 91], ["PRRSV", "ORGANISM", 100, 105], ["piglets", "ORGANISM", 179, 186], ["MDAs", "PROTEIN", 6, 10], ["neutralizing antibodies", "PROTEIN", 31, 54], ["MDNAs", "PROTEIN", 56, 61], ["piglets", "SPECIES", 84, 91], ["PRRSV", "SPECIES", 100, 105], ["piglets", "SPECIES", 179, 186], ["piglets", "SPECIES", 84, 91], ["PRRSV", "SPECIES", 100, 105], ["neutralizing antibodies", "TREATMENT", 31, 54], ["PRRSV infection", "PROBLEM", 100, 115], ["viremia", "PROBLEM", 161, 168], ["viremia", "OBSERVATION", 161, 168]]], ["However, we recently demonstrated a negative impact of MDNAs on PRRSV vaccination in piglets vaccinated at 3 weeks of age (woa) with a PRRSV-1 MLV vaccine [14] .", [["MDNAs", "CHEMICAL", 55, 60], ["MDNAs", "GENE_OR_GENE_PRODUCT", 55, 60], ["PRRSV", "ORGANISM", 64, 69], ["piglets", "ORGANISM", 85, 92], ["PRRSV-1 MLV", "ORGANISM", 135, 146], ["MDNAs", "PROTEIN", 55, 60], ["piglets", "SPECIES", 85, 92], ["PRRSV", "SPECIES", 64, 69], ["piglets", "SPECIES", 85, 92], ["PRRSV-1", "SPECIES", 135, 142], ["PRRSV vaccination", "TREATMENT", 64, 81], ["a PRRSV-1 MLV vaccine", "TREATMENT", 133, 154], ["negative", "OBSERVATION", 36, 44]]], ["In this study, vaccine strain replication was impaired and both PRRSV antibody and IFNg-secreting cell production were inhibited for 4 weeks post-vaccination (pv) in piglets with high levels of MDNAs.", [["cell", "ANATOMY", 98, 102], ["PRRSV", "ORGANISM", 64, 69], ["IFNg", "GENE_OR_GENE_PRODUCT", 83, 87], ["cell", "CELL", 98, 102], ["piglets", "ORGANISM", 166, 173], ["MDNAs", "GENE_OR_GENE_PRODUCT", 194, 199], ["PRRSV antibody", "PROTEIN", 64, 78], ["IFNg", "PROTEIN", 83, 87], ["MDNAs", "PROTEIN", 194, 199], ["PRRSV", "SPECIES", 64, 69], ["piglets", "SPECIES", 166, 173], ["PRRSV", "SPECIES", 64, 69], ["this study", "TEST", 3, 13], ["vaccine strain replication", "TREATMENT", 15, 41], ["both PRRSV antibody", "TEST", 59, 78], ["IFNg-secreting cell production", "PROBLEM", 83, 113], ["high levels of MDNAs", "PROBLEM", 179, 199], ["secreting cell", "OBSERVATION", 88, 102]]], ["This interference of MDNAs with postvaccination immune response suggested weak protection against PRRSV infection of piglets vaccinated in presence of high MDNA levels that could explain the lower vaccine efficacy observed in the field.", [["PRRSV infection", "DISEASE", 98, 113], ["MDNAs", "GENE_OR_GENE_PRODUCT", 21, 26], ["PRRSV", "ORGANISM", 98, 103], ["piglets", "ORGANISM", 117, 124], ["MDNA", "GENE_OR_GENE_PRODUCT", 156, 160], ["MDNAs", "PROTEIN", 21, 26], ["MDNA", "PROTEIN", 156, 160], ["PRRSV", "SPECIES", 98, 103], ["piglets", "SPECIES", 117, 124], ["PRRSV", "SPECIES", 98, 103], ["piglets", "SPECIES", 117, 124], ["postvaccination immune response", "PROBLEM", 32, 63], ["weak protection", "PROBLEM", 74, 89], ["PRRSV infection", "PROBLEM", 98, 113], ["piglets vaccinated", "PROBLEM", 117, 135], ["high MDNA levels", "PROBLEM", 151, 167], ["the lower vaccine efficacy", "PROBLEM", 187, 213]]], ["Previous studies reported that vaccination in piglets with high MDA levels had no impact on vaccine efficacy but neutralizing antibodies (NAs) were not considered [15] .", [["MDA", "CHEMICAL", 64, 67], ["MDA", "CHEMICAL", 64, 67], ["piglets", "ORGANISM", 46, 53], ["MDA", "SIMPLE_CHEMICAL", 64, 67], ["neutralizing antibodies", "PROTEIN", 113, 136], ["piglets", "SPECIES", 46, 53], ["Previous studies", "TEST", 0, 16], ["vaccination in piglets", "TREATMENT", 31, 53], ["high MDA levels", "PROBLEM", 59, 74], ["vaccine efficacy", "TREATMENT", 92, 108], ["neutralizing antibodies", "TEST", 113, 136]]], ["In the present study, piglets were vaccinated in the presence of low or high MDNA levels and further challenged with a wild PRRSV-1 to assess the impact of MDNAs on the efficacy of PRRSV-1 MLV vaccination.Animal selection and experimental designThe experiment was performed using 56 (Large White * Landrace) * Pietrain piglets selected in a conventional farrow-tofinish herd free from PRRSV circulation in growing pigs and sows but that maintains PRRS-1 MLV mass vaccination of sows with Porcilis PRRS (MSD, Beaucouz\u00e9, France) in order to keep a certain level of immunity in case of PRRSV reintroduction in the herd.", [["Porcilis PRRS", "DISEASE", 488, 501], ["piglets", "ORGANISM", 22, 29], ["PRRSV-1", "ORGANISM", 124, 131], ["MDNAs", "SIMPLE_CHEMICAL", 156, 161], ["PRRSV-1 MLV", "ORGANISM", 181, 192], ["piglets", "ORGANISM", 319, 326], ["PRRSV", "ORGANISM", 385, 390], ["pigs", "ORGANISM", 414, 418], ["MLV", "ORGANISM", 454, 457], ["sows", "ORGANISM", 478, 482], ["PRRSV", "ORGANISM", 583, 588], ["herd", "ORGANISM_SUBDIVISION", 611, 615], ["MDNA", "PROTEIN", 77, 81], ["piglets", "SPECIES", 22, 29], ["piglets", "SPECIES", 319, 326], ["pigs", "SPECIES", 414, 418], ["PRRS", "SPECIES", 497, 501], ["piglets", "SPECIES", 22, 29], ["PRRSV-1", "SPECIES", 124, 131], ["PRRSV-1", "SPECIES", 181, 188], ["PRRSV", "SPECIES", 385, 390], ["pigs", "SPECIES", 414, 418], ["PRRS-1", "SPECIES", 447, 453], ["Porcilis PRRS", "SPECIES", 488, 501], ["PRRSV", "SPECIES", 583, 588], ["the present study", "TEST", 3, 20], ["low or high MDNA levels", "PROBLEM", 65, 88], ["a wild PRRSV", "TEST", 117, 129], ["PRRSV", "PROBLEM", 181, 186], ["1 MLV vaccination", "TREATMENT", 187, 204], ["Animal selection", "TREATMENT", 205, 221], ["Large White * Landrace)", "TREATMENT", 284, 307], ["Pietrain piglets", "TREATMENT", 310, 326], ["PRRS", "TEST", 447, 451], ["MLV mass vaccination", "TREATMENT", 454, 474], ["PRRSV reintroduction", "TREATMENT", 583, 603], ["low", "OBSERVATION_MODIFIER", 65, 68]]], ["Before starting the study, the absence of PRRSV circulation was individually checked by ELISA in pigs sampled at the end of the fattening period and by PCR in weaned piglets using sample pools of 5 animals.", [["PRRSV", "ORGANISM", 42, 47], ["pigs", "ORGANISM", 97, 101], ["piglets", "ORGANISM", 166, 173], ["pigs", "SPECIES", 97, 101], ["piglets", "SPECIES", 166, 173], ["PRRSV", "SPECIES", 42, 47], ["pigs", "SPECIES", 97, 101], ["the study", "TEST", 16, 25], ["PRRSV circulation", "PROBLEM", 42, 59], ["ELISA", "TEST", 88, 93], ["PCR", "TEST", 152, 155], ["sample pools", "TEST", 180, 192], ["PRRSV circulation", "OBSERVATION", 42, 59]]], ["Piglets used in this study were born from 4 sows with high PRRSV NA titres and from 5 sows with low PRRSV NA titers.", [["NA", "CHEMICAL", 65, 67], ["NA", "CHEMICAL", 106, 108], ["Piglets", "ORGANISM", 0, 7], ["sows", "ORGANISM", 44, 48], ["PRRSV", "ORGANISM", 59, 64], ["Piglets", "SPECIES", 0, 7], ["PRRSV", "SPECIES", 59, 64], ["PRRSV", "SPECIES", 100, 105], ["Piglets", "TREATMENT", 0, 7], ["this study", "TEST", 16, 26], ["high PRRSV NA titres", "PROBLEM", 54, 74], ["low PRRSV NA titers", "PROBLEM", 96, 115]]], ["At 1 woa, blood was collected from piglets in order to assign them according to their PRRSV-specific MDNA level: A+ (high level, mean NA titre 201 \u00b1 73) and A\u00c0 (low level, mean NA titre 10 \u00b1 5).", [["blood", "ANATOMY", 10, 15], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["piglets", "ORGANISM", 35, 42], ["PRRSV", "ORGANISM", 86, 91], ["MDNA", "GENE_OR_GENE_PRODUCT", 101, 105], ["A+", "SIMPLE_CHEMICAL", 113, 115], ["MDNA", "PROTEIN", 101, 105], ["piglets", "SPECIES", 35, 42], ["mean NA titre", "TEST", 129, 142], ["A\u00c0", "TEST", 157, 159], ["mean NA titre", "TEST", 172, 185]]], ["At 3 woa, study piglets were weaned, transferred to the Anses biosafety level 3 animal facilities in Ploufragan and randomly distributed according to A+/A\u00c0 status, weight and gender ( Fig. 1; 8 piglets per group).", [["piglets", "ORGANISM", 16, 23], ["piglets", "ORGANISM", 194, 201], ["piglets", "SPECIES", 16, 23], ["study piglets", "TREATMENT", 10, 23], ["Ploufragan", "TREATMENT", 101, 111], ["weight", "TEST", 164, 170]]], ["The absence of PRRSV infection in piglets at 3 woa was checked by RT-PCR using sample pools of 5 animals.", [["PRRSV infection", "DISEASE", 15, 30], ["PRRSV", "ORGANISM", 15, 20], ["piglets", "ORGANISM", 34, 41], ["piglets", "SPECIES", 34, 41], ["PRRSV", "SPECIES", 15, 20], ["PRRSV infection", "PROBLEM", 15, 30], ["PCR", "TEST", 69, 72], ["sample pools", "TEST", 79, 91], ["PRRSV", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 21, 30]]], ["The decay of MDA was then individually evaluated at 3 woa afterwards (A+: mean NA titer 10 \u00b1 5; A\u00c0: no-longer detectable NA).", [["MDA", "CHEMICAL", 13, 16], ["MDA", "SIMPLE_CHEMICAL", 13, 16], ["MDA", "TEST", 13, 16], ["mean NA titer", "TEST", 74, 87]]], ["Piglets were vaccinated (V+) or not (V\u00c0) twice at 3 and 4 woa using one dose of Porcilis PRRS vaccine (MSD, Beaucouz\u00e9, France) by intramuscular injection in the neck using a syringe with a needle 0.6 * 25 mm (vaccine lot No.", [["intramuscular", "ANATOMY", 130, 143], ["neck", "ANATOMY", 161, 165], ["Piglets", "ORGANISM", 0, 7], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 130, 143], ["neck", "ORGANISM_SUBDIVISION", 161, 165], ["Piglets", "SPECIES", 0, 7], ["Porcilis PRRS", "SPECIES", 80, 93], ["Porcilis PRRS vaccine", "TREATMENT", 80, 101], ["a syringe with a needle", "TREATMENT", 172, 195], ["neck", "ANATOMY", 161, 165]]], ["A208DB01).", [["A208DB01", "PROTEIN", 0, 8]]], ["At 5 weeks postfirst vaccination (W5 pv), half of the piglets were inoculated with 5\u00c110 5 TCID 50 /pig of the PRRSV-1 Finistere strain (PRRS-FR-2005-29-24-1) by nasal inoculation using a syringe without needle (2.5 mL per nostril).", [["nasal", "ANATOMY", 161, 166], ["nostril", "ANATOMY", 222, 229], ["piglets", "ORGANISM", 54, 61], ["pig", "ORGANISM", 99, 102], ["PRRSV", "ORGANISM", 110, 115], ["nasal", "ORGAN", 161, 166], ["nostril", "ORGANISM_SUBDIVISION", 222, 229], ["piglets", "SPECIES", 54, 61], ["pig", "SPECIES", 99, 102], ["PRRSV", "SPECIES", 110, 115], ["pig", "SPECIES", 99, 102], ["PRRSV-1 Finistere strain (PRRS-FR-2005-29-24-1", "SPECIES", 110, 156], ["the PRRSV", "TEST", 106, 115], ["a syringe without needle", "TREATMENT", 185, 209], ["nasal", "ANATOMY", 161, 166], ["inoculation", "OBSERVATION", 167, 178]]], ["The day after, non-inoculated contact (C) piglets of the same immune status were mingled with inoculated (I) piglets in the same pens (2 C and 2 I piglets by pen).", [["piglets", "ORGANISM", 42, 49], ["piglets", "ORGANISM", 109, 116], ["piglets", "ORGANISM", 147, 154], ["piglets", "SPECIES", 42, 49], ["piglets", "SPECIES", 109, 116]]], ["Eight unvaccinated and non-inoculated piglets (4 A+ and 4 A\u00c0) were assigned to control groups.", [["piglets", "ORGANISM", 38, 45], ["piglets", "SPECIES", 38, 45], ["non-inoculated piglets", "OBSERVATION", 23, 45]]], ["Due to the waning of MDNA, at the time of PRRSV inoculation the A+ piglets from the V\u00c0 and control groups had undetectable PRRS antibody levels (VNT and ELISA tests, data not shown).", [["MDNA", "GENE_OR_GENE_PRODUCT", 21, 25], ["PRRSV", "ORGANISM", 42, 47], ["A+ piglets", "ORGANISM", 64, 74], ["MDNA", "PROTEIN", 21, 25], ["PRRS antibody", "PROTEIN", 123, 136], ["piglets", "SPECIES", 67, 74], ["PRRSV", "SPECIES", 42, 47], ["PRRS", "SPECIES", 123, 127], ["MDNA", "PROBLEM", 21, 25], ["PRRSV inoculation", "TREATMENT", 42, 59], ["the V\u00c0", "TEST", 80, 86], ["undetectable PRRS antibody levels", "PROBLEM", 110, 143], ["VNT", "TEST", 145, 148], ["ELISA tests", "TEST", 153, 164]]], ["This identical immune status between A+ and A\u00c0 allowed us to mingle the results of the A+ and A\u00c0 piglets from V\u00c0 and control groups for the post-inoculation period.Animal selection and experimental designBlood samples were collected from the jugular vein once a week for 5 weeks pv to individually detect viremia and monitor humoral and cellular immune responses.", [["designBlood samples", "ANATOMY", 198, 217], ["jugular vein", "ANATOMY", 242, 254], ["cellular", "ANATOMY", 337, 345], ["viremia", "DISEASE", 305, 312], ["A\u00c0 piglets", "ORGANISM", 94, 104], ["designBlood samples", "CANCER", 198, 217], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 242, 254], ["cellular", "CELL", 337, 345], ["piglets", "SPECIES", 97, 104], ["V\u00c0 and control groups", "TREATMENT", 110, 131], ["Animal selection", "TREATMENT", 164, 180], ["experimental designBlood samples", "TEST", 185, 217], ["viremia", "PROBLEM", 305, 312], ["jugular vein", "ANATOMY", 242, 254], ["viremia", "OBSERVATION", 305, 312]]], ["After challenge, clinical signs were recorded daily and blood was collected twice a week until animals were euthanized at day 42 post-inoculation (D42 pi) to individually quantify the Finistere strain viremia and to evaluate the immune response.", [["blood", "ANATOMY", 56, 61], ["viremia", "DISEASE", 201, 208], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["clinical signs", "TEST", 17, 31], ["blood", "TEST", 56, 61], ["inoculation (D42 pi", "TREATMENT", 134, 153], ["the Finistere strain viremia", "PROBLEM", 180, 208]]], ["All experiments were authorized by the FrenchVirus neutralization testPRRSV-specific NAs were quantified in serum on MARC145 cells targeting the vaccine strain, as previously described [14] .RT-PCRBefore challenge, the vaccine strain genome was detected using the Adiavet TM PRRS real-time RT-PCR kit (Adiagene, Saint-Brieuc, France).", [["serum", "ANATOMY", 108, 113], ["MARC145 cells", "ANATOMY", 117, 130], ["FrenchVirus", "GENE_OR_GENE_PRODUCT", 39, 50], ["testPRRSV", "GENE_OR_GENE_PRODUCT", 66, 75], ["NAs", "ORGANISM", 85, 88], ["serum", "ORGANISM_SUBSTANCE", 108, 113], ["MARC145 cells", "CELL", 117, 130], ["MARC145 cells", "CELL_LINE", 117, 130], ["vaccine strain genome", "DNA", 219, 240], ["the vaccine strain", "PROBLEM", 141, 159], [".RT-PCRBefore challenge", "TREATMENT", 190, 213], ["the vaccine strain genome", "TREATMENT", 215, 240], ["the Adiavet TM PRRS", "TREATMENT", 260, 279]]], ["After challenge, specific detection of the Finistere strain genome was assessed by qRT-PCR, as described by Rose et al. [8] .ELISPOTPRRSV-specific IFNg-secreting cells (IFNg-SCs) were quantified as previously described [14] , using 16 h PRRSV stimulation of 4 \u00c2 10 5 PBMCs with a multiplicity of infection of 0.2 for either the vaccine strain or the Finistere strain.", [["IFNg-secreting cells", "ANATOMY", 147, 167], ["IFNg-SCs", "ANATOMY", 169, 177], ["PBMCs", "ANATOMY", 267, 272], ["infection", "DISEASE", 296, 305], ["ELISPOTPRRSV", "SIMPLE_CHEMICAL", 125, 137], ["IFNg", "GENE_OR_GENE_PRODUCT", 147, 151], ["cells", "CELL", 162, 167], ["IFNg-SCs", "CELL", 169, 177], ["PRRSV", "ORGANISM", 237, 242], ["PBMCs", "CELL", 267, 272], ["Finistere strain genome", "DNA", 43, 66], ["ELISPOTPRRSV-specific IFNg-secreting cells", "CELL_LINE", 125, 167], ["IFNg", "CELL_TYPE", 169, 173], ["SCs", "CELL_TYPE", 174, 177], ["PBMCs", "CELL_TYPE", 267, 272], ["PRRSV", "SPECIES", 237, 242], ["specific detection", "TEST", 17, 35], ["the Finistere strain genome", "PROBLEM", 39, 66], ["ELISPOTPRRSV", "TEST", 125, 137], ["16 h PRRSV stimulation", "TREATMENT", 232, 254], ["infection", "PROBLEM", 296, 305], ["the vaccine strain", "PROBLEM", 324, 342], ["the Finistere strain", "PROBLEM", 346, 366], ["secreting cells", "OBSERVATION", 152, 167], ["infection", "OBSERVATION", 296, 305]]], ["The number of spots per well was counted using an ImmunoSpot S5 UV Analyzer (CTL, Shaker Heights, OH, USA).ELISAAntibodies against PRRSV were detected in serum using PRRS X3 Ab ELISA tests (IDEXX laboratories, Liebefeld, Switzerland).", [["serum", "ANATOMY", 154, 159], ["ELISAAntibodies", "SIMPLE_CHEMICAL", 107, 122], ["PRRSV", "ORGANISM", 131, 136], ["serum", "ORGANISM_SUBSTANCE", 154, 159], ["PRRSV", "SPECIES", 131, 136], ["PRRSV", "SPECIES", 131, 136], ["PRRS", "SPECIES", 166, 170], ["an ImmunoSpot S5 UV Analyzer", "TEST", 47, 75], ["ELISAAntibodies", "TREATMENT", 107, 122], ["PRRSV", "PROBLEM", 131, 136], ["Ab ELISA tests", "TEST", 174, 188]]], ["Sample-to-positive (S/P) ratios with values equal to or greater than 0.4 were considered positive.ELISAPorcine IFNa was quantified in serum using an in-house ELISA test, as previously described [16] .Statistical analysisAll the data and calculated areas under the curve (AUCs) were compared between groups using the Kruskal-Wallis test (p < 0.05).", [["serum", "ANATOMY", 134, 139], ["ELISAPorcine", "SIMPLE_CHEMICAL", 98, 110], ["IFNa", "GENE_OR_GENE_PRODUCT", 111, 115], ["serum", "ORGANISM_SUBSTANCE", 134, 139], ["IFNa", "PROTEIN", 111, 115], ["Sample", "TEST", 0, 6], ["S/P) ratios", "TEST", 20, 31], ["values", "TEST", 37, 43], ["Statistical analysis", "TEST", 200, 220], ["the data", "TEST", 224, 232], ["the curve (AUCs", "TEST", 260, 275], ["the Kruskal-Wallis test", "TEST", 312, 335]]], ["Post hoc pairwise comparisons were then performed using the Holm test to adjust the p-values of these comparisons according to the number of tests conducted (p < 0.05).", [["the Holm test", "TEST", 56, 69], ["these comparisons", "TEST", 96, 113], ["tests", "TEST", 141, 146]]], ["The relationship between the blood genomic viral load and the number of IFNg-SCs for all the inoculated animals during the post-challenge follow-up period was assessed with a Spearman correlation test (p < 0.05).Statistical analysisThe estimation of the transmission parameters was based on a SEIR model, where each individual was considered according to the virological results as susceptible (uninfected), exposed (infected without virus excretion), infectious (infected with virus excretion) or removed (protected without a role in the infectious process).", [["blood", "ANATOMY", 29, 34], ["IFNg-SCs", "ANATOMY", 72, 80], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["IFNg-SCs", "CELL", 72, 80], ["IFNg", "PROTEIN", 72, 76], ["SCs", "CELL_TYPE", 77, 80], ["the blood genomic viral load", "TEST", 25, 53], ["IFNg-SCs", "TREATMENT", 72, 80], ["a Spearman correlation test", "TEST", 173, 200], ["Statistical analysis", "TEST", 212, 232], ["a SEIR model", "TEST", 291, 303], ["virus excretion", "PROBLEM", 434, 449], ["infectious", "PROBLEM", 452, 462], ["virus excretion", "TREATMENT", 478, 493], ["viral load", "OBSERVATION", 43, 53], ["infectious", "OBSERVATION_MODIFIER", 452, 462], ["infectious", "OBSERVATION", 539, 549]]], ["The duration of the latency period and the transmission rate of the virus were estimated by Bayesian inference using the Metropolis-Hastings algorithm, as previously used [8] .", [["the virus", "PROBLEM", 64, 73], ["Hastings algorithm", "TREATMENT", 132, 150]]], ["Convergence was assessed by visual inspection and diagnostic tests (Gelman-Rubin, autocorrelation, Heidelberger).MDNAs reduce PRRS immunization in vaccinated pigletsAt W1 pv, the vaccine strain was detected in only 2 out of 16 A\u00c0V+ piglets ( Fig. 2A) .", [["PRRS", "DISEASE", 126, 130], ["MDNAs", "GENE_OR_GENE_PRODUCT", 113, 118], ["PRRS", "ORGANISM", 126, 130], ["piglets", "ORGANISM", 158, 165], ["W1 pv", "GENE_OR_GENE_PRODUCT", 168, 173], ["MDNAs", "PROTEIN", 113, 118], ["piglets", "SPECIES", 158, 165], ["piglets", "SPECIES", 232, 239], ["PRRS", "SPECIES", 126, 130], ["piglets", "SPECIES", 158, 165], ["visual inspection", "TEST", 28, 45], ["diagnostic tests", "TEST", 50, 66], ["PRRS immunization", "TREATMENT", 126, 143], ["vaccinated piglets", "TREATMENT", 147, 165], ["the vaccine strain", "TREATMENT", 175, 193]]], ["A second vaccination was thus performed at W1 pv in the same conditions as the first.", [["A second vaccination", "TREATMENT", 0, 20]]], ["At W2 pv, 11 out of 16 A\u00c0V+ piglets (69%) were viremic, whereas only 1 out 16 (6%) were so in the A+V+ piglets.", [["A\u00c0V", "GENE_OR_GENE_PRODUCT", 23, 26], ["piglets", "ORGANISM", 28, 35], ["piglets", "ORGANISM", 103, 110], ["piglets", "SPECIES", 28, 35], ["piglets", "SPECIES", 103, 110], ["A\u00c0V", "TEST", 23, 26], ["piglets", "TEST", 28, 35], ["viremic", "PROBLEM", 47, 54]]], ["The difference between A+V+ and A\u00c0V+ was maintained until W5 pv, with two-fold fewer viremic piglets in A+V+ compared to A\u00c0V+ piglets ( Fig. 2A) .", [["A+V+", "SIMPLE_CHEMICAL", 23, 27], ["A\u00c0V+", "SIMPLE_CHEMICAL", 32, 36], ["piglets", "ORGANISM", 93, 100], ["A\u00c0V+ piglets", "ORGANISM", 121, 133], ["A+V", "PROTEIN", 23, 26], ["piglets", "SPECIES", 93, 100], ["piglets", "SPECIES", 126, 133], ["A\u00c0V", "SPECIES", 121, 124], ["A+V", "TEST", 23, 26], ["A\u00c0V", "TEST", 32, 35], ["viremic piglets", "TREATMENT", 85, 100], ["viremic piglets", "OBSERVATION", 85, 100]]], ["A significant IFNg response was observed at W3 pv and W5 pv for A\u00c0V+ piglets, whereas for the A+V+ group, the number of IFNg-SCs was only significantly increased at W3 pv (Fig. 2B) .", [["A\u00c0V+ piglets", "ANATOMY", 64, 76], ["IFNg-SCs", "ANATOMY", 120, 128], ["IFNg", "CANCER", 14, 18], ["W5 pv", "GENE_OR_GENE_PRODUCT", 54, 59], ["A\u00c0V", "GENE_OR_GENE_PRODUCT", 64, 67], ["IFNg-SCs", "CELL", 120, 128], ["IFNg", "PROTEIN", 14, 18], ["A\u00c0V", "PROTEIN", 64, 67], ["IFNg", "PROTEIN", 120, 124], ["SCs", "CELL_TYPE", 125, 128], ["A significant IFNg response", "PROBLEM", 0, 27], ["piglets", "PROBLEM", 69, 76], ["the A+V", "TEST", 90, 97], ["IFNg-SCs", "TREATMENT", 120, 128], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["IFNg response", "OBSERVATION", 14, 27]]], ["Regarding the seroconversion, all A\u00c0V+ piglets except one showed a detectable PRRSV antibody level in serum at W5 pv (Fig. 2D) , while at the same time, only 7 out of 16 A+V+ piglets were seropositive (Fig. 2C ).MDNAs reduce PRRS vaccine efficacy in challenged pigletsAfter PRRSV challenge, very mild clinical signs were observed.", [["serum", "ANATOMY", 102, 107], ["PRRS", "DISEASE", 225, 229], ["A\u00c0V+ piglets", "ORGANISM", 34, 46], ["PRRSV", "ORGANISM", 78, 83], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["piglets", "ORGANISM", 175, 182], ["MDNAs", "GENE_OR_GENE_PRODUCT", 212, 217], ["PRRS", "ORGANISM", 225, 229], ["piglets", "ORGANISM", 261, 268], ["PRRSV", "ORGANISM", 274, 279], ["PRRSV antibody", "PROTEIN", 78, 92], ["piglets", "SPECIES", 39, 46], ["piglets", "SPECIES", 175, 182], ["piglets", "SPECIES", 261, 268], ["A\u00c0V", "SPECIES", 34, 37], ["PRRSV", "SPECIES", 78, 83], ["PRRS", "SPECIES", 225, 229], ["piglets", "SPECIES", 261, 268], ["PRRSV", "SPECIES", 274, 279], ["the seroconversion", "PROBLEM", 10, 28], ["a detectable PRRSV antibody level", "PROBLEM", 65, 98], ["serum", "TEST", 102, 107], ["PRRS vaccine efficacy", "TREATMENT", 225, 246], ["PRRSV challenge", "TREATMENT", 274, 289], ["very mild clinical signs", "PROBLEM", 291, 315], ["PRRSV antibody", "OBSERVATION", 78, 92], ["very", "OBSERVATION_MODIFIER", 291, 295], ["mild", "OBSERVATION_MODIFIER", 296, 300]]], ["Unvaccinated inoculated (V-I) piglets showed a significant raise of rectal temperature at 3, 8 and 9 days post-challenge compared to unchallenged control piglets but no statistical difference was observed in growth performance ( Supplementary Fig. 1 ).", [["rectal", "ANATOMY", 68, 74], ["piglets", "ORGANISM", 30, 37], ["rectal", "ORGAN", 68, 74], ["piglets", "ORGANISM", 154, 161], ["piglets", "SPECIES", 30, 37], ["piglets", "SPECIES", 154, 161], ["rectal temperature", "PROBLEM", 68, 86], ["unchallenged control piglets", "TREATMENT", 133, 161], ["statistical difference", "PROBLEM", 169, 191], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["rectal", "ANATOMY", 68, 74]]], ["In the vaccinated inoculated pigs, whatever their MDNA status (A+V+I and A\u00c0V+I), no significant difference was observed with the V-I group for rectal temperature nor growth performance.MDNAs reduce PRRS vaccine efficacy in challenged pigletsA lower Finistere strain viral load was detected for A\u00c0V+I piglets compared to V\u00c0I animals (AUC = 21.8 log10 equivalent TCID 50 / mL * week \u00b1 7.8 and 53.0 log10 equivalent TCID 50 /mL * week \u00b1 4.7 respectively; p = 0.003), with 100-fold lower values at D10 pi (p = 0.019) (Fig. 3A) .", [["rectal", "ANATOMY", 143, 149], ["PRRS", "DISEASE", 198, 202], ["pigs", "ORGANISM", 29, 33], ["A\u00c0V+I", "GENE_OR_GENE_PRODUCT", 73, 78], ["V-I", "GENE_OR_GENE_PRODUCT", 129, 132], ["rectal", "ORGAN", 143, 149], ["MDNAs", "GENE_OR_GENE_PRODUCT", 185, 190], ["PRRS", "ORGANISM", 198, 202], ["piglets", "ORGANISM", 234, 241], ["A\u00c0V+I piglets", "ORGANISM", 294, 307], ["V\u00c0I animals", "ORGANISM", 320, 331], ["pigs", "SPECIES", 29, 33], ["piglets", "SPECIES", 234, 241], ["piglets", "SPECIES", 300, 307], ["pigs", "SPECIES", 29, 33], ["PRRS", "SPECIES", 198, 202], ["A\u00c0V", "SPECIES", 294, 297], ["V\u00c0I", "SPECIES", 320, 323], ["significant difference", "PROBLEM", 84, 106], ["rectal temperature", "TEST", 143, 161], ["MDNAs", "TREATMENT", 185, 190], ["PRRS vaccine efficacy", "TREATMENT", 198, 219], ["challenged piglets", "PROBLEM", 223, 241], ["A lower Finistere strain viral load", "PROBLEM", 241, 276], ["V\u00c0I animals", "TEST", 320, 331], ["AUC", "TEST", 333, 336], ["no", "UNCERTAINTY", 81, 83], ["significant", "OBSERVATION_MODIFIER", 84, 95], ["difference", "OBSERVATION", 96, 106], ["rectal", "ANATOMY", 143, 149]]], ["No difference was observed between the A +V+I and V\u00c0I groups, or between vaccinated groups.", [["A +V+I", "GENE_OR_GENE_PRODUCT", 39, 45], ["V\u00c0I", "SIMPLE_CHEMICAL", 50, 53], ["difference", "OBSERVATION_MODIFIER", 3, 13]]], ["Mean viremia duration was shortened from 21 \u00b1 6 days for V\u00c0I or 21 \u00b1 7 days for A+V+I to 16 \u00b1 9 days for A\u00c0V+I animals, but not significantly.MDNAs reduce PRRS vaccine efficacy in challenged pigletsVaccination induced an early IFNg response against the Finistere strain at D7 pi in inoculated piglets for both the A\u00c0V+ and A +V+ groups (Fig. 3B) .", [["viremia", "DISEASE", 5, 12], ["PRRS", "DISEASE", 155, 159], ["MDNAs", "GENE_OR_GENE_PRODUCT", 142, 147], ["PRRS", "ORGANISM", 155, 159], ["piglets", "ORGANISM", 191, 198], ["IFNg", "CANCER", 227, 231], ["piglets", "ORGANISM", 293, 300], ["piglets", "SPECIES", 191, 198], ["piglets", "SPECIES", 293, 300], ["A\u00c0V", "SPECIES", 105, 108], ["PRRS", "SPECIES", 155, 159], ["piglets", "SPECIES", 191, 198], ["Mean viremia duration", "PROBLEM", 0, 21], ["V\u00c0I", "TEST", 57, 60], ["A\u00c0V", "PROBLEM", 105, 108], ["PRRS vaccine efficacy", "TREATMENT", 155, 176], ["Vaccination", "TREATMENT", 198, 209], ["an early IFNg response", "PROBLEM", 218, 240], ["the A\u00c0V", "TEST", 310, 317], ["viremia", "OBSERVATION", 5, 12], ["early", "OBSERVATION_MODIFIER", 221, 226], ["IFNg response", "OBSERVATION", 227, 240]]], ["Even though more IFNg-SCs were detected in A\u00c0V+I compared to A+V+I piglets, the difference was not significant.", [["IFNg-SCs", "ANATOMY", 17, 25], ["IFNg-SCs", "CELL", 17, 25], ["A+V+I piglets", "ORGANISM", 61, 74], ["IFNg", "PROTEIN", 17, 21], ["SCs", "CELL_TYPE", 22, 25], ["A\u00c0V", "PROTEIN", 43, 46], ["piglets", "SPECIES", 67, 74], ["A\u00c0V", "SPECIES", 43, 46], ["not", "UNCERTAINTY", 95, 98], ["significant", "OBSERVATION_MODIFIER", 99, 110]]], ["Interestingly, considering all inoculated pigs during the D7-D15 pi period, a negative correlation could be established between the number of IFNg-SC and the Finistere strain genomic load in serum (r = \u00c00.55; p < 0.05).", [["serum", "ANATOMY", 191, 196], ["pigs", "ORGANISM", 42, 46], ["IFNg-SC", "GENE_OR_GENE_PRODUCT", 142, 149], ["serum", "ORGANISM_SUBSTANCE", 191, 196], ["IFNg", "PROTEIN", 142, 146], ["pigs", "SPECIES", 42, 46], ["pigs", "SPECIES", 42, 46], ["IFNg", "TEST", 142, 146], ["serum", "TEST", 191, 196]]], ["NAs were detected from D30 pi in inoculated pigs.", [["D30 pi", "GENE_OR_GENE_PRODUCT", 23, 29], ["pigs", "ORGANISM", 44, 48], ["pigs", "SPECIES", 44, 48], ["pigs", "SPECIES", 44, 48], ["inoculated pigs", "OBSERVATION", 33, 48]]], ["At D42 pi, 6 out of 8 A\u00c0V+I piglets had quantifiable NAs titres (>10) compared to 3 out of 8 for A+V+I and 1 out of 8 in V-I animals ( Supplementary Fig. 2 ).MDNAs impair vaccine reduction of PRRSV transmissionA reduction in viremia was observed in A\u00c0V+ C contact pigs compared to V-C piglets (AUC = 30.3 log10 equivalent TCID 50 / mL * week \u00b1 15.5 and 56.9 log10 equivalent TCID 50 / mL * week \u00b1 10.3 respectively; p = 0.002), but not in A+V+C piglets (Fig. 3C) .", [["viremia", "DISEASE", 225, 232], ["piglets", "ORGANISM", 28, 35], ["MDNAs", "GENE_OR_GENE_PRODUCT", 158, 163], ["PRRSV", "ORGANISM", 192, 197], ["A\u00c0V+ C contact pigs", "ORGANISM", 249, 268], ["V-C piglets", "ORGANISM", 281, 292], ["V+C piglets", "ORGANISM", 441, 452], ["MDNAs", "PROTEIN", 158, 163], ["piglets", "SPECIES", 28, 35], ["pigs", "SPECIES", 264, 268], ["piglets", "SPECIES", 285, 292], ["piglets", "SPECIES", 445, 452], ["V-I", "SPECIES", 121, 124], ["PRRSV", "SPECIES", 192, 197], ["A\u00c0V", "SPECIES", 249, 252], ["quantifiable NAs titres", "TEST", 40, 63], ["MDNAs impair vaccine reduction", "TREATMENT", 158, 188], ["PRRSV transmissionA reduction", "TREATMENT", 192, 221], ["viremia", "PROBLEM", 225, 232], ["AUC", "TEST", 294, 297], ["viremia", "OBSERVATION", 225, 232]]], ["At D7 pi, the Finistere strain was not yet detected in A\u00c0V +C piglets, whereas the first positive piglets were identified at D4 pi in the other contact groups (Fig. 3D) .", [["D7 pi", "GENE_OR_GENE_PRODUCT", 3, 8], ["A\u00c0V +C piglets", "ORGANISM", 55, 69], ["piglets", "ORGANISM", 98, 105], ["piglets", "SPECIES", 62, 69], ["piglets", "SPECIES", 98, 105], ["A\u00c0V", "SPECIES", 55, 58], ["the Finistere strain", "TREATMENT", 10, 30]]], ["The mean viremia duration for A\u00c0V+C was shortened to 6 \u00b1 3 days compared to 12 \u00b1 6 and 19 \u00b1 6 days for the A+V+C and V-C groups, respectively.", [["viremia", "DISEASE", 9, 16], ["V-C", "SIMPLE_CHEMICAL", 117, 120], ["A\u00c0V", "SPECIES", 30, 33], ["The mean viremia duration", "TEST", 0, 25], ["A\u00c0V+C", "TEST", 30, 35], ["the A+V", "TEST", 103, 110], ["mean viremia", "OBSERVATION", 4, 16]]], ["The Finistere strain was detected in all unvaccinated piglets.", [["piglets", "ORGANISM", 54, 61], ["piglets", "SPECIES", 54, 61], ["The Finistere strain", "PROBLEM", 0, 20], ["unvaccinated piglets", "OBSERVATION", 41, 61]]], ["In vaccinated groups, all the contact animals became infected, except one A+V +C pig (Fig. 3D) .MDNAs impair vaccine reduction of PRRSV transmissionThe A+V+C piglet that remained uninfected had seroconverted post-vaccination.", [["MDNAs", "CHEMICAL", 96, 101], ["animals", "ORGANISM", 38, 45], ["MDNAs", "GENE_OR_GENE_PRODUCT", 96, 101], ["PRRSV", "ORGANISM", 130, 135], ["A+V+C piglet", "ORGANISM", 152, 164], ["MDNAs", "PROTEIN", 96, 101], ["C pig", "SPECIES", 79, 84], ["PRRSV", "SPECIES", 130, 135], ["piglet", "SPECIES", 158, 164], ["pig", "SPECIES", 81, 84], ["PRRSV", "SPECIES", 130, 135], ["infected", "PROBLEM", 53, 61], ["MDNAs impair vaccine reduction", "TREATMENT", 96, 126], ["infected", "OBSERVATION", 53, 61], ["piglet", "ANATOMY", 158, 164]]], ["Considering this outlier animal as protected against PRRSV infection with no role in the transmission process, the estimates for the transmission rate of the A+V+ group was comparable to those of the V\u00c0 group (0.44 [0.18; 1.76] and 0.32 [0.14; 0.68] for A+V+ and V\u00c0 respectively; Table 1 ).", [["PRRSV infection", "DISEASE", 53, 68], ["PRRSV", "ORGANISM", 53, 58], ["PRRSV", "SPECIES", 53, 58], ["PRRSV", "SPECIES", 53, 58], ["PRRSV infection", "PROBLEM", 53, 68], ["the transmission rate", "TEST", 129, 150], ["A+V", "TEST", 254, 257]]], ["For the A\u00c0V+ group, the estimated transmission rate was reduced to 0.15 [0.07; 0.29].High IFNa level was present at the time of the first vaccinationIn order to understand the unexpectedly low vaccine viremia detected in A\u00c0 piglets after the first vaccination, the IFNa level was assessed in serum samples collected at W0 pv during the present experiment (Experiment B) and compared with those collected at the same time during our previous study [14] (Experiment A) where the vaccine viremia was detected in most of the A\u00c0 animals after vaccination.", [["serum samples", "ANATOMY", 292, 305], ["viremia", "DISEASE", 201, 208], ["viremia", "DISEASE", 485, 492], ["A\u00c0V+", "SIMPLE_CHEMICAL", 8, 12], ["IFNa", "GENE_OR_GENE_PRODUCT", 90, 94], ["A\u00c0 piglets", "ORGANISM", 221, 231], ["IFNa", "GENE_OR_GENE_PRODUCT", 265, 269], ["serum samples", "ORGANISM_SUBSTANCE", 292, 305], ["IFNa", "PROTEIN", 90, 94], ["IFNa", "PROTEIN", 265, 269], ["piglets", "SPECIES", 224, 231], ["A\u00c0", "SPECIES", 221, 223], ["the estimated transmission rate", "TEST", 20, 51], ["High IFNa level", "PROBLEM", 85, 100], ["the first vaccination", "TREATMENT", 128, 149], ["the unexpectedly low vaccine viremia", "PROBLEM", 172, 208], ["the first vaccination", "TREATMENT", 238, 259], ["the IFNa level", "TEST", 261, 275], ["serum samples", "TEST", 292, 305], ["our previous study", "TEST", 428, 446], ["the vaccine viremia", "PROBLEM", 473, 492], ["vaccination", "TREATMENT", 538, 549], ["viremia", "OBSERVATION", 485, 492]]], ["The results showed significantly higher levels of IFNa for piglets in Experiment B than for those in Experiment A (Fig. 4A) .", [["IFNa", "GENE_OR_GENE_PRODUCT", 50, 54], ["IFNa", "PROTEIN", 50, 54], ["piglets", "SPECIES", 59, 66], ["significantly higher levels of IFNa", "PROBLEM", 19, 54]]], ["A relationship could be thus hypothesized between high IFNa levels detected at the time of vaccination and low subsequent vaccine strain detection (Fig. 4B ).DiscussionVaccination programs hardly eradicate PRRSV circulation in farms whereas PRRS MLV showed a good efficacy in piglets to control PRRSV transmission in experimental conditions [5, 8] .", [["IFNa", "GENE_OR_GENE_PRODUCT", 55, 59], ["PRRSV", "ORGANISM", 206, 211], ["PRRS MLV", "ORGANISM", 241, 249], ["piglets", "ORGANISM", 276, 283], ["PRRSV", "ORGANISM", 295, 300], ["IFNa", "PROTEIN", 55, 59], ["PRRS", "SPECIES", 241, 245], ["piglets", "SPECIES", 276, 283], ["PRRSV", "SPECIES", 206, 211], ["PRRS", "SPECIES", 241, 245], ["MLV", "SPECIES", 246, 249], ["piglets", "SPECIES", 276, 283], ["PRRSV", "SPECIES", 295, 300], ["high IFNa levels", "PROBLEM", 50, 66], ["vaccination", "TREATMENT", 91, 102], ["low subsequent vaccine strain detection", "TREATMENT", 107, 146], ["DiscussionVaccination programs", "TREATMENT", 158, 188], ["good", "OBSERVATION_MODIFIER", 259, 263]]], ["In a previous study, we demonstrated an interference of MDNAs on postvaccine immune responses induction during 4 weeks postvaccination, suggesting a negative impact of MDNAs on vaccine efficacy in piglets [14] .", [["MDNAs", "CHEMICAL", 168, 173], ["MDNAs", "GENE_OR_GENE_PRODUCT", 56, 61], ["MDNAs", "SIMPLE_CHEMICAL", 168, 173], ["piglets", "ORGANISM", 197, 204], ["MDNAs", "PROTEIN", 56, 61], ["MDNAs", "PROTEIN", 168, 173], ["piglets", "SPECIES", 197, 204], ["a previous study", "TEST", 3, 19], ["postvaccine immune responses induction", "TREATMENT", 65, 103], ["vaccine efficacy", "TREATMENT", 177, 193]]], ["To test this hypothesis, PRRSV-1 MLV vaccinated piglets with low or high levels of MDNAs were challenged with a field PRRSV-1 strain.DiscussionDespite the animals had to be vaccinated twice in the present study, vaccine viremia was detected in only one A+V+ piglet whereas it was detected in 11 A\u00c0V+ piglets at W2 pv, which was in accordance with our previous data [14] and confirmed the interference of MDNAs with vaccine viremia.", [["piglet", "ANATOMY", 258, 264], ["viremia", "DISEASE", 220, 227], ["viremia", "DISEASE", 423, 430], ["PRRSV-1 MLV", "ORGANISM", 25, 36], ["piglets", "ORGANISM", 48, 55], ["MDNAs", "GENE_OR_GENE_PRODUCT", 83, 88], ["PRRSV-1", "ORGANISM", 118, 125], ["animals", "ORGANISM", 155, 162], ["piglet", "ORGAN", 258, 264], ["A\u00c0V+ piglets", "ORGANISM", 295, 307], ["MDNAs", "GENE_OR_GENE_PRODUCT", 404, 409], ["MDNAs", "PROTEIN", 83, 88], ["MDNAs", "PROTEIN", 404, 409], ["piglets", "SPECIES", 48, 55], ["piglets", "SPECIES", 300, 307], ["PRRSV-1", "SPECIES", 25, 32], ["PRRSV-1", "SPECIES", 118, 125], ["A\u00c0V", "SPECIES", 295, 298], ["PRRSV", "TEST", 25, 30], ["low or high levels of MDNAs", "PROBLEM", 61, 88], ["a field PRRSV", "TEST", 110, 123], ["vaccine viremia", "PROBLEM", 212, 227], ["vaccine viremia", "PROBLEM", 415, 430]]], ["This experiment also indi-cated that in piglets with low levels of MDNAs, vaccination induced significant humoral and cellular post-vaccine immune response, which also corroborates our previous results [14] .DiscussionIn the present study, we observed a lower interference of MDNAs on post-vaccine immune responses compared to the previous one reported by Fablet [14] where a complete impairment was observed during 4 weeks pv.", [["cellular", "ANATOMY", 118, 126], ["piglets", "ORGANISM", 40, 47], ["MDNAs", "GENE_OR_GENE_PRODUCT", 67, 72], ["cellular", "CELL", 118, 126], ["MDNAs", "GENE_OR_GENE_PRODUCT", 276, 281], ["MDNAs", "PROTEIN", 276, 281], ["piglets", "SPECIES", 40, 47], ["low levels of MDNAs", "PROBLEM", 53, 72], ["vaccination", "TREATMENT", 74, 85], ["significant humoral and cellular post-vaccine immune response", "PROBLEM", 94, 155], ["the present study", "TEST", 221, 238], ["a complete impairment", "PROBLEM", 374, 395]]], ["This reduced interference could be ascribed to the need to vaccinate the piglets twice and the ensuing decrease of MDNAs levels at the time of the second vaccination.", [["piglets", "ORGANISM", 73, 80], ["MDNAs", "GENE_OR_GENE_PRODUCT", 115, 120], ["MDNAs", "PROTEIN", 115, 120], ["piglets", "SPECIES", 73, 80], ["MDNAs levels", "TEST", 115, 127], ["the second vaccination", "TREATMENT", 143, 165], ["decrease", "OBSERVATION_MODIFIER", 103, 111]]], ["At the time of first vaccination (3 woa), the decrease of MDNA level was already high but the mean NA titre in the present study (10 \u00b1 5) was comparable to the one in Fablet's study (20 \u00b1 15) .", [["NA", "CHEMICAL", 99, 101], ["MDNA", "GENE_OR_GENE_PRODUCT", 58, 62], ["MDNA", "PROTEIN", 58, 62], ["the decrease of MDNA level", "PROBLEM", 42, 68], ["the mean NA titre", "TEST", 90, 107], ["Fablet's study", "TEST", 167, 181], ["decrease", "OBSERVATION_MODIFIER", 46, 54]]], ["Despite the slightly reduced post-vaccine differences between A +V+ and A\u00c0V+ we observed in the present study, the postchallenge results demonstrated for the first time that the PRRSV vaccination was effective only in piglets with low levels of MDNAs.", [["A +V+", "GENE_OR_GENE_PRODUCT", 62, 67], ["A\u00c0V+", "SIMPLE_CHEMICAL", 72, 76], ["PRRSV", "ORGANISM", 178, 183], ["piglets", "ORGANISM", 218, 225], ["MDNAs", "GENE_OR_GENE_PRODUCT", 245, 250], ["MDNAs", "PROTEIN", 245, 250], ["piglets", "SPECIES", 218, 225], ["A\u00c0V", "SPECIES", 72, 75], ["PRRSV", "SPECIES", 178, 183], ["the slightly reduced post-vaccine differences", "PROBLEM", 8, 53], ["the present study", "TEST", 92, 109], ["the PRRSV vaccination", "TREATMENT", 174, 195], ["low levels of MDNAs", "PROBLEM", 231, 250], ["slightly", "OBSERVATION_MODIFIER", 12, 20], ["reduced", "OBSERVATION_MODIFIER", 21, 28], ["low levels", "OBSERVATION_MODIFIER", 231, 241]]], ["The low virulence of the PRRSV-1 strain used to challenge the animals limited the evaluation of the vaccine efficacy to virological parameters only.", [["PRRSV-1 strain", "ORGANISM", 25, 39], ["PRRSV-1", "SPECIES", 25, 32], ["PRRSV-1", "SPECIES", 25, 32], ["the evaluation", "TEST", 78, 92], ["the vaccine efficacy", "TREATMENT", 96, 116], ["virological parameters", "TEST", 120, 142], ["low virulence", "OBSERVATION_MODIFIER", 4, 17]]], ["We previously demonstrated that the Porcilis PRRS vaccine can protect SPF piglets (no MDAs) from a challenge with the same low virulent strain, decreasing the viremia in inoculated piglets and considerably reducing the transmission of the Finistere strain to contact piglets [8] .", [["viremia", "DISEASE", 159, 166], ["Porcilis PRRS", "ORGANISM", 36, 49], ["SPF piglets", "ORGANISM", 70, 81], ["piglets", "ORGANISM", 181, 188], ["piglets", "SPECIES", 74, 81], ["piglets", "SPECIES", 181, 188], ["piglets", "SPECIES", 267, 274], ["Porcilis PRRS", "SPECIES", 36, 49], ["SPF", "SPECIES", 70, 73], ["the Porcilis PRRS vaccine", "TREATMENT", 32, 57], ["the same low virulent strain", "PROBLEM", 114, 142], ["the viremia", "PROBLEM", 155, 166], ["viremia", "OBSERVATION", 159, 166], ["inoculated piglets", "OBSERVATION", 170, 188]]], ["In the present study, the challenge strain viral load was significantly reduced only in A\u00c0V+ inoculated and contact piglets compared to unvaccinated piglets.", [["A\u00c0V", "CHEMICAL", 88, 91], ["piglets", "ORGANISM", 116, 123], ["piglets", "ORGANISM", 149, 156], ["piglets", "SPECIES", 116, 123], ["piglets", "SPECIES", 149, 156], ["A\u00c0V", "SPECIES", 88, 91], ["piglets", "SPECIES", 116, 123], ["the present study", "TEST", 3, 20], ["the challenge strain viral load", "TEST", 22, 53], ["viral load", "OBSERVATION", 43, 53]]], ["In a similar unpublished study, we also showed that PRRSV challenge strain viremia was significantly reduced for A\u00c0V+ inoculated piglets compared to A+V+ animals during the first 3 weeks pi ( Supplementary Fig. 3) .", [["viremia", "DISEASE", 75, 82], ["A\u00c0V", "CHEMICAL", 113, 116], ["PRRSV", "ORGANISM", 52, 57], ["piglets", "ORGANISM", 129, 136], ["A+V+ animals", "ORGANISM", 149, 161], ["piglets", "SPECIES", 129, 136], ["PRRSV", "SPECIES", 52, 57], ["A\u00c0V", "SPECIES", 113, 116], ["A+V", "SPECIES", 149, 152], ["a similar unpublished study", "TEST", 3, 30], ["PRRSV challenge strain viremia", "PROBLEM", 52, 82], ["A\u00c0V", "PROBLEM", 113, 116], ["inoculated piglets", "PROBLEM", 118, 136], ["A+V", "TEST", 149, 152], ["Supplementary Fig", "TREATMENT", 192, 209], ["inoculated piglets", "OBSERVATION", 118, 136]]], ["In this study, vaccine viremia was also only detected in 1 out of 12 A\u00c0V+ piglet at W2 post-vaccination but a second vaccination was not performed before challenge, indicating that the negative impact of MDNAs on PRRS vaccine efficacy also occurred in the absence of vaccine viremia and with usual single vaccination protocols implemented in the field.DiscussionUsing a closely-related approach, Jeong et al. evaluated the efficacy of a PRRSV-2 MLV vaccine in 1-day-old piglets with maternally-derived antibodies (MDAs) but no impact of MDAs was observed [17] .", [["piglet", "ANATOMY", 74, 80], ["viremia", "DISEASE", 23, 30], ["MDNAs", "CHEMICAL", 204, 209], ["PRRS", "DISEASE", 213, 217], ["viremia", "DISEASE", 275, 282], ["A\u00c0V+ piglet", "ORGANISM", 69, 80], ["MDNAs", "GENE_OR_GENE_PRODUCT", 204, 209], ["PRRS", "ORGANISM", 213, 217], ["PRRSV-2 MLV", "ORGANISM", 437, 448], ["piglets", "ORGANISM", 470, 477], ["MDAs", "SIMPLE_CHEMICAL", 537, 541], ["maternally-derived antibodies", "PROTEIN", 483, 512], ["MDAs", "PROTEIN", 514, 518], ["piglets", "SPECIES", 470, 477], ["A\u00c0V", "SPECIES", 69, 72], ["piglet", "SPECIES", 74, 80], ["PRRS", "SPECIES", 213, 217], ["PRRSV-2 MLV", "SPECIES", 437, 448], ["this study", "TEST", 3, 13], ["vaccine viremia", "PROBLEM", 15, 30], ["a second vaccination", "TEST", 108, 128], ["PRRS vaccine efficacy", "TREATMENT", 213, 234], ["vaccine viremia", "PROBLEM", 267, 282], ["usual single vaccination protocols", "TREATMENT", 292, 326], ["a closely-related approach", "TREATMENT", 368, 394], ["a PRRSV", "TREATMENT", 435, 442], ["2 MLV vaccine", "TREATMENT", 443, 456], ["maternally-derived antibodies", "PROBLEM", 483, 512], ["MDAs", "PROBLEM", 537, 541], ["viremia", "OBSERVATION", 23, 30]]], ["In Jeong's study, all the piglets were MDA+ at vaccination (no MDA-group included) and thus this precluded to clearly evaluating the impact of MDAs on the vaccine efficacy.", [["MDA", "CHEMICAL", 39, 42], ["MDAs", "CHEMICAL", 143, 147], ["MDA", "CHEMICAL", 39, 42], ["MDA", "CHEMICAL", 63, 66], ["piglets", "ORGANISM", 26, 33], ["MDA", "SIMPLE_CHEMICAL", 39, 42], ["MDA", "SIMPLE_CHEMICAL", 63, 66], ["MDAs", "SIMPLE_CHEMICAL", 143, 147], ["piglets", "SPECIES", 26, 33], ["Jeong's study", "TEST", 3, 16], ["MDA", "TEST", 39, 42], ["MDA", "TEST", 63, 66], ["the vaccine efficacy", "TREATMENT", 151, 171]]], ["As the same, Balasch et al. recently showed that vaccination of 1-day-old piglets using a new PRRSV-1 MLV in presence of MDAs induced a partial protection against a challenge at 67 days pv [18] .", [["MDAs", "CHEMICAL", 121, 125], ["piglets", "ORGANISM", 74, 81], ["PRRSV-1 MLV", "ORGANISM", 94, 105], ["MDAs", "SIMPLE_CHEMICAL", 121, 125], ["piglets", "SPECIES", 74, 81], ["PRRSV-1", "SPECIES", 94, 101], ["PRRSV-1", "SPECIES", 94, 101], ["a new PRRSV-1 MLV", "TREATMENT", 88, 105], ["MDAs", "PROBLEM", 121, 125], ["a partial protection", "TREATMENT", 134, 154]]], ["In Balasch's study, NAs were quantified in piglets at the vaccination time but here also the absence of comparison with vaccinated piglets without MDNAs limits the conclusions of the study.DiscussionThe interference of MDAs on vaccine efficacy was previously demonstrated for many other swine diseases.", [["MDAs", "CHEMICAL", 219, 223], ["swine diseases", "DISEASE", 287, 301], ["NAs", "ORGANISM", 20, 23], ["piglets", "ORGANISM", 43, 50], ["piglets", "ORGANISM", 131, 138], ["MDAs", "SIMPLE_CHEMICAL", 219, 223], ["swine", "ORGANISM", 287, 292], ["piglets", "SPECIES", 43, 50], ["piglets", "SPECIES", 131, 138], ["swine", "SPECIES", 287, 292], ["swine", "SPECIES", 287, 292], ["Balasch's study", "TEST", 3, 18], ["the study", "TEST", 179, 188], ["MDAs on vaccine efficacy", "TREATMENT", 219, 243], ["many other swine diseases", "PROBLEM", 276, 301]]], ["Using a killed vaccine against porcine circovirus type 2, a similar study comparing vaccine efficacy in piglets with low or high MDA levels showed a significant reduction of percentage of PCR positive animals in A\u00c0V+ group compared to A+V+ group at 22 days post-challenge [19] .", [["MDA", "CHEMICAL", 129, 132], ["A\u00c0V", "CHEMICAL", 212, 215], ["MDA", "CHEMICAL", 129, 132], ["porcine circovirus type 2", "ORGANISM", 31, 56], ["piglets", "ORGANISM", 104, 111], ["MDA", "SIMPLE_CHEMICAL", 129, 132], ["A\u00c0V+", "SIMPLE_CHEMICAL", 212, 216], ["A+V+", "SIMPLE_CHEMICAL", 235, 239], ["porcine circovirus", "SPECIES", 31, 49], ["piglets", "SPECIES", 104, 111], ["porcine circovirus type 2", "SPECIES", 31, 56], ["piglets", "SPECIES", 104, 111], ["a killed vaccine", "TREATMENT", 6, 22], ["porcine circovirus type", "TREATMENT", 31, 54], ["a similar study", "TEST", 58, 73], ["low or high MDA levels", "PROBLEM", 117, 139], ["a significant reduction of percentage of PCR positive animals", "PROBLEM", 147, 208], ["A+V", "TEST", 235, 238], ["significant", "OBSERVATION_MODIFIER", 149, 160], ["reduction", "OBSERVATION_MODIFIER", 161, 170]]], ["Using a MLV against classical swine fever, 83% of piglets with high MDNA levels at vaccination died from a challenge at 10 weeks of age, whereas all piglets with low MDNA levels, survived from the challenge [20] .DiscussionIn addition, considering the contact animals, our results also demonstrated that MDNAs decreased the PRRS vaccine efficacy on virus transmission.", [["swine fever", "DISEASE", 30, 41], ["MDNA", "CHEMICAL", 68, 72], ["MDNAs", "CHEMICAL", 304, 309], ["PRRS", "DISEASE", 324, 328], ["MLV", "ORGANISM", 8, 11], ["piglets", "ORGANISM", 50, 57], ["MDNA", "GENE_OR_GENE_PRODUCT", 68, 72], ["piglets", "ORGANISM", 149, 156], ["MDNAs", "SIMPLE_CHEMICAL", 304, 309], ["PRRS", "ORGANISM", 324, 328], ["MDNA", "PROTEIN", 68, 72], ["MDNA", "PROTEIN", 166, 170], ["swine", "SPECIES", 30, 35], ["piglets", "SPECIES", 50, 57], ["piglets", "SPECIES", 149, 156], ["MLV", "SPECIES", 8, 11], ["swine", "SPECIES", 30, 35], ["piglets", "SPECIES", 50, 57], ["PRRS", "SPECIES", 324, 328], ["a MLV", "TREATMENT", 6, 11], ["classical swine fever", "PROBLEM", 20, 41], ["high MDNA levels", "PROBLEM", 63, 79], ["low MDNA levels", "PROBLEM", 162, 177], ["the PRRS vaccine", "TREATMENT", 320, 336], ["virus transmission", "TREATMENT", 349, 367]]], ["In the present study, PRRS vaccination in A\u00c0V+ piglets reduced the transmission rate of the Finistere strain two-fold compared to the rate estimated for the V-group.", [["PRRS", "DISEASE", 22, 26], ["A\u00c0V", "CHEMICAL", 42, 45], ["PRRS", "ORGANISM", 22, 26], ["A\u00c0V+ piglets", "ORGANISM", 42, 54], ["piglets", "SPECIES", 47, 54], ["PRRS", "SPECIES", 22, 26], ["A\u00c0V", "SPECIES", 42, 45], ["the present study", "TEST", 3, 20], ["PRRS vaccination", "TREATMENT", 22, 38], ["piglets", "PROBLEM", 47, 54], ["the rate", "TEST", 130, 138], ["piglets", "OBSERVATION_MODIFIER", 47, 54], ["reduced", "OBSERVATION_MODIFIER", 55, 62]]], ["The magnitude of the effect is substantially lower than what was found in our previous study with a ten-fold reduced transmission rate in vaccinated SPF pigs, with non MDA [8] .", [["MDA", "CHEMICAL", 168, 171], ["MDA", "CHEMICAL", 168, 171], ["SPF pigs", "ORGANISM", 149, 157], ["pigs", "SPECIES", 153, 157], ["SPF", "SPECIES", 149, 152], ["our previous study", "TEST", 74, 92], ["a ten-fold reduced transmission rate", "PROBLEM", 98, 134], ["vaccinated SPF pigs", "TREATMENT", 138, 157], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["substantially", "OBSERVATION_MODIFIER", 31, 44], ["lower", "OBSERVATION_MODIFIER", 45, 50]]], ["One possible explanation for this discrepancy may be the intradermal route (ID) used for vaccination in our previous work.", [["this discrepancy", "PROBLEM", 29, 45], ["vaccination", "TREATMENT", 89, 100], ["possible explanation for", "UNCERTAINTY", 4, 28]]], ["This immunization route was previously shown to induce an enhanced cell-mediated immune response after PRRSV exposure and a lower respiratory clinical score compared to IM vaccination [5] .", [["cell", "ANATOMY", 67, 71], ["cell", "CELL", 67, 71], ["PRRSV", "ORGANISM", 103, 108], ["PRRSV", "SPECIES", 103, 108], ["This immunization route", "TREATMENT", 0, 23], ["an enhanced cell", "PROBLEM", 55, 71], ["PRRSV exposure", "PROBLEM", 103, 117], ["a lower respiratory clinical score", "PROBLEM", 122, 156]]], ["The better immune response, especially at the mucosal sites, elicited after ID immunization, may have limited viral replication in the respiratory tract, thus reducing virus excretion and transmission.", [["mucosal sites", "ANATOMY", 46, 59], ["respiratory tract", "ANATOMY", 135, 152], ["mucosal sites", "MULTI-TISSUE_STRUCTURE", 46, 59], ["respiratory tract", "ORGANISM_SUBDIVISION", 135, 152], ["ID immunization", "TREATMENT", 76, 91], ["limited viral replication in the respiratory tract", "PROBLEM", 102, 152], ["reducing virus excretion", "PROBLEM", 159, 183], ["immune response", "OBSERVATION", 11, 26], ["mucosal sites", "ANATOMY", 46, 59], ["viral replication", "OBSERVATION", 110, 127], ["respiratory tract", "ANATOMY", 135, 152], ["virus excretion", "OBSERVATION", 168, 183]]], ["In Fablet et al. study [14] , vaccine viremia was detected in 60% of A\u00c0V+ piglets at W2 pv whereas only in 12.5% of A\u00c0V+ piglets of the present study after the first vaccination.", [["viremia", "DISEASE", 38, 45], ["vaccine", "ORGANISM", 30, 37], ["A\u00c0V+ piglets", "ORGANISM", 69, 81], ["A\u00c0V+ piglets", "ORGANISM", 116, 128], ["piglets", "SPECIES", 74, 81], ["piglets", "SPECIES", 121, 128], ["A\u00c0V", "SPECIES", 69, 72], ["A\u00c0V", "SPECIES", 116, 119], ["study", "TEST", 17, 22], ["vaccine viremia", "PROBLEM", 30, 45], ["A\u00c0V", "TEST", 69, 72], ["the present study", "TEST", 132, 149], ["the first vaccination", "TREATMENT", 156, 177]]], ["To explore these unexpected results, we attempted to investigate the origin of this low vaccine replication displayed in A\u00c0V+ piglets after vaccination at 3 woa.", [["A\u00c0V+ piglets", "ORGANISM", 121, 133], ["piglets", "SPECIES", 126, 133], ["A\u00c0V", "SPECIES", 121, 124], ["this low vaccine replication", "TREATMENT", 79, 107], ["A\u00c0V+ piglets", "TREATMENT", 121, 133], ["vaccination", "TREATMENT", 140, 151]]], ["The vaccine strain was titrated, but no problem was detected.", [["The vaccine strain", "TREATMENT", 0, 18], ["problem", "PROBLEM", 40, 47]]], ["As IFNa was recently shown to strongly inhibit the replication of a genotype 2 PRRS MLV [21] , we hypothesized this cytokine could be responsible for the inhibition of vaccine replication in our A\u00c0V+ piglets.", [["IFNa", "CHEMICAL", 3, 7], ["IFNa", "GENE_OR_GENE_PRODUCT", 3, 7], ["PRRS MLV", "ORGANISM", 79, 87], ["A\u00c0V+ piglets", "ORGANISM", 195, 207], ["IFNa", "PROTEIN", 3, 7], ["cytokine", "PROTEIN", 116, 124], ["PRRS", "SPECIES", 79, 83], ["piglets", "SPECIES", 200, 207], ["PRRS", "SPECIES", 79, 83], ["A\u00c0V", "SPECIES", 195, 198], ["a genotype 2 PRRS MLV", "TREATMENT", 66, 87], ["vaccine replication", "TREATMENT", 168, 187]]], ["Indeed, the levels of IFNa detected in piglets from the present study at 3 woa were much higher than those from our previous study [14] and in the same range as the concentration shown to be able to completely inhibit PRRS MLV replication [22] .DiscussionTo bring some preliminary conclusions, it seems that IFNa concentrations likely to interfere with PRRS MLV replication could be achieved in piglets under field conditions.", [["IFNa", "CHEMICAL", 308, 312], ["IFNa", "CHEMICAL", 308, 312], ["IFNa", "GENE_OR_GENE_PRODUCT", 22, 26], ["piglets", "ORGANISM", 39, 46], ["PRRS MLV", "ORGANISM", 218, 226], ["IFNa", "GENE_OR_GENE_PRODUCT", 308, 312], ["PRRS MLV", "ORGANISM", 353, 361], ["piglets", "ORGANISM", 395, 402], ["IFNa", "PROTEIN", 22, 26], ["IFNa", "PROTEIN", 308, 312], ["piglets", "SPECIES", 39, 46], ["piglets", "SPECIES", 395, 402], ["PRRS", "SPECIES", 218, 222], ["PRRS", "SPECIES", 353, 357], ["IFNa", "TEST", 22, 26], ["the present study", "TEST", 52, 69], ["our previous study", "TEST", 112, 130], ["IFNa concentrations", "PROBLEM", 308, 327], ["PRRS MLV replication", "TREATMENT", 353, 373]]], ["In the absence of suitable samples (not of the right type or not collected at the right time) for further exploration, we were not able to identify the cause of these increased IFNa levels.", [["samples", "ANATOMY", 27, 34], ["samples", "CANCER", 27, 34], ["IFNa", "GENE_OR_GENE_PRODUCT", 177, 181], ["IFNa", "PROTEIN", 177, 181], ["suitable samples", "TEST", 18, 34], ["further exploration", "TEST", 98, 117], ["these increased IFNa levels", "PROBLEM", 161, 188], ["right", "ANATOMY_MODIFIER", 47, 52], ["increased", "OBSERVATION", 167, 176]]], ["However, this cytokine is known to be produced in response to many viral infections such as swine influenza [23] or porcine respiratory coronavirus [24, 25] that could infect piglets at weaning when they are frequently vaccinated against PRRSV.", [["viral infections", "DISEASE", 67, 83], ["swine influenza", "DISEASE", 92, 107], ["respiratory coronavirus", "DISEASE", 124, 147], ["swine influenza [23]", "ORGANISM", 92, 112], ["porcine respiratory coronavirus", "ORGANISM", 116, 147], ["piglets", "ORGANISM", 175, 182], ["PRRSV", "ORGANISM", 238, 243], ["cytokine", "PROTEIN", 14, 22], ["swine influenza", "SPECIES", 92, 107], ["porcine respiratory coronavirus", "SPECIES", 116, 147], ["piglets", "SPECIES", 175, 182], ["PRRSV", "SPECIES", 238, 243], ["swine", "SPECIES", 92, 97], ["porcine respiratory coronavirus", "SPECIES", 116, 147], ["PRRSV", "SPECIES", 238, 243], ["many viral infections", "PROBLEM", 62, 83], ["swine influenza", "PROBLEM", 92, 107], ["porcine respiratory coronavirus", "PROBLEM", 116, 147], ["PRRSV", "PROBLEM", 238, 243], ["viral", "OBSERVATION_MODIFIER", 67, 72], ["infections", "OBSERVATION", 73, 83]]], ["As a result, this potential viral interference with the PRRS MLV vaccine may be another possible explanation for the limited PRRS MLV vaccine efficacy observed in the field.ConclusionsOur results confirm that MDNAs impair PRRS vaccine strain replication and post-vaccination immune response.", [["PRRS MLV", "ORGANISM", 56, 64], ["PRRS", "ORGANISM", 125, 129], ["MDNAs", "GENE_OR_GENE_PRODUCT", 209, 214], ["PRRS", "ORGANISM", 222, 226], ["MDNAs", "PROTEIN", 209, 214], ["PRRS", "SPECIES", 222, 226], ["PRRS", "SPECIES", 56, 60], ["PRRS", "SPECIES", 125, 129], ["PRRS", "SPECIES", 222, 226], ["viral interference", "PROBLEM", 28, 46], ["the PRRS MLV vaccine", "TREATMENT", 52, 72], ["the limited PRRS MLV vaccine efficacy", "TREATMENT", 113, 150], ["MDNAs impair PRRS vaccine strain replication", "TREATMENT", 209, 253]]], ["Furthermore, we demonstrated for the first time that this impaired immune response results in decreased vaccine efficacy based on virological parameters evaluation after a low virulent PRRSV challenge.", [["PRRSV", "ORGANISM", 185, 190], ["PRRSV", "SPECIES", 185, 190], ["this impaired immune response", "PROBLEM", 53, 82], ["decreased vaccine efficacy", "PROBLEM", 94, 120], ["virological parameters evaluation", "TEST", 130, 163], ["a low virulent PRRSV challenge", "TREATMENT", 170, 200]]], ["The use of a more virulent strain for the challenge of the animals may bring further clinical arguments regarding the reduced vaccine efficacy in presence of high levels of MDNAs.", [["MDNAs", "GENE_OR_GENE_PRODUCT", 173, 178], ["MDNAs", "PROTEIN", 173, 178], ["a more virulent strain", "TREATMENT", 11, 33], ["the reduced vaccine efficacy", "TREATMENT", 114, 142], ["high levels of MDNAs", "PROBLEM", 158, 178]]], ["Unexpectedly, we also showed that other factors such as IFNa may interfere with PRRS MLV vaccination.", [["IFNa", "GENE_OR_GENE_PRODUCT", 56, 60], ["PRRS MLV", "ORGANISM", 80, 88], ["IFNa", "PROTEIN", 56, 60], ["PRRS", "SPECIES", 80, 84], ["other factors", "PROBLEM", 34, 47], ["PRRS MLV vaccination", "TREATMENT", 80, 100]]], ["Further research is needed to explore a possible viral interference phenomenon toward PRRS MLV vaccines.", [["PRRS", "ORGANISM", 86, 90], ["MLV", "ORGANISM", 91, 94], ["PRRS", "SPECIES", 86, 90], ["viral interference phenomenon", "PROBLEM", 49, 78], ["PRRS MLV vaccines", "TREATMENT", 86, 103]]], ["At the end, the low efficacy of PRRS vaccination observed in the field could thus result from endogenous (MDAs) as well as exogenous (viral infection) factors.", [["PRRS", "DISEASE", 32, 36], ["viral infection", "DISEASE", 134, 149], ["PRRS", "ORGANISM", 32, 36], ["MDAs", "GENE_OR_GENE_PRODUCT", 106, 110], ["PRRS", "SPECIES", 32, 36], ["PRRS vaccination", "TREATMENT", 32, 48], ["endogenous (MDAs)", "PROBLEM", 94, 111], ["exogenous (viral infection) factors", "PROBLEM", 123, 158], ["low efficacy", "OBSERVATION_MODIFIER", 16, 28], ["endogenous", "OBSERVATION_MODIFIER", 94, 104]]], ["RT-PCR at one week post-vaccination (W1 pv) in Experiment B or at W2 pv in Experiment A. All data are reported as the mean (\u00b1SEM) of results obtained from piglets in each group.", [["piglets", "ORGANISM", 155, 162], ["piglets", "SPECIES", 155, 162], ["RT-PCR", "TEST", 0, 6]]]], "db3740f1b16a6b6522968a6a5eed62e9bd894493": [["Deciding on the number of psychotherapy sessions to satisfactorily treat a patient is a vital clinical as well as economic issue in most mental health systems worldwide.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["psychotherapy sessions", "TREATMENT", 26, 48]]], ["The length of outpatient psychotherapy in naturalistic conditions ranges from a single session to hundreds of sessions [1] .", [["outpatient psychotherapy", "TREATMENT", 14, 38], ["length", "OBSERVATION_MODIFIER", 4, 10]]], ["In randomized clinical trials, the number of sessions is typically fixed to deliver manualized treatments and to control for dosage effects (e.g., in a 16-session format [2] ).", [["manualized treatments", "TREATMENT", 84, 105], ["dosage effects", "PROBLEM", 125, 139]]], ["Using data from Routine Outcome Monitoring studies [3, 4] , we investigated whether the treatments under naturalistic conditions were fixed to a particular number of sessions or not (H1), whether naturalistic conditions tended to include unusually long treatments (e.g., > 100 sessions) (H2), and how the observed number of sessions was distributed across countries (H3).", [["Routine Outcome Monitoring studies", "TEST", 16, 50], ["naturalistic conditions", "PROBLEM", 196, 219]]]], "7a5bc9a848fbf197657c7ccb6f8d7ae361a4b9d2": [["\"It is this sentiment, the germ of which all of us carry inside to a greater or lesser degree, that drives certain poets into clinics and anatomy theaters, and women to public executions.\"", [["germ", "ANATOMY", 27, 31], ["women", "ORGANISM", 160, 165], ["women", "SPECIES", 160, 165], ["lesser degree", "OBSERVATION_MODIFIER", 80, 93]]], ["Taken to excess on the artistic canvas, ugliness and the absurd have been characterized as maximalism, a modern movement in literature and the arts that celebrates richness, decoration, sensuality, luxury, and fantasy.", [["maximalism", "DISEASE", 91, 101]]], ["A genre that thrives on redundancy and overt accumulation, maximalism emphasizes a creative process or art-making that is also laborious and cumulative.", [["overt accumulation", "PROBLEM", 39, 57], ["a creative process", "PROBLEM", 81, 99], ["overt", "OBSERVATION_MODIFIER", 39, 44], ["accumulation", "OBSERVATION_MODIFIER", 45, 57]]], ["Sponsored by the Famous Artists Institute in Minneapolis, the contest was advertised on matchbook covers and comic books and invited children to draw a lumberjack or a baby deer.", [["children", "ORGANISM", 133, 141], ["children", "SPECIES", 133, 141]]], ["His roots in colloquial drawing, doodling, and pop culture remain strong in many of his pieces, where comic strips provide the background for figures, showing his penchant for poking fun at sacred cows in society and in art.", [["roots", "ANATOMY", 4, 9], ["roots", "ORGAN", 4, 9], ["doodling", "TREATMENT", 33, 41], ["pop culture", "TEST", 47, 58], ["comic strips", "TREATMENT", 102, 114], ["roots", "ANATOMY", 4, 9]]], ["These ideas lay out aspects of human behavior in mocking and irreverent scenes often filled with beastly or hybrid characters.", [["human", "ORGANISM", 31, 36], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["human behavior", "PROBLEM", 31, 45], ["hybrid characters", "PROBLEM", 108, 125]]]], "PMC302018": [["IntroductionThe efficiency of +1 ribosomal frameshifting at a specific codon is used as a sensor to regulate polyamine levels in mammalian cells.", [["ribosomal", "ANATOMY", 33, 42], ["cells", "ANATOMY", 139, 144], ["polyamine", "CHEMICAL", 109, 118], ["polyamine", "CHEMICAL", 109, 118], ["ribosomal", "CELLULAR_COMPONENT", 33, 42], ["polyamine", "SIMPLE_CHEMICAL", 109, 118], ["mammalian cells", "CELL", 129, 144], ["mammalian cells", "CELL_TYPE", 129, 144], ["+1 ribosomal frameshifting", "PROBLEM", 30, 56], ["a specific codon", "TREATMENT", 60, 76], ["polyamine levels", "TEST", 109, 125], ["ribosomal frameshifting", "OBSERVATION", 33, 56], ["mammalian cells", "OBSERVATION", 129, 144]]], ["The frameshifting occurs in decoding the gene antizyme 1, which has two partially overlapping open reading frames (ORFs).", [["antizyme 1", "GENE_OR_GENE_PRODUCT", 46, 56], ["gene antizyme 1", "DNA", 41, 56], ["open reading frames", "DNA", 94, 113], ["ORFs", "DNA", 115, 119], ["The frameshifting", "PROBLEM", 0, 17], ["decoding the gene antizyme", "TREATMENT", 28, 54], ["frameshifting", "OBSERVATION", 4, 17]]], ["Protein sequencing showed that the reading-frame shift occurs at the last codon of ORF1, causing a proportion of ribosomes to enter ORF2 to synthesize a transframe protein (Matsufuji et al., 1995).", [["ORF1", "GENE_OR_GENE_PRODUCT", 83, 87], ["ribosomes", "CELLULAR_COMPONENT", 113, 122], ["ORF2", "GENE_OR_GENE_PRODUCT", 132, 136], ["ORF1", "DNA", 83, 87], ["ORF2", "DNA", 132, 136], ["transframe protein", "PROTEIN", 153, 171], ["Protein sequencing", "TEST", 0, 18]]], ["ORF2 encodes the main functional domains (Matsufuji et al., 1990; Miyazaki et al., 1992) of antizyme but has no ribosome initiation site of its own.", [["ribosome", "ANATOMY", 112, 120], ["ORF2", "GENE_OR_GENE_PRODUCT", 0, 4], ["antizyme", "GENE_OR_GENE_PRODUCT", 92, 100], ["ORF2", "DNA", 0, 4], ["antizyme", "PROTEIN", 92, 100], ["ribosome initiation site", "DNA", 112, 136], ["antizyme", "TREATMENT", 92, 100], ["main", "OBSERVATION_MODIFIER", 17, 21], ["no", "UNCERTAINTY", 109, 111], ["ribosome initiation", "OBSERVATION", 112, 131]]], ["The antizyme 1 protein binds to ornithine decarboxylase (ODC) (Murakami et al., 1992a; Li and Coffino, 1993, 1994), inhibits it (Heller et al., 1976) and targets it for degradation by the 26S proteosome without ubiquitylation (Murakami et al., 1992b, 1999).", [["ornithine", "CHEMICAL", 32, 41], ["Li", "CHEMICAL", 87, 89], ["ornithine", "CHEMICAL", 32, 41], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 4, 14], ["ornithine decarboxylase", "GENE_OR_GENE_PRODUCT", 32, 55], ["ODC", "SIMPLE_CHEMICAL", 57, 60], ["26S proteosome", "GENE_OR_GENE_PRODUCT", 188, 202], ["antizyme 1 protein", "PROTEIN", 4, 22], ["ornithine decarboxylase", "PROTEIN", 32, 55], ["26S proteosome", "PROTEIN", 188, 202], ["The antizyme", "TEST", 0, 12], ["ornithine decarboxylase", "TEST", 32, 55]]], ["ODC catalyzes the first and usually rate-limiting step in the synthesis of polyamines, conversion of ornithine to putrescine.", [["polyamines", "CHEMICAL", 75, 85], ["ornithine", "CHEMICAL", 101, 110], ["putrescine", "CHEMICAL", 114, 124], ["polyamines", "CHEMICAL", 75, 85], ["ornithine", "CHEMICAL", 101, 110], ["putrescine", "CHEMICAL", 114, 124], ["ODC", "GENE_OR_GENE_PRODUCT", 0, 3], ["polyamines", "SIMPLE_CHEMICAL", 75, 85], ["ornithine", "SIMPLE_CHEMICAL", 101, 110], ["putrescine", "SIMPLE_CHEMICAL", 114, 124], ["ODC", "PROTEIN", 0, 3], ["ODC catalyzes", "TEST", 0, 13], ["polyamines", "TREATMENT", 75, 85], ["ornithine to putrescine", "TREATMENT", 101, 124]]], ["Putrescine is a substrate for the synthesis of spermidine and spermine.", [["Putrescine", "CHEMICAL", 0, 10], ["spermidine", "CHEMICAL", 47, 57], ["spermine", "CHEMICAL", 62, 70], ["Putrescine", "CHEMICAL", 0, 10], ["spermidine", "CHEMICAL", 47, 57], ["spermine", "CHEMICAL", 62, 70], ["Putrescine", "SIMPLE_CHEMICAL", 0, 10], ["spermidine", "SIMPLE_CHEMICAL", 47, 57], ["spermine", "SIMPLE_CHEMICAL", 62, 70], ["Putrescine", "TREATMENT", 0, 10], ["the synthesis of spermidine and spermine", "TREATMENT", 30, 70]]], ["Because of its inhibition of ODC, antizyme 1 is a negative regulator of the synthesis of polyamines.", [["polyamines", "CHEMICAL", 89, 99], ["polyamines", "CHEMICAL", 89, 99], ["ODC", "GENE_OR_GENE_PRODUCT", 29, 32], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 34, 44], ["polyamines", "SIMPLE_CHEMICAL", 89, 99], ["ODC", "PROTEIN", 29, 32], ["antizyme 1", "PROTEIN", 34, 44], ["antizyme", "TREATMENT", 34, 42], ["the synthesis of polyamines", "TREATMENT", 72, 99]]], ["In addition, antizyme 1 is a negative regulator of the polyamine transporter (Mitchell et al., 1994; Suzuki et al., 1994; Sakata et al., 1997).", [["polyamine", "CHEMICAL", 55, 64], ["polyamine", "CHEMICAL", 55, 64], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 13, 23], ["polyamine", "SIMPLE_CHEMICAL", 55, 64], ["antizyme 1", "PROTEIN", 13, 23], ["polyamine transporter", "PROTEIN", 55, 76]]], ["As discovered by Matsufuji and colleagues (Gesteland et al., 1992) and Rom and Kahana (1994), increasing polyamine levels elevate frameshifting in decoding antizyme 1 mRNA and so increase the level of antizyme 1.", [["polyamine", "CHEMICAL", 105, 114], ["polyamine", "CHEMICAL", 105, 114], ["polyamine", "SIMPLE_CHEMICAL", 105, 114], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 156, 166], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 201, 211], ["antizyme 1 mRNA", "RNA", 156, 171], ["antizyme 1", "PROTEIN", 201, 211], ["increasing polyamine levels", "PROBLEM", 94, 121], ["decoding antizyme", "TREATMENT", 147, 164], ["the level of antizyme", "TREATMENT", 188, 209]]], ["Since antizyme 1 negatively regulates the synthesis and uptake of polyamines, the frameshifting is the sensor for an autoregulatory circuit.", [["polyamines", "CHEMICAL", 66, 76], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 6, 16], ["polyamines", "SIMPLE_CHEMICAL", 66, 76], ["antizyme 1", "PROTEIN", 6, 16], ["polyamines", "TREATMENT", 66, 76], ["the frameshifting", "PROBLEM", 78, 95], ["an autoregulatory circuit", "TREATMENT", 114, 139], ["autoregulatory circuit", "OBSERVATION", 117, 139]]], ["A second mammalian paralog of antizyme, antizyme 2, has very similar properties to antizyme 1, including the regulatory frameshifting, but does not stimulate degradation of ODC under certain conditions where antizyme 1 is active (Ivanov et al., 1998a; Zhu et al., 1999; Y.Murakami, S.Matsufuji, I.P.Ivanov, R.F.Gesteland and J.F.Atkins, in preparation).", [["antizyme", "GENE_OR_GENE_PRODUCT", 30, 38], ["antizyme 2", "GENE_OR_GENE_PRODUCT", 40, 50], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 83, 93], ["ODC", "GENE_OR_GENE_PRODUCT", 173, 176], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 208, 218], ["antizyme", "PROTEIN", 30, 38], ["antizyme 2", "PROTEIN", 40, 50], ["antizyme 1", "PROTEIN", 83, 93], ["ODC", "PROTEIN", 173, 176], ["antizyme 1", "PROTEIN", 208, 218], ["A second mammalian paralog of antizyme", "TREATMENT", 0, 38], ["antizyme 2", "TREATMENT", 40, 50], ["antizyme 1", "TREATMENT", 83, 93], ["the regulatory frameshifting", "TREATMENT", 105, 133], ["frameshifting", "OBSERVATION", 120, 133]]], ["Just like antizyme 1, antizyme 2 mRNA is ubiquitously expressed in the body but is 16 times less abundant than mRNA of antizyme 1 (Ivanov et al., 1998a).", [["body", "ANATOMY", 71, 75], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 10, 20], ["antizyme 2", "GENE_OR_GENE_PRODUCT", 22, 32], ["body", "ORGANISM_SUBDIVISION", 71, 75], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 119, 129], ["antizyme 1, antizyme 2 mRNA", "RNA", 10, 37], ["mRNA", "RNA", 111, 115], ["antizyme", "TREATMENT", 10, 18], ["antizyme 2 mRNA", "TREATMENT", 22, 37], ["antizyme", "TREATMENT", 119, 127], ["body", "ANATOMY", 71, 75], ["16 times", "OBSERVATION_MODIFIER", 83, 91]]], ["In addition to antizyme 1 and 2, mammals have a third paralog of the gene, antizyme 3 (also encoded by two ORFs), which is expressed only during spermatogenesis (Ivanov et al., 2000).", [["antizyme 1", "GENE_OR_GENE_PRODUCT", 15, 25], ["2", "GENE_OR_GENE_PRODUCT", 30, 31], ["mammals", "ORGANISM", 33, 40], ["antizyme 3", "GENE_OR_GENE_PRODUCT", 75, 85], ["antizyme 1 and 2", "PROTEIN", 15, 31], ["antizyme 3", "PROTEIN", 75, 85], ["ORFs", "DNA", 107, 111], ["antizyme", "TREATMENT", 15, 23], ["antizyme", "TREATMENT", 75, 83]]], ["Zebrafish also have multiple antizyme genes, which differ in their expression patterns and activities (Saito et al., 2000).IntroductionNumerous studies have addressed the regulation of fungal ODC in response to exogenously added polyamines.", [["polyamines", "CHEMICAL", 229, 239], ["polyamines", "CHEMICAL", 229, 239], ["Zebrafish", "ORGANISM", 0, 9], ["antizyme", "GENE_OR_GENE_PRODUCT", 29, 37], ["ODC", "GENE_OR_GENE_PRODUCT", 192, 195], ["polyamines", "SIMPLE_CHEMICAL", 229, 239], ["antizyme genes", "DNA", 29, 43], ["fungal ODC", "PROTEIN", 185, 195], ["Zebrafish", "SPECIES", 0, 9], ["Zebrafish", "SPECIES", 0, 9], ["multiple antizyme genes", "TREATMENT", 20, 43], ["Numerous studies", "TEST", 135, 151], ["fungal ODC", "TREATMENT", 185, 195], ["exogenously added polyamines", "TREATMENT", 211, 239], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["antizyme genes", "OBSERVATION", 29, 43]]], ["In the cases examined, Physarum polycephalum (Mitchell and Wilson, 1983), Saccharomyces cerevisiae (Fonzi, 1989; Toth and Coffino, 1999) and Neurospora crassa (Barnett et al., 1988; Williams et al., 1992), added polyamines, especially spermidine, result in significant repression of ODC activity.", [["polyamines", "CHEMICAL", 212, 222], ["spermidine", "CHEMICAL", 235, 245], ["polyamines", "CHEMICAL", 212, 222], ["spermidine", "CHEMICAL", 235, 245], ["Physarum polycephalum", "CELL", 23, 44], ["Saccharomyces cerevisiae", "ORGANISM", 74, 98], ["Neurospora crassa", "ORGANISM", 141, 158], ["polyamines", "SIMPLE_CHEMICAL", 212, 222], ["spermidine", "SIMPLE_CHEMICAL", 235, 245], ["ODC", "GENE_OR_GENE_PRODUCT", 283, 286], ["ODC", "PROTEIN", 283, 286], ["Physarum polycephalum", "SPECIES", 23, 44], ["Saccharomyces cerevisiae", "SPECIES", 74, 98], ["Neurospora crassa", "SPECIES", 141, 158], ["Physarum polycephalum (Mitchell and Wilson, 1983)", "SPECIES", 23, 72], ["Saccharomyces cerevisiae", "SPECIES", 74, 98], ["Neurospora crassa", "SPECIES", 141, 158], ["polyamines", "TREATMENT", 212, 222], ["spermidine", "TREATMENT", 235, 245], ["ODC activity", "PROBLEM", 283, 295], ["Physarum polycephalum", "OBSERVATION", 23, 44], ["significant repression", "OBSERVATION", 257, 279], ["ODC activity", "OBSERVATION", 283, 295]]], ["The mechanisms of repression seem to vary from fungus to fungus and are apparently different from the mechanism of polyamine-dependent regulation of ODC in higher eukaryotes.", [["polyamine", "CHEMICAL", 115, 124], ["polyamine", "CHEMICAL", 115, 124], ["polyamine", "SIMPLE_CHEMICAL", 115, 124], ["ODC", "GENE_OR_GENE_PRODUCT", 149, 152], ["ODC", "PROTEIN", 149, 152], ["fungus", "PROBLEM", 47, 53], ["fungus", "PROBLEM", 57, 63], ["polyamine-dependent regulation", "TREATMENT", 115, 145], ["fungus", "OBSERVATION", 47, 53], ["fungus", "OBSERVATION", 57, 63], ["higher eukaryotes", "OBSERVATION", 156, 173]]], ["In some cases, the existence of an antizyme-like protein has been suggested but has either been disproved, as in the case of N.crassa (Barnett et al., 1988), or has never been substantiated, as is the case with S.cerevisiae.IntroductionAs expected from their small cationic nature and ability to neutralize negative charges locally, polyamines play key roles in processes ranging from the functioning of certain ion channels (Williams, 1997), nucleic acid packaging, DNA replication, apoptosis, transcription and translation.", [["polyamines", "CHEMICAL", 333, 343], ["nucleic acid", "CHEMICAL", 443, 455], ["polyamines", "CHEMICAL", 333, 343], ["antizyme", "GENE_OR_GENE_PRODUCT", 35, 43], ["polyamines", "SIMPLE_CHEMICAL", 333, 343], ["DNA", "CELLULAR_COMPONENT", 467, 470], ["antizyme-like protein", "PROTEIN", 35, 56], ["an antizyme-like protein", "PROBLEM", 32, 56], ["nucleic acid packaging", "TREATMENT", 443, 465], ["DNA replication", "TREATMENT", 467, 482], ["apoptosis", "PROBLEM", 484, 493]]], ["The role of polyamines can be complex as illustrated by the transfer of the butylamine moiety of spermidine to a lysine residue to form hypusine in mammalian translation initiation factor eIF-5A, the only known substrate for this reaction (Tome et al., 1997; Lee et al., 1999).", [["polyamines", "CHEMICAL", 12, 22], ["butylamine", "CHEMICAL", 76, 86], ["spermidine", "CHEMICAL", 97, 107], ["lysine", "CHEMICAL", 113, 119], ["hypusine", "CHEMICAL", 136, 144], ["polyamines", "CHEMICAL", 12, 22], ["butylamine", "CHEMICAL", 76, 86], ["spermidine", "CHEMICAL", 97, 107], ["lysine", "CHEMICAL", 113, 119], ["hypusine", "CHEMICAL", 136, 144], ["polyamines", "SIMPLE_CHEMICAL", 12, 22], ["butylamine", "SIMPLE_CHEMICAL", 76, 86], ["spermidine", "SIMPLE_CHEMICAL", 97, 107], ["hypusine", "SIMPLE_CHEMICAL", 136, 144], ["eIF-5A", "GENE_OR_GENE_PRODUCT", 188, 194], ["mammalian translation initiation factor eIF-5A", "PROTEIN", 148, 194], ["polyamines", "TREATMENT", 12, 22], ["the butylamine moiety of spermidine", "TREATMENT", 72, 107], ["a lysine residue", "TREATMENT", 111, 127], ["hypusine", "PROBLEM", 136, 144], ["this reaction", "PROBLEM", 225, 238]]], ["Spermine negatively regulates the growth of prostatic carcinoma cells at their primary site (Smith et al., 1995), but at later stages of tumor progression it fails to induce antizyme, which correlates with cells becoming refractory to spermine (Koike et al., 1999).", [["prostatic carcinoma cells", "ANATOMY", 44, 69], ["primary site", "ANATOMY", 79, 91], ["tumor", "ANATOMY", 137, 142], ["cells", "ANATOMY", 206, 211], ["Spermine", "CHEMICAL", 0, 8], ["prostatic carcinoma", "DISEASE", 44, 63], ["tumor", "DISEASE", 137, 142], ["spermine", "CHEMICAL", 235, 243], ["Spermine", "CHEMICAL", 0, 8], ["spermine", "CHEMICAL", 235, 243], ["Spermine", "SIMPLE_CHEMICAL", 0, 8], ["prostatic carcinoma cells", "CELL", 44, 69], ["tumor", "CANCER", 137, 142], ["antizyme", "GENE_OR_GENE_PRODUCT", 174, 182], ["cells", "CELL", 206, 211], ["spermine", "SIMPLE_CHEMICAL", 235, 243], ["prostatic carcinoma cells", "CELL_TYPE", 44, 69], ["antizyme", "PROTEIN", 174, 182], ["prostatic carcinoma cells", "PROBLEM", 44, 69], ["tumor progression", "PROBLEM", 137, 154], ["antizyme", "PROBLEM", 174, 182], ["growth", "OBSERVATION_MODIFIER", 34, 40], ["prostatic", "ANATOMY", 44, 53], ["carcinoma", "OBSERVATION", 54, 63], ["tumor", "OBSERVATION", 137, 142]]], ["Lack of antizyme function is also important in the early de-regulation of cellular proliferation in oral tumors (Tsuji et al., 1998) and probably others.", [["cellular", "ANATOMY", 74, 82], ["oral tumors", "ANATOMY", 100, 111], ["oral tumors", "DISEASE", 100, 111], ["antizyme", "GENE_OR_GENE_PRODUCT", 8, 16], ["cellular", "CELL", 74, 82], ["oral tumors", "CANCER", 100, 111], ["antizyme", "PROTEIN", 8, 16], ["Lack of antizyme function", "PROBLEM", 0, 25], ["cellular proliferation", "PROBLEM", 74, 96], ["oral tumors", "PROBLEM", 100, 111], ["antizyme function", "OBSERVATION", 8, 25], ["cellular proliferation", "OBSERVATION", 74, 96], ["tumors", "OBSERVATION", 105, 111]]], ["The levels of polyamines are altered in many tumors, and inhibitors of polyamine synthesis are being tested for antiproliferative and cell death effects.", [["tumors", "ANATOMY", 45, 51], ["cell", "ANATOMY", 134, 138], ["polyamines", "CHEMICAL", 14, 24], ["tumors", "DISEASE", 45, 51], ["polyamine", "CHEMICAL", 71, 80], ["death", "DISEASE", 139, 144], ["polyamines", "CHEMICAL", 14, 24], ["polyamine", "CHEMICAL", 71, 80], ["polyamines", "SIMPLE_CHEMICAL", 14, 24], ["tumors", "CANCER", 45, 51], ["polyamine", "SIMPLE_CHEMICAL", 71, 80], ["cell", "CELL", 134, 138], ["polyamines", "TREATMENT", 14, 24], ["many tumors", "PROBLEM", 40, 51], ["inhibitors", "TREATMENT", 57, 67], ["polyamine synthesis", "PROBLEM", 71, 90], ["antiproliferative and cell death effects", "PROBLEM", 112, 152], ["polyamines", "OBSERVATION_MODIFIER", 14, 24], ["altered", "OBSERVATION_MODIFIER", 29, 36], ["many", "OBSERVATION_MODIFIER", 40, 44], ["tumors", "OBSERVATION", 45, 51]]], ["The synthesis of ODC varies during the cell cycle in normal cells (Linden et al., 1985; Fredlund et al., 1995).", [["cell", "ANATOMY", 39, 43], ["cells", "ANATOMY", 60, 65], ["ODC", "GENE_OR_GENE_PRODUCT", 17, 20], ["cell", "CELL", 39, 43], ["cells", "CELL", 60, 65], ["ODC", "PROTEIN", 17, 20], ["normal cells", "CELL_TYPE", 53, 65], ["The synthesis of ODC varies", "PROBLEM", 0, 27], ["the cell cycle", "TEST", 35, 49], ["normal cells", "OBSERVATION", 53, 65]]], ["It is induced by many growth stimuli and is constitutively elevated in transformed cells (Pegg, 1988; Auvinen et al., 1992) with some phosphorylated ODC being translocated to the surface membrane where it is important for mitotic cytoskeleton rearrangement events (Heiskala et al., 1999).IntroductionAntizyme is one example of certain mRNA-contained signals that can elevate specific frameshifting >1000-fold above the background level of normal translational errors.", [["cells", "ANATOMY", 83, 88], ["surface membrane", "ANATOMY", 179, 195], ["cytoskeleton", "ANATOMY", 230, 242], ["Antizyme", "CHEMICAL", 300, 308], ["cells", "CELL", 83, 88], ["Pegg", "CELL", 90, 94], ["ODC", "GENE_OR_GENE_PRODUCT", 149, 152], ["surface membrane", "CELLULAR_COMPONENT", 179, 195], ["mitotic cytoskeleton", "CELLULAR_COMPONENT", 222, 242], ["Antizyme", "SIMPLE_CHEMICAL", 300, 308], ["transformed cells", "CELL_LINE", 71, 88], ["ODC", "PROTEIN", 149, 152], ["Antizyme", "DNA", 300, 308], ["mRNA", "RNA", 335, 339], ["growth stimuli", "TEST", 22, 36], ["constitutively elevated", "PROBLEM", 44, 67], ["some phosphorylated ODC", "PROBLEM", 129, 152], ["mitotic cytoskeleton rearrangement events", "PROBLEM", 222, 263], ["IntroductionAntizyme", "TREATMENT", 288, 308], ["specific frameshifting", "PROBLEM", 375, 397], ["many", "OBSERVATION_MODIFIER", 17, 21], ["growth stimuli", "OBSERVATION", 22, 36], ["elevated", "OBSERVATION_MODIFIER", 59, 67], ["transformed cells", "OBSERVATION", 71, 88], ["phosphorylated ODC", "OBSERVATION", 134, 152], ["important for", "UNCERTAINTY", 208, 221], ["mitotic cytoskeleton rearrangement", "OBSERVATION", 222, 256], ["normal", "OBSERVATION", 439, 445], ["translational errors", "OBSERVATION", 446, 466]]], ["In addition to antizyme, frameshifting is also involved in the decoding of some bacterial and yeast genes and especially in many mammalian Retroviruses and Coronaviruses, plant viruses and bacterial insertion sequences (Atkins et al., 1999).", [["antizyme", "GENE_OR_GENE_PRODUCT", 15, 23], ["mammalian Retroviruses", "ORGANISM", 129, 151], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 156, 169], ["antizyme", "PROTEIN", 15, 23], ["bacterial and yeast genes", "DNA", 80, 105], ["bacterial insertion sequences", "DNA", 189, 218], ["yeast", "SPECIES", 94, 99], ["yeast", "SPECIES", 94, 99], ["antizyme", "TREATMENT", 15, 23], ["frameshifting", "PROBLEM", 25, 38], ["some bacterial and yeast genes", "PROBLEM", 75, 105], ["many mammalian Retroviruses", "PROBLEM", 124, 151], ["Coronaviruses", "PROBLEM", 156, 169], ["bacterial insertion sequences", "TREATMENT", 189, 218], ["frameshifting", "OBSERVATION", 25, 38], ["yeast genes", "OBSERVATION", 94, 105], ["mammalian Retroviruses", "OBSERVATION", 129, 151]]], ["The site of frameshifting in both mammalian antizyme 1 and 2 mRNAs is UCC UGA, where quadruplet translocation occurs at UCCU (underlined) to shift reading to the +1 frame, immediately before the UGA stop codon of the initiating frame (Matsufuji et al., 1995; Ivanov et al., 1998a).", [["antizyme 1", "GENE_OR_GENE_PRODUCT", 44, 54], ["2", "GENE_OR_GENE_PRODUCT", 59, 60], ["mammalian antizyme 1 and 2 mRNAs", "RNA", 34, 66], ["UCC UGA", "RNA", 70, 77], ["UCCU", "DNA", 120, 124], ["+1 frame", "DNA", 162, 170], ["UGA stop codon", "DNA", 195, 209], ["frameshifting in both mammalian antizyme", "TREATMENT", 12, 52], ["UCC UGA", "PROBLEM", 70, 77], ["quadruplet translocation", "PROBLEM", 85, 109], ["the UGA", "TREATMENT", 191, 198], ["frameshifting", "OBSERVATION", 12, 25], ["UCC UGA", "OBSERVATION", 70, 77]]], ["For the frameshifting to occur with an efficiency of 20% or more, it is important that the 3\u2032 base of the quadruplet is the first base of a stop codon.", [["quadruplet", "DNA", 106, 116], ["stop codon", "DNA", 140, 150], ["the frameshifting", "PROBLEM", 4, 21]]], ["Other important features are a pseudoknot just 3\u2032 of the shift site and a specific sequence 5\u2032 of the shift site (Matsufuji et al., 1995; Ivanov et al., 1998a).", [["a specific sequence", "TEST", 72, 91], ["pseudoknot", "OBSERVATION", 31, 41]]], ["A pseudoknot 3\u2032 of the shift site is a common stimulator for eukaryotic \u20131 frameshifting, but the synthesis of antizyme is the only known case utilizing +1 frameshifting.IntroductionComparative analysis of RNA sequences from different organisms is informative about important features and the different options selected by evolution.", [["\u20131", "GENE_OR_GENE_PRODUCT", 72, 74], ["antizyme", "GENE_OR_GENE_PRODUCT", 111, 119], ["pseudoknot 3\u2032 of the shift site", "DNA", 2, 33], ["antizyme", "PROTEIN", 111, 119], ["+1 frameshifting", "DNA", 153, 169], ["RNA sequences", "DNA", 206, 219], ["a common stimulator", "TREATMENT", 37, 56], ["eukaryotic \u20131 frameshifting", "PROBLEM", 61, 88], ["the synthesis of antizyme", "TREATMENT", 94, 119], ["IntroductionComparative analysis", "TEST", 170, 202], ["RNA sequences", "TEST", 206, 219], ["pseudoknot", "OBSERVATION", 2, 12], ["\u20131 frameshifting", "OBSERVATION", 72, 88], ["+1 frameshifting", "OBSERVATION", 153, 169]]], ["Since most of the known examples of programmed frameshifting are in viruses or chromosomal mobile elements, the opportunity for comparison of frameshift cassettes in divergent organisms where the time of divergence can be approximated is limited.", [["chromosomal", "ANATOMY", 79, 90], ["chromosomal", "CELLULAR_COMPONENT", 79, 90], ["chromosomal mobile elements", "DNA", 79, 106], ["frameshift cassettes", "DNA", 142, 162], ["programmed frameshifting", "PROBLEM", 36, 60], ["viruses", "PROBLEM", 68, 75], ["chromosomal mobile elements", "PROBLEM", 79, 106], ["frameshift cassettes in divergent organisms", "PROBLEM", 142, 185], ["programmed frameshifting", "OBSERVATION", 36, 60], ["mobile elements", "OBSERVATION", 91, 106]]], ["A start has been made with the frameshifting required for bacterial release factor 2 expression (Persson and Atkins, 1998), but antizyme provides the first opportunity for such a comparison in eukaryotes.", [["bacterial release factor 2", "GENE_OR_GENE_PRODUCT", 58, 84], ["antizyme", "GENE_OR_GENE_PRODUCT", 128, 136], ["bacterial release factor 2", "PROTEIN", 58, 84], ["antizyme", "PROTEIN", 128, 136], ["the frameshifting", "TREATMENT", 27, 44], ["bacterial release factor", "TREATMENT", 58, 82], ["antizyme", "TREATMENT", 128, 136]]], ["Antizyme genes in genetically tractable lower eukaryotes would be helpful for understanding the functionally important interactions responsible for autoregulatory programmed frameshifting.Identification of an antizyme gene in Schizosaccharomyces pombe ::: ResultsA search for DNA sequences encoding protein sequences homologous to Drosophila melanogaster antizyme (Ivanov et al., 1998b) and Homo sapiens antizyme 1 identified the same S.pombe anonymous cDNA clone (DDBJ/EMBL/GenBank accession No.", [["Antizyme", "GENE_OR_GENE_PRODUCT", 0, 8], ["antizyme", "GENE_OR_GENE_PRODUCT", 209, 217], ["Schizosaccharomyces pombe", "ORGANISM", 226, 251], ["DNA", "CELLULAR_COMPONENT", 276, 279], ["Drosophila melanogaster", "ORGANISM", 331, 354], ["Homo sapiens", "ORGANISM", 391, 403], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 404, 414], ["cDNA clone", "CELL", 453, 463], ["Antizyme genes", "DNA", 0, 14], ["antizyme gene", "DNA", 209, 222], ["DNA sequences", "DNA", 276, 289], ["Drosophila melanogaster antizyme", "PROTEIN", 331, 363], ["Homo sapiens antizyme 1", "PROTEIN", 391, 414], ["S.pombe anonymous cDNA clone", "DNA", 435, 463], ["Schizosaccharomyces pombe", "SPECIES", 226, 251], ["Drosophila melanogaster", "SPECIES", 331, 354], ["Homo sapiens", "SPECIES", 391, 403], ["Schizosaccharomyces pombe", "SPECIES", 226, 251], ["Drosophila melanogaster", "SPECIES", 331, 354], ["Homo sapiens", "SPECIES", 391, 403], ["Antizyme genes", "TREATMENT", 0, 14], ["autoregulatory programmed frameshifting", "PROBLEM", 148, 187], ["an antizyme gene", "TREATMENT", 206, 222], ["DNA sequences", "TEST", 276, 289], ["protein sequences homologous", "TREATMENT", 299, 327], ["Drosophila melanogaster antizyme", "TREATMENT", 331, 363], ["Homo sapiens antizyme", "TREATMENT", 391, 412]]], ["D89228).", [["D89228", "CHEMICAL", 0, 6]]], ["The similarity is limited (\u223c10% identity, 24% similarity to both human antizyme 1 and D.melanogaster antizyme); however, it is highest in regions that are most highly conserved among the previously identified antizymes (Figure 1A).", [["human", "ORGANISM", 65, 70], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 71, 81], ["D.melanogaster antizyme", "GENE_OR_GENE_PRODUCT", 86, 109], ["human antizyme 1", "PROTEIN", 65, 81], ["D.melanogaster antizyme", "PROTEIN", 86, 109], ["antizymes", "PROTEIN", 209, 218], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["both human antizyme", "TREATMENT", 60, 79], ["D.melanogaster antizyme", "TREATMENT", 86, 109], ["highest", "OBSERVATION_MODIFIER", 127, 134]]], ["Closer examination of the cDNA nucleotide sequence provided further evidence that it encodes an S.pombe homolog of antizyme.", [["nucleotide", "CHEMICAL", 31, 41], ["S.pombe homolog", "GENE_OR_GENE_PRODUCT", 96, 111], ["antizyme", "GENE_OR_GENE_PRODUCT", 115, 123], ["cDNA nucleotide sequence", "DNA", 26, 50], ["S.pombe homolog", "PROTEIN", 96, 111], ["antizyme", "PROTEIN", 115, 123], ["Closer examination", "TEST", 0, 18], ["the cDNA nucleotide sequence", "TEST", 22, 50], ["antizyme", "TREATMENT", 115, 123]]], ["The initiating AUG codon for the ORF that is similar to higher eukaryotic antizymes (ORF2 of those genes) is not the 5\u2032-most AUG in this cDNA.", [["antizymes", "GENE_OR_GENE_PRODUCT", 74, 83], ["cDNA", "CELLULAR_COMPONENT", 137, 141], ["AUG codon", "DNA", 15, 24], ["ORF", "DNA", 33, 36], ["eukaryotic antizymes", "DNA", 63, 83], ["ORF2", "DNA", 85, 89], ["5\u2032", "DNA", 117, 119], ["AUG", "DNA", 125, 128], ["cDNA", "DNA", 137, 141], ["AUG codon", "TREATMENT", 15, 24], ["the ORF", "PROBLEM", 29, 36]]], ["In fact, there are eight AUGs closer to the 5\u2032 end.", [["5\u2032 end", "DNA", 44, 50]]], ["The first or the second AUGs would initiate translation of an ORF (ORF1) that overlaps the longer downstream ORF (ORF2) such that a +1 translational frameshifting event in the overlap would generate a protein product analogous to the products of antizyme genes from higher eukaryotes.", [["ORF1", "GENE_OR_GENE_PRODUCT", 67, 71], ["ORF2", "GENE_OR_GENE_PRODUCT", 114, 118], ["antizyme", "GENE_OR_GENE_PRODUCT", 246, 254], ["AUGs", "DNA", 24, 28], ["ORF", "DNA", 62, 65], ["ORF1", "DNA", 67, 71], ["ORF", "DNA", 109, 112], ["ORF2", "DNA", 114, 118], ["+1 translational frameshifting event", "DNA", 132, 168], ["antizyme genes", "DNA", 246, 260], ["an ORF (ORF1", "TREATMENT", 59, 71], ["the longer downstream ORF", "PROBLEM", 87, 112], ["a +1 translational frameshifting event", "PROBLEM", 130, 168], ["a protein product", "TREATMENT", 199, 216], ["antizyme genes", "TREATMENT", 246, 260], ["translational frameshifting", "OBSERVATION", 135, 162]]], ["Furthermore, the last 12 nucleotides of ORF1 (UGG-UGC-UCC-UGA) are identical to the last 12 nucleotides of mammalian antizyme 1 ORF1s, including the frameshift site.", [["nucleotides", "CHEMICAL", 92, 103], ["ORF1", "GENE_OR_GENE_PRODUCT", 40, 44], ["UGG-UGC-UCC-UGA", "GENE_OR_GENE_PRODUCT", 46, 61], ["antizyme 1 ORF1s", "GENE_OR_GENE_PRODUCT", 117, 133], ["ORF1", "DNA", 40, 44], ["UGG", "DNA", 46, 49], ["UGC", "DNA", 50, 53], ["UCC", "DNA", 54, 57], ["UGA", "DNA", 58, 61], ["mammalian antizyme 1 ORF1s", "DNA", 107, 133], ["frameshift site", "DNA", 149, 164], ["ORF1", "TEST", 40, 44], ["UGG", "TEST", 46, 49], ["UGC", "TEST", 50, 53], ["mammalian antizyme", "TREATMENT", 107, 125], ["the frameshift site", "PROBLEM", 145, 164], ["frameshift site", "OBSERVATION", 149, 164]]], ["Eleven of these 12 nucleotides are identical to the corresponding regions of all previously identified antizyme genes (Figure 1B).", [["nucleotides", "CHEMICAL", 19, 30], ["antizyme", "GENE_OR_GENE_PRODUCT", 103, 111], ["antizyme genes", "DNA", 103, 117], ["antizyme genes", "OBSERVATION", 103, 117]]], ["Previous experiments with the mammalian frameshift sequence tested in S.pombe have shown that this short 12 nucleotide sequence, by itself, is sufficient to stimulate measurable levels (up to 0.5%) of +1 frameshifting (Ivanov et al., 1998c).", [["nucleotide", "CHEMICAL", 108, 118], ["nucleotide", "CHEMICAL", 108, 118], ["mammalian frameshift sequence", "DNA", 30, 59], ["short 12 nucleotide sequence", "DNA", 99, 127], ["the mammalian frameshift sequence", "TEST", 26, 59], ["this short 12 nucleotide sequence", "PROBLEM", 94, 127]]], ["To confirm the ORF configuration of the putative S.pombe antizyme gene, a region corresponding to the two overlapping ORFs plus \u223c80 nucleotides of the 5\u2032 UTR and 370 nucleotides of the 3\u2032 UTR, was amplified from both S.pombe genomic DNA and a cDNA library.", [["nucleotides", "CHEMICAL", 132, 143], ["nucleotides", "CHEMICAL", 166, 177], ["S.pombe antizyme", "GENE_OR_GENE_PRODUCT", 49, 65], ["DNA", "CELLULAR_COMPONENT", 233, 236], ["ORF", "DNA", 15, 18], ["S.pombe antizyme gene", "DNA", 49, 70], ["ORFs", "DNA", 118, 122], ["UTR", "DNA", 154, 157], ["UTR", "DNA", 188, 191], ["S.pombe genomic DNA", "DNA", 217, 236], ["cDNA library", "DNA", 243, 255], ["UTR", "TEST", 154, 157], ["nucleotides", "TEST", 166, 177], ["a cDNA library", "TREATMENT", 241, 255]]], ["The sequence of the amplified DNA confirmed that there are indeed two overlapping ORFs with the deduced configuration.", [["DNA", "CELLULAR_COMPONENT", 30, 33], ["amplified DNA", "DNA", 20, 33], ["ORFs", "DNA", 82, 86], ["the amplified DNA", "TEST", 16, 33], ["overlapping", "OBSERVATION_MODIFIER", 70, 81], ["ORFs", "OBSERVATION", 82, 86], ["deduced configuration", "OBSERVATION", 96, 117]]], ["This sequence (DDBJ/EMBL/GenBank accession No.", [["This sequence", "TEST", 0, 13]]], ["AF217277) differs from the previously sequenced cDNA clone by three nucleotides (two in the coding region and one in the 3\u2032 UTR); one changes an alanine codon to proline, another is a silent mutation within a proline codon.", [["AF217277", "CHEMICAL", 0, 8], ["alanine", "CHEMICAL", 145, 152], ["proline", "CHEMICAL", 162, 169], ["nucleotides", "CHEMICAL", 68, 79], ["alanine", "CHEMICAL", 145, 152], ["proline", "CHEMICAL", 162, 169], ["proline", "CHEMICAL", 209, 216], ["cDNA clone", "CELL", 48, 58], ["alanine", "AMINO_ACID", 145, 152], ["proline", "AMINO_ACID", 162, 169], ["cDNA clone", "DNA", 48, 58], ["coding region", "DNA", 92, 105], ["3\u2032 UTR", "DNA", 121, 127], ["proline codon", "DNA", 209, 222], ["an alanine codon to proline", "TREATMENT", 142, 169], ["a silent mutation", "PROBLEM", 182, 199], ["a proline codon", "TREATMENT", 207, 222], ["alanine codon", "OBSERVATION", 145, 158], ["proline codon", "OBSERVATION", 209, 222]]], ["Since the sequences from the cDNA library and genomic DNA are identical, we conclude that the differences with clone No.", [["DNA", "CELLULAR_COMPONENT", 54, 57], ["cDNA library", "DNA", 29, 41], ["genomic DNA", "DNA", 46, 57], ["the sequences", "TEST", 6, 19], ["the cDNA library", "TEST", 25, 41]]], ["D89228 are most likely due to strain variation.", [["D89228", "CHEMICAL", 0, 6], ["D89228", "SIMPLE_CHEMICAL", 0, 6], ["strain variation", "PROBLEM", 30, 46], ["most likely due to", "UNCERTAINTY", 11, 29], ["strain variation", "OBSERVATION", 30, 46]]], ["This gene contains no introns within the amplified region.Identification of an antizyme gene in Schizosaccharomyces pombe ::: ResultsThe S.pombe protein was tested for antizyme activity using a gene fusion with glutathione S-transferase (GST).", [["glutathione", "CHEMICAL", 211, 222], ["glutathione", "CHEMICAL", 211, 222], ["S", "CHEMICAL", 223, 224], ["antizyme", "GENE_OR_GENE_PRODUCT", 79, 87], ["Schizosaccharomyces pombe", "ORGANISM", 96, 121], ["S.pombe", "GENE_OR_GENE_PRODUCT", 137, 144], ["antizyme", "GENE_OR_GENE_PRODUCT", 168, 176], ["glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 211, 236], ["GST", "GENE_OR_GENE_PRODUCT", 238, 241], ["introns", "DNA", 22, 29], ["amplified region", "DNA", 41, 57], ["antizyme gene", "DNA", 79, 92], ["S.pombe protein", "PROTEIN", 137, 152], ["antizyme", "PROTEIN", 168, 176], ["glutathione S-transferase", "PROTEIN", 211, 236], ["GST", "PROTEIN", 238, 241], ["Schizosaccharomyces pombe", "SPECIES", 96, 121], ["Schizosaccharomyces pombe", "SPECIES", 96, 121], ["introns within the amplified region", "PROBLEM", 22, 57], ["The S.pombe protein", "TEST", 133, 152], ["antizyme activity", "TREATMENT", 168, 185], ["a gene fusion", "TREATMENT", 192, 205], ["glutathione S", "TREATMENT", 211, 224], ["no introns", "OBSERVATION", 19, 29]]], ["In this construct, ORF1 and ORF2 of antizyme are fused in-frame by deleting the T nucleotide that encodes U of the stop codon of ORF1.", [["nucleotide", "CHEMICAL", 82, 92], ["ORF1", "GENE_OR_GENE_PRODUCT", 19, 23], ["ORF2", "GENE_OR_GENE_PRODUCT", 28, 32], ["antizyme", "GENE_OR_GENE_PRODUCT", 36, 44], ["U", "GENE_OR_GENE_PRODUCT", 106, 107], ["ORF1", "GENE_OR_GENE_PRODUCT", 129, 133], ["ORF1", "DNA", 19, 23], ["ORF2", "DNA", 28, 32], ["antizyme", "DNA", 36, 44], ["T nucleotide", "DNA", 80, 92], ["U of the stop codon", "DNA", 106, 125], ["ORF1", "DNA", 129, 133], ["ORF1", "TREATMENT", 19, 23], ["ORF2 of antizyme", "TREATMENT", 28, 44], ["the T nucleotide", "TREATMENT", 76, 92]]], ["This GST\u2013antizyme fusion gene was expressed in Escherichia coli and the protein was purified by affinity chromatography.", [["GST\u2013antizyme", "CHEMICAL", 5, 17], ["GST\u2013antizyme", "GENE_OR_GENE_PRODUCT", 5, 17], ["Escherichia coli", "ORGANISM", 47, 63], ["GST\u2013antizyme fusion gene", "DNA", 5, 29], ["Escherichia coli", "SPECIES", 47, 63], ["Escherichia coli", "SPECIES", 47, 63], ["This GST\u2013antizyme fusion gene", "TREATMENT", 0, 29], ["Escherichia coli", "PROBLEM", 47, 63], ["the protein", "TEST", 68, 79], ["affinity chromatography", "TEST", 96, 119], ["Escherichia coli", "OBSERVATION", 47, 63]]], ["ODC inhibitory activity was tested by incubating the recombinant antizyme protein with an S.pombe crude extract and then assaying the mixture for ODC activity.", [["extract", "ANATOMY", 104, 111], ["ODC", "GENE_OR_GENE_PRODUCT", 0, 3], ["antizyme", "GENE_OR_GENE_PRODUCT", 65, 73], ["ODC", "SIMPLE_CHEMICAL", 146, 149], ["ODC", "PROTEIN", 0, 3], ["recombinant antizyme protein", "PROTEIN", 53, 81], ["ODC", "PROTEIN", 146, 149], ["ODC inhibitory activity", "PROBLEM", 0, 23], ["the recombinant antizyme protein", "TREATMENT", 49, 81], ["an S.pombe crude extract", "TREATMENT", 87, 111], ["ODC activity", "PROBLEM", 146, 158]]], ["The results (Figure 2) show that the recombinant protein can inhibit S.pombe ODC.", [["S.pombe ODC", "GENE_OR_GENE_PRODUCT", 69, 80], ["recombinant protein", "PROTEIN", 37, 56], ["the recombinant protein", "PROBLEM", 33, 56]]], ["GST alone (1 \u00b5g) does not inhibit S.pombe ODC (data not shown).", [["GST", "GENE_OR_GENE_PRODUCT", 0, 3], ["GST", "PROTEIN", 0, 3]]], ["In light of these results, the S.pombe gene will be called S.pombe ODC antizyme (SPA).", [["S.pombe", "GENE_OR_GENE_PRODUCT", 31, 38], ["S.pombe ODC antizyme", "GENE_OR_GENE_PRODUCT", 59, 79], ["S.pombe gene", "DNA", 31, 43], ["S.pombe ODC antizyme", "PROTEIN", 59, 79], ["SPA", "PROTEIN", 81, 84]]], ["Interestingly, the S.pombe ODC was also inhibited by mouse antizyme 1 and antizyme 2 (both expressed as GST fusions); however, the yeast fusion protein did not inhibit mouse ODC (data not shown).Deletion and overexpression of SPA ::: ResultsAlthough the effects of overexpression of antizyme on cellular physiology have been tested previously in mammalian cells, the physiological changes associated with complete absence of antizyme activity have not yet been investigated because of the complication of multiple antizymes.", [["cellular", "ANATOMY", 295, 303], ["cells", "ANATOMY", 356, 361], ["S.pombe ODC", "GENE_OR_GENE_PRODUCT", 19, 30], ["mouse", "ORGANISM", 53, 58], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 59, 69], ["antizyme 2", "GENE_OR_GENE_PRODUCT", 74, 84], ["GST", "GENE_OR_GENE_PRODUCT", 104, 107], ["mouse", "ORGANISM", 168, 173], ["ODC", "GENE_OR_GENE_PRODUCT", 174, 177], ["antizyme", "GENE_OR_GENE_PRODUCT", 283, 291], ["cellular", "CELL", 295, 303], ["mammalian cells", "CELL", 346, 361], ["antizyme", "GENE_OR_GENE_PRODUCT", 425, 433], ["antizymes", "GENE_OR_GENE_PRODUCT", 514, 523], ["S.pombe ODC", "PROTEIN", 19, 30], ["mouse antizyme 1", "PROTEIN", 53, 69], ["antizyme 2", "PROTEIN", 74, 84], ["GST fusions", "PROTEIN", 104, 115], ["yeast fusion protein", "PROTEIN", 131, 151], ["mouse ODC", "PROTEIN", 168, 177], ["SPA", "PROTEIN", 226, 229], ["antizyme", "PROTEIN", 283, 291], ["mammalian cells", "CELL_TYPE", 346, 361], ["antizyme", "PROTEIN", 425, 433], ["mouse", "SPECIES", 53, 58], ["yeast", "SPECIES", 131, 136], ["mouse", "SPECIES", 168, 173], ["mouse", "SPECIES", 53, 58], ["yeast", "SPECIES", 131, 136], ["mouse", "SPECIES", 168, 173], ["mouse antizyme", "TREATMENT", 53, 67], ["antizyme 2", "TREATMENT", 74, 84], ["GST fusions", "TEST", 104, 115], ["the yeast fusion protein", "TEST", 127, 151], ["overexpression of antizyme on cellular physiology", "PROBLEM", 265, 314], ["the physiological changes", "PROBLEM", 363, 388], ["antizyme activity", "PROBLEM", 425, 442], ["multiple antizymes", "TREATMENT", 505, 523], ["SPA", "ANATOMY", 226, 229]]], ["The single S.pombe antizyme provides the chance to explore a knockout.", [["S.pombe antizyme", "PROTEIN", 11, 27], ["The single S.pombe antizyme", "TREATMENT", 0, 27]]], ["SPA deletion strains were generated by replacing the two ORFs of the gene with the ORFs of either URA4 or LEU2 (see Materials and methods).", [["SPA", "GENE_OR_GENE_PRODUCT", 0, 3], ["LEU2", "GENE_OR_GENE_PRODUCT", 106, 110], ["ORFs", "DNA", 57, 61], ["ORFs", "DNA", 83, 87], ["URA4", "DNA", 98, 102], ["LEU2", "DNA", 106, 110], ["SPA deletion strains", "PROBLEM", 0, 20]]], ["Complete deletion of SPA (both ORFs) did not affect the viability of S.pombe cells in rich (YE) or minimal (MM) media.", [["S.pombe cells", "ANATOMY", 69, 82], ["MM", "ANATOMY", 108, 110], ["SPA", "GENE_OR_GENE_PRODUCT", 21, 24], ["S.pombe cells", "CELL", 69, 82], ["SPA", "DNA", 21, 24], ["ORFs", "DNA", 31, 35], ["S.pombe cells", "CELL_LINE", 69, 82], ["Complete deletion of SPA", "PROBLEM", 0, 24], ["minimal (MM) media", "PROBLEM", 99, 117], ["SPA", "ANATOMY", 21, 24]]], ["Temperature had no differential effect on mutant and wild-type cell growth.", [["cell", "ANATOMY", 63, 67], ["cell", "CELL", 63, 67], ["Temperature", "TEST", 0, 11], ["differential effect", "PROBLEM", 19, 38], ["type cell growth", "PROBLEM", 58, 74], ["no", "UNCERTAINTY", 16, 18], ["differential", "OBSERVATION_MODIFIER", 19, 31]]], ["Similarly, the growth rates, mating efficiencies and overall morphology of the knockout strains are apparently indistinguishable from those of wild-type cells (results not shown).Deletion and overexpression of SPA ::: ResultsIn wild-type S.pombe cells the most abundant polyamine is spermidine followed by putrescine (Figure 3).", [["cells", "ANATOMY", 153, 158], ["S.pombe cells", "ANATOMY", 238, 251], ["polyamine", "CHEMICAL", 270, 279], ["spermidine", "CHEMICAL", 283, 293], ["putrescine", "CHEMICAL", 306, 316], ["polyamine", "CHEMICAL", 270, 279], ["spermidine", "CHEMICAL", 283, 293], ["putrescine", "CHEMICAL", 306, 316], ["cells", "CELL", 153, 158], ["S.pombe cells", "CELL", 238, 251], ["polyamine", "SIMPLE_CHEMICAL", 270, 279], ["spermidine", "SIMPLE_CHEMICAL", 283, 293], ["putrescine", "SIMPLE_CHEMICAL", 306, 316], ["wild-type cells", "CELL_TYPE", 143, 158], ["SPA", "PROTEIN", 210, 213], ["wild-type S.pombe cells", "CELL_LINE", 228, 251], ["the growth rates", "PROBLEM", 11, 27], ["mating efficiencies", "PROBLEM", 29, 48], ["the knockout strains", "PROBLEM", 75, 95], ["type S.pombe cells", "PROBLEM", 233, 251], ["growth", "OBSERVATION_MODIFIER", 15, 21], ["rates", "OBSERVATION_MODIFIER", 22, 27], ["knockout strains", "OBSERVATION", 79, 95], ["SPA", "ANATOMY", 210, 213]]], ["Spermine and cadaverine are found in much smaller amounts.", [["Spermine", "CHEMICAL", 0, 8], ["cadaverine", "CHEMICAL", 13, 23], ["Spermine", "CHEMICAL", 0, 8], ["cadaverine", "CHEMICAL", 13, 23], ["Spermine", "SIMPLE_CHEMICAL", 0, 8], ["cadaverine", "SIMPLE_CHEMICAL", 13, 23], ["Spermine", "TREATMENT", 0, 8], ["cadaverine", "TREATMENT", 13, 23], ["cadaverine", "OBSERVATION", 13, 23], ["much smaller", "OBSERVATION_MODIFIER", 37, 49], ["amounts", "OBSERVATION_MODIFIER", 50, 57]]], ["This distribution of polyamine content is very similar to that in other fungi for which polyamine concentrations have been measured (for references, see review by Tabor and Tabor, 1985).", [["polyamine", "CHEMICAL", 21, 30], ["polyamine", "CHEMICAL", 88, 97], ["polyamine", "CHEMICAL", 21, 30], ["polyamine", "CHEMICAL", 88, 97], ["polyamine", "SIMPLE_CHEMICAL", 21, 30], ["polyamine", "SIMPLE_CHEMICAL", 88, 97], ["polyamine content", "PROBLEM", 21, 38], ["polyamine concentrations", "PROBLEM", 88, 112], ["polyamine content", "OBSERVATION", 21, 38]]], ["The effect of SPA deletion on cellular polyamine contents was examined in both exponentially growing and stationary phase cells (Figure 3).", [["cellular", "ANATOMY", 30, 38], ["cells", "ANATOMY", 122, 127], ["polyamine", "CHEMICAL", 39, 48], ["polyamine", "CHEMICAL", 39, 48], ["SPA", "GENE_OR_GENE_PRODUCT", 14, 17], ["cellular", "CELL", 30, 38], ["polyamine", "SIMPLE_CHEMICAL", 39, 48], ["cells", "CELL", 122, 127], ["SPA deletion", "DNA", 14, 26], ["stationary phase cells", "CELL_TYPE", 105, 127], ["SPA deletion", "PROBLEM", 14, 26], ["cellular polyamine contents", "PROBLEM", 30, 57], ["SPA deletion", "OBSERVATION", 14, 26], ["polyamine contents", "OBSERVATION", 39, 57]]], ["The cellular concentrations of putrescine, spermidine and cadaverine (but not spermine) were higher in the knockout strains than in wild-type cells.", [["cellular", "ANATOMY", 4, 12], ["wild-type cells", "ANATOMY", 132, 147], ["putrescine", "CHEMICAL", 31, 41], ["spermidine", "CHEMICAL", 43, 53], ["cadaverine", "CHEMICAL", 58, 68], ["spermine", "CHEMICAL", 78, 86], ["putrescine", "CHEMICAL", 31, 41], ["spermidine", "CHEMICAL", 43, 53], ["cadaverine", "CHEMICAL", 58, 68], ["spermine", "CHEMICAL", 78, 86], ["cellular", "CELL", 4, 12], ["putrescine", "SIMPLE_CHEMICAL", 31, 41], ["spermidine", "SIMPLE_CHEMICAL", 43, 53], ["cadaverine", "SIMPLE_CHEMICAL", 58, 68], ["spermine", "SIMPLE_CHEMICAL", 78, 86], ["cells", "CELL", 142, 147], ["wild-type cells", "CELL_TYPE", 132, 147], ["putrescine", "TREATMENT", 31, 41], ["spermidine", "TREATMENT", 43, 53], ["cadaverine", "TREATMENT", 58, 68], ["the knockout strains", "PROBLEM", 103, 123], ["cellular", "OBSERVATION_MODIFIER", 4, 12], ["concentrations", "OBSERVATION_MODIFIER", 13, 27], ["higher", "OBSERVATION_MODIFIER", 93, 99], ["type cells", "OBSERVATION", 137, 147]]], ["The greatest effect was seen on putrescine and cadaverine content, with smaller effects on spermidine, presumably because eukaryotic ODC activity directly catalyzes decarboxylation of both ornithine and lysine to produce putrescine and cadaverine, respectively (Pegg and McGill, 1979), but subsequent regulatory events affect homeostasis of spermidine and spermine.", [["putrescine", "CHEMICAL", 32, 42], ["cadaverine", "CHEMICAL", 47, 57], ["spermidine", "CHEMICAL", 91, 101], ["ornithine", "CHEMICAL", 189, 198], ["lysine", "CHEMICAL", 203, 209], ["putrescine", "CHEMICAL", 221, 231], ["cadaverine", "CHEMICAL", 236, 246], ["spermidine", "CHEMICAL", 341, 351], ["spermine", "CHEMICAL", 356, 364], ["putrescine", "CHEMICAL", 32, 42], ["cadaverine", "CHEMICAL", 47, 57], ["spermidine", "CHEMICAL", 91, 101], ["ornithine", "CHEMICAL", 189, 198], ["lysine", "CHEMICAL", 203, 209], ["putrescine", "CHEMICAL", 221, 231], ["cadaverine", "CHEMICAL", 236, 246], ["spermidine", "CHEMICAL", 341, 351], ["spermine", "CHEMICAL", 356, 364], ["putrescine", "SIMPLE_CHEMICAL", 32, 42], ["cadaverine", "SIMPLE_CHEMICAL", 47, 57], ["spermidine", "SIMPLE_CHEMICAL", 91, 101], ["ODC", "GENE_OR_GENE_PRODUCT", 133, 136], ["ornithine", "SIMPLE_CHEMICAL", 189, 198], ["lysine", "AMINO_ACID", 203, 209], ["putrescine", "SIMPLE_CHEMICAL", 221, 231], ["cadaverine", "SIMPLE_CHEMICAL", 236, 246], ["spermidine", "SIMPLE_CHEMICAL", 341, 351], ["spermine", "SIMPLE_CHEMICAL", 356, 364], ["ODC", "PROTEIN", 133, 136], ["putrescine", "TREATMENT", 32, 42], ["spermidine", "TREATMENT", 91, 101], ["eukaryotic ODC activity", "PROBLEM", 122, 145], ["both ornithine and lysine", "TREATMENT", 184, 209], ["putrescine and cadaverine", "TREATMENT", 221, 246], ["spermidine and spermine", "TREATMENT", 341, 364], ["greatest", "OBSERVATION_MODIFIER", 4, 12], ["effect", "OBSERVATION_MODIFIER", 13, 19], ["cadaverine content", "OBSERVATION", 47, 65], ["smaller", "OBSERVATION_MODIFIER", 72, 79]]], ["The effect of inactivating antizyme on the polyamine contents in exponentially growing cells is modest (<2-fold in all cases).", [["cells", "ANATOMY", 87, 92], ["polyamine", "CHEMICAL", 43, 52], ["polyamine", "CHEMICAL", 43, 52], ["antizyme", "GENE_OR_GENE_PRODUCT", 27, 35], ["polyamine", "SIMPLE_CHEMICAL", 43, 52], ["cells", "CELL", 87, 92], ["inactivating antizyme", "PROTEIN", 14, 35], ["inactivating antizyme", "PROBLEM", 14, 35], ["the polyamine contents", "TEST", 39, 61], ["exponentially growing cells", "PROBLEM", 65, 92], ["polyamine contents", "OBSERVATION", 43, 61], ["exponentially", "OBSERVATION_MODIFIER", 65, 78], ["growing cells", "OBSERVATION", 79, 92], ["modest", "OBSERVATION_MODIFIER", 96, 102]]], ["The effect becomes very pronounced in cells in stationary phase with up to 40- and 10-fold increases of putrescine and cadaverine contents, respectively, in the knockout strains.Deletion and overexpression of SPA ::: ResultsTo test overexpression of SPA, two versions of the gene were cloned into pREP3 expression vector behind a strong, thiamine-repressible promoter (nmt1).", [["cells", "ANATOMY", 38, 43], ["putrescine", "CHEMICAL", 104, 114], ["cadaverine", "CHEMICAL", 119, 129], ["thiamine", "CHEMICAL", 338, 346], ["putrescine", "CHEMICAL", 104, 114], ["cadaverine", "CHEMICAL", 119, 129], ["thiamine", "CHEMICAL", 338, 346], ["cells", "CELL", 38, 43], ["putrescine", "SIMPLE_CHEMICAL", 104, 114], ["cadaverine", "SIMPLE_CHEMICAL", 119, 129], ["SPA", "GENE_OR_GENE_PRODUCT", 250, 253], ["pREP3", "GENE_OR_GENE_PRODUCT", 297, 302], ["thiamine", "SIMPLE_CHEMICAL", 338, 346], ["SPA", "PROTEIN", 209, 212], ["SPA", "PROTEIN", 250, 253], ["pREP3 expression vector", "DNA", 297, 320], ["thiamine-repressible promoter", "DNA", 338, 367], ["nmt1", "DNA", 369, 373], ["putrescine and cadaverine contents", "PROBLEM", 104, 138], ["thiamine-repressible promoter", "TREATMENT", 338, 367], ["very", "OBSERVATION_MODIFIER", 19, 23], ["pronounced", "OBSERVATION_MODIFIER", 24, 34], ["cadaverine contents", "OBSERVATION", 119, 138], ["SPA", "ANATOMY", 209, 212]]], ["One had the wild-type SPA sequence while in the second, ORF1 and ORF2 are fused in-frame.", [["ORF1", "GENE_OR_GENE_PRODUCT", 56, 60], ["ORF2", "GENE_OR_GENE_PRODUCT", 65, 69], ["wild-type SPA sequence", "DNA", 12, 34], ["ORF1", "DNA", 56, 60], ["ORF2", "DNA", 65, 69], ["the wild-type SPA sequence", "PROBLEM", 8, 34], ["ORF1 and ORF2", "TREATMENT", 56, 69]]], ["SPA wild type and an SPA deletion strain were transformed with each of the overexpression constructs.", [["SPA", "GENE_OR_GENE_PRODUCT", 21, 24], ["overexpression constructs", "DNA", 75, 100], ["an SPA deletion strain", "PROBLEM", 18, 40], ["the overexpression constructs", "TREATMENT", 71, 100]]], ["Derepression of the nmt1 promoter is a gradual process since it requires dilution of the intracellular pool of thiamine (the repressor) through cell division.", [["intracellular", "ANATOMY", 89, 102], ["cell", "ANATOMY", 144, 148], ["thiamine", "CHEMICAL", 111, 119], ["thiamine", "CHEMICAL", 111, 119], ["nmt1", "GENE_OR_GENE_PRODUCT", 20, 24], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 89, 102], ["thiamine", "SIMPLE_CHEMICAL", 111, 119], ["cell", "CELL", 144, 148], ["nmt1 promoter", "DNA", 20, 33], ["the intracellular pool of thiamine", "TREATMENT", 85, 119]]], ["After 2.5 days of exponential growth under derepressed conditions, yeast strains transformed with either SPA overexpression construct show significant increases in doubling time (Figure 4A).", [["SPA", "GENE_OR_GENE_PRODUCT", 105, 108], ["SPA overexpression construct", "DNA", 105, 133], ["yeast", "SPECIES", 67, 72], ["yeast", "SPECIES", 67, 72], ["exponential growth under derepressed conditions", "PROBLEM", 18, 65], ["yeast strains", "PROBLEM", 67, 80], ["SPA overexpression construct", "TEST", 105, 133], ["significant", "OBSERVATION_MODIFIER", 139, 150], ["increases", "OBSERVATION_MODIFIER", 151, 160]]], ["The growth inhibition is greater with the construct expressing the in-frame version of SPA and after prolonged incubation (5\u20137 days); these cells cease growth and accumulate in G1 as determined by flow cytometry (data not shown).", [["cells", "ANATOMY", 140, 145], ["SPA", "GENE_OR_GENE_PRODUCT", 87, 90], ["cells", "CELL", 140, 145], ["SPA", "PROTEIN", 87, 90], ["prolonged incubation", "TREATMENT", 101, 121], ["these cells", "PROBLEM", 134, 145], ["flow cytometry", "TEST", 197, 211], ["growth", "OBSERVATION_MODIFIER", 4, 10], ["inhibition", "OBSERVATION_MODIFIER", 11, 21], ["greater", "OBSERVATION_MODIFIER", 25, 32]]], ["The fact that the in-frame overexpression construct, which differs by a single nucleotide from the wild-type construct, confers a more severe phenotype is consistent with the hypothesis that translational frameshifting is required for expression of SPA.", [["nucleotide", "CHEMICAL", 79, 89], ["nucleotide", "CHEMICAL", 79, 89], ["SPA", "GENE_OR_GENE_PRODUCT", 249, 252], ["in-frame overexpression construct", "DNA", 18, 51], ["wild-type construct", "DNA", 99, 118], ["SPA", "PROTEIN", 249, 252], ["a more severe phenotype", "PROBLEM", 128, 151], ["translational frameshifting", "PROBLEM", 191, 218], ["consistent with", "UNCERTAINTY", 155, 170], ["translational frameshifting", "OBSERVATION", 191, 218]]], ["The growth phenotype associated with SPA overexpression is only partially relieved by adding 100 \u00b5M putrescine to the media (1 mM had no further effect) (data not shown).", [["putrescine", "CHEMICAL", 100, 110], ["putrescine", "CHEMICAL", 100, 110], ["SPA", "GENE_OR_GENE_PRODUCT", 37, 40], ["putrescine", "SIMPLE_CHEMICAL", 100, 110], ["SPA", "PROTEIN", 37, 40], ["The growth phenotype", "PROBLEM", 0, 20], ["SPA overexpression", "PROBLEM", 37, 55], ["growth phenotype", "OBSERVATION", 4, 20]]], ["To see whether the slower growth is correlated with aberrant polyamine levels the polyamine contents of the deletion strain carrying in-frame SPA overexpression vector were measured under derepressed and repressed conditions, in both cases after 2 days of exponential growth (Figure 4B).", [["polyamine", "CHEMICAL", 61, 70], ["polyamine", "CHEMICAL", 82, 91], ["polyamine", "CHEMICAL", 61, 70], ["polyamine", "CHEMICAL", 82, 91], ["polyamine", "SIMPLE_CHEMICAL", 61, 70], ["polyamine", "SIMPLE_CHEMICAL", 82, 91], ["SPA", "GENE_OR_GENE_PRODUCT", 142, 145], ["SPA overexpression vector", "DNA", 142, 167], ["the slower growth", "PROBLEM", 15, 32], ["aberrant polyamine levels the polyamine contents", "PROBLEM", 52, 100], ["the deletion strain", "PROBLEM", 104, 123], ["frame SPA overexpression vector", "TREATMENT", 136, 167], ["exponential growth", "PROBLEM", 256, 274], ["polyamine levels", "OBSERVATION", 61, 77], ["polyamine contents", "OBSERVATION", 82, 100]]], ["As expected, overexpression of SPA results in significant reduction in the intracellular levels of all four polyamines.", [["intracellular", "ANATOMY", 75, 88], ["polyamines", "CHEMICAL", 108, 118], ["SPA", "GENE_OR_GENE_PRODUCT", 31, 34], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 88], ["polyamines", "SIMPLE_CHEMICAL", 108, 118], ["SPA", "PROTEIN", 31, 34], ["overexpression of SPA", "PROBLEM", 13, 34], ["significant reduction", "PROBLEM", 46, 67], ["the intracellular levels", "TEST", 71, 95], ["all four polyamines", "TREATMENT", 99, 118], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["reduction", "OBSERVATION_MODIFIER", 58, 67]]], ["After longer (4\u20135 days) incubation under derepressed conditions, no putrescine and cadaverine can be detected (data not shown).Translational frameshifting during expression of SPA ::: ResultsPreviously, we developed an assay for measuring antizyme translational frameshifting in both S.cerevisiae (Matsufuji et al., 1996) and S.pombe (Ivanov et al., 1998c).", [["putrescine", "CHEMICAL", 68, 78], ["cadaverine", "CHEMICAL", 83, 93], ["putrescine", "CHEMICAL", 68, 78], ["cadaverine", "CHEMICAL", 83, 93], ["putrescine", "SIMPLE_CHEMICAL", 68, 78], ["cadaverine", "SIMPLE_CHEMICAL", 83, 93], ["antizyme", "GENE_OR_GENE_PRODUCT", 239, 247], ["SPA", "PROTEIN", 176, 179], ["antizyme", "PROTEIN", 239, 247], ["putrescine", "TREATMENT", 68, 78], ["cadaverine", "TREATMENT", 83, 93], ["an assay", "TEST", 216, 224], ["measuring antizyme translational frameshifting", "TREATMENT", 229, 275], ["frameshifting", "OBSERVATION", 141, 154]]], ["Briefly, the nucleotide sequence to be assayed is inserted between GST and lacZ, such that ORF1 of the assayed sequence is fused in-frame to GST, while ORF2 is fused in-frame to lacZ. \u03b2-galactosidase activity provides a measure of frameshifting efficiency.", [["nucleotide", "CHEMICAL", 13, 23], ["nucleotide", "CHEMICAL", 13, 23], ["GST", "GENE_OR_GENE_PRODUCT", 67, 70], ["lacZ", "GENE_OR_GENE_PRODUCT", 75, 79], ["ORF1", "GENE_OR_GENE_PRODUCT", 91, 95], ["GST", "GENE_OR_GENE_PRODUCT", 141, 144], ["ORF2", "GENE_OR_GENE_PRODUCT", 152, 156], ["lacZ", "GENE_OR_GENE_PRODUCT", 178, 182], ["\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 184, 199], ["GST", "PROTEIN", 67, 70], ["lacZ", "DNA", 75, 79], ["ORF1", "DNA", 91, 95], ["assayed sequence", "DNA", 103, 119], ["GST", "DNA", 141, 144], ["ORF2", "DNA", 152, 156], ["lacZ", "DNA", 178, 182], ["the nucleotide sequence", "TEST", 9, 32], ["lacZ", "TREATMENT", 75, 79], ["the assayed sequence", "TEST", 99, 119], ["ORF2", "TEST", 152, 156], ["galactosidase activity", "PROBLEM", 186, 208], ["frameshifting efficiency", "PROBLEM", 231, 255], ["frameshifting efficiency", "OBSERVATION", 231, 255]]], ["To determine whether translational frameshifting occurs in the overlap of ORF1 and ORF2 of SPA, a region of SPA including all but the first codon of ORF1 plus 180 nucleotides downstream of the ORF1 stop codon was tested. +1 frameshifting occurred at 2.2% compared with a construct in which ORF1 and ORF2 are fused in-frame.", [["nucleotides", "CHEMICAL", 163, 174], ["ORF1", "GENE_OR_GENE_PRODUCT", 74, 78], ["ORF2", "GENE_OR_GENE_PRODUCT", 83, 87], ["SPA", "GENE_OR_GENE_PRODUCT", 91, 94], ["SPA", "GENE_OR_GENE_PRODUCT", 108, 111], ["ORF1", "GENE_OR_GENE_PRODUCT", 149, 153], ["ORF1", "GENE_OR_GENE_PRODUCT", 290, 294], ["ORF2", "GENE_OR_GENE_PRODUCT", 299, 303], ["ORF1", "DNA", 74, 78], ["ORF2", "DNA", 83, 87], ["SPA", "DNA", 91, 94], ["SPA", "DNA", 108, 111], ["ORF1", "DNA", 149, 153], ["180 nucleotides downstream", "DNA", 159, 185], ["ORF1 stop codon", "DNA", 193, 208], ["ORF1", "DNA", 290, 294], ["ORF2", "DNA", 299, 303], ["translational frameshifting", "PROBLEM", 21, 48], ["ORF1", "TREATMENT", 74, 78], ["ORF1", "TEST", 149, 153], ["nucleotides downstream", "TEST", 163, 185], ["the ORF1 stop codon", "TREATMENT", 189, 208], ["+1 frameshifting", "PROBLEM", 221, 237], ["ORF1", "TEST", 290, 294], ["ORF2", "TEST", 299, 303], ["translational frameshifting", "OBSERVATION", 21, 48], ["SPA", "ANATOMY", 91, 94], ["SPA", "ANATOMY", 108, 111], ["ORF1", "ANATOMY", 193, 197], ["stop codon", "OBSERVATION", 198, 208], ["frameshifting", "OBSERVATION", 224, 237]]], ["This result is consistent with +1 frameshifting being crucial for expression of SPA.Translational frameshifting during expression of SPA ::: ResultsPrevious experiments have shown that the frameshift cassette of mammalian antizyme 1 can direct efficient +1 frameshifting when tested in S.pombe.", [["SPA", "GENE_OR_GENE_PRODUCT", 80, 83], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 222, 232], ["SPA", "PROTEIN", 80, 83], ["SPA", "PROTEIN", 133, 136], ["frameshift cassette", "DNA", 189, 208], ["mammalian antizyme 1", "PROTEIN", 212, 232], ["+1 frameshifting", "PROBLEM", 31, 47], ["mammalian antizyme", "TREATMENT", 212, 230], ["consistent with", "UNCERTAINTY", 15, 30], ["+1 frameshifting", "OBSERVATION", 31, 47], ["frameshifting", "OBSERVATION", 98, 111], ["frameshifting", "OBSERVATION", 257, 270]]], ["The SPA gene was translated in vitro in rabbit reticulocyte lysate and its resulting frameshift efficiency measured.", [["reticulocyte lysate", "ANATOMY", 47, 66], ["SPA", "GENE_OR_GENE_PRODUCT", 4, 7], ["rabbit", "ORGANISM", 40, 46], ["reticulocyte lysate", "ORGANISM_SUBSTANCE", 47, 66], ["SPA gene", "DNA", 4, 12], ["rabbit", "SPECIES", 40, 46], ["rabbit", "SPECIES", 40, 46], ["The SPA gene", "TREATMENT", 0, 12], ["vitro in rabbit reticulocyte lysate", "TREATMENT", 31, 66], ["frameshift efficiency", "PROBLEM", 85, 106], ["SPA", "ANATOMY", 4, 7], ["rabbit reticulocyte lysate", "OBSERVATION", 40, 66], ["frameshift efficiency", "OBSERVATION", 85, 106]]], ["With no addition of polyamines, frameshifting efficiency is \u223c1.5%.", [["polyamines", "CHEMICAL", 20, 30], ["polyamines", "CHEMICAL", 20, 30], ["polyamines", "SIMPLE_CHEMICAL", 20, 30], ["polyamines", "TREATMENT", 20, 30], ["frameshifting efficiency", "PROBLEM", 32, 56], ["polyamines", "OBSERVATION", 20, 30], ["frameshifting efficiency", "OBSERVATION", 32, 56]]], ["Addition of spermidine to the translation mixture to a final concentration of 1 mM results in a 3.7-fold increase in frameshifting to \u223c5.5%, a level even higher than that observed in the endogenous system in vivo (autoradiogram not shown).Translational frameshifting during expression of SPA ::: ResultsThe observed efficiency of frameshifting with the SPA frameshifting cassette in vivo in S.pombe is significantly more than that expected from its limited nucleotide similarity to the antizyme frameshift sites of higher eukaryotes.", [["spermidine", "CHEMICAL", 12, 22], ["nucleotide", "CHEMICAL", 457, 467], ["spermidine", "CHEMICAL", 12, 22], ["nucleotide", "CHEMICAL", 457, 467], ["spermidine", "SIMPLE_CHEMICAL", 12, 22], ["SPA", "PROTEIN", 288, 291], ["SPA frameshifting cassette", "DNA", 353, 379], ["antizyme frameshift sites", "DNA", 486, 511], ["spermidine", "TREATMENT", 12, 22], ["a 3.7-fold increase in frameshifting", "PROBLEM", 94, 130], ["frameshifting", "PROBLEM", 330, 343], ["the SPA frameshifting cassette", "TREATMENT", 349, 379], ["the antizyme frameshift sites", "PROBLEM", 482, 511], ["3.7-fold", "OBSERVATION_MODIFIER", 96, 104], ["increase", "OBSERVATION_MODIFIER", 105, 113], ["frameshifting", "OBSERVATION", 117, 130], ["higher", "OBSERVATION_MODIFIER", 154, 160], ["endogenous system", "OBSERVATION", 187, 204], ["frameshifting", "OBSERVATION", 253, 266], ["efficiency", "OBSERVATION_MODIFIER", 316, 326], ["frameshifting", "OBSERVATION", 330, 343], ["antizyme frameshift", "OBSERVATION", 486, 505], ["higher eukaryotes", "OBSERVATION", 515, 532]]], ["This prompted a search for additional stimulatory elements within the SPA frameshift cassette.", [["stimulatory elements", "DNA", 38, 58], ["SPA frameshift cassette", "DNA", 70, 93], ["additional stimulatory elements", "TREATMENT", 27, 58]]], ["The following experiments were done in a strain carrying deletion of SPA (high polyamines) because it gives higher frameshifting and higher \u03b2-galactosidase activity in general; however, we obtained similar ratios for mutant to wild-type frameshifting efficiency in a strain with the intact SPA gene.", [["polyamines", "CHEMICAL", 79, 89], ["polyamines", "CHEMICAL", 79, 89], ["SPA", "GENE_OR_GENE_PRODUCT", 69, 72], ["\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 140, 155], ["SPA", "GENE_OR_GENE_PRODUCT", 290, 293], ["SPA", "PROTEIN", 69, 72], ["\u03b2-galactosidase", "PROTEIN", 140, 155], ["SPA gene", "DNA", 290, 298], ["SPA (high polyamines", "TREATMENT", 69, 89], ["higher frameshifting", "PROBLEM", 108, 128], ["type frameshifting efficiency", "PROBLEM", 232, 261], ["a strain", "PROBLEM", 265, 273], ["higher frameshifting", "OBSERVATION", 108, 128]]], ["Deleting 5\u2032 sequences up to the third to last sense codon of ORF1 has little or no effect on frameshifting efficiency.", [["ORF1", "GENE_OR_GENE_PRODUCT", 61, 65], ["5\u2032 sequences", "DNA", 9, 21], ["third to last sense codon", "DNA", 32, 57], ["ORF1", "DNA", 61, 65], ["frameshifting efficiency", "PROBLEM", 93, 117], ["no", "UNCERTAINTY", 80, 82], ["frameshifting efficiency", "OBSERVATION", 93, 117]]], ["Deleting all but the last sense codon (UCC) of ORF1 leads to a 4- to 5-fold reduction in frameshifting efficiency (Figure 5A).", [["ORF1", "GENE_OR_GENE_PRODUCT", 47, 51], ["last sense codon", "DNA", 21, 37], ["ORF1", "DNA", 47, 51], ["5-fold reduction", "TREATMENT", 69, 85], ["frameshifting efficiency", "PROBLEM", 89, 113], ["frameshifting efficiency", "OBSERVATION", 89, 113]]], ["This implies that the conservation of the six nucleotides 5\u2032 of the UCC-UGA frameshift site is due to their importance for stimulating +1 frameshifting.", [["nucleotides", "CHEMICAL", 46, 57], ["nucleotides 5\u2032 of the UCC-UGA frameshift site", "DNA", 46, 91], ["the six nucleotides", "TREATMENT", 38, 57], ["the UCC", "PROBLEM", 64, 71], ["UGA frameshift site", "PROBLEM", 72, 91], ["stimulating +1 frameshifting", "PROBLEM", 123, 151], ["UGA frameshift", "OBSERVATION", 72, 86], ["frameshifting", "OBSERVATION", 138, 151]]], ["It also suggests that no additional ORF1 sequences of SPA stimulate the +1 recoding event.", [["SPA", "GENE_OR_GENE_PRODUCT", 54, 57], ["ORF1 sequences", "DNA", 36, 50], ["SPA", "PROTEIN", 54, 57], ["additional ORF1 sequences", "TEST", 25, 50]]], ["The 180 nucleotide 3\u2032 region was searched for possible structure by computer RNA folding algorithms plus visual inspection.", [["nucleotide", "CHEMICAL", 8, 18], ["nucleotide", "CHEMICAL", 8, 18], ["180 nucleotide 3\u2032 region", "DNA", 4, 28], ["visual inspection", "TEST", 105, 122]]], ["The algorithms predicted several minimal structures in that region.", [["The algorithms", "TEST", 0, 14], ["several", "OBSERVATION_MODIFIER", 25, 32], ["minimal", "OBSERVATION_MODIFIER", 33, 40], ["structures", "OBSERVATION", 41, 51], ["region", "ANATOMY_MODIFIER", 60, 66]]], ["3\u2032 deletion constructs (constructs del.3,3\u2032\u201381,3\u2032) tested the importance of any putative structure on the frameshifting efficiency.", [["3\u2032 deletion constructs", "DNA", 0, 22], ["the frameshifting efficiency", "PROBLEM", 102, 130], ["frameshifting efficiency", "OBSERVATION", 106, 130]]], ["The results (Figure 5B and C) show that all of these deletions lead to a significant (\u223c10-fold) reduction in +1 frameshifting, indicating the presence of a major 3\u2032 stimulatory element in the 180 nucleotide region immediately following the frameshift site of SPA.", [["nucleotide", "CHEMICAL", 196, 206], ["+1 frameshifting", "RNA", 109, 125], ["major 3\u2032 stimulatory element", "DNA", 156, 184], ["180 nucleotide region", "DNA", 192, 213], ["SPA", "PROTEIN", 259, 262], ["Figure 5B and C)", "TEST", 13, 29], ["these deletions", "PROBLEM", 47, 62], ["a significant (\u223c10-fold) reduction in +1 frameshifting", "PROBLEM", 71, 125], ["a major 3\u2032 stimulatory element", "PROBLEM", 154, 184], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["+1 frameshifting", "OBSERVATION", 109, 125], ["stimulatory element", "OBSERVATION", 165, 184], ["SPA", "ANATOMY", 259, 262]]], ["Several additional 3\u2032 deletions delineated the boundaries of this stimulatory element from the frameshift site to 150 and 180 nucleotides downstream (since construct del.150,3\u2032 stimulates 5.5-fold more +1 frameshifting than del.129,3\u2032, 150 nucleotides downstream probably contain most of the 3\u2032 stimulator).Translational frameshifting during expression of SPA ::: ResultsIn the experiments described above, two of the characteristics of the autoregulatory circuit of mammalian antizyme 1 were confirmed: SPA inhibition of ODC and the +1 translational frameshifting.", [["nucleotides", "CHEMICAL", 126, 137], ["nucleotides", "CHEMICAL", 240, 251], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 477, 487], ["SPA", "GENE_OR_GENE_PRODUCT", 504, 507], ["ODC", "GENE_OR_GENE_PRODUCT", 522, 525], ["3\u2032 deletions", "DNA", 19, 31], ["stimulatory element", "DNA", 66, 85], ["frameshift site", "DNA", 95, 110], ["150 and 180 nucleotides downstream", "DNA", 114, 148], ["129,3\u2032, 150 nucleotides downstream", "DNA", 228, 262], ["SPA", "PROTEIN", 356, 359], ["mammalian antizyme 1", "PROTEIN", 467, 487], ["ODC", "PROTEIN", 522, 525], ["+1 translational frameshifting", "DNA", 534, 564], ["Several additional 3\u2032 deletions", "TREATMENT", 0, 31], ["this stimulatory element", "TREATMENT", 61, 85], ["the frameshift site", "PROBLEM", 91, 110], ["nucleotides downstream", "TEST", 126, 148], ["nucleotides downstream", "TREATMENT", 240, 262], ["mammalian antizyme", "TREATMENT", 467, 485], ["SPA inhibition of ODC", "PROBLEM", 504, 525], ["the +1 translational frameshifting", "PROBLEM", 530, 564], ["stimulatory element", "OBSERVATION", 66, 85], ["+1 frameshifting", "OBSERVATION", 202, 218], ["frameshifting", "OBSERVATION", 321, 334], ["autoregulatory circuit", "OBSERVATION", 441, 463], ["+1 translational frameshifting", "OBSERVATION", 534, 564]]], ["The key question left is whether the recoding event is responsive to polyamine levels in cells.", [["cells", "ANATOMY", 89, 94], ["polyamine", "CHEMICAL", 69, 78], ["polyamine", "CHEMICAL", 69, 78], ["polyamine", "SIMPLE_CHEMICAL", 69, 78], ["cells", "CELL", 89, 94], ["polyamine levels in cells", "PROBLEM", 69, 94]]], ["As shown above, overexpression of SPA leads to significant reduction of polyamine levels in S.pombe.", [["polyamine", "CHEMICAL", 72, 81], ["polyamine", "CHEMICAL", 72, 81], ["SPA", "GENE_OR_GENE_PRODUCT", 34, 37], ["polyamine", "SIMPLE_CHEMICAL", 72, 81], ["SPA", "PROTEIN", 34, 37], ["overexpression of SPA", "PROBLEM", 16, 37], ["significant reduction of polyamine levels", "TREATMENT", 47, 88], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["reduction", "OBSERVATION_MODIFIER", 59, 68], ["polyamine levels", "OBSERVATION", 72, 88]]], ["An SPA+ strain was co-transformed with an SPA wild-type overexpressing plasmid (cells overexpressing wild-type SPA grow slowly but continuously) and a construct that monitors the +1 frameshifting from an SPA frameshift sequence.", [["plasmid", "ANATOMY", 71, 78], ["cells", "ANATOMY", 80, 85], ["SPA", "GENE_OR_GENE_PRODUCT", 3, 6], ["cells", "CELL", 80, 85], ["SPA wild-type overexpressing plasmid", "DNA", 42, 78], ["SPA frameshift sequence", "DNA", 204, 227], ["An SPA+ strain", "PROBLEM", 0, 14], ["an SPA wild", "TEST", 39, 50], ["an SPA frameshift sequence", "TEST", 201, 227], ["SPA", "ANATOMY", 3, 6], ["+1 frameshifting", "OBSERVATION", 179, 195]]], ["The +1 frameshifting was compared with that in SPA non-overexpressing cells (in both cases frameshifting was measured relative to in-frame control).", [["cells", "ANATOMY", 70, 75], ["SPA non-overexpressing cells", "CELL", 47, 75], ["SPA non-overexpressing cells", "CELL_LINE", 47, 75], ["The +1 frameshifting", "PROBLEM", 0, 20], ["+1 frameshifting", "OBSERVATION", 4, 20]]], ["The results (Figure 6) show a significant reduction (6.5-fold) in frameshifting efficiency in SPA-overproducing cells that correlates with a decrease of polyamine content (4.5-fold for putrescine and 3.9-fold for spermidine).", [["cells", "ANATOMY", 112, 117], ["polyamine", "CHEMICAL", 153, 162], ["putrescine", "CHEMICAL", 185, 195], ["spermidine", "CHEMICAL", 213, 223], ["polyamine", "CHEMICAL", 153, 162], ["putrescine", "CHEMICAL", 185, 195], ["spermidine", "CHEMICAL", 213, 223], ["SPA", "SIMPLE_CHEMICAL", 94, 97], ["cells", "CELL", 112, 117], ["polyamine", "SIMPLE_CHEMICAL", 153, 162], ["putrescine", "SIMPLE_CHEMICAL", 185, 195], ["spermidine", "SIMPLE_CHEMICAL", 213, 223], ["SPA-overproducing cells", "CELL_LINE", 94, 117], ["a significant reduction (6.5-fold)", "PROBLEM", 28, 62], ["frameshifting efficiency in SPA-overproducing cells", "PROBLEM", 66, 117], ["a decrease of polyamine content", "PROBLEM", 139, 170], ["putrescine", "TEST", 185, 195], ["spermidine", "TREATMENT", 213, 223], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["reduction", "OBSERVATION_MODIFIER", 42, 51], ["frameshifting efficiency", "OBSERVATION", 66, 90], ["SPA", "ANATOMY", 94, 97], ["overproducing cells", "OBSERVATION", 98, 117], ["decrease", "OBSERVATION_MODIFIER", 141, 149], ["polyamine content", "OBSERVATION", 153, 170]]], ["This indicates that polyamines modulate the frameshifting efficiency of SPA.", [["polyamines", "CHEMICAL", 20, 30], ["polyamines", "CHEMICAL", 20, 30], ["polyamines", "SIMPLE_CHEMICAL", 20, 30], ["SPA", "GENE_OR_GENE_PRODUCT", 72, 75], ["SPA", "PROTEIN", 72, 75], ["polyamines modulate the frameshifting efficiency of SPA", "PROBLEM", 20, 75], ["polyamines modulate", "OBSERVATION", 20, 39], ["frameshifting efficiency", "OBSERVATION", 44, 68]]], ["An alternative but less likely possibility is that SPA overexpression reduces frameshifting because high levels of SPA transcript titrate some factor limiting for frameshifting.Translational frameshifting during expression of SPA ::: ResultsThe SPA frameshift signals direct 2-fold more frameshifting in \u0394spa::LEU2 cells (4.4%) than in SPA+ cells (in both cases the measurement is done during stationary phase); however, the relatively high standard deviations for both measurements make it difficult to draw firm conclusions from this particular result.Identification of antizyme genes in nematodes ::: ResultsA search of Caenorhabditis elegans expressed sequence tag (EST) sequences with mammalian antizyme 1 sequence identified 20 clones.", [["LEU2 cells", "ANATOMY", 310, 320], ["SPA+ cells", "ANATOMY", 336, 346], ["SPA", "GENE_OR_GENE_PRODUCT", 51, 54], ["SPA", "GENE_OR_GENE_PRODUCT", 115, 118], ["SPA", "GENE_OR_GENE_PRODUCT", 226, 229], ["\u0394spa", "GENE_OR_GENE_PRODUCT", 304, 308], ["LEU2 cells", "CELL", 310, 320], ["SPA+ cells", "CELL", 336, 346], ["antizyme", "GENE_OR_GENE_PRODUCT", 572, 580], ["Caenorhabditis elegans", "ORGANISM", 623, 645], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 700, 710], ["SPA", "PROTEIN", 51, 54], ["SPA transcript", "RNA", 115, 129], ["SPA", "PROTEIN", 226, 229], ["\u0394spa", "CELL_LINE", 304, 308], ["LEU2 cells", "CELL_LINE", 310, 320], ["SPA+ cells", "CELL_LINE", 336, 346], ["antizyme genes", "DNA", 572, 586], ["Caenorhabditis elegans expressed sequence tag (EST) sequences", "DNA", 623, 684], ["mammalian antizyme 1 sequence", "DNA", 690, 719], ["Caenorhabditis elegans", "SPECIES", 623, 645], ["Caenorhabditis elegans", "SPECIES", 623, 645], ["SPA overexpression reduces frameshifting", "PROBLEM", 51, 91], ["SPA transcript", "TREATMENT", 115, 129], ["frameshifting", "PROBLEM", 163, 176], ["Translational frameshifting", "PROBLEM", 177, 204], ["The SPA frameshift signals", "TEST", 241, 267], ["LEU2 cells", "TEST", 310, 320], ["SPA+ cells", "TEST", 336, 346], ["Caenorhabditis elegans", "PROBLEM", 623, 645], ["sequence tag (EST) sequences", "TEST", 656, 684], ["mammalian antizyme 1 sequence", "TEST", 690, 719], ["less likely possibility", "UNCERTAINTY", 19, 42], ["frameshifting", "OBSERVATION", 191, 204], ["SPA", "ANATOMY", 336, 339], ["antizyme genes", "OBSERVATION", 572, 586]]], ["These sequences could be deconvoluted into a contiguous cDNA sequence.", [["contiguous cDNA sequence", "DNA", 45, 69], ["These sequences", "TEST", 0, 15], ["a contiguous cDNA sequence", "TEST", 43, 69]]], ["Primers designed on the basis of this sequence were used to PCR amplify and subclone this cDNA from a C.elegans cDNA library.", [["cDNA", "DNA", 90, 94], ["C.elegans cDNA library", "DNA", 102, 124], ["C.elegans", "SPECIES", 102, 111], ["this sequence", "TREATMENT", 33, 46], ["PCR", "TEST", 60, 63]]], ["The sequence of the subcloned cDNA was confirmed (DDBJ/EMBL/GenBank accession No.", [["subcloned cDNA", "DNA", 20, 34], ["the subcloned cDNA", "TEST", 16, 34]]], ["AF217278); the subsequently released genomic sequence of this C.elegans gene (DDBJ/EMBL/GenBank accession No.", [["AF217278", "CHEMICAL", 0, 8], ["C.elegans gene", "DNA", 62, 76]]], ["AF040659) confirms our cDNA data.", [["AF040659", "CHEMICAL", 0, 8], ["AF040659", "CHEMICAL", 0, 8], ["our cDNA data", "TEST", 19, 32]]], ["The amino acid sequence deduced from the cDNA sequence revealed that the longer ORF has similarity to previously reported antizyme sequences (overall 27% identity, 39% similarity to human antizyme 1; 19% identity, 34% similarity to Drosophila antizyme).", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["antizyme", "GENE_OR_GENE_PRODUCT", 122, 130], ["human", "ORGANISM", 182, 187], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 188, 198], ["Drosophila", "ORGANISM", 232, 242], ["antizyme", "GENE_OR_GENE_PRODUCT", 243, 251], ["cDNA sequence", "DNA", 41, 54], ["ORF", "DNA", 80, 83], ["antizyme sequences", "DNA", 122, 140], ["human antizyme 1", "PROTEIN", 182, 198], ["Drosophila antizyme", "PROTEIN", 232, 251], ["human", "SPECIES", 182, 187], ["Drosophila", "SPECIES", 232, 242], ["human", "SPECIES", 182, 187], ["Drosophila", "SPECIES", 232, 242], ["The amino acid sequence", "TEST", 0, 23], ["the cDNA sequence", "TEST", 37, 54], ["the longer ORF", "PROBLEM", 69, 83], ["antizyme sequences", "TEST", 122, 140], ["human antizyme", "TEST", 182, 196], ["Drosophila antizyme", "TREATMENT", 232, 251]]], ["These similarities are higher than that of SPA to these two antizyme genes and again are concentrated in the regions most highly conserved among previously identified antizymes (Figure 1A).", [["SPA", "GENE_OR_GENE_PRODUCT", 43, 46], ["antizyme", "GENE_OR_GENE_PRODUCT", 60, 68], ["SPA", "PROTEIN", 43, 46], ["antizyme genes", "DNA", 60, 74], ["antizymes", "DNA", 167, 176], ["higher", "OBSERVATION_MODIFIER", 23, 29], ["concentrated", "OBSERVATION_MODIFIER", 89, 101], ["regions", "ANATOMY_MODIFIER", 109, 116]]], ["Just like mammalian antizymes, the longer ORF (ORF2) lacks an appropriate in-frame initiation codon, and expression could be provided by initiation in a short upstream overlapping ORF (ORF1) leading to +1 ribosomal frameshifting in the overlap.", [["ribosomal", "ANATOMY", 205, 214], ["antizymes", "GENE_OR_GENE_PRODUCT", 20, 29], ["ORF2", "GENE_OR_GENE_PRODUCT", 47, 51], ["ribosomal", "CELLULAR_COMPONENT", 205, 214], ["mammalian antizymes", "DNA", 10, 29], ["ORF", "DNA", 42, 45], ["ORF2", "DNA", 47, 51], ["in-frame initiation codon", "DNA", 74, 99], ["short upstream overlapping ORF", "DNA", 153, 183], ["ORF1", "DNA", 185, 189], ["the longer ORF", "PROBLEM", 31, 45], ["a short upstream overlapping ORF", "PROBLEM", 151, 183], ["+1 ribosomal frameshifting", "PROBLEM", 202, 228], ["mammalian antizymes", "OBSERVATION", 10, 29], ["ribosomal frameshifting", "OBSERVATION", 205, 228]]], ["The putative C.elegans antizyme frameshift site (the nucleotides proximal to the end of ORF1) has 18 of 26 nucleotides identical to the consensus sequence for antizyme frameshift sites (Figure 1B).Identification of antizyme genes in nematodes ::: ResultsFrameshifting for expression of C.elegans antizyme was investigated in heterologous systems.", [["nucleotides", "CHEMICAL", 107, 118], ["antizyme", "GENE_OR_GENE_PRODUCT", 215, 223], ["C.elegans", "ORGANISM", 286, 295], ["antizyme", "GENE_OR_GENE_PRODUCT", 296, 304], ["C.elegans antizyme frameshift site", "DNA", 13, 47], ["nucleotides proximal", "DNA", 53, 73], ["ORF1", "DNA", 88, 92], ["consensus sequence", "DNA", 136, 154], ["antizyme frameshift sites", "DNA", 159, 184], ["antizyme genes", "DNA", 215, 229], ["C.elegans antizyme", "PROTEIN", 286, 304], ["The putative C.elegans antizyme frameshift site", "TREATMENT", 0, 47], ["the nucleotides", "TREATMENT", 49, 64], ["ORF1", "TEST", 88, 92], ["nucleotides", "TREATMENT", 107, 118], ["antizyme frameshift sites", "PROBLEM", 159, 184], ["C.elegans antizyme", "TREATMENT", 286, 304], ["antizyme frameshift", "OBSERVATION", 23, 42], ["antizyme genes", "OBSERVATION", 215, 229]]], ["Two constructs containing the entire antizyme cDNA, one with the wild-type sequence and one with a single nucleotide deletion that fuses ORF1 to ORF2 in-frame (in-frame control), were transcribed in vitro and the RNA was translated in rabbit reticulocyte lysate.", [["reticulocyte lysate", "ANATOMY", 242, 261], ["nucleotide", "CHEMICAL", 106, 116], ["nucleotide", "CHEMICAL", 106, 116], ["antizyme", "GENE_OR_GENE_PRODUCT", 37, 45], ["rabbit", "ORGANISM", 235, 241], ["reticulocyte lysate", "ORGANISM_SUBSTANCE", 242, 261], ["antizyme cDNA", "DNA", 37, 50], ["wild-type sequence", "DNA", 65, 83], ["single nucleotide deletion", "DNA", 99, 125], ["ORF1", "DNA", 137, 141], ["ORF2", "DNA", 145, 149], ["rabbit", "SPECIES", 235, 241], ["rabbit", "SPECIES", 235, 241], ["the entire antizyme cDNA", "TREATMENT", 26, 50], ["a single nucleotide deletion", "PROBLEM", 97, 125], ["ORF2", "TEST", 145, 149], ["rabbit reticulocyte lysate", "TREATMENT", 235, 261], ["rabbit reticulocyte lysate", "OBSERVATION", 235, 261]]], ["The main product from both constructs has an apparent Mr of 21 kDa, slightly greater than the predicted Mr of 17.7 kDa [aberrant, slower than expected, mobility is observed with antizyme proteins from other species (Ivanov et al., 1998a)].", [["antizyme proteins", "GENE_OR_GENE_PRODUCT", 178, 195], ["Mr", "PROTEIN", 54, 56], ["Mr", "PROTEIN", 104, 106], ["antizyme proteins", "PROTEIN", 178, 195], ["21 kDa", "PROBLEM", 60, 66], ["the predicted Mr", "TEST", 90, 106], ["kDa", "TEST", 115, 118], ["antizyme proteins", "PROBLEM", 178, 195], ["main", "OBSERVATION_MODIFIER", 4, 8], ["both constructs", "OBSERVATION", 22, 37], ["21 kDa", "OBSERVATION_MODIFIER", 60, 66], ["slightly", "OBSERVATION_MODIFIER", 68, 76], ["greater", "OBSERVATION_MODIFIER", 77, 84], ["17.7 kDa", "OBSERVATION_MODIFIER", 110, 118], ["aberrant", "OBSERVATION_MODIFIER", 120, 128], ["slower", "OBSERVATION_MODIFIER", 130, 136]]], ["From the ratio of wild-type to in-frame product, we estimate that the efficiency of frameshifting of C.elegans antizyme in reticulocyte lysate is \u223c0.8%, which is somewhat lower than SPA frameshifting in the same system.", [["reticulocyte lysate", "ANATOMY", 123, 142], ["C.elegans antizyme", "GENE_OR_GENE_PRODUCT", 101, 119], ["reticulocyte", "CELL", 123, 135], ["C.elegans antizyme", "PROTEIN", 101, 119], ["C.elegans", "SPECIES", 101, 110], ["frameshifting of C.elegans antizyme", "TREATMENT", 84, 119], ["reticulocyte lysate", "TEST", 123, 142], ["SPA frameshifting", "PROBLEM", 182, 199], ["frameshifting", "OBSERVATION", 84, 97], ["reticulocyte lysate", "OBSERVATION", 123, 142], ["somewhat", "OBSERVATION_MODIFIER", 162, 170], ["lower", "OBSERVATION_MODIFIER", 171, 176], ["SPA frameshifting", "OBSERVATION", 182, 199]]], ["Addition of spermidine to the translation reactions almost doubles the efficiency of frameshifting to \u223c1.5% (the exact numbers are not easy to determine because of difficulty in defining background values).", [["spermidine", "CHEMICAL", 12, 22], ["spermidine", "CHEMICAL", 12, 22], ["spermidine", "SIMPLE_CHEMICAL", 12, 22], ["spermidine", "TREATMENT", 12, 22], ["the translation reactions", "PROBLEM", 26, 51]]], ["The frameshifting properties of C.elegans antizyme mRNA were also tested in vivo in S.pombe cells.", [["S.pombe cells", "ANATOMY", 84, 97], ["C.elegans", "ORGANISM", 32, 41], ["antizyme", "GENE_OR_GENE_PRODUCT", 42, 50], ["S.pombe cells", "CELL", 84, 97], ["C.elegans antizyme mRNA", "RNA", 32, 55], ["S.pombe cells", "CELL_LINE", 84, 97], ["The frameshifting properties", "TREATMENT", 0, 28], ["C.elegans antizyme mRNA", "TREATMENT", 32, 55]]], ["A sequence including all but the first codon of ORF1 plus 180 nucleotides downstream was inserted between GST and lacZ of the PIU-LAC plasmid.", [["nucleotides", "CHEMICAL", 62, 73], ["ORF1", "GENE_OR_GENE_PRODUCT", 48, 52], ["GST", "GENE_OR_GENE_PRODUCT", 106, 109], ["lacZ", "GENE_OR_GENE_PRODUCT", 114, 118], ["PIU", "GENE_OR_GENE_PRODUCT", 126, 129], ["ORF1", "DNA", 48, 52], ["180 nucleotides downstream", "DNA", 58, 84], ["GST and lacZ of the PIU-LAC plasmid", "DNA", 106, 141], ["A sequence", "TEST", 0, 10], ["ORF1", "TEST", 48, 52], ["nucleotides downstream", "TREATMENT", 62, 84], ["GST", "TEST", 106, 109], ["LAC plasmid", "TREATMENT", 130, 141], ["LAC plasmid", "OBSERVATION", 130, 141]]], ["Comparison of the \u03b2-galactosidase activity of cells (\u0394spa::LEU2 strain) transformed with the wild-type construct and the in-frame control constructs indicated 3.5% +1 frameshifting.", [["cells", "ANATOMY", 46, 51], ["\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 18, 33], ["cells", "CELL", 46, 51], ["LEU2", "GENE_OR_GENE_PRODUCT", 59, 63], ["\u03b2-galactosidase", "PROTEIN", 18, 33], ["wild-type construct", "DNA", 93, 112], ["in-frame control constructs", "DNA", 121, 148], ["LEU2 strain", "PROBLEM", 59, 70], ["the in-frame control constructs", "TREATMENT", 117, 148], ["+1 frameshifting", "OBSERVATION", 164, 180]]], ["From the frameshifting observed in the heterologous systems, as well as the sequence considerations discussed above, we conclude that expression of this C.elegans gene requires ribosomal frameshifting.Identification of antizyme genes in nematodes ::: ResultsSearching the EST database with the newly discovered C.elegans antizyme identified antizyme orthologs in four other nematode species.", [["ribosomal", "ANATOMY", 177, 186], ["C.elegans", "GENE_OR_GENE_PRODUCT", 153, 162], ["ribosomal", "CELLULAR_COMPONENT", 177, 186], ["antizyme", "GENE_OR_GENE_PRODUCT", 219, 227], ["antizyme", "GENE_OR_GENE_PRODUCT", 341, 349], ["C.elegans gene", "DNA", 153, 167], ["antizyme genes", "DNA", 219, 233], ["C.elegans antizyme", "PROTEIN", 311, 329], ["antizyme orthologs", "DNA", 341, 359], ["the frameshifting", "PROBLEM", 5, 22], ["ribosomal frameshifting", "TREATMENT", 177, 200], ["the EST database", "TEST", 268, 284], ["C.elegans antizyme", "TREATMENT", 311, 329], ["antizyme orthologs", "PROBLEM", 341, 359], ["frameshifting", "OBSERVATION", 9, 22], ["ribosomal frameshifting", "OBSERVATION", 177, 200], ["antizyme genes", "OBSERVATION", 219, 233], ["nematode species", "OBSERVATION", 374, 390]]], ["In two cases (Necator americanus and Haemonchus contortus), the cDNA sequences in the database were sufficient to make contigs of the complete coding regions.", [["Necator americanus", "ORGANISM", 14, 32], ["Haemonchus contortus", "ORGANISM", 37, 57], ["cDNA sequences", "DNA", 64, 78], ["coding regions", "DNA", 143, 157], ["Necator americanus", "SPECIES", 14, 32], ["Haemonchus contortus", "SPECIES", 37, 57], ["Necator americanus", "SPECIES", 14, 32], ["Haemonchus contortus", "SPECIES", 37, 57], ["Haemonchus contortus", "TREATMENT", 37, 57], ["the cDNA sequences", "TEST", 60, 78]]], ["In the other two cases [Onchocerca volvulus (DDBJ/EMBL/GenBank accession No.", [["Onchocerca volvulus", "DISEASE", 24, 43], ["Onchocerca volvulus", "ORGANISM", 24, 43], ["Onchocerca volvulus", "SPECIES", 24, 43], ["Onchocerca volvulus", "SPECIES", 24, 43], ["Onchocerca volvulus", "PROBLEM", 24, 43], ["Onchocerca volvulus", "OBSERVATION", 24, 43]]], ["AF217279) and Pristioncus pacificus (DDBJ/EMBL/GenBank accession No.", [["AF217279", "CHEMICAL", 0, 8], ["Pristioncus pacificus", "ORGANISM", 14, 35], ["Pristioncus pacificus", "SPECIES", 14, 35], ["Pristioncus pacificus", "SPECIES", 14, 35]]], ["AF217280)] the complete cDNA sequences were obtained by PCR amplifying and sequencing the full genes from cDNA libraries.", [["AF217280", "CHEMICAL", 0, 8], ["AF217280", "CHEMICAL", 0, 8], ["AF217280", "SIMPLE_CHEMICAL", 0, 8], ["cDNA sequences", "DNA", 24, 38], ["cDNA libraries", "DNA", 106, 120], ["the complete cDNA sequences", "TEST", 11, 38]]], ["As with the previously identified eukaryotic antizyme genes, the ORF configuration of the newly found nematode orthologs implies the necessity for +1 frameshifting for synthesis of full-length protein.Identification of antizyme genes in nematodes ::: ResultsThe C.elegans antizyme mRNA frameshift site UUU-UGA is unique, differing from the UCC-UGA of previously known antizyme mRNAs.", [["antizyme", "GENE_OR_GENE_PRODUCT", 45, 53], ["antizyme", "GENE_OR_GENE_PRODUCT", 219, 227], ["C.elegans antizyme", "GENE_OR_GENE_PRODUCT", 262, 280], ["antizyme", "GENE_OR_GENE_PRODUCT", 368, 376], ["eukaryotic antizyme genes", "DNA", 34, 59], ["nematode orthologs", "DNA", 102, 120], ["full-length protein", "PROTEIN", 181, 200], ["antizyme genes", "DNA", 219, 233], ["C.elegans antizyme mRNA frameshift site", "RNA", 262, 301], ["UUU", "DNA", 302, 305], ["UGA", "DNA", 306, 309], ["UCC-UGA of previously known antizyme mRNAs", "RNA", 340, 382], ["the previously identified eukaryotic antizyme genes", "PROBLEM", 8, 59], ["nematode orthologs", "PROBLEM", 102, 120], ["+1 frameshifting", "TREATMENT", 147, 163], ["synthesis of full-length protein", "TREATMENT", 168, 200], ["The C.elegans antizyme mRNA frameshift", "PROBLEM", 258, 296], ["the UCC", "TEST", 336, 343], ["previously known antizyme mRNAs", "PROBLEM", 351, 382], ["antizyme genes", "OBSERVATION", 45, 59], ["antizyme genes", "OBSERVATION", 219, 233], ["antizyme mRNAs", "OBSERVATION", 368, 382]]], ["The C.elegans antizyme gene shares this feature with N.americanus and H.contortus but not with P.pacificus and O.volvulus antizymes.", [["C.elegans antizyme", "GENE_OR_GENE_PRODUCT", 4, 22], ["N.americanus", "SIMPLE_CHEMICAL", 53, 65], ["P.pacificus", "GENE_OR_GENE_PRODUCT", 95, 106], ["O.volvulus antizymes", "CELL", 111, 131], ["C.elegans antizyme gene", "DNA", 4, 27], ["The C.elegans antizyme gene", "TREATMENT", 0, 27]]], ["The phylogenetic tree of nematode antizyme protein sequences matches exactly the phylogenetic relationship (Blaxter, 1998) of the nematodes expressing them, indicating that these gene sequences are the result of divergent evolution within the nematode lineage (data not shown).", [["nematode antizyme protein sequences", "DNA", 25, 60], ["nematode lineage", "CELL_TYPE", 243, 259], ["nematode antizyme protein sequences", "PROBLEM", 25, 60], ["these gene sequences", "TEST", 173, 193], ["tree", "OBSERVATION_MODIFIER", 17, 21], ["divergent", "OBSERVATION_MODIFIER", 212, 221], ["nematode lineage", "OBSERVATION", 243, 259]]], ["These results also show that the UUU-UGA frameshift site evolved after the last common ancestor of P.pacificus and C.elegans but before the divergence of C.elegans, N.americanus and H.contortus (probably 450\u2013500 million years ago).Identification of antizyme genes in nematodes ::: ResultsThe ability of UUU-UGA sequence to direct +1 frameshifting was further tested in a mammalian system in the context of the mammalian antizyme mRNA (i.e. in the presence of the 3\u2032 RNA pseudoknot and 5\u2032 stimulator).", [["antizyme", "GENE_OR_GENE_PRODUCT", 249, 257], ["UUU", "GENE_OR_GENE_PRODUCT", 303, 306], ["antizyme", "GENE_OR_GENE_PRODUCT", 420, 428], ["UUU-UGA frameshift site", "DNA", 33, 56], ["antizyme genes", "DNA", 249, 263], ["UUU", "DNA", 303, 306], ["UGA sequence", "DNA", 307, 319], ["mammalian antizyme mRNA", "RNA", 410, 433], ["UGA frameshift site", "PROBLEM", 37, 56], ["P.pacificus and C.elegans", "PROBLEM", 99, 124], ["direct +1 frameshifting", "PROBLEM", 323, 346], ["the mammalian antizyme mRNA", "PROBLEM", 406, 433], ["RNA pseudoknot and 5\u2032 stimulator", "TREATMENT", 466, 498], ["UGA frameshift", "OBSERVATION", 37, 51], ["antizyme genes", "OBSERVATION", 249, 263], ["mammalian", "OBSERVATION", 410, 419], ["antizyme mRNA", "OBSERVATION", 420, 433], ["pseudoknot", "OBSERVATION", 470, 480]]], ["A BMV-coat-protein\u2013antizyme 1 gene fusion construct, which has a TCC-TGA to TTT-TGA substitution, was transcribed and then translated in a rabbit reticulocyte lysate.", [["reticulocyte lysate", "ANATOMY", 146, 165], ["BMV-coat-protein\u2013antizyme 1", "GENE_OR_GENE_PRODUCT", 2, 29], ["rabbit", "ORGANISM", 139, 145], ["reticulocyte lysate", "ORGANISM_SUBSTANCE", 146, 165], ["BMV-coat-protein\u2013antizyme 1 gene fusion construct", "DNA", 2, 51], ["TCC", "PROTEIN", 65, 68], ["rabbit", "SPECIES", 139, 145], ["rabbit", "SPECIES", 139, 145], ["A BMV", "TEST", 0, 5], ["coat-protein\u2013antizyme 1 gene fusion construct", "TREATMENT", 6, 51], ["a TCC", "TEST", 63, 68], ["TTT", "TEST", 76, 79], ["TGA substitution", "PROBLEM", 80, 96], ["a rabbit reticulocyte lysate", "TREATMENT", 137, 165]]], ["Eleven percent frameshift efficiency was seen in the absence of exogenously added polyamines, 2.2 times the efficiency seen with the UCC-UGA transcript.", [["polyamines", "CHEMICAL", 82, 92], ["polyamines", "SIMPLE_CHEMICAL", 82, 92], ["UCC-UGA transcript", "RNA", 133, 151], ["Eleven percent frameshift efficiency", "PROBLEM", 0, 36], ["exogenously added polyamines", "TREATMENT", 64, 92], ["percent", "OBSERVATION_MODIFIER", 7, 14], ["frameshift efficiency", "OBSERVATION", 15, 36], ["UGA transcript", "OBSERVATION", 137, 151]]], ["The frameshift efficiency becomes 18% when 0.6 mM spermidine is added, which is 1.3 times that with the wild type (Matsufuji et al., 1995).", [["spermidine", "CHEMICAL", 50, 60], ["spermidine", "CHEMICAL", 50, 60], ["spermidine", "SIMPLE_CHEMICAL", 50, 60], ["The frameshift efficiency", "PROBLEM", 0, 25], ["frameshift efficiency", "OBSERVATION", 4, 25]]], ["Similar results were obtained in cultured mammalian (Cos7) cells transfected with TTT-TGA mutant construct, the frameshift being higher than that of wild-type construct in both high- and low-polyamine conditions (our unpublished results).", [["Cos7) cells", "ANATOMY", 53, 64], ["polyamine", "CHEMICAL", 191, 200], ["polyamine", "CHEMICAL", 191, 200], ["mammalian (Cos7) cells", "CELL", 42, 64], ["cultured mammalian (Cos7) cells", "CELL_LINE", 33, 64], ["TTT-TGA mutant construct", "DNA", 82, 106], ["wild-type construct", "DNA", 149, 168], ["TTT", "TEST", 82, 85], ["the frameshift", "PROBLEM", 108, 122]]], ["These results demonstrate that the putative C.elegans frameshift site (UUU-UGA) is, if anything, shiftier than UCC-UGA in the antizyme 1 context and is subject to polyamine stimulation.DiscussionThe results presented show that the yeast S.pombe has a homolog of mammalian antizyme.", [["polyamine", "CHEMICAL", 163, 172], ["S.pombe", "CHEMICAL", 237, 244], ["polyamine", "CHEMICAL", 163, 172], ["UUU-UGA", "GENE_OR_GENE_PRODUCT", 71, 78], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 126, 136], ["polyamine", "SIMPLE_CHEMICAL", 163, 172], ["yeast S.pombe", "ORGANISM", 231, 244], ["mammalian antizyme", "GENE_OR_GENE_PRODUCT", 262, 280], ["C.elegans frameshift site", "DNA", 44, 69], ["UUU", "DNA", 71, 74], ["UGA", "DNA", 75, 78], ["UCC", "DNA", 111, 114], ["UGA", "DNA", 115, 118], ["mammalian antizyme", "PROTEIN", 262, 280], ["yeast", "SPECIES", 231, 236], ["yeast", "SPECIES", 231, 236], ["the putative C.elegans frameshift site", "PROBLEM", 31, 69], ["UCC", "TEST", 111, 114], ["polyamine stimulation", "TREATMENT", 163, 184], ["mammalian antizyme", "TREATMENT", 262, 280], ["polyamine stimulation", "OBSERVATION", 163, 184]]], ["This is the first documented example of antizyme-type regulation of ODC in a lower eukaryote.DiscussionDeleting SPA from the yeast genome has no detectable effect on viability or any other overt phenotypic effect but, as expected, it results in altered accumulation of polyamines in the cell.", [["cell", "ANATOMY", 287, 291], ["polyamines", "CHEMICAL", 269, 279], ["polyamines", "CHEMICAL", 269, 279], ["antizyme", "GENE_OR_GENE_PRODUCT", 40, 48], ["ODC", "GENE_OR_GENE_PRODUCT", 68, 71], ["SPA", "GENE_OR_GENE_PRODUCT", 112, 115], ["polyamines", "SIMPLE_CHEMICAL", 269, 279], ["cell", "CELL", 287, 291], ["antizyme", "PROTEIN", 40, 48], ["ODC", "PROTEIN", 68, 71], ["SPA", "PROTEIN", 112, 115], ["yeast genome", "DNA", 125, 137], ["yeast", "SPECIES", 125, 130], ["yeast", "SPECIES", 125, 130], ["antizyme", "TREATMENT", 40, 48], ["the yeast genome", "PROBLEM", 121, 137], ["detectable effect on viability", "PROBLEM", 145, 175], ["any other overt phenotypic effect", "PROBLEM", 179, 212], ["altered accumulation of polyamines in the cell", "PROBLEM", 245, 291], ["yeast genome", "OBSERVATION", 125, 137], ["no", "UNCERTAINTY", 142, 144], ["altered", "OBSERVATION_MODIFIER", 245, 252], ["accumulation of polyamines", "OBSERVATION", 253, 279], ["cell", "ANATOMY", 287, 291]]], ["Interestingly, the effect is most pronounced in cells in stationary phase, where the knockout cells accumulate up to 40 times more putrescine than wild-type counterparts.", [["cells", "ANATOMY", 48, 53], ["cells", "ANATOMY", 94, 99], ["putrescine", "CHEMICAL", 131, 141], ["putrescine", "CHEMICAL", 131, 141], ["cells", "CELL", 48, 53], ["cells", "CELL", 94, 99], ["putrescine", "SIMPLE_CHEMICAL", 131, 141], ["knockout cells", "CELL_TYPE", 85, 99], ["the knockout cells", "PROBLEM", 81, 99], ["most pronounced", "OBSERVATION_MODIFIER", 29, 44], ["stationary phase", "OBSERVATION_MODIFIER", 57, 73], ["knockout cells", "OBSERVATION", 85, 99]]], ["This compares with a <2-fold increase of putrescine in exponentially growing cells.", [["cells", "ANATOMY", 77, 82], ["putrescine", "CHEMICAL", 41, 51], ["putrescine", "CHEMICAL", 41, 51], ["putrescine", "SIMPLE_CHEMICAL", 41, 51], ["cells", "CELL", 77, 82], ["a <2-fold increase of putrescine in exponentially growing cells", "PROBLEM", 19, 82], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["putrescine", "OBSERVATION_MODIFIER", 41, 51], ["exponentially", "OBSERVATION_MODIFIER", 55, 68], ["growing cells", "OBSERVATION", 69, 82]]], ["A likely explanation for this observation is that the usual rate of ornithine decarboxylation in exponentially growing cells is close to capacity given \u2018normal\u2019 concentrations of substrate, enzyme and product.", [["cells", "ANATOMY", 119, 124], ["ornithine", "CHEMICAL", 68, 77], ["ornithine", "CHEMICAL", 68, 77], ["ornithine", "SIMPLE_CHEMICAL", 68, 77], ["cells", "CELL", 119, 124], ["exponentially growing cells", "CELL_LINE", 97, 124], ["enzyme", "PROTEIN", 190, 196], ["this observation", "TEST", 25, 41], ["ornithine decarboxylation", "PROBLEM", 68, 93], ["exponentially growing cells", "PROBLEM", 97, 124], ["likely explanation for", "UNCERTAINTY", 2, 24]]], ["At the same time, all newly synthesized polyamines are continuously diluted through cell growth and division at a rate that is almost identical to the rate of maximum capacity synthesis.", [["cell", "ANATOMY", 84, 88], ["polyamines", "CHEMICAL", 40, 50], ["polyamines", "SIMPLE_CHEMICAL", 40, 50], ["cell", "CELL", 84, 88], ["all newly synthesized polyamines", "TREATMENT", 18, 50], ["a rate", "TEST", 112, 118], ["maximum capacity synthesis", "PROBLEM", 159, 185], ["maximum", "OBSERVATION_MODIFIER", 159, 166], ["capacity synthesis", "OBSERVATION", 167, 185]]], ["Cells in stationary phase can no longer dilute newly synthesized polyamines, and more importantly lack an effective antizyme- independent mechanism of shutting off ODC.", [["Cells", "ANATOMY", 0, 5], ["polyamines", "CHEMICAL", 65, 75], ["Cells", "CELL", 0, 5], ["polyamines", "SIMPLE_CHEMICAL", 65, 75], ["antizyme", "SIMPLE_CHEMICAL", 116, 124], ["ODC", "GENE_OR_GENE_PRODUCT", 164, 167], ["antizyme", "PROTEIN", 116, 124], ["ODC", "PROTEIN", 164, 167], ["dilute newly synthesized polyamines", "PROBLEM", 40, 75], ["an effective antizyme", "TREATMENT", 103, 124]]], ["This suggests that SPA is the primary regulator of ODC activity in S.pombe, not only during cell growth (short term regulation) but also in non-dividing cells (longer term regulation).DiscussionOverexpression of SPA (5\u20137 days derepression) leads to complete depletion of intracellular putrescine.", [["cell", "ANATOMY", 92, 96], ["cells", "ANATOMY", 153, 158], ["intracellular", "ANATOMY", 271, 284], ["putrescine", "CHEMICAL", 285, 295], ["putrescine", "CHEMICAL", 285, 295], ["SPA", "GENE_OR_GENE_PRODUCT", 19, 22], ["ODC", "GENE_OR_GENE_PRODUCT", 51, 54], ["cell", "CELL", 92, 96], ["cells", "CELL", 153, 158], ["SPA", "GENE_OR_GENE_PRODUCT", 212, 215], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 271, 284], ["putrescine", "SIMPLE_CHEMICAL", 285, 295], ["SPA", "PROTEIN", 19, 22], ["ODC", "PROTEIN", 51, 54], ["non-dividing cells", "CELL_TYPE", 140, 158], ["SPA", "PROTEIN", 212, 215], ["ODC activity in S.pombe", "PROBLEM", 51, 74], ["intracellular putrescine", "TREATMENT", 271, 295], ["SPA", "OBSERVATION", 19, 22], ["ODC activity", "OBSERVATION", 51, 63], ["non-dividing cells", "OBSERVATION", 140, 158], ["SPA", "ANATOMY", 212, 215], ["intracellular putrescine", "OBSERVATION", 271, 295]]], ["This result implies that in S.pombe ornithine decarboxylation is the only source of putrescine synthesis (the pathway from arginine via agmatine is not utilized).", [["ornithine", "CHEMICAL", 36, 45], ["putrescine", "CHEMICAL", 84, 94], ["arginine", "CHEMICAL", 123, 131], ["agmatine", "CHEMICAL", 136, 144], ["ornithine", "CHEMICAL", 36, 45], ["putrescine", "CHEMICAL", 84, 94], ["arginine", "CHEMICAL", 123, 131], ["agmatine", "CHEMICAL", 136, 144], ["S.pombe", "SIMPLE_CHEMICAL", 28, 35], ["ornithine", "SIMPLE_CHEMICAL", 36, 45], ["putrescine", "SIMPLE_CHEMICAL", 84, 94], ["arginine", "SIMPLE_CHEMICAL", 123, 131], ["agmatine", "SIMPLE_CHEMICAL", 136, 144], ["S.pombe ornithine decarboxylation", "TREATMENT", 28, 61], ["putrescine synthesis", "PROBLEM", 84, 104], ["arginine via agmatine", "TREATMENT", 123, 144]]], ["The complete depletion of cadaverine in SPA overexpressing cells suggests that ODC is the only enzyme in S.pombe that can decarboxylate lysine, which is also the case in rat tissues (Pegg and McGill, 1979).DiscussionIt is somewhat perplexing that addition of putrescine to the media leads to only partial relief of the growth phenotype associated with SPA overexpression.", [["cells", "ANATOMY", 59, 64], ["tissues", "ANATOMY", 174, 181], ["cadaverine", "CHEMICAL", 26, 36], ["lysine", "CHEMICAL", 136, 142], ["putrescine", "CHEMICAL", 259, 269], ["cadaverine", "CHEMICAL", 26, 36], ["lysine", "CHEMICAL", 136, 142], ["putrescine", "CHEMICAL", 259, 269], ["cadaverine", "SIMPLE_CHEMICAL", 26, 36], ["cells", "CELL", 59, 64], ["ODC", "GENE_OR_GENE_PRODUCT", 79, 82], ["S.pombe", "SIMPLE_CHEMICAL", 105, 112], ["lysine", "AMINO_ACID", 136, 142], ["rat", "ORGANISM", 170, 173], ["tissues", "TISSUE", 174, 181], ["putrescine", "SIMPLE_CHEMICAL", 259, 269], ["SPA", "GENE_OR_GENE_PRODUCT", 352, 355], ["SPA overexpressing cells", "CELL_LINE", 40, 64], ["ODC", "PROTEIN", 79, 82], ["SPA", "PROTEIN", 352, 355], ["rat", "SPECIES", 170, 173], ["rat", "SPECIES", 170, 173], ["cadaverine in SPA overexpressing cells", "TREATMENT", 26, 64], ["decarboxylate lysine", "TREATMENT", 122, 142], ["putrescine", "TREATMENT", 259, 269], ["the growth phenotype", "PROBLEM", 315, 335], ["SPA overexpression", "PROBLEM", 352, 370], ["complete", "OBSERVATION_MODIFIER", 4, 12], ["depletion", "OBSERVATION", 13, 22], ["growth phenotype", "OBSERVATION", 319, 335]]], ["There are two likely explanations. (i) Perhaps S.pombe imports putrescine poorly. (ii) Alternatively, like the mammalian system, maybe SPA inhibits not only ODC but also the polyamine transporter.", [["putrescine", "CHEMICAL", 63, 73], ["polyamine", "CHEMICAL", 174, 183], ["putrescine", "CHEMICAL", 63, 73], ["polyamine", "CHEMICAL", 174, 183], ["S.pombe", "SIMPLE_CHEMICAL", 47, 54], ["putrescine", "SIMPLE_CHEMICAL", 63, 73], ["SPA", "GENE_OR_GENE_PRODUCT", 135, 138], ["ODC", "GENE_OR_GENE_PRODUCT", 157, 160], ["polyamine", "SIMPLE_CHEMICAL", 174, 183], ["ODC", "PROTEIN", 157, 160], ["polyamine transporter", "PROTEIN", 174, 195], ["the polyamine transporter", "PROBLEM", 170, 195], ["two likely explanations", "UNCERTAINTY", 10, 33], ["polyamine transporter", "OBSERVATION", 174, 195]]], ["Further experiments will help to distinguish between these two models.DiscussionIt is unclear how widespread the antizyme gene is within the fungal kingdom.", [["antizyme", "GENE_OR_GENE_PRODUCT", 113, 121], ["antizyme gene", "DNA", 113, 126], ["fungal kingdom", "OBSERVATION", 141, 155]]], ["We have identified and cloned antizyme homologs from two other fission yeasts (Schizosaccharomyces octosporus and Schizosaccharomyces japonicus) and from two distantly related fungi (Botryotinia fuckeliana and Emericella nidulans) (our unpublished results).", [["antizyme", "GENE_OR_GENE_PRODUCT", 30, 38], ["Schizosaccharomyces octosporus", "ORGANISM", 79, 109], ["Schizosaccharomyces japonicus", "ORGANISM", 114, 143], ["Botryotinia fuckeliana", "ORGANISM", 183, 205], ["Emericella nidulans", "ORGANISM", 210, 229], ["antizyme homologs", "PROTEIN", 30, 47], ["Schizosaccharomyces octosporus", "SPECIES", 79, 109], ["Schizosaccharomyces japonicus", "SPECIES", 114, 143], ["Botryotinia fuckeliana", "SPECIES", 183, 205], ["Emericella nidulans", "SPECIES", 210, 229], ["Schizosaccharomyces octosporus", "SPECIES", 79, 109], ["Schizosaccharomyces japonicus", "SPECIES", 114, 143], ["Botryotinia fuckeliana", "SPECIES", 183, 205], ["Emericella nidulans", "SPECIES", 210, 229], ["antizyme homologs", "TREATMENT", 30, 47], ["two other fission yeasts", "PROBLEM", 53, 77], ["Schizosaccharomyces octosporus", "TREATMENT", 79, 109], ["Schizosaccharomyces japonicus", "PROBLEM", 114, 143], ["two distantly related fungi (Botryotinia fuckeliana and Emericella nidulans", "PROBLEM", 154, 229], ["fission yeasts", "OBSERVATION", 63, 77]]], ["The antizyme frameshift site of the latter two fungi has evolved in a unique way different from all other known antizymes, but nevertheless even these two distantly related fungi have conserved the autoregulatory +1 frameshifting.", [["antizymes", "GENE_OR_GENE_PRODUCT", 112, 121], ["antizyme frameshift site", "DNA", 4, 28], ["autoregulatory +1 frameshifting", "DNA", 198, 229], ["The antizyme frameshift site", "PROBLEM", 0, 28], ["the latter two fungi", "PROBLEM", 32, 52], ["antizyme frameshift", "OBSERVATION", 4, 23], ["site", "OBSERVATION_MODIFIER", 24, 28], ["latter", "OBSERVATION_MODIFIER", 36, 42], ["two", "OBSERVATION_MODIFIER", 43, 46], ["fungi", "OBSERVATION", 47, 52], ["autoregulatory", "OBSERVATION", 198, 212], ["+1 frameshifting", "OBSERVATION", 213, 229]]], ["The fact that the yeast S.pombe has an antizyme gene suggests the possibility that the higher eukaryotic metazoans may all have an antizyme gene.DiscussionThe only previously reported antizyme activity in unicellular organisms is from E.coli, but recent analyses suggest that E.coli does not have a true antizyme (Ivanov et al., 1998d).", [["yeast S.pombe", "ORGANISM", 18, 31], ["antizyme", "GENE_OR_GENE_PRODUCT", 131, 139], ["antizyme", "GENE_OR_GENE_PRODUCT", 184, 192], ["yeast S.pombe", "DNA", 18, 31], ["antizyme gene", "DNA", 39, 52], ["antizyme gene", "DNA", 131, 144], ["antizyme", "PROTEIN", 184, 192], ["yeast", "SPECIES", 18, 23], ["yeast", "SPECIES", 18, 23], ["the yeast S.pombe", "PROBLEM", 14, 31], ["an antizyme gene", "TREATMENT", 36, 52], ["the higher eukaryotic metazoans", "PROBLEM", 83, 114], ["an antizyme gene", "TREATMENT", 128, 144], ["antizyme activity", "PROBLEM", 184, 201], ["unicellular organisms", "PROBLEM", 205, 226], ["E.coli", "PROBLEM", 235, 241], ["recent analyses", "TEST", 247, 262], ["E.coli", "PROBLEM", 276, 282], ["yeast S.pombe", "OBSERVATION", 18, 31], ["suggests the possibility", "UNCERTAINTY", 53, 77], ["unicellular organisms", "OBSERVATION", 205, 226], ["E.coli", "OBSERVATION", 235, 241], ["E.coli", "OBSERVATION", 276, 282]]], ["This makes SPA the first bona fide antizyme in a unicellular organism.DiscussionThe remarkable similarity of the core sequence important for antizyme frameshifting from S.pombe to humans could be due to convergent or divergent evolution.", [["antizyme", "GENE_OR_GENE_PRODUCT", 35, 43], ["antizyme", "GENE_OR_GENE_PRODUCT", 141, 149], ["humans", "ORGANISM", 180, 186], ["bona fide antizyme", "PROTEIN", 25, 43], ["core sequence", "DNA", 113, 126], ["humans", "SPECIES", 180, 186], ["humans", "SPECIES", 180, 186], ["a unicellular organism", "PROBLEM", 47, 69], ["the core sequence", "TEST", 109, 126], ["antizyme frameshifting", "PROBLEM", 141, 163], ["unicellular organism", "OBSERVATION", 49, 69]]], ["The near identity of this sequence in worms, Drosophila, Xenopus, zebrafish and humans argues against convergent evolution, as if antizyme frameshifting arose in a common ancestor perhaps more than one billion years ago.DiscussionThree cis-acting RNA elements are known to stimulate mammalian antizyme 1 frameshifting.", [["Xenopus, zebrafish", "ORGANISM", 57, 75], ["humans", "ORGANISM", 80, 86], ["antizyme", "GENE_OR_GENE_PRODUCT", 130, 138], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 293, 303], ["cis-acting RNA elements", "DNA", 236, 259], ["worms", "SPECIES", 38, 43], ["Drosophila", "SPECIES", 45, 55], ["zebrafish", "SPECIES", 66, 75], ["humans", "SPECIES", 80, 86], ["Drosophila", "SPECIES", 45, 55], ["humans", "SPECIES", 80, 86], ["this sequence in worms", "TEST", 21, 43], ["Drosophila", "PROBLEM", 45, 55], ["antizyme frameshifting", "PROBLEM", 130, 152], ["mammalian antizyme", "TREATMENT", 283, 301]]], ["One is a 50 nucleotide sequence immediately 5\u2032 of the shift site (Matsufuji et al., 1995; our unpublished results).", [["nucleotide", "CHEMICAL", 12, 22], ["50 nucleotide sequence", "DNA", 9, 31], ["a 50 nucleotide sequence", "TREATMENT", 7, 31]]], ["A second stimulator is the UGA stop codon of ORF1 and the third is an RNA pseudoknot starting 3 nucleotides 3\u2032 of the UGA stop codon.", [["ORF1", "GENE_OR_GENE_PRODUCT", 45, 49], ["UGA stop codon", "DNA", 27, 41], ["ORF1", "DNA", 45, 49], ["RNA pseudoknot", "RNA", 70, 84], ["UGA stop codon", "DNA", 118, 132], ["A second stimulator", "TREATMENT", 0, 19], ["the UGA", "TREATMENT", 23, 30], ["codon of ORF1", "TREATMENT", 36, 49], ["an RNA pseudoknot", "TREATMENT", 67, 84], ["3 nucleotides", "TREATMENT", 94, 107], ["the UGA", "TREATMENT", 114, 121], ["RNA pseudoknot", "OBSERVATION", 70, 84]]], ["Among frameshift sites of the previously identified antizymes from mammals all the way to Drosophila, there is substantial similarity in the sequences immediately 5\u2032 of the shift site.", [["frameshift sites", "DNA", 6, 22], ["antizymes", "DNA", 52, 61], ["sequences immediately 5\u2032 of the shift site", "DNA", 141, 183], ["Drosophila", "SPECIES", 90, 100], ["Drosophila", "SPECIES", 90, 100], ["Among frameshift sites", "PROBLEM", 0, 22], ["substantial", "OBSERVATION_MODIFIER", 111, 122], ["similarity", "OBSERVATION", 123, 133]]], ["Sixteen of the last 18 nucleotides of ORF1 are completely conserved in these genes.", [["nucleotides", "CHEMICAL", 23, 34], ["ORF1", "GENE_OR_GENE_PRODUCT", 38, 42], ["ORF1", "DNA", 38, 42], ["ORF1", "TREATMENT", 38, 42]]], ["Schizosaccharomyces pombe and C.elegans antizymes have 9 of 9 and 6 of 9 (14 out of 19 in O.volvulus) nucleotides identical to the consensus, respectively.", [["nucleotides", "CHEMICAL", 102, 113], ["Schizosaccharomyces pombe", "ORGANISM", 0, 25], ["C.elegans antizymes", "ORGANISM", 30, 49], ["Schizosaccharomyces pombe", "SPECIES", 0, 25], ["Schizosaccharomyces pombe", "SPECIES", 0, 25], ["Schizosaccharomyces pombe", "TEST", 0, 25], ["C.elegans antizymes", "TEST", 30, 49], ["nucleotides", "TREATMENT", 102, 113]]], ["For the 5\u2032 sequences, generally, the more distantly related two antizymes are, the more the similarity is confined to the 3\u2032 end of that region.", [["antizymes", "GENE_OR_GENE_PRODUCT", 64, 73], ["5\u2032 sequences", "DNA", 8, 20], ["antizymes", "DNA", 64, 73], ["3\u2032 end", "DNA", 122, 128], ["the 5\u2032 sequences", "TEST", 4, 20], ["region", "ANATOMY_MODIFIER", 137, 143]]], ["Our SPA ORF1 deletion data show that mutation of nucleotides that are part of the 5\u2032 consensus sequence leads to reduced frameshifting efficiency.", [["nucleotides", "CHEMICAL", 49, 60], ["SPA ORF1 deletion data", "DNA", 4, 26], ["5\u2032 consensus sequence", "DNA", 82, 103], ["Our SPA ORF1 deletion data", "TEST", 0, 26], ["mutation of nucleotides", "PROBLEM", 37, 60], ["reduced frameshifting efficiency", "PROBLEM", 113, 145], ["reduced", "OBSERVATION_MODIFIER", 113, 120], ["frameshifting efficiency", "OBSERVATION", 121, 145]]], ["This is another indication that conservation of nucleotide sequence in this region is because of its importance for stimulating efficient +1 frameshifting.", [["nucleotide", "CHEMICAL", 48, 58], ["nucleotide", "CHEMICAL", 48, 58], ["nucleotide sequence", "TREATMENT", 48, 67], ["stimulating efficient +1 frameshifting", "PROBLEM", 116, 154], ["+1 frameshifting", "OBSERVATION", 138, 154]]], ["It is quite striking that in all antizyme gene sequences identified so far, including a number of unpublished ones, ORF1 ends with a UGA stop codon.", [["ORF1", "GENE_OR_GENE_PRODUCT", 116, 120], ["antizyme gene sequences", "DNA", 33, 56], ["ORF1 ends", "DNA", 116, 125], ["UGA stop codon", "DNA", 133, 147], ["all antizyme gene sequences", "TEST", 29, 56], ["ORF1 ends", "TREATMENT", 116, 125], ["a UGA", "TREATMENT", 131, 136]]], ["This is particularly surprising since any of the other two stop codons can substitute for UGA to stimulate antizyme 1 frameshifting, although slightly less efficiently, in vitro (Matsufuji et al., 1995) and in vivo (our unpublished results).DiscussionThe 3\u2032 pseudoknot that stimulates frameshifting in antizyme 1 is highly conserved in all known vertebrate antizymes, including mammalian antizyme 2 (Figure 1B).", [["UGA", "SIMPLE_CHEMICAL", 90, 93], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 107, 117], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 302, 312], ["antizymes", "GENE_OR_GENE_PRODUCT", 357, 366], ["antizyme 2", "GENE_OR_GENE_PRODUCT", 388, 398], ["Figure 1B", "GENE_OR_GENE_PRODUCT", 400, 409], ["UGA", "DNA", 90, 93], ["antizyme 1", "PROTEIN", 107, 117], ["antizyme 1", "PROTEIN", 302, 312], ["mammalian antizyme 2", "PROTEIN", 378, 398], ["UGA", "TREATMENT", 90, 93], ["antizyme 1 frameshifting", "TREATMENT", 107, 131], ["The 3\u2032 pseudoknot", "TREATMENT", 251, 268], ["frameshifting in antizyme", "TREATMENT", 285, 310], ["mammalian antizyme", "TREATMENT", 378, 396]]], ["None of the invertebrate antizyme mRNAs identified so far, including those presented here, has a sequence in the equivalent region that can be simply folded to a comparable RNA structure.", [["antizyme", "GENE_OR_GENE_PRODUCT", 25, 33], ["invertebrate antizyme mRNAs", "RNA", 12, 39], ["the invertebrate antizyme mRNAs", "TEST", 8, 39], ["a sequence", "TEST", 95, 105], ["antizyme mRNAs", "OBSERVATION", 25, 39]]], ["However, sequences immediately 3\u2032 of the frameshift site are conserved between invertebrates and vertebrates.", [["frameshift site", "DNA", 41, 56], ["sequences", "TEST", 9, 18], ["the frameshift site", "PROBLEM", 37, 56]]], ["The conservation of this region between Drosophila and the vertebrate counterparts has already been noted (Ivanov et al., 1998b).", [["Drosophila", "SPECIES", 40, 50], ["Drosophila", "ANATOMY_MODIFIER", 40, 50]]], ["The C.elegans antizyme gene contains the sequence YGYCCCYCA (Y = pyrimidine) in this region, which is identical to the consensus.", [["pyrimidine", "CHEMICAL", 65, 75], ["pyrimidine", "CHEMICAL", 65, 75], ["C.elegans antizyme", "GENE_OR_GENE_PRODUCT", 4, 22], ["C.elegans antizyme gene", "DNA", 4, 27], ["The C.elegans antizyme gene", "TREATMENT", 0, 27], ["the sequence YGYCCCYCA (Y = pyrimidine", "TREATMENT", 37, 75]]], ["The antizyme genes from the other four nematodes also have a similar sequence (Figure 1B).", [["antizyme", "GENE_OR_GENE_PRODUCT", 4, 12], ["antizyme genes", "DNA", 4, 18], ["The antizyme genes", "TREATMENT", 0, 18], ["antizyme genes", "OBSERVATION", 4, 18]]], ["The significance of this similarity is not clear [in fact, sequences in this region appear to play no role in antizyme 1 in vitro frameshifting outside of the RNA pseudoknot context (Matsufuji et al., 1995)].DiscussionOnly two examples are known where RNA elements 3\u2032 of the frameshift site stimulate +1 frameshifting.", [["antizyme 1", "GENE_OR_GENE_PRODUCT", 110, 120], ["antizyme 1", "PROTEIN", 110, 120], ["RNA elements 3\u2032 of the frameshift site", "DNA", 252, 290], ["antizyme", "TREATMENT", 110, 118], ["RNA elements", "PROBLEM", 252, 264], ["the frameshift site", "PROBLEM", 271, 290], ["not", "UNCERTAINTY", 39, 42], ["clear", "OBSERVATION", 43, 48], ["+1 frameshifting", "OBSERVATION", 301, 317]]], ["One is the RNA pseudoknot of mammalian antizyme 1 and the second is a short RNA sequence immediately following the frameshift site of Ty3 (Farabaugh et al., 1993).", [["antizyme 1", "GENE_OR_GENE_PRODUCT", 39, 49], ["RNA pseudoknot", "RNA", 11, 25], ["mammalian antizyme 1", "PROTEIN", 29, 49], ["short RNA sequence", "DNA", 70, 88], ["mammalian antizyme", "TREATMENT", 29, 47], ["a short RNA sequence", "PROBLEM", 68, 88], ["RNA pseudoknot", "OBSERVATION", 11, 25], ["mammalian antizyme", "OBSERVATION", 29, 47]]], ["Additional examples would be very helpful in deciphering the role such elements play in the mechanism of +1 frameshifting.", [["+1 frameshifting", "OBSERVATION", 105, 121]]], ["It is currently not known how many and which of the invertebrate antizyme genes contain 3\u2032 frameshift stimulators.", [["antizyme", "GENE_OR_GENE_PRODUCT", 65, 73], ["invertebrate antizyme genes", "DNA", 52, 79], ["the invertebrate antizyme genes", "TREATMENT", 48, 79]]], ["The results presented here show that an S.pombe 3\u2032 stimulator enhances frameshifting \u223c10-fold.", [["S.pombe 3", "GENE_OR_GENE_PRODUCT", 40, 49], ["an S.pombe 3\u2032 stimulator", "TREATMENT", 37, 61]]], ["This stimulator appears completely different from the 3\u2032 RNA pseudoknot in vertebrates.", [["RNA pseudoknot", "RNA", 57, 71], ["This stimulator", "TREATMENT", 0, 15], ["RNA pseudoknot in vertebrates", "PROBLEM", 57, 86], ["pseudoknot", "OBSERVATION", 61, 71], ["vertebrates", "OBSERVATION_MODIFIER", 75, 86]]], ["Our deletion experiments indicate that none of the predicted RNA structures contained within the minimally required 3\u2032 region [up to 150\u2013180 nucleotides downstream of the frameshift site (Figure 5C)] are sufficient to confer the stimulatory effect.", [["nucleotides", "CHEMICAL", 141, 152], ["3\u2032 region", "DNA", 116, 125], ["150\u2013180 nucleotides downstream", "DNA", 133, 163], ["frameshift site", "DNA", 171, 186], ["Our deletion experiments", "TEST", 0, 24], ["the predicted RNA structures", "PROBLEM", 47, 75], ["minimally", "OBSERVATION_MODIFIER", 97, 106]]], ["The SPA 3\u2032 stimulator may act directly through sequence or may have an unusual RNA structure involving non-Watson\u2013Crick base pairing.", [["SPA 3", "GENE_OR_GENE_PRODUCT", 4, 9], ["SPA 3\u2032 stimulator", "PROTEIN", 4, 21], ["The SPA 3\u2032 stimulator", "TREATMENT", 0, 21], ["an unusual RNA structure", "PROBLEM", 68, 92]]], ["More detailed mutagenesis combined with phylogenetic analysis would be required to discern the nature of the 3\u2032 stimulator of SPA.DiscussionThe nematode antizymes were analyzed for the presence of possible 5\u2032 or 3\u2032 stimulators flanking the core frameshift site.", [["SPA", "GENE_OR_GENE_PRODUCT", 126, 129], ["antizymes", "GENE_OR_GENE_PRODUCT", 153, 162], ["SPA", "PROTEIN", 126, 129], ["5\u2032 or 3\u2032 stimulators", "DNA", 206, 226], ["core frameshift site", "DNA", 240, 260], ["phylogenetic analysis", "TEST", 40, 61], ["The nematode antizymes", "TREATMENT", 140, 162], ["3\u2032 stimulators", "TREATMENT", 212, 226], ["core frameshift", "OBSERVATION", 240, 255]]], ["More importantly, phylogenetic analysis with the five identified nematode antizymes failed to identify any conservation of primary RNA sequence (or for that matter potential secondary structure) outside of the core region that is shared between two or more members.", [["nematode antizymes", "DNA", 65, 83], ["primary RNA sequence", "DNA", 123, 143], ["phylogenetic analysis", "TEST", 18, 39], ["primary RNA sequence", "TEST", 123, 143], ["secondary structure", "OBSERVATION", 174, 193], ["core", "ANATOMY_MODIFIER", 210, 214], ["region", "ANATOMY_MODIFIER", 215, 221]]], ["This could indicate that no such extra cis-acting stimulators exist in nematode antizymes or that they are located in a very different place within the mRNA, for example the 3\u2032 untranslated region (the latter suggestion is not supported by our sequence analysis).DiscussionA common mechanism for frameshifting is re-pairing of the peptidyl tRNA in the new reading frame.", [["peptidyl tRNA", "GENE_OR_GENE_PRODUCT", 331, 344], ["mRNA", "RNA", 152, 156], ["3\u2032 untranslated region", "DNA", 174, 196], ["peptidyl tRNA", "PROTEIN", 331, 344], ["new reading frame", "DNA", 352, 369], ["such extra cis-acting stimulators", "PROBLEM", 28, 61], ["our sequence analysis", "TEST", 240, 261], ["frameshifting", "PROBLEM", 296, 309], ["the peptidyl tRNA", "TREATMENT", 327, 344], ["frameshifting", "OBSERVATION", 296, 309]]], ["However, an alternative mechanism whereby the peptidyl tRNA merely occludes the first base of the next codon, has been documented for yeast Ty3 frameshifting (Farabaugh et al., 1993).", [["peptidyl tRNA", "GENE_OR_GENE_PRODUCT", 46, 59], ["peptidyl tRNA", "PROTEIN", 46, 59], ["yeast", "SPECIES", 134, 139], ["yeast", "SPECIES", 134, 139], ["the peptidyl tRNA", "TREATMENT", 42, 59], ["peptidyl tRNA", "OBSERVATION", 46, 59], ["Ty3 frameshifting", "OBSERVATION", 140, 157]]], ["Results of experiments with some mutants of the mammalian antizyme 1 shift site pointed to an occlusion mechanism (Matsufuji et al., 1995).", [["antizyme 1", "GENE_OR_GENE_PRODUCT", 58, 68], ["mammalian antizyme 1 shift site", "DNA", 48, 79], ["the mammalian antizyme", "TREATMENT", 44, 66], ["occlusion", "OBSERVATION", 94, 103]]], ["However, the mechanism with the wild-type, UCC-UGA, shift site is not clear.", [["UCC-UGA", "GENE_OR_GENE_PRODUCT", 43, 50], ["wild-type, UCC-UGA, shift site", "DNA", 32, 62], ["not", "UNCERTAINTY", 66, 69], ["clear", "OBSERVATION", 70, 75]]], ["For C.elegans antizyme the UUU-UGA sequence would be an obvious candidate for a re-pairing since Phe-tRNA could pair perfectly with UUU in both frames.", [["C.elegans antizyme", "GENE_OR_GENE_PRODUCT", 4, 22], ["Phe-tRNA", "SIMPLE_CHEMICAL", 97, 105], ["C.elegans antizyme the UUU-UGA sequence", "DNA", 4, 43], ["Phe-tRNA", "PROTEIN", 97, 105], ["UUU", "DNA", 132, 135], ["C.elegans antizyme", "TREATMENT", 4, 22]]], ["But with UCC-UGA the Ser-tRNA first reading UCC could at best pair two out of three with CCU.", [["UCC-UGA", "DNA", 9, 16], ["Ser-tRNA first reading UCC", "DNA", 21, 47], ["UCC", "TEST", 9, 12]]], ["This important problem warrants further investigation.DiscussionThe frameshift efficiency of SPA frameshift site is lower than that observed with mammalian antizyme 1 even when both are tested in the same organism (S.pombe) [for the frameshift efficiency of antizyme 1 cassette in S.pombe, see Ivanov et al. (1998c)].", [["antizyme 1", "GENE_OR_GENE_PRODUCT", 156, 166], ["antizyme 1", "GENE_OR_GENE_PRODUCT", 258, 268], ["SPA frameshift site", "DNA", 93, 112], ["mammalian antizyme 1", "PROTEIN", 146, 166], ["antizyme 1 cassette", "DNA", 258, 277], ["further investigation", "TEST", 32, 53], ["The frameshift efficiency", "PROBLEM", 64, 89], ["SPA frameshift site", "PROBLEM", 93, 112], ["mammalian antizyme", "TREATMENT", 146, 164], ["antizyme 1 cassette", "TREATMENT", 258, 277], ["SPA frameshift", "OBSERVATION", 93, 107], ["lower", "OBSERVATION_MODIFIER", 116, 121]]], ["It is possible that the observed efficiencies for S.pombe antizyme are artificially low because the constructs do not include all the cis-acting stimulatory elements.", [["S.pombe antizyme", "GENE_OR_GENE_PRODUCT", 50, 66], ["S.pombe antizyme", "PROTEIN", 50, 66], ["cis-acting stimulatory elements", "DNA", 134, 165], ["the observed efficiencies", "PROBLEM", 20, 45], ["S.pombe antizyme", "TREATMENT", 50, 66], ["stimulatory elements", "OBSERVATION", 145, 165]]], ["On the other hand there is no reason why a lower level of frameshifting does not correctly reflect the evolved balance with the other characteristics of the complex system such as relative protein stabilities.DiscussionLike other core cellular processes, the antizyme polyamine regulatory scheme is conserved from yeast S.pombe to human.", [["cellular", "ANATOMY", 235, 243], ["polyamine", "CHEMICAL", 268, 277], ["polyamine", "CHEMICAL", 268, 277], ["cellular", "CELL", 235, 243], ["antizyme", "GENE_OR_GENE_PRODUCT", 259, 267], ["polyamine", "SIMPLE_CHEMICAL", 268, 277], ["human", "ORGANISM", 331, 336], ["yeast", "SPECIES", 314, 319], ["human", "SPECIES", 331, 336], ["yeast", "SPECIES", 314, 319], ["human", "SPECIES", 331, 336], ["a lower level of frameshifting", "PROBLEM", 41, 71], ["relative protein stabilities", "PROBLEM", 180, 208], ["DiscussionLike other core cellular processes", "PROBLEM", 209, 253], ["the antizyme polyamine regulatory scheme", "TREATMENT", 255, 295], ["no reason", "UNCERTAINTY", 27, 36], ["frameshifting", "OBSERVATION", 58, 71], ["balance", "OBSERVATION", 111, 118], ["protein stabilities", "OBSERVATION", 189, 208], ["cellular processes", "OBSERVATION", 235, 253]]], ["It is not obvious why this very special mechanism is so exquisitely preserved over vast evolutionary time.", [["not obvious", "UNCERTAINTY", 6, 17]]], ["From this viewpoint it would seem very important to exploit the genetics systems of S.pombe and C.elegans to understand more thoroughly the physiological effects of perturbing the antizyme system.DNA manipulation and sequencing ::: Materials and methodsThe SPA gene was amplified using the following primers: 5\u2032-CAAAACAAGTTTTCATTATTGGTTTTTTTTAAATCAATCCCC (sense) and 5\u2032-CGTAAATCCAATCTAAATTTAATCTTCAACTAAATCATGAAAAGCCTC (antisense).", [["antizyme", "GENE_OR_GENE_PRODUCT", 180, 188], ["DNA", "CELLULAR_COMPONENT", 196, 199], ["SPA", "GENE_OR_GENE_PRODUCT", 257, 260], ["antizyme", "PROTEIN", 180, 188], ["SPA gene", "DNA", 257, 265], ["the antizyme system", "TREATMENT", 176, 195], ["DNA manipulation", "TEST", 196, 212], ["5\u2032-CAAAACAAGTTTTCATTATTGGTTTTTTTTAAATCAATCCCC (sense)", "TREATMENT", 309, 362], ["5\u2032-CGTAAATCCAATCTAAATTTAATCTTCAACTAAATCATGAAAAGCCTC (antisense)", "TREATMENT", 367, 430], ["SPA", "ANATOMY", 257, 260]]], ["The S.pombe cDNA library used as a template in the amplification was kindly provided by R.Rowley (University of Utah).", [["S.pombe cDNA library", "DNA", 4, 24], ["The S.pombe cDNA library", "TREATMENT", 0, 24], ["a template", "TREATMENT", 33, 43]]], ["The C.elegans antizyme gene was amplified using the following primers: 5\u2032-CCCAGGAATTCCTCGAGTATTTTGA GTATAATTTTAC (sense) and 5\u2032-CGGCCGCTCGAGTTAGACCTT GTAGCTCATGATG (antisense).", [["C.elegans antizyme", "GENE_OR_GENE_PRODUCT", 4, 22], ["C.elegans antizyme gene", "DNA", 4, 27], ["The C.elegans antizyme gene", "TREATMENT", 0, 27], ["CCCAGGAATTCCTCGAGTATTTTGA GTATAATTTTAC (sense)", "TREATMENT", 74, 120], ["5\u2032-CGGCCGCTCGAGTTAGACCTT GTAGCTCATGATG (antisense)", "TREATMENT", 125, 175]]], ["This same amplified DNA was used to make the constructs for in vitro transcription and translation of C.elegans antizyme by cloning it into pTZ18U plasmid using the SacI and HindIII sites incorporated in the two primers.", [["DNA", "CELLULAR_COMPONENT", 20, 23], ["C.elegans antizyme", "GENE_OR_GENE_PRODUCT", 102, 120], ["pTZ18U", "GENE_OR_GENE_PRODUCT", 140, 146], ["SacI", "GENE_OR_GENE_PRODUCT", 165, 169], ["HindIII", "GENE_OR_GENE_PRODUCT", 174, 181], ["amplified DNA", "DNA", 10, 23], ["C.elegans antizyme", "PROTEIN", 102, 120], ["pTZ18U plasmid", "DNA", 140, 154], ["SacI and HindIII sites", "DNA", 165, 187], ["C.elegans", "SPECIES", 102, 111], ["vitro transcription", "TREATMENT", 63, 82], ["C.elegans antizyme", "TREATMENT", 102, 120], ["pTZ18U plasmid", "TREATMENT", 140, 154], ["the SacI and HindIII sites", "TREATMENT", 161, 187]]], ["The in-frame construct was made using a two-step PCR.", [["a two-step PCR", "TREATMENT", 38, 52]]], ["The cDNA sequences of O.volvulus and P.pacificus antizyme genes were obtained by performing 5\u2032 and 3\u2032 RACE PCR with cDNA libraries, which were kindly provided by Ralf Sommer (P.pacificus) and Susan Haynes (O.volvulus).", [["O.volvulus", "GENE_OR_GENE_PRODUCT", 22, 32], ["P.pacificus antizyme", "GENE_OR_GENE_PRODUCT", 37, 57], ["cDNA sequences", "DNA", 4, 18], ["O.volvulus and P.pacificus antizyme genes", "DNA", 22, 63], ["RACE PCR", "DNA", 102, 110], ["cDNA libraries", "DNA", 116, 130], ["The cDNA sequences", "TEST", 0, 18], ["O.volvulus", "TEST", 22, 32], ["P.pacificus antizyme genes", "TEST", 37, 63], ["RACE PCR", "TEST", 102, 110], ["cDNA libraries", "TREATMENT", 116, 130]]], ["The SPA overexpression constructs were made by amplifying the gene with the primers 5\u2032-GCATCCGAATTCCCAAATCCAAGCATCATACGCC (sense) and 5\u2032-GCATCCGGATCCGCCAGTGTTCTTACTTTGAGA TGC (antisense), and then inserting BamHI-digested product between the MscI and BamHI sites of pREP3 plasmid.", [["SPA", "GENE_OR_GENE_PRODUCT", 4, 7], ["BamHI", "GENE_OR_GENE_PRODUCT", 207, 212], ["MscI", "GENE_OR_GENE_PRODUCT", 242, 246], ["BamHI", "GENE_OR_GENE_PRODUCT", 251, 256], ["pREP3", "GENE_OR_GENE_PRODUCT", 266, 271], ["SPA overexpression constructs", "DNA", 4, 33], ["primers 5", "DNA", 76, 85], ["BamHI", "DNA", 207, 212], ["MscI and BamHI sites", "DNA", 242, 262], ["pREP3 plasmid", "DNA", 266, 279], ["The SPA overexpression constructs", "TREATMENT", 0, 33], ["the primers", "TREATMENT", 72, 83], ["GCATCCGAATTCCCAAATCCAAGCATCATACGCC (sense)", "TREATMENT", 87, 129], ["5\u2032-GCATCCGGATCCGCCAGTGTTCTTACTTTGAGA TGC (antisense)", "TREATMENT", 134, 186], ["BamHI-digested product", "TREATMENT", 207, 229], ["the MscI and BamHI sites of pREP3 plasmid", "TREATMENT", 238, 279]]], ["The in-frame construct was made by two-step PCR and subsequently all in-frame SPA constructs described below were made by one-step PCR using this plasmid\u2019s DNA as a template.", [["DNA", "CELLULAR_COMPONENT", 156, 159], ["in-frame construct", "DNA", 4, 22], ["SPA constructs", "DNA", 78, 92], ["plasmid", "DNA", 146, 153], ["two-step PCR", "TEST", 35, 47], ["this plasmid\u2019s DNA", "TREATMENT", 141, 159], ["a template", "TREATMENT", 163, 173]]], ["To make the constructs for frameshift assays in S.pombe, DNA fragments with a given nucleotide length (as described in the main text), were amplified from both the SPA and C.elegans antizyme constructs described above.", [["nucleotide", "CHEMICAL", 84, 94], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["S.pombe", "DNA", 48, 55], ["DNA fragments", "DNA", 57, 70], ["SPA and C.elegans antizyme constructs", "DNA", 164, 201], ["frameshift assays", "TEST", 27, 44], ["DNA fragments", "PROBLEM", 57, 70], ["a given nucleotide length", "TREATMENT", 76, 101], ["C.elegans antizyme constructs", "TREATMENT", 172, 201], ["SPA", "ANATOMY", 164, 167]]], ["These fragments were then cloned between the KpnI and BstEII sites of PIU-LAC plasmid (Ivanov et al., 1998c).", [["fragments", "ANATOMY", 6, 15], ["KpnI", "GENE_OR_GENE_PRODUCT", 45, 49], ["BstEII", "GENE_OR_GENE_PRODUCT", 54, 60], ["PIU", "GENE_OR_GENE_PRODUCT", 70, 73], ["KpnI and BstEII sites", "DNA", 45, 66], ["PIU-LAC plasmid", "DNA", 70, 85], ["These fragments", "PROBLEM", 0, 15], ["the KpnI", "TREATMENT", 41, 49], ["PIU-LAC plasmid", "TREATMENT", 70, 85], ["fragments", "OBSERVATION", 6, 15], ["KpnI", "ANATOMY", 45, 49], ["LAC plasmid", "OBSERVATION", 74, 85]]], ["The PCR primers included an \u2018AC\u2019 spacer between the 5\u2032 cloning site (BstEII) and the antizyme sequences in order to correct the reading frame.", [["PCR primers", "DNA", 4, 15], ["\u2018AC\u2019 spacer", "DNA", 28, 39], ["5\u2032 cloning site", "DNA", 52, 67], ["BstEII", "DNA", 69, 75], ["antizyme sequences", "DNA", 85, 103], ["reading frame", "DNA", 128, 141], ["The PCR primers", "TEST", 0, 15], ["an \u2018AC\u2019 spacer", "TREATMENT", 25, 39], ["the antizyme sequences", "TEST", 81, 103]]], ["The in vivo frameshifting assays in S.pombe (strains ura4-D18 leu1-32 ade6-M216 h\u2013 and \u0394spa::LEU2 ura4-D18 leu1-32 ade6-M216 h\u2013) were done as described (Ivanov et al., 1998c).", [["S.pombe", "ORGANISM", 36, 43], ["\u0394spa", "DNA", 87, 91], ["LEU2 ura4", "DNA", 93, 102], ["D18 leu1", "DNA", 103, 111], ["32 ade6", "DNA", 112, 119], ["M216 h\u2013", "DNA", 120, 127], ["ura4", "TEST", 53, 57], ["leu1", "TEST", 62, 66], ["LEU2 ura4", "TEST", 93, 102], ["leu1", "TEST", 107, 111]]], ["The plasmid for GST\u2013SPA expression was made by PCR amplifying SPA (all but the first codon of ORF1 through the downstream ORF2) from an in-frame template and cloning the product into the EcoRI and XhoI restriction sites of pGEX-5X-3 plasmid.", [["plasmid", "ANATOMY", 4, 11], ["GST", "GENE_OR_GENE_PRODUCT", 16, 19], ["SPA", "GENE_OR_GENE_PRODUCT", 20, 23], ["SPA", "GENE_OR_GENE_PRODUCT", 62, 65], ["ORF1", "GENE_OR_GENE_PRODUCT", 94, 98], ["ORF2", "GENE_OR_GENE_PRODUCT", 122, 126], ["EcoRI", "GENE_OR_GENE_PRODUCT", 187, 192], ["XhoI", "GENE_OR_GENE_PRODUCT", 197, 201], ["pGEX-5X-3", "GENE_OR_GENE_PRODUCT", 223, 232], ["GST", "PROTEIN", 16, 19], ["SPA", "PROTEIN", 20, 23], ["SPA", "DNA", 62, 65], ["ORF1", "DNA", 94, 98], ["ORF2", "DNA", 122, 126], ["in-frame template", "DNA", 136, 153], ["EcoRI and XhoI restriction sites", "DNA", 187, 219], ["pGEX-5X-3 plasmid", "DNA", 223, 240], ["The plasmid", "TREATMENT", 0, 11], ["GST\u2013SPA expression", "TREATMENT", 16, 34], ["ORF1", "TREATMENT", 94, 98], ["the downstream ORF2", "TREATMENT", 107, 126], ["an in-frame template", "TREATMENT", 133, 153], ["the EcoRI and XhoI restriction sites", "TREATMENT", 183, 219], ["pGEX", "TEST", 223, 227]]], ["The antizyme frameshift site in the BMV-coat-antizyme fusion construct (C3NE) (Matsufuji et al., 1995) was mutated with a two-step PCR.", [["antizyme", "GENE_OR_GENE_PRODUCT", 4, 12], ["BMV", "ORGANISM", 36, 39], ["antizyme frameshift site", "DNA", 4, 28], ["BMV-coat-antizyme fusion construct", "DNA", 36, 70], ["The antizyme frameshift", "TREATMENT", 0, 23], ["the BMV", "TREATMENT", 32, 39], ["coat-antizyme fusion construct", "TREATMENT", 40, 70], ["antizyme frameshift", "OBSERVATION", 4, 23]]], ["To generate the two knockout strains, \u0394spa::URA4 and \u0394spa::LEU2, both ORFs of SPA were replaced exactly with the ORF of either URA4 or LEU2.", [["\u0394spa", "GENE_OR_GENE_PRODUCT", 38, 42], ["URA4", "GENE_OR_GENE_PRODUCT", 44, 48], ["\u0394spa", "GENE_OR_GENE_PRODUCT", 53, 57], ["LEU2", "GENE_OR_GENE_PRODUCT", 59, 63], ["SPA", "GENE_OR_GENE_PRODUCT", 78, 81], ["URA4", "GENE_OR_GENE_PRODUCT", 127, 131], ["LEU2", "GENE_OR_GENE_PRODUCT", 135, 139], ["\u0394spa::URA4 and \u0394spa::LEU2", "DNA", 38, 63], ["ORFs", "DNA", 70, 74], ["SPA", "DNA", 78, 81], ["ORF", "DNA", 113, 116], ["URA4", "DNA", 127, 131], ["LEU2", "DNA", 135, 139], ["LEU2", "TREATMENT", 59, 63], ["SPA", "ANATOMY", 78, 81]]], ["To accomplish this, two pairs of primers amplified URA4 and LEU2 such that 50\u201360 nucleotides, which normally flank the two ORFs of SPA, flank the ORFs of the two genes.", [["URA4", "GENE_OR_GENE_PRODUCT", 51, 55], ["LEU2", "GENE_OR_GENE_PRODUCT", 60, 64], ["SPA", "GENE_OR_GENE_PRODUCT", 131, 134], ["URA4", "DNA", 51, 55], ["LEU2", "DNA", 60, 64], ["50\u201360 nucleotides", "DNA", 75, 92], ["ORFs", "DNA", 123, 127], ["SPA", "DNA", 131, 134], ["ORFs", "DNA", 146, 150], ["flank", "ANATOMY_MODIFIER", 109, 114], ["SPA", "ANATOMY", 131, 134], ["flank", "ANATOMY", 136, 141], ["two genes", "ANATOMY_MODIFIER", 158, 167]]], ["The amplified DNA products were gel purified and 2 \u00b5g of each were used to electroporate into ura4-D18 leu1-32 ade6-M216 h\u2013 cells.", [["ura4-D18 leu1-32 ade6-M216 h\u2013 cells", "ANATOMY", 94, 129], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["amplified DNA products", "PROTEIN", 4, 26], ["ura4-D18 leu1-32 ade6-M216 h\u2013 cells", "CELL_LINE", 94, 129], ["The amplified DNA products", "TREATMENT", 0, 26], ["ura4", "TEST", 94, 98]]], ["URA+ and LEU+ transformants were selected by growth on URA\u2013 and LEU\u2013 media, respectively.", [["LEU+ transformants", "ANATOMY", 9, 27], ["URA", "GENE_OR_GENE_PRODUCT", 0, 3], ["URA+ and LEU+ transformants", "DNA", 0, 27], ["URA", "TEST", 0, 3], ["LEU+ transformants", "PROBLEM", 9, 27], ["URA\u2013", "TEST", 55, 59], ["LEU", "ANATOMY_MODIFIER", 9, 12]]], ["PCR screen and partial sequencing, with primers flanking the regions used for the homologous recombination, confirmed the SPA disruptions.", [["PCR screen", "TEST", 0, 10], ["partial sequencing", "TEST", 15, 33], ["primers flanking the regions", "PROBLEM", 40, 68], ["the homologous recombination", "TREATMENT", 78, 106], ["the SPA disruptions", "PROBLEM", 118, 137], ["SPA disruptions", "OBSERVATION", 122, 137]]], ["All DNA clones were sequenced with automated sequencing machines (ABI 100).ODC antizyme assays ::: Materials and methodsSchizosaccharomyces pombe ODC active crude extracts were prepared as follows: S.pombe (strain 1519, leu1-32, h\u2013) provided by R.Rowley was grown to OD600 0.7 in 50 ml of minimal media + LEU.", [["extracts", "ANATOMY", 163, 171], ["leu1-32, h\u2013", "CHEMICAL", 220, 231], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["ODC", "SIMPLE_CHEMICAL", 75, 78], ["Schizosaccharomyces pombe", "ORGANISM", 120, 145], ["ODC", "ORGANISM", 146, 149], ["extracts", "ORGANISM_SUBSTANCE", 163, 171], ["S.pombe", "SIMPLE_CHEMICAL", 198, 205], ["leu1-32", "SIMPLE_CHEMICAL", 220, 227], ["h\u2013", "ORGANISM", 229, 231], ["DNA clones", "DNA", 4, 14], ["Schizosaccharomyces pombe", "SPECIES", 120, 145], ["Schizosaccharomyces pombe", "SPECIES", 120, 145], ["All DNA clones", "TREATMENT", 0, 14], ["automated sequencing machines", "TREATMENT", 35, 64], ["ABI", "TEST", 66, 69], ["ODC antizyme assays", "TEST", 75, 94], ["Materials", "TREATMENT", 99, 108], ["methodsSchizosaccharomyces", "TREATMENT", 113, 139], ["LEU", "ANATOMY", 305, 308]]], ["Ten milligrams of lysing enzymes (Sigma) were added, followed by continued incubation for 30 min at 30\u00b0C. Cells were harvested and washed once with cold homogenization buffer [25 mM Tris\u2013HCl pH 7, 0.25 M sucrose, 1 mM dithiothreitol (DTT), 20 \u00b5M pyridoxal-5-phosphate, 2 mM EDTA] then resuspended in 0.75 ml of homogenization buffer.", [["Cells", "ANATOMY", 106, 111], ["sucrose", "CHEMICAL", 204, 211], ["dithiothreitol", "CHEMICAL", 218, 232], ["DTT", "CHEMICAL", 234, 237], ["pyridoxal-5-phosphate", "CHEMICAL", 246, 267], ["HCl", "CHEMICAL", 187, 190], ["sucrose", "CHEMICAL", 204, 211], ["dithiothreitol", "CHEMICAL", 218, 232], ["DTT", "CHEMICAL", 234, 237], ["pyridoxal-5-phosphate", "CHEMICAL", 246, 267], ["EDTA", "CHEMICAL", 274, 278], ["Cells", "CELL", 106, 111], ["sucrose", "SIMPLE_CHEMICAL", 204, 211], ["dithiothreitol", "SIMPLE_CHEMICAL", 218, 232], ["DTT", "SIMPLE_CHEMICAL", 234, 237], ["pyridoxal-5-phosphate", "SIMPLE_CHEMICAL", 246, 267], ["EDTA", "SIMPLE_CHEMICAL", 274, 278], ["lysing enzymes", "PROTEIN", 18, 32], ["lysing enzymes", "TEST", 18, 32], ["cold homogenization buffer", "TREATMENT", 148, 174], ["pH", "TEST", 191, 193], ["1 mM dithiothreitol (DTT)", "TREATMENT", 213, 238], ["pyridoxal", "TREATMENT", 246, 255], ["phosphate", "TREATMENT", 258, 267], ["homogenization buffer", "TREATMENT", 311, 332]]], ["Cells were broken open and the lysate was clarified by centrifugation at 10 000 r.p.m. for 15 min at 4\u00b0C. Extracts were dialyzed overnight in dialysis buffer (25 mM Tris\u2013HCl pH 7.4, 1 mM DTT, 20 \u00b5M pyridoxal-5-phosphate, 0.1 mM EDTA).", [["Cells", "ANATOMY", 0, 5], ["lysate", "ANATOMY", 31, 37], ["Extracts", "ANATOMY", 106, 114], ["pyridoxal-5-phosphate", "CHEMICAL", 198, 219], ["DTT", "CHEMICAL", 187, 190], ["pyridoxal-5-phosphate", "CHEMICAL", 198, 219], ["EDTA", "CHEMICAL", 228, 232], ["Cells", "CELL", 0, 5], ["Extracts", "ORGANISM_SUBSTANCE", 106, 114], ["pyridoxal-5-phosphate", "SIMPLE_CHEMICAL", 198, 219], ["EDTA", "SIMPLE_CHEMICAL", 228, 232], ["the lysate", "TREATMENT", 27, 37], ["dialysis buffer", "TREATMENT", 142, 157], ["pH", "TEST", 174, 176], ["DTT", "TEST", 187, 190], ["pyridoxal", "TEST", 198, 207], ["phosphate", "TEST", 210, 219]]], ["A volume of 25 \u00b5l of extract was used for each ODC assay.", [["extract", "ANATOMY", 21, 28], ["A volume", "TEST", 0, 8], ["each ODC assay", "TEST", 42, 56], ["volume", "OBSERVATION_MODIFIER", 2, 8]]], ["ODC activity was assayed by measuring the release of 14CO2 from l-[1-14C]ornithine (Amersham) as described (Nishiyama et al., 1988).", [["14CO2", "CHEMICAL", 53, 58], ["l-[1-14C]ornithine", "CHEMICAL", 64, 82], ["14CO2", "CHEMICAL", 53, 58], ["l-[1-14C]ornithine", "CHEMICAL", 64, 82], ["ODC", "GENE_OR_GENE_PRODUCT", 0, 3], ["14CO2", "SIMPLE_CHEMICAL", 53, 58], ["l-[1-14C]ornithine", "SIMPLE_CHEMICAL", 64, 82], ["Amersham", "SIMPLE_CHEMICAL", 84, 92], ["ODC", "PROTEIN", 0, 3], ["ODC activity", "PROBLEM", 0, 12]]], ["Pre-incubation of S.pombe extract with 0.1 mM difluoromethyl ornithine (DFMO) for 15 min led to >99% inhibition of 14CO2 release.Polyamine measurements ::: Materials and methodsThe cells were collected by centrifugation, washed twice with 1 ml of phosphate-buffered saline (PBS) and then the pellet was frozen at \u201380\u00b0C until use.", [["cells", "ANATOMY", 181, 186], ["pellet", "ANATOMY", 292, 298], ["S.pombe extract", "CHEMICAL", 18, 33], ["difluoromethyl ornithine", "CHEMICAL", 46, 70], ["DFMO", "CHEMICAL", 72, 76], ["14CO2", "CHEMICAL", 115, 120], ["Polyamine", "CHEMICAL", 129, 138], ["phosphate", "CHEMICAL", 247, 256], ["difluoromethyl ornithine", "CHEMICAL", 46, 70], ["DFMO", "CHEMICAL", 72, 76], ["14CO2", "CHEMICAL", 115, 120], ["Polyamine", "CHEMICAL", 129, 138], ["phosphate", "CHEMICAL", 247, 256], ["difluoromethyl ornithine", "SIMPLE_CHEMICAL", 46, 70], ["DFMO", "SIMPLE_CHEMICAL", 72, 76], ["14CO2", "SIMPLE_CHEMICAL", 115, 120], ["Polyamine", "SIMPLE_CHEMICAL", 129, 138], ["cells", "CELL", 181, 186], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 247, 272], ["S.pombe extract", "TREATMENT", 18, 33], ["0.1 mM difluoromethyl ornithine (DFMO)", "TREATMENT", 39, 77], ["Polyamine measurements", "TEST", 129, 151], ["phosphate-buffered saline (PBS", "TREATMENT", 247, 277]]], ["The pellet was resuspended in 0.1 ml of PBS.", [["pellet", "ANATOMY", 4, 10], ["The pellet", "TREATMENT", 0, 10], ["PBS", "TREATMENT", 40, 43]]], ["An aliquot of the suspension was mixed with an equal volume of 8% perchloric acid, vortexed for 1 min, kept on ice for 5 min and centrifuged at 15 000 r.p.m., 4\u00b0C for 5 min.", [["perchloric acid", "CHEMICAL", 66, 81], ["perchloric acid", "CHEMICAL", 66, 81], ["perchloric acid", "SIMPLE_CHEMICAL", 66, 81], ["An aliquot of the suspension", "TREATMENT", 0, 28], ["an equal volume", "TREATMENT", 44, 59], ["8% perchloric acid", "TREATMENT", 63, 81], ["ice", "TREATMENT", 111, 114]]], ["Ten microliters of the supernatant were subjected to polyamine analysis using fluorometry on high-performance liquid chromatography as described previously (Murakami et al., 1989).", [["supernatant", "ANATOMY", 23, 34], ["polyamine", "CHEMICAL", 53, 62], ["polyamine", "CHEMICAL", 53, 62], ["polyamine", "SIMPLE_CHEMICAL", 53, 62], ["the supernatant", "TREATMENT", 19, 34], ["polyamine analysis", "TEST", 53, 71], ["fluorometry", "TEST", 78, 89], ["high-performance liquid chromatography", "TREATMENT", 93, 131]]], ["Protein concentrations were determined with the BCA protein assay kit (Pierce).In vitro transcription and translation ::: Materials and methodsThe experiments with the BMV-coat-antizyme fusion constructs were performed as described previously (Matsufuji et al., 1995).", [["BMV", "ORGANISM", 168, 171], ["antizyme", "GENE_OR_GENE_PRODUCT", 177, 185], ["BMV-coat-antizyme fusion constructs", "DNA", 168, 203], ["Protein concentrations", "TEST", 0, 22], ["the BMV", "TREATMENT", 164, 171], ["coat-antizyme fusion constructs", "TREATMENT", 172, 203]]], ["All other plasmid DNA templates were prepared using QIAGEN Miniprep Kit and then digested with HindIII.", [["plasmid", "ANATOMY", 10, 17], ["DNA", "CELLULAR_COMPONENT", 18, 21], ["HindIII", "GENE_OR_GENE_PRODUCT", 95, 102], ["plasmid DNA templates", "DNA", 10, 31], ["HindIII", "DNA", 95, 102], ["All other plasmid DNA templates", "TREATMENT", 0, 31], ["QIAGEN Miniprep Kit", "TREATMENT", 52, 71], ["HindIII", "TREATMENT", 95, 102], ["plasmid DNA", "OBSERVATION", 10, 21]]], ["Transcripts for SPA in vitro translation were made from PCR templates that had a T7 promoter incorporated into the PCR primers.", [["PCR templates", "DNA", 56, 69], ["T7 promoter", "DNA", 81, 92], ["PCR primers", "DNA", 115, 126], ["SPA in vitro translation", "TREATMENT", 16, 40], ["PCR templates", "TREATMENT", 56, 69], ["a T7 promoter", "TREATMENT", 79, 92], ["the PCR primers", "TREATMENT", 111, 126]]], ["Linearized DNA (1 \u00b5g) was used as a template for in vitro transcription with Ambion MEGAshortscriptTM T7 Kit.", [["DNA", "CELLULAR_COMPONENT", 11, 14], ["Linearized DNA", "DNA", 0, 14], ["Linearized DNA", "TREATMENT", 0, 14], ["vitro transcription", "TREATMENT", 52, 71], ["Ambion MEGAshortscriptTM T7 Kit", "TREATMENT", 77, 108]]], ["The DNase-treated RNAs were recovered and resuspended in 40 \u00b5l of RNase-free water.", [["DNase", "GENE_OR_GENE_PRODUCT", 4, 9], ["RNase", "GENE_OR_GENE_PRODUCT", 66, 71], ["DNase", "PROTEIN", 4, 9], ["RNase", "PROTEIN", 66, 71], ["The DNase-treated RNAs", "TREATMENT", 0, 22], ["RNase", "TREATMENT", 66, 71]]], ["One microliter of each specified transcript suspension was used in each in vitro translation reaction [0.5 \u00b5l of 1 mM amino acid mix \u2013Met, 7 \u00b5l of reticulocyte lysate (Promega), 0.5 \u00b5l of [35S]Met (Amersham)] to a total volume of 10 \u00b5l.", [["reticulocyte lysate", "ANATOMY", 147, 166], ["amino acid", "CHEMICAL", 118, 128], ["Met", "CHEMICAL", 134, 137], ["[35S]Met", "CHEMICAL", 188, 196], ["amino acid", "CHEMICAL", 118, 128], ["Met", "CHEMICAL", 134, 137], ["[35S]Met", "CHEMICAL", 188, 196], ["amino acid", "AMINO_ACID", 118, 128], ["reticulocyte", "ORGANISM_SUBSTANCE", 147, 159], ["lysate", "ORGANISM_SUBSTANCE", 160, 166], ["[35S]Met", "SIMPLE_CHEMICAL", 188, 196], ["Amersham", "SIMPLE_CHEMICAL", 198, 206], ["each specified transcript suspension", "TREATMENT", 18, 54], ["1 mM amino acid mix", "TREATMENT", 113, 132], ["Met", "TEST", 134, 137], ["reticulocyte lysate (Promega)", "TREATMENT", 147, 176], ["35S]Met (Amersham)", "TREATMENT", 189, 207], ["a total volume", "TREATMENT", 212, 226], ["transcript suspension", "OBSERVATION", 33, 54]]], ["The reactions were stopped by adding 1 \u00b5l of RNase (10 mg/ml).", [["RNase", "GENE_OR_GENE_PRODUCT", 45, 50], ["RNase", "PROTEIN", 45, 50], ["The reactions", "PROBLEM", 0, 13], ["RNase", "TREATMENT", 45, 50]]], ["The frameshift efficiencies were quantified as described (Ivanov et al., 1998a).", [["The frameshift efficiencies", "PROBLEM", 0, 27], ["frameshift efficiencies", "OBSERVATION", 4, 27]]]], "6eadee150e435c3bd7da60f259661964b932640f": [["Most community acquired pneumonias are bacterial and the hospitalised patient, often elderly, is rapidly rendered pathogen free by broad spectrum antibiotics.", [["pneumonias", "DISEASE", 24, 34], ["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["Most community acquired pneumonias", "PROBLEM", 0, 34], ["bacterial", "PROBLEM", 39, 48], ["broad spectrum antibiotics", "TREATMENT", 131, 157], ["pneumonias", "OBSERVATION", 24, 34], ["bacterial", "OBSERVATION_MODIFIER", 39, 48]]], ["There is no particular threat of pathogen transmission to other patients or to hospital nurses or doctors.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["no particular", "UNCERTAINTY", 9, 22], ["pathogen", "OBSERVATION", 33, 41]]], ["It was therefore an unpleasant and unexpected surprise when a cluster of hospital staff and trainee medical students in a Hong Kong hospital became ill with cough, breathlessness and a high temperature.", [["cough", "DISEASE", 157, 162], ["breathlessness", "DISEASE", 164, 178], ["cough", "PROBLEM", 157, 162], ["breathlessness", "PROBLEM", 164, 178], ["a high temperature", "PROBLEM", 183, 201]]], ["These were all contacts with a 64-year-old doctor who had been admitted into the hospital with the initial diagnosis of community acquired pneumonia.", [["pneumonia", "DISEASE", 139, 148], ["doctor", "ORGANISM", 43, 49], ["community acquired pneumonia", "PROBLEM", 120, 148], ["community acquired", "OBSERVATION", 120, 138], ["pneumonia", "OBSERVATION", 139, 148]]], ["This was the first indication in Hong Kong that a viral not bacterial infection, having apparently arisen in the nearby and adjacent province of Guangdong several months earlier, had spread to the colony.", [["colony", "ANATOMY", 197, 203], ["bacterial infection", "DISEASE", 60, 79], ["a viral not bacterial infection", "PROBLEM", 48, 79], ["bacterial", "OBSERVATION_MODIFIER", 60, 69], ["infection", "OBSERVATION", 70, 79], ["colony", "OBSERVATION", 197, 203]]], ["1 A WHO epidemiologist, C. Urbani, categorised the new clinical syndrome severe acute respiratory syndrome (SARS) in Vietnam in February and later died of the virus which is now named after him.", [["acute respiratory syndrome", "DISEASE", 80, 106], ["SARS", "DISEASE", 108, 112], ["the new clinical syndrome", "PROBLEM", 47, 72], ["severe acute respiratory syndrome", "PROBLEM", 73, 106], ["the virus", "PROBLEM", 155, 164], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["respiratory syndrome", "OBSERVATION", 86, 106], ["virus", "OBSERVATION", 159, 164]]], ["Whilst acknowledging that the scientific and medical communities will be in the lower range of a long ladder of step by step learning, it is already clear that modern molecular virology can identify a new virus and devise molecular testing with speed.", [["a new virus", "PROBLEM", 199, 210], ["molecular testing", "TEST", 222, 239]]], ["However, on the negative side there is international and national panic.", [["panic", "DISEASE", 66, 71], ["international and national panic", "PROBLEM", 39, 71]]], ["It is important that the scientific community appreciates how a modern society in the 21st century reacts to an infectious disease threat.", [["an infectious disease threat", "PROBLEM", 109, 137], ["infectious", "OBSERVATION", 112, 122]]], ["This information will be of value to the WHO, which has issued a template plan for preparation in the event of a global outbreak of a much more contagious and life threatening disease, namely emergent influenza A virus.Why do new respiratory viruses arise in south-east Asia?The world experienced three huge global outbreaks of influenza in the 20th century, in 1918, 1957 and 1968.", [["influenza A virus", "DISEASE", 201, 218], ["respiratory viruses", "DISEASE", 230, 249], ["influenza", "DISEASE", 328, 337], ["influenza A virus", "ORGANISM", 201, 218], ["influenza A virus", "SPECIES", 201, 218], ["influenza A virus", "SPECIES", 201, 218], ["a much more contagious and life threatening disease", "PROBLEM", 132, 183], ["emergent influenza A virus", "PROBLEM", 192, 218], ["new respiratory viruses", "PROBLEM", 226, 249], ["influenza", "PROBLEM", 328, 337], ["respiratory viruses", "OBSERVATION", 230, 249], ["huge", "OBSERVATION_MODIFIER", 303, 307], ["global", "OBSERVATION_MODIFIER", 308, 314], ["outbreaks", "OBSERVATION", 315, 324], ["influenza", "OBSERVATION", 328, 337]]], ["2 Total deaths around the world were 50, 5 and 2 million, respectively, and the social and economic disruption proportional.", [["deaths", "DISEASE", 8, 14], ["Total deaths", "PROBLEM", 2, 14], ["economic disruption", "OBSERVATION", 91, 110], ["proportional", "OBSERVATION_MODIFIER", 111, 123]]], ["Commonly in influenza epidemics, for every death five times as many patients are hospitalised, with elderly persons often having long stays of 9-10 days.Why do new respiratory viruses arise in south-east Asia?Pandemic influenza A is recognised as the classic emerging disease.", [["influenza epidemics", "DISEASE", 12, 31], ["death", "DISEASE", 43, 48], ["respiratory viruses", "DISEASE", 164, 183], ["influenza", "DISEASE", 218, 227], ["patients", "ORGANISM", 68, 76], ["persons", "ORGANISM", 108, 115], ["patients", "SPECIES", 68, 76], ["persons", "SPECIES", 108, 115], ["Pandemic influenza", "SPECIES", 209, 227], ["influenza epidemics", "PROBLEM", 12, 31], ["new respiratory viruses", "PROBLEM", 160, 183], ["Pandemic influenza", "PROBLEM", 209, 227], ["the classic emerging disease", "PROBLEM", 247, 275], ["influenza", "OBSERVATION", 12, 21], ["respiratory viruses", "OBSERVATION", 164, 183], ["influenza", "OBSERVATION", 218, 227], ["disease", "OBSERVATION", 268, 275]]], ["Before the end of the ice age, 12 000 or so years ago, human communities were too dispersed to sustain any respiratory virus requiring a continuous chain of person to person infection.", [["infection", "DISEASE", 174, 183], ["human", "ORGANISM", 55, 60], ["human", "SPECIES", 55, 60], ["person", "SPECIES", 157, 163], ["person", "SPECIES", 167, 173], ["human", "SPECIES", 55, 60], ["any respiratory virus", "PROBLEM", 103, 124], ["infection", "PROBLEM", 174, 183], ["respiratory", "ANATOMY", 107, 118], ["virus", "OBSERVATION", 119, 124], ["infection", "OBSERVATION", 174, 183]]], ["At that stage influenza, and presumably viruses of other families, was an avian virus, but able to cross the species barrier and firmly establish itself in humans, equines, pigs, seals and whales.", [["influenza", "DISEASE", 14, 23], ["humans", "ORGANISM", 156, 162], ["pigs", "ORGANISM", 173, 177], ["humans", "SPECIES", 156, 162], ["pigs", "SPECIES", 173, 177], ["humans", "SPECIES", 156, 162], ["that stage influenza", "PROBLEM", 3, 23], ["an avian virus", "PROBLEM", 71, 85], ["stage", "OBSERVATION_MODIFIER", 8, 13], ["influenza", "OBSERVATION", 14, 23], ["presumably", "UNCERTAINTY", 29, 39], ["viruses", "OBSERVATION", 40, 47]]], ["The so-called 'Asian' influenza arose in 1957 whilst 'Mao' flu had its origin in 1968 in China.", [["influenza", "DISEASE", 22, 31], ["influenza", "PROBLEM", 22, 31]]], ["The origin of the Great Pandemic of 1918 was completely different and for the first time we have scientific evidence of an origin in the vast city army camp at Etaples, France, during the war First World War itself.", [["origin", "ANATOMY_MODIFIER", 4, 10], ["Great", "OBSERVATION_MODIFIER", 18, 23], ["Pandemic", "OBSERVATION", 24, 32], ["origin", "OBSERVATION_MODIFIER", 123, 129]]], ["4 However, in each influenza pandemic, and most likely in the current SARS outbreak, the special circumstances which allowed and encouraged the cross-species emergence and transmission were large numbers of young people living in overcrowded conditions and at the same time in contact with domestic chickens, turkeys, geese and pigs.", [["influenza", "DISEASE", 19, 28], ["SARS", "DISEASE", 70, 74], ["people", "ORGANISM", 213, 219], ["chickens", "ORGANISM", 299, 307], ["turkeys", "ORGANISM", 309, 316], ["geese", "ORGANISM", 318, 323], ["pigs", "ORGANISM", 328, 332], ["people", "SPECIES", 213, 219], ["chickens", "SPECIES", 299, 307], ["turkeys", "SPECIES", 309, 316], ["pigs", "SPECIES", 328, 332], ["chickens", "SPECIES", 299, 307], ["turkeys", "SPECIES", 309, 316], ["each influenza pandemic", "PROBLEM", 14, 37], ["most likely", "UNCERTAINTY", 43, 54]]], ["Either a new influenza virus emerges directly from an avian source as in 1997 5 or indirectly via an intermediate mixing host in the pigs.", [["pigs", "ORGANISM", 133, 137], ["pigs", "SPECIES", 133, 137], ["a new influenza virus", "PROBLEM", 7, 28], ["new", "OBSERVATION_MODIFIER", 9, 12], ["influenza virus", "OBSERVATION", 13, 28]]], ["A formidable barrier is the chemical structure of proteins on the influenza virus haemagglutinin (HA) and the receptor binding site's affinity for sialylated glycoproteins on respiratory cells of humans relative to birds.", [["respiratory cells", "ANATOMY", 175, 192], ["influenza virus haemagglutinin", "ORGANISM", 66, 96], ["HA", "GENE_OR_GENE_PRODUCT", 98, 100], ["respiratory cells", "CELL", 175, 192], ["humans", "ORGANISM", 196, 202], ["birds", "ORGANISM", 215, 220], ["influenza virus haemagglutinin", "PROTEIN", 66, 96], ["HA", "PROTEIN", 98, 100], ["sialylated glycoproteins", "PROTEIN", 147, 171], ["respiratory cells", "CELL_TYPE", 175, 192], ["influenza virus haemagglutinin", "SPECIES", 66, 96], ["humans", "SPECIES", 196, 202], ["humans", "SPECIES", 196, 202], ["A formidable barrier", "TREATMENT", 0, 20], ["the influenza virus haemagglutinin (HA)", "PROBLEM", 62, 101], ["the receptor binding site", "PROBLEM", 106, 131], ["sialylated glycoproteins", "PROBLEM", 147, 171], ["formidable", "OBSERVATION_MODIFIER", 2, 12], ["barrier", "OBSERVATION", 13, 20], ["respiratory cells", "OBSERVATION", 175, 192]]], ["The pig has respiratory epithelial cells which would allow attachment of either avian or human influenza HA's.", [["respiratory epithelial cells", "ANATOMY", 12, 40], ["pig", "ORGANISM", 4, 7], ["respiratory epithelial cells", "CELL", 12, 40], ["avian", "ORGANISM", 80, 85], ["human", "ORGANISM", 89, 94], ["influenza HA", "ORGANISM", 95, 107], ["respiratory epithelial cells", "CELL_TYPE", 12, 40], ["pig", "SPECIES", 4, 7], ["human", "SPECIES", 89, 94], ["pig", "SPECIES", 4, 7], ["human", "SPECIES", 89, 94], ["respiratory epithelial cells", "PROBLEM", 12, 40], ["human influenza HA's", "PROBLEM", 89, 109], ["respiratory epithelial cells", "OBSERVATION", 12, 40]]], ["South-east China and Hong Kong appear to have a climate conducive to the spread of a range of respiratory viruses.", [["respiratory viruses", "DISEASE", 94, 113], ["respiratory viruses", "PROBLEM", 94, 113], ["respiratory viruses", "OBSERVATION", 94, 113]]], ["In the Northern and Southern hemispheres influenza A is epidemic and very seasonal, appearing at the beginning of winter.", [["epidemic", "PROBLEM", 56, 64], ["influenza", "OBSERVATION", 41, 50], ["epidemic", "OBSERVATION_MODIFIER", 56, 64]]], ["In contrast, Hong Kong and Southern China experiences influenza outbreaks all the year round.", [["influenza outbreaks", "DISEASE", 54, 73], ["influenza outbreaks", "PROBLEM", 54, 73]]], ["6 Intense surveillance in Hong Kong for influenza can simultaneously detect other respiratory virusesWhy do new respiratory viruses arise in south-east Asia?The World Health Organization has issued a template pandemic plan for influenza, and recognises that south-east Asia is an epicentre for emergence of a new influenza A pandemic.", [["influenza", "DISEASE", 40, 49], ["respiratory viruses", "DISEASE", 82, 101], ["respiratory viruses", "DISEASE", 112, 131], ["influenza", "DISEASE", 227, 236], ["influenza A pandemic", "DISEASE", 313, 333], ["influenza", "PROBLEM", 40, 49], ["other respiratory viruses", "PROBLEM", 76, 101], ["new respiratory viruses", "PROBLEM", 108, 131], ["influenza", "PROBLEM", 227, 236], ["a new influenza A pandemic", "PROBLEM", 307, 333], ["respiratory viruses", "OBSERVATION", 82, 101], ["respiratory viruses", "OBSERVATION", 112, 131]]], ["There has therefore been substantial virological and scientific investment in this area to monitor birds, pigs and humans for new influenza viruses and two outbreaks with family deaths of influenza H5 (avian type) have been described over the last 3 years.", [["influenza viruses", "DISEASE", 130, 147], ["deaths", "DISEASE", 178, 184], ["influenza", "DISEASE", 188, 197], ["birds", "ORGANISM", 99, 104], ["pigs", "ORGANISM", 106, 110], ["humans", "ORGANISM", 115, 121], ["influenza H5", "ORGANISM", 188, 200], ["pigs", "SPECIES", 106, 110], ["humans", "SPECIES", 115, 121], ["influenza H5", "SPECIES", 188, 200], ["pigs", "SPECIES", 106, 110], ["humans", "SPECIES", 115, 121], ["pigs", "TREATMENT", 106, 110], ["new influenza viruses", "PROBLEM", 126, 147], ["influenza", "PROBLEM", 188, 197], ["substantial", "OBSERVATION_MODIFIER", 25, 36], ["virological", "OBSERVATION", 37, 48]]], ["The virologists in Hong Kong were therefore well equipped to identify any new respiratory viruses, in this case the cause of SARS the newly identified coronavirus.", [["respiratory viruses", "DISEASE", 78, 97], ["SARS", "DISEASE", 125, 129], ["coronavirus", "DISEASE", 151, 162], ["coronavirus", "ORGANISM", 151, 162], ["any new respiratory viruses", "PROBLEM", 70, 97], ["SARS", "PROBLEM", 125, 129], ["coronavirus", "PROBLEM", 151, 162], ["new", "OBSERVATION_MODIFIER", 74, 77], ["respiratory viruses", "OBSERVATION", 78, 97], ["coronavirus", "OBSERVATION", 151, 162]]], ["1 The family coronaviridae It has been recognised for four decades that there are respiratory viruses yet to be discovered.", [["respiratory viruses", "DISEASE", 82, 101], ["respiratory viruses", "PROBLEM", 82, 101], ["respiratory viruses", "OBSERVATION", 82, 101]]], ["Coronaviruses themselves were first found, unexpectedly, as a cause of the common cold in volunteers at the Common Cold Unit in Salisbury.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13]]], ["7 Electron microscopy identified them as spherical but with a strikingly detached corona of knobbed spikes, giving an appearance of a globe with a separate halo of small knobs (Fig. 1) .", [["Electron microscopy", "TEST", 2, 21], ["a strikingly detached corona of knobbed spikes", "PROBLEM", 60, 106], ["a globe", "PROBLEM", 132, 139], ["spherical", "OBSERVATION_MODIFIER", 41, 50], ["strikingly", "OBSERVATION_MODIFIER", 62, 72], ["detached", "OBSERVATION_MODIFIER", 73, 81], ["corona", "OBSERVATION_MODIFIER", 82, 88], ["knobbed spikes", "OBSERVATION", 92, 106], ["globe", "ANATOMY", 134, 139], ["halo", "OBSERVATION", 156, 160], ["small knobs", "OBSERVATION", 164, 175], ["Fig", "OBSERVATION_MODIFIER", 177, 180]]], ["Over the next four decades little attention was paid to this human virus family, although it was recognised that the total range of pathogenicity within the wider family was very wide, encompassing gastroenteritis in pigs, bronchitis in chickens and liver disease in mice.", [["liver", "ANATOMY", 250, 255], ["gastroenteritis", "DISEASE", 198, 213], ["bronchitis", "DISEASE", 223, 233], ["liver disease", "DISEASE", 250, 263], ["human", "ORGANISM", 61, 66], ["pigs", "ORGANISM", 217, 221], ["chickens", "ORGANISM", 237, 245], ["liver", "ORGAN", 250, 255], ["mice", "ORGANISM", 267, 271], ["human", "SPECIES", 61, 66], ["pigs", "SPECIES", 217, 221], ["chickens", "SPECIES", 237, 245], ["mice", "SPECIES", 267, 271], ["human virus", "SPECIES", 61, 72], ["pigs", "SPECIES", 217, 221], ["chickens", "SPECIES", 237, 245], ["mice", "SPECIES", 267, 271], ["gastroenteritis", "PROBLEM", 198, 213], ["bronchitis", "PROBLEM", 223, 233], ["liver disease in mice", "PROBLEM", 250, 271], ["gastroenteritis", "OBSERVATION", 198, 213], ["bronchitis", "OBSERVATION", 223, 233], ["liver", "ANATOMY", 250, 255], ["disease", "OBSERVATION", 256, 263]]], ["There were some warnings of viral pneumonia in humans, but only in army camps and other rather closed communities.", [["pneumonia", "DISEASE", 34, 43], ["humans", "ORGANISM", 47, 53], ["humans", "SPECIES", 47, 53], ["humans", "SPECIES", 47, 53], ["viral pneumonia in humans", "PROBLEM", 28, 53], ["viral", "OBSERVATION_MODIFIER", 28, 33], ["pneumonia", "OBSERVATION", 34, 43]]], ["8 Most adults in the world have antibody and presumably immunity to the two classic virus serotypes and there is little evidence of antigenic drift or changes over the years.Why do new respiratory viruses arise in south-east Asia?Overall the coronavirus family was viewed as causing mild upper respiratory tract infections, cough and sore throat.", [["upper respiratory tract", "ANATOMY", 288, 311], ["respiratory viruses", "DISEASE", 185, 204], ["upper respiratory tract infections", "DISEASE", 288, 322], ["cough", "DISEASE", 324, 329], ["sore throat", "DISEASE", 334, 345], ["adults", "ORGANISM", 7, 13], ["coronavirus", "ORGANISM", 242, 253], ["upper", "ORGANISM_SUBDIVISION", 288, 293], ["respiratory tract", "ORGANISM_SUBDIVISION", 294, 311], ["antibody", "PROBLEM", 32, 40], ["the two classic virus serotypes", "PROBLEM", 68, 99], ["antigenic drift", "PROBLEM", 132, 147], ["new respiratory viruses", "PROBLEM", 181, 204], ["mild upper respiratory tract infections", "PROBLEM", 283, 322], ["cough", "PROBLEM", 324, 329], ["sore throat", "PROBLEM", 334, 345], ["little evidence of", "UNCERTAINTY", 113, 131], ["antigenic drift", "OBSERVATION", 132, 147], ["respiratory viruses", "OBSERVATION", 185, 204], ["coronavirus", "OBSERVATION", 242, 253], ["mild", "OBSERVATION_MODIFIER", 283, 287], ["upper", "ANATOMY_MODIFIER", 288, 293], ["respiratory tract", "ANATOMY", 294, 311], ["infections", "OBSERVATION", 312, 322], ["cough", "OBSERVATION", 324, 329], ["sore throat", "ANATOMY", 334, 345]]], ["The human coronavirus to date has not proven to be easily cultivated in the laboratory and virologists have had to resort to origin cultures of human trachea.", [["trachea", "ANATOMY", 150, 157], ["human", "ORGANISM", 4, 9], ["coronavirus", "ORGANISM", 10, 21], ["human", "ORGANISM", 144, 149], ["trachea", "ORGAN", 150, 157], ["human", "SPECIES", 4, 9], ["coronavirus", "SPECIES", 10, 21], ["human", "SPECIES", 144, 149], ["human coronavirus", "SPECIES", 4, 21], ["human", "SPECIES", 144, 149], ["The human coronavirus", "PROBLEM", 0, 21], ["human", "ANATOMY_MODIFIER", 144, 149], ["trachea", "ANATOMY", 150, 157]]], ["The mildness of infection relative to the disease around the world, particularly in children, is the reason why this virus family have never been a focus for development of new drugs or vaccines.The new human Urbani SARS coronavirusThe classical techniques of virus cultivation in cell culture, along with electron microscopy, successfully identified the new virus associated with the current SARS outbreak.", [["cell culture", "ANATOMY", 281, 293], ["infection", "DISEASE", 16, 25], ["SARS coronavirus", "DISEASE", 216, 232], ["SARS", "DISEASE", 393, 397], ["children", "ORGANISM", 84, 92], ["human", "ORGANISM", 203, 208], ["Urbani SARS coronavirus", "ORGANISM", 209, 232], ["cell", "CELL", 281, 285], ["children", "SPECIES", 84, 92], ["human", "SPECIES", 203, 208], ["coronavirus", "SPECIES", 221, 232], ["human Urbani SARS coronavirus", "SPECIES", 203, 232], ["infection", "PROBLEM", 16, 25], ["the disease", "PROBLEM", 38, 49], ["new drugs", "TREATMENT", 173, 182], ["vaccines", "TREATMENT", 186, 194], ["The new human Urbani SARS coronavirus", "PROBLEM", 195, 232], ["virus cultivation", "TREATMENT", 260, 277], ["cell culture", "TEST", 281, 293], ["electron microscopy", "TEST", 306, 325], ["the new virus", "PROBLEM", 351, 364], ["the current SARS outbreak", "PROBLEM", 381, 406], ["infection", "OBSERVATION", 16, 25], ["disease", "OBSERVATION", 42, 49], ["new", "OBSERVATION_MODIFIER", 355, 358], ["virus", "OBSERVATION", 359, 364]]], ["Thereafter, complete genome sequence of cultivated clinical material from the first SARS cases showed the virus as new.", [["SARS", "DISEASE", 84, 88], ["cultivated clinical material", "PROBLEM", 40, 68], ["the first SARS cases", "TEST", 74, 94], ["the virus", "PROBLEM", 102, 111], ["virus", "OBSERVATION", 106, 111], ["new", "OBSERVATION_MODIFIER", 115, 118]]], ["Virus genes were detected in lung but also in kidney and liver.", [["lung", "ANATOMY", 29, 33], ["kidney", "ANATOMY", 46, 52], ["liver", "ANATOMY", 57, 62], ["Virus", "ORGANISM", 0, 5], ["lung", "ORGAN", 29, 33], ["kidney", "ORGAN", 46, 52], ["liver", "ORGAN", 57, 62], ["Virus genes", "DNA", 0, 11], ["Virus genes", "PROBLEM", 0, 11], ["lung", "ANATOMY", 29, 33], ["kidney", "ANATOMY", 46, 52], ["liver", "ANATOMY", 57, 62]]], ["Initial genetic analysis showed a weak homology to the family coronaviridae.", [["Initial genetic analysis", "TEST", 0, 24]]], ["The new SARS virus is allocated into a new grouping of its own.", [["SARS", "DISEASE", 8, 12], ["SARS virus", "SPECIES", 8, 18], ["The new SARS virus", "PROBLEM", 0, 18], ["new", "OBSERVATION_MODIFIER", 4, 7], ["SARS virus", "OBSERVATION", 8, 18]]], ["The other three groupings are the human coronavirus 229E and porcine epidemic diarrhoea (group I); bovine coronavirus, mouse hepaptitis virus and human coronavirus OC43 (group II); and avian infectious bronchitis (group III).", [["coronavirus 229E", "DISEASE", 40, 56], ["porcine epidemic diarrhoea", "DISEASE", 61, 87], ["bovine coronavirus", "DISEASE", 99, 117], ["mouse hepaptitis", "DISEASE", 119, 135], ["coronavirus OC43", "DISEASE", 152, 168], ["avian infectious bronchitis", "DISEASE", 185, 212], ["human", "ORGANISM", 34, 39], ["coronavirus 229E", "ORGANISM", 40, 56], ["porcine epidemic diarrhoea", "ORGANISM", 61, 87], ["bovine", "ORGANISM", 99, 105], ["coronavirus", "ORGANISM", 106, 117], ["mouse hepaptitis virus", "ORGANISM", 119, 141], ["human", "ORGANISM", 146, 151], ["coronavirus OC43", "ORGANISM", 152, 168], ["human", "SPECIES", 34, 39], ["coronavirus", "SPECIES", 40, 51], ["porcine", "SPECIES", 61, 68], ["bovine", "SPECIES", 99, 105], ["coronavirus", "SPECIES", 106, 117], ["mouse", "SPECIES", 119, 124], ["hepaptitis virus", "SPECIES", 125, 141], ["human", "SPECIES", 146, 151], ["coronavirus", "SPECIES", 152, 163], ["avian", "SPECIES", 185, 190], ["human coronavirus", "SPECIES", 34, 51], ["porcine epidemic diarrhoea (group I", "SPECIES", 61, 96], ["bovine coronavirus", "SPECIES", 99, 117], ["mouse hepaptitis virus", "SPECIES", 119, 141], ["human coronavirus", "SPECIES", 146, 163], ["the human coronavirus", "PROBLEM", 30, 51], ["porcine epidemic diarrhoea (group I)", "PROBLEM", 61, 97], ["bovine coronavirus", "PROBLEM", 99, 117], ["mouse hepaptitis virus", "PROBLEM", 119, 141], ["human coronavirus OC43", "PROBLEM", 146, 168], ["avian infectious bronchitis", "PROBLEM", 185, 212], ["infectious", "OBSERVATION_MODIFIER", 191, 201], ["bronchitis", "OBSERVATION", 202, 212]]], ["Serologically, human antibodies to the two human viruses 229E and OC43 do not cross react with the new virus.", [["human", "ORGANISM", 15, 20], ["human viruses 229E", "ORGANISM", 43, 61], ["OC43", "GENE_OR_GENE_PRODUCT", 66, 70], ["human antibodies", "PROTEIN", 15, 31], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 15, 20], ["human viruses", "SPECIES", 43, 56], ["Serologically", "TEST", 0, 13], ["human antibodies", "TEST", 15, 31], ["two human viruses", "TEST", 39, 56], ["OC43", "TEST", 66, 70], ["the new virus", "PROBLEM", 95, 108]]], ["The rapidity of modern molecular techniques has lead to the development of new diagnostic tests for the virus using reverse transcriptase polymerase chain reaction (RT-PCR) and also serological tests within 6 weeks of the first isolation of virus.", [["reverse transcriptase", "PROTEIN", 116, 137], ["modern molecular techniques", "PROBLEM", 16, 43], ["new diagnostic tests", "TEST", 75, 95], ["the virus", "PROBLEM", 100, 109], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 116, 163], ["RT-PCR", "TEST", 165, 171], ["serological tests", "TEST", 182, 199], ["virus", "PROBLEM", 241, 246], ["rapidity", "OBSERVATION_MODIFIER", 4, 12], ["virus", "OBSERVATION", 241, 246]]], ["8 To date the latter have failed to detect antiviral antibody in non-ill controls, whereas clinically ill patients, as expected, show rises in specific antibody to the new coronavirus but not to the two known, more mild, human coronaviruses.", [["patients", "ORGANISM", 106, 114], ["coronavirus", "ORGANISM", 172, 183], ["human", "ORGANISM", 221, 226], ["antiviral antibody", "PROTEIN", 43, 61], ["patients", "SPECIES", 106, 114], ["human", "SPECIES", 221, 226], ["human coronaviruses", "SPECIES", 221, 240], ["antiviral antibody", "TEST", 43, 61], ["rises in specific antibody", "PROBLEM", 134, 160], ["the new coronavirus", "PROBLEM", 164, 183], ["more mild, human coronaviruses", "PROBLEM", 210, 240], ["mild", "OBSERVATION_MODIFIER", 215, 219], ["coronaviruses", "OBSERVATION", 227, 240]]], ["This simultaneously shows that SARS virus is new to the human community and different from the classic human corona viruses.The new human Urbani SARS coronavirusSo it would appear, unexpectedly, that a novel coronavirus has emerged in south-east Asia, possibly from a civet cat, and caused pneumonia in patients with a rather high mortality of 13% in younger persons and up to 50% in the over 60 category, and has subsequently spread to 22 countries including the UK.Epidemiological characteristics of the outbreakAs a comparator, a truly global respiratory virus like influenza, having arisen in this region in the past, rather quickly emerged to infect millions of persons worldwide.", [["community", "ANATOMY", 62, 71], ["SARS", "DISEASE", 31, 35], ["SARS coronavirus", "DISEASE", 145, 161], ["coronavirus", "DISEASE", 208, 219], ["pneumonia", "DISEASE", 290, 299], ["influenza", "DISEASE", 569, 578], ["SARS virus", "ORGANISM", 31, 41], ["human", "ORGANISM", 56, 61], ["human", "ORGANISM", 103, 108], ["corona viruses", "ORGANISM", 109, 123], ["human", "ORGANISM", 132, 137], ["Urbani SARS coronavirus", "ORGANISM", 138, 161], ["coronavirus", "ORGANISM", 208, 219], ["cat", "ORGANISM", 274, 277], ["patients", "ORGANISM", 303, 311], ["UK", "GENE_OR_GENE_PRODUCT", 464, 466], ["persons", "ORGANISM", 667, 674], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 132, 137], ["coronavirus", "SPECIES", 150, 161], ["patients", "SPECIES", 303, 311], ["persons", "SPECIES", 359, 366], ["persons", "SPECIES", 667, 674], ["SARS virus", "SPECIES", 31, 41], ["human", "SPECIES", 56, 61], ["human corona viruses", "SPECIES", 103, 123], ["human Urbani SARS coronavirus", "SPECIES", 132, 161], ["SARS virus", "PROBLEM", 31, 41], ["The new human Urbani SARS coronavirus", "PROBLEM", 124, 161], ["a novel coronavirus", "PROBLEM", 200, 219], ["a civet cat", "PROBLEM", 266, 277], ["pneumonia", "PROBLEM", 290, 299], ["a truly global respiratory virus", "PROBLEM", 531, 563], ["influenza", "PROBLEM", 569, 578], ["SARS virus", "OBSERVATION", 31, 41], ["new", "OBSERVATION_MODIFIER", 45, 48], ["corona viruses", "OBSERVATION", 109, 123], ["pneumonia", "OBSERVATION", 290, 299], ["outbreak", "OBSERVATION_MODIFIER", 506, 514], ["respiratory virus", "OBSERVATION", 546, 563], ["influenza", "OBSERVATION", 569, 578]]], ["Given the remarkable extent of air travel today, compared to even 1968, the SARS virus is not spreading rapidly, at least to date.", [["SARS", "DISEASE", 76, 80], ["SARS virus", "SPECIES", 76, 86], ["the SARS virus", "PROBLEM", 72, 86], ["remarkable", "OBSERVATION_MODIFIER", 10, 20], ["extent", "OBSERVATION_MODIFIER", 21, 27], ["air travel", "OBSERVATION", 31, 41], ["not", "UNCERTAINTY", 90, 93], ["spreading", "OBSERVATION_MODIFIER", 94, 103]]], ["Although 22 other countries have reported cases, they are predominantly from persons who recently visited south-east Asia.", [["persons", "ORGANISM", 77, 84], ["persons", "SPECIES", 77, 84]]], ["There have been few secondary cases outside the south-east Asia epicentre in persons in Europe having been in contact with an index case.", [["persons", "ORGANISM", 77, 84], ["persons", "SPECIES", 77, 84], ["few", "OBSERVATION_MODIFIER", 16, 19], ["secondary", "OBSERVATION_MODIFIER", 20, 29]]], ["The one apparent exception, Toronto in Canada, may be explained by community and Chinese ethnic closeness of the group infected in Canada itself.", [["may be explained", "UNCERTAINTY", 47, 63]]], ["This limited spread is the hallmark of a virus with low communicability.", [["a virus", "PROBLEM", 39, 46], ["virus", "OBSERVATION", 41, 46]]], ["It is possible that the particular climate of south-east Asia, together with the highdensity living and youthful population may allow a limited virus spread, whereas only infrequently would the virus be able to cause severe problems elsewhere in the world.", [["the highdensity living", "PROBLEM", 77, 99], ["a limited virus spread", "PROBLEM", 134, 156], ["the virus", "PROBLEM", 190, 199], ["severe problems", "PROBLEM", 217, 232]]], ["The epidemiological observation that SARS was first detected in Guangdong province in November 2002 and took four months to spread even to the immediately neighbouring Hong Kong, despite easy exchange of family members between the two areas, does suggest, fortunately, a virus with a low infectiousness.", [["SARS", "DISEASE", 37, 41], ["SARS", "PROBLEM", 37, 41], ["a virus", "PROBLEM", 269, 276], ["a low infectiousness", "PROBLEM", 282, 302]]], ["In the past, respiratory viruses of this family have been known to spread by inhalation of a contaminated cough cloud from an afflicted person, or by touching crockery or cutlery surfaces contaminated with cough droplets which have been deposited on surfaces, there to survive for several hours.", [["cough", "DISEASE", 106, 111], ["person", "SPECIES", 136, 142], ["respiratory viruses", "PROBLEM", 13, 32], ["a contaminated cough", "PROBLEM", 91, 111], ["cough droplets", "PROBLEM", 206, 220], ["respiratory", "ANATOMY", 13, 24], ["viruses", "OBSERVATION", 25, 32]]], ["In high density community buildings, communal areas such as lifts would be a focus for infection.", [["infection", "DISEASE", 87, 96], ["infection", "PROBLEM", 87, 96], ["high density", "OBSERVATION_MODIFIER", 3, 15], ["community buildings", "OBSERVATION", 16, 35], ["communal", "OBSERVATION_MODIFIER", 37, 45], ["infection", "OBSERVATION", 87, 96]]], ["Family transmission, particularly in families with young children is common, often via shared towels, glasses, toothbrushes and virus contaminated bedclothes.", [["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65]]], ["Faecal-oral transmission remains possible.", [["oral", "ANATOMY", 7, 11], ["Faecal", "ORGANISM_SUBSTANCE", 0, 6], ["oral", "ORGANISM_SUBDIVISION", 7, 11]]], ["Analysis of SARS cases in a region outside China, namely the USA illustrates how careful barrier control can reduce transmissibility and also the mortality.", [["SARS", "DISEASE", 12, 16], ["SARS cases", "PROBLEM", 12, 22], ["careful barrier control", "TREATMENT", 81, 104]]], ["The US Center For Disease Control (CDC) has reported 166 suspected cases of SARS from 30 American states and 81% of the cases were in adults, 93% of them having travelled within the 10 days before illness onset to Asia.", [["SARS", "DISEASE", 76, 80], ["illness", "DISEASE", 197, 204], ["SARS", "PROBLEM", 76, 80]]], ["9 There have been no secondary cases or deaths in the USA, nor in the UK or the rest of Europe.", [["deaths", "DISEASE", 40, 46], ["secondary cases", "PROBLEM", 21, 36], ["no", "UNCERTAINTY", 18, 20], ["secondary", "OBSERVATION_MODIFIER", 21, 30], ["cases", "OBSERVATION", 31, 36]]], ["Most recent genome analysis of 14 isolates worldwide, suggests genetic homogeneity which would help engender enthusiasm for vaccine development.", [["genetic homogeneity", "PROBLEM", 63, 82], ["vaccine development", "TREATMENT", 124, 143]]], ["10A SARS vaccine or antiviral drugThe initial question, raised by commentators and sufferers alike, is how quickly can vaccine a be developed.", [["SARS", "DISEASE", 4, 8], ["10A SARS vaccine", "TREATMENT", 0, 16], ["antiviral drug", "TREATMENT", 20, 34]]], ["But it should be appreciated that vaccine development is in the realm of commerce and requires a considerable investment of 500 million Euros at least to complete the science, toxicology, and phase I to III clinical trials.", [["vaccine", "TREATMENT", 34, 41]]], ["Unfortunately, there is no precedent for coronavirus vaccines in humans.", [["coronavirus", "DISEASE", 41, 52], ["coronavirus", "ORGANISM", 41, 52], ["humans", "ORGANISM", 65, 71], ["humans", "SPECIES", 65, 71], ["humans", "SPECIES", 65, 71], ["coronavirus vaccines", "TREATMENT", 41, 61], ["no precedent for", "UNCERTAINTY", 24, 40], ["coronavirus", "OBSERVATION", 41, 52]]], ["Another significant problem is antigenic variability.", [["antigenic variability", "PROBLEM", 31, 52], ["significant", "OBSERVATION_MODIFIER", 8, 19], ["problem", "OBSERVATION", 20, 27], ["antigenic variability", "OBSERVATION", 31, 52]]], ["If a new serotype has emerged, what could prevent even more appearing and so compromising vaccine immunity.", [["a new serotype", "PROBLEM", 3, 17], ["new", "OBSERVATION_MODIFIER", 5, 8]]], ["But the most serious question is the economic one.", [["most serious", "OBSERVATION_MODIFIER", 8, 20]]], ["Should the virus spread widely, then undoubtedly a pharmaceutical company would make the investment.", [["the virus", "PROBLEM", 7, 16], ["virus", "OBSERVATION", 11, 16]]], ["However, an alternative, more circumscribed strategy would be a vaccine to protect health care workers, much as a smallpox vaccine is viewed at present.", [["a vaccine", "TREATMENT", 62, 71], ["a smallpox vaccine", "TREATMENT", 112, 130]]], ["The first candidate coronavirus protein for induction of immunity is the spike (S) protein.", [["coronavirus", "ORGANISM", 20, 31], ["spike (S)", "GENE_OR_GENE_PRODUCT", 73, 82], ["coronavirus protein", "PROTEIN", 20, 39], ["spike (S) protein", "PROTEIN", 73, 90], ["coronavirus protein", "TREATMENT", 20, 39], ["induction of immunity", "TREATMENT", 44, 65]]], ["The spike is a receptor protein of the virus which mediates membrane fusion as the virus enters a cell.", [["membrane", "ANATOMY", 60, 68], ["cell", "ANATOMY", 98, 102], ["membrane", "CELLULAR_COMPONENT", 60, 68], ["cell", "CELL", 98, 102], ["receptor protein", "PROTEIN", 15, 31], ["The spike", "PROBLEM", 0, 9], ["a receptor protein of the virus", "PROBLEM", 13, 44], ["membrane fusion", "TREATMENT", 60, 75], ["the virus", "PROBLEM", 79, 88], ["membrane fusion", "OBSERVATION", 60, 75]]], ["There is an inverse relationship between severity of disease with pre-existing serum antibody.", [["serum", "ANATOMY", 79, 84], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["serum antibody", "PROTEIN", 79, 93], ["disease", "PROBLEM", 53, 60], ["pre-existing serum antibody", "PROBLEM", 66, 93], ["disease", "OBSERVATION", 53, 60], ["serum antibody", "OBSERVATION", 79, 93]]], ["8 Predominantly the postinfection response is against the S protein, but antibody to the internal nucleoprotein (NP) and matrix (M) proteins is also detected.", [["matrix (M)", "GENE_OR_GENE_PRODUCT", 121, 131], ["S protein", "PROTEIN", 58, 67], ["internal nucleoprotein", "PROTEIN", 89, 111], ["NP", "PROTEIN", 113, 115], ["matrix (M) proteins", "PROTEIN", 121, 140], ["the S protein", "TEST", 54, 67], ["antibody", "TEST", 73, 81], ["matrix (M) proteins", "TEST", 121, 140], ["postinfection response", "OBSERVATION", 20, 42], ["internal nucleoprotein", "ANATOMY", 89, 111]]], ["11 At least in the human coronaviruses that have been studied to date the majority of neutralising epitopes are in the amino terminal half of the S protein with glycosylation an important factor.", [["amino", "CHEMICAL", 119, 124], ["human", "ORGANISM", 19, 24], ["coronaviruses", "ORGANISM", 25, 38], ["neutralising epitopes", "PROTEIN", 86, 107], ["amino terminal half", "PROTEIN", 119, 138], ["S protein", "PROTEIN", 146, 155], ["human", "SPECIES", 19, 24], ["human coronaviruses", "SPECIES", 19, 38], ["the human coronaviruses", "PROBLEM", 15, 38], ["neutralising epitopes", "PROBLEM", 86, 107], ["glycosylation", "TREATMENT", 161, 174], ["human coronaviruses", "ANATOMY", 19, 38], ["neutralising", "OBSERVATION", 86, 98]]], ["In the wider coronavirus family, antibody to M can also neutralise virus in vitro 12 , whilst antibodies to HE (haemagglutinin esterase) neutralise bovine coronavirus 13 and the CD4 T-cell response to the internal N protein may contribute to immunity.", [["CD4 T-cell", "ANATOMY", 178, 188], ["coronavirus", "ORGANISM", 13, 24], ["HE", "GENE_OR_GENE_PRODUCT", 108, 110], ["haemagglutinin esterase", "GENE_OR_GENE_PRODUCT", 112, 135], ["bovine coronavirus 13", "ORGANISM", 148, 169], ["CD4", "GENE_OR_GENE_PRODUCT", 178, 181], ["antibodies", "PROTEIN", 94, 104], ["HE", "PROTEIN", 108, 110], ["haemagglutinin esterase", "PROTEIN", 112, 135], ["CD4", "PROTEIN", 178, 181], ["internal N protein", "PROTEIN", 205, 223], ["bovine", "SPECIES", 148, 154], ["coronavirus", "SPECIES", 155, 166], ["bovine coronavirus", "SPECIES", 148, 166], ["haemagglutinin esterase", "TEST", 112, 135], ["bovine coronavirus", "PROBLEM", 148, 166], ["the CD4 T", "TEST", 174, 183], ["the internal N protein", "TREATMENT", 201, 223]]], ["An equally likely scenario is development of a new antiviral drug.", [["a new antiviral drug", "TREATMENT", 45, 65], ["equally likely", "UNCERTAINTY", 3, 17], ["scenario", "OBSERVATION", 18, 26], ["new", "OBSERVATION_MODIFIER", 47, 50], ["antiviral drug", "OBSERVATION", 51, 65]]], ["Sidwell 14 has described inhibition of coronavirus replication by the triazole nucleoside Ribavirin and the compound has been used in some patients with SARS.", [["triazole nucleoside", "CHEMICAL", 70, 89], ["Ribavirin", "CHEMICAL", 90, 99], ["SARS", "DISEASE", 153, 157], ["triazole", "CHEMICAL", 70, 78], ["Ribavirin", "CHEMICAL", 90, 99], ["coronavirus", "ORGANISM", 39, 50], ["triazole nucleoside Ribavirin", "SIMPLE_CHEMICAL", 70, 99], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["coronavirus", "SPECIES", 39, 50], ["coronavirus replication", "TREATMENT", 39, 62], ["the triazole nucleoside Ribavirin", "TREATMENT", 66, 99], ["SARS", "PROBLEM", 153, 157], ["coronavirus replication", "OBSERVATION", 39, 62]]], ["1 The virus has unique RNA replicase, esterase and proteinase enzymes for drug targets.", [["esterase", "GENE_OR_GENE_PRODUCT", 38, 46], ["proteinase enzymes", "GENE_OR_GENE_PRODUCT", 51, 69], ["RNA replicase", "PROTEIN", 23, 36], ["esterase", "PROTEIN", 38, 46], ["proteinase enzymes", "PROTEIN", 51, 69], ["The virus", "PROBLEM", 2, 11], ["esterase", "TEST", 38, 46], ["proteinase enzymes", "TEST", 51, 69], ["drug targets", "TREATMENT", 74, 86], ["virus", "OBSERVATION", 6, 11], ["RNA replicase", "OBSERVATION", 23, 36]]], ["This novel outbreak could provide the impetus for a new strategy to use the knowledge of the human genome to pinpoint cell genes which are up or down regulated in respiratory infections, and thereby to develop for the first time a blocker to all the respiratory virus families including myxovirus, paramyxovirus, coronavirus and rhinovirus.", [["cell", "ANATOMY", 118, 122], ["respiratory", "ANATOMY", 163, 174], ["respiratory infections", "DISEASE", 163, 185], ["paramyxovirus, coronavirus and rhinovirus", "DISEASE", 298, 339], ["human", "ORGANISM", 93, 98], ["cell", "CELL", 118, 122], ["respiratory virus", "ORGANISM", 250, 267], ["myxovirus", "GENE_OR_GENE_PRODUCT", 287, 296], ["paramyxovirus", "ORGANISM", 298, 311], ["coronavirus", "ORGANISM", 313, 324], ["rhinovirus", "ORGANISM", 329, 339], ["human genome", "DNA", 93, 105], ["cell genes", "DNA", 118, 128], ["human", "SPECIES", 93, 98], ["paramyxovirus, coronavirus", "SPECIES", 298, 324], ["human", "SPECIES", 93, 98], ["pinpoint cell genes", "PROBLEM", 109, 128], ["respiratory infections", "PROBLEM", 163, 185], ["a blocker", "TREATMENT", 229, 238], ["myxovirus", "PROBLEM", 287, 296], ["paramyxovirus", "PROBLEM", 298, 311], ["coronavirus", "PROBLEM", 313, 324], ["rhinovirus", "PROBLEM", 329, 339], ["pinpoint cell genes", "OBSERVATION", 109, 128], ["respiratory", "ANATOMY", 163, 174], ["infections", "OBSERVATION", 175, 185], ["respiratory virus", "ANATOMY", 250, 267]]], ["Such a discovery, alongside an S plus N vaccine for SARS, would be a magnificent scientific beginning to the new millennium.", [["SARS", "DISEASE", 52, 56], ["an S plus N vaccine", "TREATMENT", 28, 47], ["SARS", "PROBLEM", 52, 56]]]], "PMC5829646": [], "PMC3658953": [["BackgroundRotavirus, a member of family Reoviridae, is one of the causative agents of viral diarrhea in young children and animals worldwide [1-3].", [["BackgroundRotavirus", "CHEMICAL", 0, 19], ["viral diarrhea", "DISEASE", 86, 100], ["Reoviridae", "GENE_OR_GENE_PRODUCT", 40, 50], ["children", "ORGANISM", 110, 118], ["children", "SPECIES", 110, 118], ["viral diarrhea", "PROBLEM", 86, 100], ["viral diarrhea", "OBSERVATION", 86, 100]]], ["Rotavirus is approximately 75 nm in diameter and has multilayered icosahedral protein capsid composed of an outer layer, an inner layer, and a core [4].", [["outer layer", "ANATOMY", 108, 119], ["inner layer", "ANATOMY", 124, 135], ["Rotavirus", "DISEASE", 0, 9], ["Rotavirus", "ORGANISM", 0, 9], ["multilayered icosahedral protein capsid", "PROTEIN", 53, 92], ["Rotavirus", "PROBLEM", 0, 9], ["multilayered icosahedral protein capsid", "PROBLEM", 53, 92], ["approximately", "OBSERVATION_MODIFIER", 13, 26], ["75 nm", "OBSERVATION_MODIFIER", 27, 32], ["multilayered", "OBSERVATION_MODIFIER", 53, 65], ["icosahedral", "OBSERVATION_MODIFIER", 66, 77], ["protein capsid", "OBSERVATION", 78, 92], ["outer", "OBSERVATION_MODIFIER", 108, 113], ["layer", "OBSERVATION_MODIFIER", 114, 119], ["inner", "OBSERVATION_MODIFIER", 124, 129], ["layer", "OBSERVATION_MODIFIER", 130, 135]]], ["The virus genome is comprised of 11 segments of double-stranded RNA, encoding six structural proteins (VP1-VP4, VP6, VP7) and six nonstructural proteins (NSP) [5,6].", [["VP1-VP4", "GENE_OR_GENE_PRODUCT", 103, 110], ["VP6", "GENE_OR_GENE_PRODUCT", 112, 115], ["VP7", "GENE_OR_GENE_PRODUCT", 117, 120], ["virus genome", "DNA", 4, 16], ["double-stranded RNA", "RNA", 48, 67], ["structural proteins", "PROTEIN", 82, 101], ["VP1", "PROTEIN", 103, 106], ["VP4", "PROTEIN", 107, 110], ["VP6", "PROTEIN", 112, 115], ["VP7", "PROTEIN", 117, 120], ["nonstructural proteins", "PROTEIN", 130, 152], ["NSP", "PROTEIN", 154, 157], ["The virus genome", "PROBLEM", 0, 16], ["double-stranded RNA", "PROBLEM", 48, 67], ["VP1", "TEST", 103, 106], ["VP4", "TEST", 107, 110], ["VP6", "TEST", 112, 115], ["VP7", "TEST", 117, 120], ["virus genome", "OBSERVATION", 4, 16], ["11 segments", "OBSERVATION_MODIFIER", 33, 44], ["double", "OBSERVATION_MODIFIER", 48, 54], ["stranded RNA", "OBSERVATION", 55, 67], ["nonstructural proteins", "OBSERVATION", 130, 152]]], ["The outer capsid layer proteins of rotavirus, VP4 and VP7, may elicit neutralizing antibodies independently; in addition, the two proteins can be used to classify rotaviruses into P and G genotypes, respectively [7-9].BackgroundVP1, VP2 and VP3 proteins consist of the rotavirus core particles.", [["rotavirus", "ORGANISM", 35, 44], ["VP4", "GENE_OR_GENE_PRODUCT", 46, 49], ["VP7", "GENE_OR_GENE_PRODUCT", 54, 57], ["BackgroundVP1", "GENE_OR_GENE_PRODUCT", 218, 231], ["VP2", "GENE_OR_GENE_PRODUCT", 233, 236], ["VP3", "GENE_OR_GENE_PRODUCT", 241, 244], ["rotavirus", "ORGANISM", 269, 278], ["outer capsid layer proteins", "PROTEIN", 4, 31], ["VP4", "PROTEIN", 46, 49], ["VP7", "PROTEIN", 54, 57], ["neutralizing antibodies", "PROTEIN", 70, 93], ["BackgroundVP1", "PROTEIN", 218, 231], ["VP2", "PROTEIN", 233, 236], ["VP3 proteins", "PROTEIN", 241, 253], ["rotavirus", "PROBLEM", 35, 44], ["VP4 and VP7", "TEST", 46, 57], ["neutralizing antibodies independently", "PROBLEM", 70, 107], ["rotaviruses", "PROBLEM", 163, 174], ["BackgroundVP1", "TEST", 218, 231], ["VP2", "TEST", 233, 236], ["VP3 proteins", "TEST", 241, 253], ["the rotavirus core particles", "PROBLEM", 265, 293], ["outer", "OBSERVATION_MODIFIER", 4, 9], ["capsid", "OBSERVATION_MODIFIER", 10, 16], ["layer", "OBSERVATION_MODIFIER", 17, 22], ["rotavirus", "OBSERVATION", 35, 44], ["neutralizing antibodies", "OBSERVATION", 70, 93], ["VP2", "ANATOMY", 233, 236], ["VP3 proteins", "OBSERVATION", 241, 253], ["rotavirus core particles", "OBSERVATION", 269, 293]]], ["VP1 was partially accessible to iodination in single-shelled particles [10].", [["VP1", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP1", "PROBLEM", 0, 3], ["iodination in single-shelled particles", "TREATMENT", 32, 70]]], ["The accession degree of VP1 to the immune system may affect the reaction of anti-PRV to VP1 protein [4].", [["immune system", "ANATOMY", 35, 48], ["VP1", "GENE_OR_GENE_PRODUCT", 24, 27], ["VP1", "GENE_OR_GENE_PRODUCT", 88, 91], ["VP1", "PROTEIN", 24, 27], ["VP1 protein", "PROTEIN", 88, 99], ["PRV", "SPECIES", 81, 84], ["VP1", "PROBLEM", 24, 27], ["the reaction", "PROBLEM", 60, 72]]], ["VP2 is the most abundant structural protein in core particles [11].", [["VP2", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP2", "PROTEIN", 0, 3], ["structural protein", "PROTEIN", 25, 43], ["VP2", "TREATMENT", 0, 3], ["most abundant", "OBSERVATION_MODIFIER", 11, 24], ["structural protein", "OBSERVATION", 25, 43]]], ["Anti-VP2 serum is a good indicator of prior infection due to its high immunogenicity [12].", [["serum", "ANATOMY", 9, 14], ["infection", "DISEASE", 44, 53], ["Anti-VP2", "GENE_OR_GENE_PRODUCT", 0, 8], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["Anti-VP2 serum", "TEST", 0, 14], ["prior infection", "PROBLEM", 38, 53], ["its high immunogenicity", "PROBLEM", 61, 84], ["infection", "OBSERVATION", 44, 53]]], ["VP3 is a minor structural protein that may comigrate with the outer capsid protein VP4 in many gel systems and it may be involved in RNA replication; VP4 is cleaved to form VP5 and VP8 [4,11].BackgroundVP6 is the major structural protein in virus particles located on the outer surface of single-shelled particles, in addition, VP6 is known as a subgroup antigen [4].", [["outer surface", "ANATOMY", 272, 285], ["VP3", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP4", "GENE_OR_GENE_PRODUCT", 83, 86], ["VP4", "GENE_OR_GENE_PRODUCT", 150, 153], ["VP5", "GENE_OR_GENE_PRODUCT", 173, 176], ["VP8", "GENE_OR_GENE_PRODUCT", 181, 184], ["BackgroundVP6", "GENE_OR_GENE_PRODUCT", 192, 205], ["outer surface", "CELLULAR_COMPONENT", 272, 285], ["VP6", "GENE_OR_GENE_PRODUCT", 328, 331], ["VP3", "PROTEIN", 0, 3], ["minor structural protein", "PROTEIN", 9, 33], ["outer capsid protein", "PROTEIN", 62, 82], ["VP4", "PROTEIN", 83, 86], ["VP4", "PROTEIN", 150, 153], ["VP5", "PROTEIN", 173, 176], ["VP8", "PROTEIN", 181, 184], ["BackgroundVP6", "PROTEIN", 192, 205], ["VP6", "PROTEIN", 328, 331], ["VP3", "PROBLEM", 0, 3], ["a minor structural protein", "PROBLEM", 7, 33], ["the outer capsid protein VP4", "TREATMENT", 58, 86], ["RNA replication", "TREATMENT", 133, 148], ["VP4", "PROBLEM", 150, 153], ["VP5", "TEST", 173, 176], ["VP8", "TEST", 181, 184], ["the major structural protein in virus particles", "PROBLEM", 209, 256], ["protein", "OBSERVATION", 26, 33], ["major", "OBSERVATION_MODIFIER", 213, 218], ["structural protein", "OBSERVATION", 219, 237], ["virus particles", "OBSERVATION", 241, 256], ["outer", "OBSERVATION_MODIFIER", 272, 277], ["surface", "OBSERVATION_MODIFIER", 278, 285], ["shelled particles", "OBSERVATION", 296, 313]]], ["VP6 is required not only for polymerase activity and but also for maintaining the proper structure of the viral core or the core protein-based transcriptional complex.", [["VP6", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP6", "PROTEIN", 0, 3], ["transcriptional complex", "PROTEIN", 143, 166], ["VP6", "TREATMENT", 0, 3], ["polymerase activity", "PROBLEM", 29, 48], ["viral", "OBSERVATION", 106, 111], ["transcriptional complex", "OBSERVATION", 143, 166]]], ["Myristylation of VP6 is required for virus particle formation as well as targeting single-shelled particles to the ER membrane for budding [13].", [["particle", "ANATOMY", 43, 51], ["ER membrane", "ANATOMY", 115, 126], ["VP6", "GENE_OR_GENE_PRODUCT", 17, 20], ["ER membrane", "CELLULAR_COMPONENT", 115, 126], ["VP6", "PROTEIN", 17, 20], ["ER", "PROTEIN", 115, 117], ["Myristylation of VP6", "TREATMENT", 0, 20], ["virus particle formation", "TREATMENT", 37, 61], ["single-shelled particles", "TREATMENT", 83, 107]]], ["As VP6 is both highly immunogenic and antigenic, it is the most frequently used in diagnostic assays to detect PRV [14].", [["VP6", "GENE_OR_GENE_PRODUCT", 3, 6], ["VP6", "PROTEIN", 3, 6], ["PRV", "SPECIES", 111, 114], ["diagnostic assays", "TEST", 83, 100], ["highly", "OBSERVATION_MODIFIER", 15, 21], ["immunogenic", "OBSERVATION", 22, 33]]], ["Herein, we expressed the VP6 gene from a PRV Chinese isolate DN30209 by cloning this gene into a bacterial expression system.", [["DN30209", "CHEMICAL", 61, 68], ["VP6", "GENE_OR_GENE_PRODUCT", 25, 28], ["DN30209", "CANCER", 61, 68], ["VP6 gene", "DNA", 25, 33], ["PRV", "SPECIES", 41, 44], ["a PRV Chinese isolate", "TREATMENT", 39, 60], ["a bacterial expression system", "TREATMENT", 95, 124], ["bacterial expression", "OBSERVATION", 97, 117]]], ["We then generated rabbit polyclonal anti-serum and ascertained its immunoreactivity to VP6 protein.", [["anti-serum", "ANATOMY", 36, 46], ["rabbit", "ORGANISM", 18, 24], ["VP6", "GENE_OR_GENE_PRODUCT", 87, 90], ["rabbit polyclonal anti-serum", "PROTEIN", 18, 46], ["VP6 protein", "PROTEIN", 87, 98], ["rabbit", "SPECIES", 18, 24], ["rabbit", "SPECIES", 18, 24], ["rabbit polyclonal anti-serum", "TREATMENT", 18, 46]]], ["Using the anti-VP6 antibody, we established a differentiating ELISA for PRV.", [["anti-VP6", "GENE_OR_GENE_PRODUCT", 10, 18], ["PRV", "ORGANISM", 72, 75], ["anti-VP6 antibody", "PROTEIN", 10, 27], ["PRV", "SPECIES", 72, 75], ["the anti-VP6 antibody", "TREATMENT", 6, 27]]], ["These experiments provided basis for determination of PRV.Cloning and phylogeny of VP6 gene of PRV ::: Results and discussionPRV may cause piglet diarrhea andV P6 is an important structural component of viral particles.", [["piglet", "ANATOMY", 139, 145], ["diarrhea", "DISEASE", 146, 154], ["PRV", "ORGANISM", 54, 57], ["VP6", "GENE_OR_GENE_PRODUCT", 83, 86], ["PRV", "ORGANISM", 125, 128], ["piglet", "ORGANISM_SUBDIVISION", 139, 145], ["VP6 gene", "DNA", 83, 91], ["PRV", "SPECIES", 54, 57], ["PRV", "SPECIES", 95, 98], ["PRV", "SPECIES", 125, 128], ["PRV", "TREATMENT", 54, 57], ["piglet diarrhea", "PROBLEM", 139, 154], ["P6", "PROBLEM", 160, 162], ["viral particles", "PROBLEM", 203, 218], ["viral particles", "OBSERVATION", 203, 218]]], ["In this study, we cloned the VP6 gene from a Chinese PRV isolate DN30209.", [["DN30209", "CHEMICAL", 65, 72], ["VP6", "GENE_OR_GENE_PRODUCT", 29, 32], ["VP6 gene", "DNA", 29, 37], ["Chinese PRV isolate DN30209", "SPECIES", 45, 72], ["this study", "TEST", 3, 13], ["a Chinese PRV isolate", "TREATMENT", 43, 64]]], ["The sequencing results showed that the cloned VP6 gene was 1356 bp containing a complete open reading frame (ORF) encoding 397 amino acids.", [["amino acids", "CHEMICAL", 127, 138], ["amino acids", "CHEMICAL", 127, 138], ["VP6", "GENE_OR_GENE_PRODUCT", 46, 49], ["amino acids", "AMINO_ACID", 127, 138], ["cloned VP6 gene", "DNA", 39, 54], ["open reading frame", "DNA", 89, 107], ["ORF", "DNA", 109, 112], ["The sequencing", "TEST", 0, 14], ["bp", "TEST", 64, 66], ["amino acids", "TEST", 127, 138]]], ["Compared with PRV JL94, there were three mutations at N94H, G126R and I182V; compared with PRV GD, three mutations N94H, I182V and T244A were identified.", [["PRV JL94", "ORGANISM", 14, 22], ["PRV", "SPECIES", 14, 17], ["PRV", "SPECIES", 91, 94], ["PRV JL94", "TEST", 14, 22]]], ["As DN30209, JL94 and GD all were isolated from northern China, these viruses may be geographical prevalent in northern areas in China.", [["JL94", "GENE_OR_GENE_PRODUCT", 12, 16], ["these viruses", "PROBLEM", 63, 76], ["viruses", "OBSERVATION", 69, 76]]], ["Based on the randomly selected PRV reference strains, the VP6 amino acid sequences were compared.", [["amino acid", "CHEMICAL", 62, 72], ["amino acid", "CHEMICAL", 62, 72], ["VP6", "GENE_OR_GENE_PRODUCT", 58, 61], ["amino acid", "AMINO_ACID", 62, 72], ["VP6 amino acid sequences", "PROTEIN", 58, 82], ["PRV", "SPECIES", 31, 34], ["the VP6 amino acid sequences", "TEST", 54, 82]]], ["As shown in Figure 1, PRVs DN30209 and several PRV group A strains OSU, JL94 GD, CRW-8, 4F and 4S etc. had more than 90% homologous identity at amino acid level.", [["amino acid", "CHEMICAL", 144, 154], ["amino acid", "CHEMICAL", 144, 154], ["amino acid", "AMINO_ACID", 144, 154], ["GD", "TEST", 77, 79], ["CRW", "TEST", 81, 84], ["amino acid level", "TEST", 144, 160]]], ["RNA-PAGE analysis showed that the rotavirus represented long electropherotype migration pattern of porcine group A rotaviruses (Figure 2).", [["porcine group A rotaviruses", "SPECIES", 99, 126], ["RNA-PAGE analysis", "TEST", 0, 17], ["the rotavirus", "PROBLEM", 30, 43], ["long electropherotype migration", "PROBLEM", 56, 87], ["long", "OBSERVATION_MODIFIER", 56, 60], ["electropherotype migration", "OBSERVATION", 61, 87]]], ["Further phylogenetic tree analysis also indicated that PRV DN30203 located in the same clade with above-mentioned PRV group A strains (Figure 3).", [["PRV DN30203", "ORGANISM", 55, 66], ["PRV DN30203", "DNA", 55, 66], ["PRV", "SPECIES", 55, 58], ["Further phylogenetic tree analysis", "TEST", 0, 34], ["PRV DN30203", "TREATMENT", 55, 66]]], ["Therefore, we speculate that PRV DN30209 also belongs to group A of rotavirus.", [["DN30209", "CHEMICAL", 33, 40], ["rotavirus", "DISEASE", 68, 77], ["PRV DN30209", "ORGANISM", 29, 40], ["rotavirus", "ORGANISM", 68, 77], ["PRV", "SPECIES", 29, 32], ["rotavirus", "PROBLEM", 68, 77]]], ["Nevertheless, it is necessary to do more serological and epidemiological investigations to get full understanding on the evolution of PRV in the future.Analysis of VP6 expression and immunoreactivities of its antibody ::: Results and discussionIt is clear that E. coli system has advantages such as low costs, high production, and manipulation convenience, etc. [15].", [["PRV", "ORGANISM", 134, 137], ["VP6", "GENE_OR_GENE_PRODUCT", 164, 167], ["E. coli", "ORGANISM", 261, 268], ["VP6", "PROTEIN", 164, 167], ["E. coli", "SPECIES", 261, 268], ["PRV", "SPECIES", 134, 137], ["E. coli", "SPECIES", 261, 268], ["epidemiological investigations", "TEST", 57, 87], ["Analysis", "TEST", 152, 160], ["VP6 expression", "TEST", 164, 178], ["E. coli system", "PROBLEM", 261, 275], ["VP6 expression", "OBSERVATION", 164, 178], ["clear", "OBSERVATION", 250, 255], ["coli system", "OBSERVATION", 264, 275]]], ["In our laboratory, we have expressed several heterologous proteins in this system [16-19].", [["heterologous proteins", "PROTEIN", 45, 66]]], ["In this study, we analyzed the bacterial expression of VP6 protein in E.coli.", [["VP6", "GENE_OR_GENE_PRODUCT", 55, 58], ["VP6 protein", "PROTEIN", 55, 66], ["E.coli", "SPECIES", 70, 76], ["this study", "TEST", 3, 13], ["VP6 protein in E.coli", "PROBLEM", 55, 76], ["bacterial expression", "OBSERVATION", 31, 51], ["VP6 protein", "OBSERVATION", 55, 66], ["E.coli", "ANATOMY", 70, 76]]], ["SDS-PAGE showed that fused VP6 protein was approx.", [["VP6", "GENE_OR_GENE_PRODUCT", 27, 30], ["VP6 protein", "PROTEIN", 27, 38], ["SDS", "TEST", 0, 3], ["fused VP6 protein", "PROBLEM", 21, 38]]], ["48 kDa as expected and accumulated in the bacteria as inclusion bodies (Figure 4).", [["bacteria", "OBSERVATION_MODIFIER", 42, 50]]], ["In this study, a rabbit anti-VP6 antibody was generated by conventional animal immunization.", [["rabbit", "ORGANISM", 17, 23], ["anti-VP6", "GENE_OR_GENE_PRODUCT", 24, 32], ["rabbit anti-VP6 antibody", "PROTEIN", 17, 41], ["rabbit", "SPECIES", 17, 23], ["rabbit", "SPECIES", 17, 23], ["this study", "TEST", 3, 13], ["a rabbit anti-VP6 antibody", "TEST", 15, 41], ["conventional animal immunization", "TREATMENT", 59, 91]]], ["The optimization of the ELISA was determined.", [["the ELISA", "TEST", 20, 29]]], ["As shown in Figure 5, after the fixation of the concentration of PRV VP6 protein, the optimal antibody dilution was1:29.", [["VP6", "GENE_OR_GENE_PRODUCT", 69, 72], ["PRV VP6 protein", "PROTEIN", 65, 80], ["PRV", "SPECIES", 65, 68], ["the fixation", "TREATMENT", 28, 40], ["PRV VP6 protein", "TREATMENT", 65, 80], ["the optimal antibody dilution", "TEST", 82, 111]]], ["In addition to reaction with VP6 protein, at such dilution, the anti-VP6 serum also had the best reactivity to PRV.", [["anti-VP6 serum", "ANATOMY", 64, 78], ["VP6", "GENE_OR_GENE_PRODUCT", 29, 32], ["anti-VP6", "GENE_OR_GENE_PRODUCT", 64, 72], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["VP6 protein", "PROTEIN", 29, 40], ["anti-VP6", "PROTEIN", 64, 72], ["PRV", "SPECIES", 111, 114], ["reaction", "PROBLEM", 15, 23], ["VP6 protein", "PROBLEM", 29, 40], ["the anti-VP6 serum", "TEST", 60, 78]]], ["The optimization of the ELISA may be useful reference to detect PRV from clinical samples in the future.", [["samples", "ANATOMY", 82, 89], ["PRV", "SPECIES", 64, 67], ["the ELISA", "TEST", 20, 29], ["PRV", "PROBLEM", 64, 67], ["clinical samples", "TEST", 73, 89]]], ["The reactivity of the protein to anti-VP6 antibody was then analyzed by Western blot.", [["anti-VP6 antibody", "GENE_OR_GENE_PRODUCT", 33, 50], ["anti-VP6 antibody", "PROTEIN", 33, 50], ["anti-VP6 antibody", "TEST", 33, 50]]], ["Our result showed that the bacterially expressed VP6 can be recognized by the antiserum, confirming that the VP6 is both highly immunogenic and antigenic (Figure 6).", [["VP6", "GENE_OR_GENE_PRODUCT", 49, 52], ["antiserum", "ORGANISM_SUBSTANCE", 78, 87], ["VP6", "GENE_OR_GENE_PRODUCT", 109, 112], ["VP6", "PROTEIN", 49, 52], ["VP6", "PROTEIN", 109, 112], ["the bacterially expressed VP6", "PROBLEM", 23, 52], ["the VP6", "TEST", 105, 112], ["highly", "OBSERVATION_MODIFIER", 121, 127], ["immunogenic", "OBSERVATION", 128, 139]]], ["The immunoreactivity of the anti-VP6 antibody to eukaryotically expressed VP6 was further analyzed by IFA.", [["anti-VP6 antibody", "GENE_OR_GENE_PRODUCT", 28, 45], ["VP6", "GENE_OR_GENE_PRODUCT", 74, 77], ["anti-VP6 antibody", "PROTEIN", 28, 45], ["VP6", "PROTEIN", 74, 77], ["the anti-VP6 antibody", "TEST", 24, 45]]], ["As shown in Figure 7, the antibody reacted with VP6-expressing cells; in contrast, no green signal was detected in mock-transfected cells, confirming the specific recognition of the anti-VP6 antibody.", [["cells", "ANATOMY", 63, 68], ["cells", "ANATOMY", 132, 137], ["VP6", "GENE_OR_GENE_PRODUCT", 48, 51], ["cells", "CELL", 63, 68], ["cells", "CELL", 132, 137], ["anti-VP6 antibody", "GENE_OR_GENE_PRODUCT", 182, 199], ["VP6", "PROTEIN", 48, 51], ["expressing cells", "CELL_TYPE", 52, 68], ["mock-transfected cells", "CELL_LINE", 115, 137], ["anti-VP6 antibody", "PROTEIN", 182, 199], ["the antibody", "TEST", 22, 34], ["VP6", "TEST", 48, 51], ["green signal", "PROBLEM", 86, 98], ["the anti-VP6 antibody", "TEST", 178, 199], ["transfected cells", "OBSERVATION", 120, 137]]], ["In this study, the anti-VP6 antibody was generated by inoculating rabbit with VP6 expressed from E.coli, however, this antibody reacted with VP6 protein transiently expressed on cells.", [["cells", "ANATOMY", 178, 183], ["anti-VP6", "GENE_OR_GENE_PRODUCT", 19, 27], ["rabbit", "ORGANISM", 66, 72], ["VP6", "GENE_OR_GENE_PRODUCT", 78, 81], ["E.coli", "GENE_OR_GENE_PRODUCT", 97, 103], ["VP6", "GENE_OR_GENE_PRODUCT", 141, 144], ["cells", "CELL", 178, 183], ["anti-VP6 antibody", "PROTEIN", 19, 36], ["VP6", "PROTEIN", 78, 81], ["VP6 protein", "PROTEIN", 141, 152], ["rabbit", "SPECIES", 66, 72], ["rabbit", "SPECIES", 66, 72], ["E.coli", "SPECIES", 97, 103], ["this study", "TEST", 3, 13], ["the anti-VP6 antibody", "TEST", 15, 36], ["VP6", "PROBLEM", 78, 81], ["E.coli", "PROBLEM", 97, 103], ["this antibody", "TEST", 114, 127], ["VP6 protein", "TEST", 141, 152], ["E.coli", "OBSERVATION", 97, 103]]], ["These data further confirm that bacterially expressed VP6 can be used as a good immunogen and the antibody can be used as good diagnostic reagent for detection of PRV VP6 protein.Discrimination ELISA for detection of PRV ::: Results and discussionLike PRV, TGEV and PEDV are capable of causing diarrhea symptoms in pigs.", [["PEDV", "CHEMICAL", 266, 270], ["diarrhea", "DISEASE", 294, 302], ["VP6", "GENE_OR_GENE_PRODUCT", 54, 57], ["PRV", "ORGANISM", 163, 166], ["VP6", "GENE_OR_GENE_PRODUCT", 167, 170], ["discussionLike PRV", "ORGANISM", 237, 255], ["TGEV", "ORGANISM", 257, 261], ["PEDV", "SIMPLE_CHEMICAL", 266, 270], ["pigs", "ORGANISM", 315, 319], ["VP6", "PROTEIN", 54, 57], ["PRV VP6 protein", "PROTEIN", 163, 178], ["pigs", "SPECIES", 315, 319], ["PRV", "SPECIES", 163, 166], ["PRV", "SPECIES", 217, 220], ["PRV", "SPECIES", 252, 255], ["TGEV", "SPECIES", 257, 261], ["pigs", "SPECIES", 315, 319], ["bacterially expressed VP6", "PROBLEM", 32, 57], ["a good immunogen", "TREATMENT", 73, 89], ["the antibody", "TEST", 94, 106], ["PRV VP6 protein", "PROBLEM", 163, 178], ["discussionLike PRV", "TREATMENT", 237, 255], ["PEDV", "PROBLEM", 266, 270], ["diarrhea symptoms", "PROBLEM", 294, 311]]], ["Other porcine viruses may cause co-infection with PRV, thus, discrimination between PRV and other viruses is important for clinical diagnosis purpose.", [["co-infection", "DISEASE", 32, 44], ["porcine", "ORGANISM", 6, 13], ["PRV", "SPECIES", 50, 53], ["PRV", "SPECIES", 84, 87], ["Other porcine viruses", "PROBLEM", 0, 21], ["co-infection", "PROBLEM", 32, 44], ["PRV", "TREATMENT", 50, 53], ["discrimination between PRV and other viruses", "PROBLEM", 61, 105], ["porcine viruses", "OBSERVATION", 6, 21], ["may cause", "UNCERTAINTY", 22, 31], ["co-infection", "OBSERVATION", 32, 44], ["viruses", "OBSERVATION", 98, 105]]], ["Recently, we have confirmed that the antiserum to VP7 protein of PRV may also serve as a diagnostic agent for detection of PRV (unpublished data).", [["antiserum", "ORGANISM_SUBSTANCE", 37, 46], ["VP7", "GENE_OR_GENE_PRODUCT", 50, 53], ["PRV", "ORGANISM", 65, 68], ["VP7 protein", "PROTEIN", 50, 61], ["PRV", "SPECIES", 65, 68], ["PRV", "SPECIES", 123, 126], ["the antiserum", "TREATMENT", 33, 46], ["VP7 protein of PRV", "TREATMENT", 50, 68], ["PRV", "PROBLEM", 123, 126]]], ["Nevertheless, it has been pointed out that PRV VP6 protein is the most frequently target protein in diagnostic assays to detect virus particles.", [["PRV", "ORGANISM", 43, 46], ["VP6", "GENE_OR_GENE_PRODUCT", 47, 50], ["PRV VP6 protein", "PROTEIN", 43, 58], ["PRV", "SPECIES", 43, 46], ["PRV VP6 protein", "TEST", 43, 58], ["diagnostic assays", "TEST", 100, 117], ["virus particles", "PROBLEM", 128, 143]]], ["As ELISA is simple, convenient and sensitive immunological assays suitable for detection of pathogens [19-22], a discrimination ELISA for detection of PRV was established using the anti-VP6 antibody.", [["PRV", "ORGANISM", 151, 154], ["anti-VP6", "GENE_OR_GENE_PRODUCT", 181, 189], ["anti-VP6 antibody", "PROTEIN", 181, 198], ["PRV", "SPECIES", 151, 154], ["sensitive immunological assays", "TEST", 35, 65], ["pathogens", "PROBLEM", 92, 101], ["a discrimination ELISA", "TEST", 111, 133], ["PRV", "PROBLEM", 151, 154], ["the anti-VP6 antibody", "TREATMENT", 177, 198]]], ["Several control viruses were included in the ELISA to determine the specificity of the ELISA.", [["Several control viruses", "PROBLEM", 0, 23], ["the ELISA", "TEST", 41, 50], ["the ELISA", "TEST", 83, 92], ["viruses", "OBSERVATION", 16, 23]]], ["The result showed that the anti-VP6 antibody had significant reactivity with PRV; in contrast, there was no positive P/N value among other controls (p<0.01) (Figure 8).", [["anti-VP6 antibody", "GENE_OR_GENE_PRODUCT", 27, 44], ["anti-VP6 antibody", "PROTEIN", 27, 44], ["PRV", "SPECIES", 77, 80], ["the anti-VP6 antibody", "TEST", 23, 44], ["positive P/N value", "PROBLEM", 108, 126]]], ["Our results have demonstrated clearly that the VP6-antibody based ELISA works well in our laboratory, however, validation of the test using clinical samples are important so that the test can be applied in the field level for detection of PRVs.", [["VP6", "GENE_OR_GENE_PRODUCT", 47, 50], ["PRVs", "PATHOLOGICAL_FORMATION", 239, 243], ["VP6", "PROTEIN", 47, 50], ["the VP6", "TEST", 43, 50], ["the test", "TEST", 125, 133], ["the test", "TEST", 179, 187], ["PRVs", "PROBLEM", 239, 243]]], ["Thus, we will evaluate the utility of this VP6-antibody based ELISA in nature by including PRV clinical samples in the future.Amplification of VP6 gene of PRV by PCR ::: MethodsPRV Chinese isolate named DN30209 was recently isolated in a pig farm in Heilongjiang Province, northeastern China.", [["DN30209", "CHEMICAL", 203, 210], ["VP6", "GENE_OR_GENE_PRODUCT", 43, 46], ["VP6", "GENE_OR_GENE_PRODUCT", 143, 146], ["DN30209", "CELL", 203, 210], ["pig", "ORGANISM", 238, 241], ["VP6", "PROTEIN", 43, 46], ["VP6 gene", "DNA", 143, 151], ["pig", "SPECIES", 238, 241], ["PRV", "SPECIES", 91, 94], ["PRV", "SPECIES", 155, 158], ["pig", "SPECIES", 238, 241], ["this VP6-antibody", "TEST", 38, 55], ["PRV clinical samples", "TEST", 91, 111], ["MethodsPRV", "TREATMENT", 170, 180]]], ["The virus was propagated in MA104 cells in presence of trypsin at a final concentration of 3 \u03bcg/mL (w/v).", [["MA104 cells", "ANATOMY", 28, 39], ["MA104 cells", "CELL", 28, 39], ["trypsin", "GENE_OR_GENE_PRODUCT", 55, 62], ["MA104 cells", "CELL_LINE", 28, 39], ["trypsin", "PROTEIN", 55, 62], ["The virus", "PROBLEM", 0, 9], ["trypsin", "TREATMENT", 55, 62], ["virus", "OBSERVATION", 4, 9]]], ["The viral total RNA was extracted with a commercial kit according to the manufacturer\u2019s instructions (HaiGene, China).", [["viral total RNA", "RNA", 4, 19], ["The viral total RNA", "TREATMENT", 0, 19], ["a commercial kit", "TREATMENT", 39, 55], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["total RNA", "OBSERVATION", 10, 19]]], ["Sense primer (VP6-1): 5'- GGCTTTTAAACGAAGTCTTC and antisense primer (VP6-2): 5'- GGTCACATCCTCTCACTA were published primers [23] and used to amplify the VP6 gene for sequencing.", [["VP6-1", "GENE_OR_GENE_PRODUCT", 14, 19], ["VP6", "GENE_OR_GENE_PRODUCT", 152, 155], ["Sense primer", "DNA", 0, 12], ["VP6", "DNA", 14, 17], ["antisense primer", "DNA", 51, 67], ["VP6 gene", "DNA", 152, 160], ["Sense primer", "TEST", 0, 12], ["VP6", "TEST", 14, 17], ["GGCTTTTAAACGAAGTCTTC", "TEST", 26, 46], ["antisense primer", "TEST", 51, 67], ["VP6", "TEST", 69, 72]]], ["The reverse transcription mixture included 5 \u03bcL of RNA (1 \u03bcg), 1 \u03bcL of primer VP6-2 (10 pmol), 4 \u03bcL of 5\u00d7RT-PCR buffer (TaKaRa, China),0.5 \u03bcL of RNase inhibitor, 1 \u03bcL of dNTP (10 mM/each), 1 \u03bcL of M-MLV reverse transcriptase (TaKaRa) and 7.5 \u03bcL of sterile water.", [["dNTP", "CHEMICAL", 170, 174], ["dNTP", "CHEMICAL", 170, 174], ["VP6-2", "GENE_OR_GENE_PRODUCT", 78, 83], ["RNase", "GENE_OR_GENE_PRODUCT", 145, 150], ["dNTP", "SIMPLE_CHEMICAL", 170, 174], ["RNase", "PROTEIN", 145, 150], ["MLV reverse transcriptase", "PROTEIN", 199, 224], ["The reverse transcription mixture", "TREATMENT", 0, 33], ["5 \u03bcL of RNA", "TREATMENT", 43, 54], ["primer VP6", "TREATMENT", 71, 81], ["5\u00d7RT-PCR buffer", "TREATMENT", 103, 118], ["RNase inhibitor", "TREATMENT", 145, 160], ["dNTP", "TREATMENT", 170, 174], ["MLV reverse transcriptase (TaKaRa)", "TREATMENT", 199, 233], ["sterile water", "TREATMENT", 248, 261]]], ["The reaction was performed at 30\u00b0C for 10 min, 42\u00b0C for 60 min and 95\u00b0C for 5 min.", [["The reaction", "PROBLEM", 0, 12]]], ["Subsequent PCR mixture included the resulting 3 \u03bcL of cDNA (3 \u03bcg), 5 \u03bcL of 10\u00d7ExTaq buffer, 1 \u03bcL of each primer (10 pmol), 4 \u03bcL of dNTP (2.5 mM/each), 0.25 \u03bcL of ExTaqDNA (TaKaRa, China) and 35.75 \u03bcL of sterile water.", [["dNTP", "CHEMICAL", 131, 135], ["dNTP", "CHEMICAL", 131, 135], ["dNTP", "SIMPLE_CHEMICAL", 131, 135], ["cDNA", "DNA", 54, 58], ["Subsequent PCR mixture", "TEST", 0, 22], ["cDNA", "TEST", 54, 58], ["dNTP", "TREATMENT", 131, 135], ["sterile water", "TREATMENT", 203, 216]]], ["The PCR was performed at 94\u00b0C for 5 min; 30 cycles of 94\u00b0C for 40 s, 52.8\u00b0C for 40 s, and 72\u00b0C for 1 min; a final extension at 72\u00b0C for 10 min.", [["The PCR", "TEST", 0, 7]]], ["The PCR product was purified and subjected to DNA sequencing.RNA-polyacrylamide gel electrophoresis (PAGE) ::: MethodsRNA of the PRV was extracted by mixing the virus suspension in PBS or PBS (negative control) with an equal volume of an extraction buffer (0.02 M Tris\u2013HCl pH7.4, 0.3 M NaCl, 0.01 M MgCl2, 0.1% SDS, 5 \u03bcM EDTA, 4% sucrose and 0.04% bromophenol blue) followed by phenol\u2013chloroform extraction at 12, 000 rpm and 4\u00b0C for 10 min.", [["NaCl", "CHEMICAL", 286, 290], ["MgCl2", "CHEMICAL", 299, 304], ["sucrose", "CHEMICAL", 330, 337], ["bromophenol blue", "CHEMICAL", 348, 364], ["phenol\u2013chloroform", "CHEMICAL", 378, 395], ["polyacrylamide", "CHEMICAL", 65, 79], ["NaCl", "CHEMICAL", 286, 290], ["MgCl2", "CHEMICAL", 299, 304], ["EDTA", "CHEMICAL", 321, 325], ["sucrose", "CHEMICAL", 330, 337], ["bromophenol blue", "CHEMICAL", 348, 364], ["phenol\u2013chloroform", "CHEMICAL", 378, 395], ["DNA", "CELLULAR_COMPONENT", 46, 49], ["PRV", "ORGANISM", 129, 132], ["EDTA", "SIMPLE_CHEMICAL", 321, 325], ["sucrose", "SIMPLE_CHEMICAL", 330, 337], ["bromophenol blue", "SIMPLE_CHEMICAL", 348, 364], ["phenol\u2013chloroform", "SIMPLE_CHEMICAL", 378, 395], ["PRV", "SPECIES", 129, 132], ["The PCR product", "TEST", 0, 15], ["DNA sequencing", "TEST", 46, 60], ["the PRV", "TREATMENT", 125, 132], ["the virus suspension", "TREATMENT", 157, 177], ["an extraction buffer", "TREATMENT", 235, 255], ["Tris\u2013HCl", "TEST", 264, 272], ["NaCl", "TEST", 286, 290], ["MgCl2", "TEST", 299, 304], ["SDS", "TEST", 311, 314], ["EDTA", "TEST", 321, 325], ["4% sucrose", "TREATMENT", 327, 337], ["0.04% bromophenol blue", "TREATMENT", 342, 364], ["phenol\u2013chloroform extraction", "TREATMENT", 378, 406]]], ["The resulting supernatant was subjected to RNA-PAGE to detect and analyze the genome of rotavirus.", [["supernatant", "ANATOMY", 14, 25], ["rotavirus", "ORGANISM", 88, 97], ["rotavirus", "PROBLEM", 88, 97], ["rotavirus", "OBSERVATION", 88, 97]]], ["The RNA-PAGE was performed in 10% polyacrylamide slab gel using discontinuous buffer system without SDS as described by Laemmli [24] for 13 h at 10 mA.", [["polyacrylamide", "CHEMICAL", 34, 48], ["The RNA", "TEST", 0, 7], ["10% polyacrylamide slab gel", "TREATMENT", 30, 57], ["discontinuous buffer system", "TREATMENT", 64, 91], ["SDS", "PROBLEM", 100, 103]]], ["Viral RNA segments were visualized in silver staining.Sequence comparison and phylogenetic analysis ::: MethodsThe obtained VP6 sequence was deposited in GenBank database and compared with reference PRV VP6 sequences using DNASTAR software.", [["silver", "CHEMICAL", 38, 44], ["silver", "CHEMICAL", 38, 44], ["silver", "SIMPLE_CHEMICAL", 38, 44], ["VP6", "GENE_OR_GENE_PRODUCT", 124, 127], ["VP6", "GENE_OR_GENE_PRODUCT", 203, 206], ["Viral RNA segments", "RNA", 0, 18], ["VP6 sequence", "DNA", 124, 136], ["PRV VP6 sequences", "DNA", 199, 216], ["PRV", "SPECIES", 199, 202], ["Viral RNA segments", "PROBLEM", 0, 18], ["phylogenetic analysis", "TEST", 78, 99], ["Methods", "TREATMENT", 104, 111], ["The obtained VP6 sequence", "TEST", 111, 136], ["GenBank database", "TEST", 154, 170], ["reference PRV VP6 sequences", "TEST", 189, 216], ["RNA segments", "OBSERVATION", 6, 18], ["silver staining", "OBSERVATION", 38, 53]]], ["The name, GenBank accession number and virus isolation location of these genes are shown in Table 1.", [["virus isolation", "TREATMENT", 39, 54]]], ["At the same time, a phylogenetic tree was constructed by neighbor-joining method base on these VP6 amino acid sequences using the DNASTAR program [25-27].", [["amino acid", "CHEMICAL", 99, 109], ["amino acid", "CHEMICAL", 99, 109], ["VP6", "GENE_OR_GENE_PRODUCT", 95, 98], ["amino acid", "AMINO_ACID", 99, 109], ["VP6 amino acid sequences", "DNA", 95, 119], ["these VP6 amino acid sequences", "TREATMENT", 89, 119], ["the DNASTAR program", "TREATMENT", 126, 145]]], ["The bootstrap probabilities of each node were calculated using 1,000 replicates.Construction of recombinant plasmids bearing VP6 gene and its bacterial expression ::: MethodsTo construct expression plasmids bearing the VP6 gene, forward primer: 5'- CCCCGGATCCATGCAAAATTACGGA(VP6F) and reverse primer (VP6R) 5'- GGGGAAGCTTGTTAGACTCGGTAATA were self designed and used to re-amplify the VP6 gene using the obtained PCR product above as template.", [["node", "ANATOMY", 36, 40], ["plasmids", "ANATOMY", 108, 116], ["plasmids", "ANATOMY", 198, 206], ["node", "MULTI-TISSUE_STRUCTURE", 36, 40], ["VP6", "GENE_OR_GENE_PRODUCT", 125, 128], ["VP6", "GENE_OR_GENE_PRODUCT", 219, 222], ["VP6", "GENE_OR_GENE_PRODUCT", 384, 387], ["recombinant plasmids", "DNA", 96, 116], ["VP6 gene", "DNA", 125, 133], ["expression plasmids", "DNA", 187, 206], ["VP6 gene", "DNA", 219, 227], ["forward primer: 5'- CCCCGGATCCATGCAAAATTACGGA(VP6F)", "DNA", 229, 280], ["reverse primer (VP6R) 5'- GGGGAAGCTTGTTAGACTCGGTAATA", "DNA", 285, 337], ["VP6 gene", "DNA", 384, 392], ["Construction of recombinant plasmids bearing VP6 gene", "TREATMENT", 80, 133], ["MethodsTo construct expression plasmids", "TREATMENT", 167, 206], ["reverse primer (VP6R)", "TREATMENT", 285, 306], ["the VP6 gene", "TREATMENT", 380, 392], ["the obtained PCR product", "TREATMENT", 399, 423], ["node", "OBSERVATION", 36, 40]]], ["Both primers contained BamH I and EcoR I sites, respectively.", [["BamH I", "GENE_OR_GENE_PRODUCT", 23, 29], ["EcoR I", "GENE_OR_GENE_PRODUCT", 34, 40], ["BamH I and EcoR I sites", "DNA", 23, 46], ["BamH I and EcoR I sites", "TREATMENT", 23, 46]]], ["Subsequent PCR was performed as above using the full-length VP6 gene as template.", [["VP6", "GENE_OR_GENE_PRODUCT", 60, 63], ["full-length VP6 gene", "DNA", 48, 68], ["Subsequent PCR", "TEST", 0, 14], ["the full-length VP6 gene as template", "TREATMENT", 44, 80]]], ["The PCR profile included 95\u00b0C for 5 min; 30 cycles of 95\u00b0C for 30 s, 52.8\u00b0C for 30 s, and 72\u00b0C for 2 min as well as a final extension at 72\u00b0C for 10 min.", [["The PCR profile", "TEST", 0, 15]]], ["The resulting PCR product was inserted into the prokaryotic expression vector pET30a and eukaryotic expression vector pVAX-1 to generate recombinant plasmids pET30a-VP6 and pVAX-VP6, respectively.Construction of recombinant plasmids bearing VP6 gene and its bacterial expression ::: MethodsThe pET30a-VP6 was transformed into Escherichia coli (E. coli) Rosetta.", [["plasmids", "ANATOMY", 149, 157], ["plasmids", "ANATOMY", 224, 232], ["pET30a", "GENE_OR_GENE_PRODUCT", 78, 84], ["pVAX-1", "GENE_OR_GENE_PRODUCT", 118, 124], ["pET30a-VP6", "GENE_OR_GENE_PRODUCT", 158, 168], ["pVAX-VP6", "GENE_OR_GENE_PRODUCT", 173, 181], ["VP6", "GENE_OR_GENE_PRODUCT", 241, 244], ["pET30a", "GENE_OR_GENE_PRODUCT", 294, 300], ["VP6", "GENE_OR_GENE_PRODUCT", 301, 304], ["Escherichia coli", "ORGANISM", 326, 342], ["E. coli", "ORGANISM", 344, 351], ["prokaryotic expression vector pET30a", "DNA", 48, 84], ["eukaryotic expression vector pVAX-1", "DNA", 89, 124], ["recombinant plasmids", "DNA", 137, 157], ["pET30a", "DNA", 158, 164], ["VP6", "DNA", 165, 168], ["pVAX", "DNA", 173, 177], ["VP6", "DNA", 178, 181], ["recombinant plasmids", "DNA", 212, 232], ["VP6 gene", "DNA", 241, 249], ["pET30a", "DNA", 294, 300], ["VP6", "DNA", 301, 304], ["Escherichia coli", "SPECIES", 326, 342], ["E. coli", "SPECIES", 344, 351], ["Escherichia coli", "SPECIES", 326, 342], ["E. coli", "SPECIES", 344, 351], ["The resulting PCR product", "TREATMENT", 0, 25], ["the prokaryotic expression vector pET30a", "TREATMENT", 44, 84], ["eukaryotic expression vector pVAX", "TREATMENT", 89, 122], ["recombinant plasmids pET30a", "TREATMENT", 137, 164], ["Construction of recombinant plasmids bearing VP6 gene", "TREATMENT", 196, 249], ["Escherichia coli (E. coli) Rosetta", "TREATMENT", 326, 360], ["Escherichia coli", "OBSERVATION", 326, 342], ["E. coli", "OBSERVATION", 344, 351]]], ["The transformed E.coli was cultured in Luria-Bertani (LB) medium supplemented with Kanamycin (50 mg/mL) with shaking at 37\u00b0C. When OD600 reached 0.6, isopropyl beta-D-thiogalactoside (IPTG) was added to the medium to a final concentration of 1 mM to induce protein expression.", [["Kanamycin", "CHEMICAL", 83, 92], ["isopropyl beta-D-thiogalactoside", "CHEMICAL", 150, 182], ["IPTG", "CHEMICAL", 184, 188], ["Kanamycin", "CHEMICAL", 83, 92], ["isopropyl beta-D-thiogalactoside", "CHEMICAL", 150, 182], ["IPTG", "CHEMICAL", 184, 188], ["E.coli", "CELL", 16, 22], ["Luria-Bertani", "CELL", 39, 52], ["Kanamycin", "SIMPLE_CHEMICAL", 83, 92], ["isopropyl beta-D-thiogalactoside", "SIMPLE_CHEMICAL", 150, 182], ["IPTG", "SIMPLE_CHEMICAL", 184, 188], ["E.coli", "SPECIES", 16, 22], ["Luria-Bertani", "SPECIES", 39, 52], ["The transformed E.coli", "PROBLEM", 0, 22], ["Kanamycin", "TREATMENT", 83, 92], ["shaking", "PROBLEM", 109, 116], ["isopropyl beta-D-thiogalactoside (IPTG)", "TREATMENT", 150, 189], ["E.coli", "OBSERVATION", 16, 22], ["protein expression", "OBSERVATION", 257, 275]]], ["Control culture containing the same bacteria transformed with empty vector was used as control.", [["Control culture", "TEST", 0, 15], ["the same bacteria", "PROBLEM", 27, 44], ["empty vector", "TREATMENT", 62, 74]]], ["The expressing protein designated as Pro-VP6 was subjected to gel-purification, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and renaturation by dialysis according to our previously reported protocols [28].Generation of polyclonal antibody to VP6 ::: MethodsGeneration of polyclonal antiserum to Pro-VP6 was processed according to references with modifications [17-19,28].", [["sodium dodecyl sulfate-polyacrylamide", "CHEMICAL", 80, 117], ["sodium dodecyl sulfate", "CHEMICAL", 80, 102], ["polyacrylamide", "CHEMICAL", 103, 117], ["Pro-VP6", "GENE_OR_GENE_PRODUCT", 37, 44], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 80, 102], ["VP6", "GENE_OR_GENE_PRODUCT", 267, 270], ["antiserum", "ORGANISM_SUBSTANCE", 307, 316], ["Pro-VP6", "GENE_OR_GENE_PRODUCT", 320, 327], ["Pro-VP6", "PROTEIN", 37, 44], ["polyclonal antibody", "PROTEIN", 244, 263], ["VP6", "PROTEIN", 267, 270], ["Pro-VP6", "PROTEIN", 320, 327], ["Pro-VP6", "TREATMENT", 37, 44], ["gel-purification", "TREATMENT", 62, 78], ["sodium dodecyl sulfate", "TREATMENT", 80, 102], ["polyacrylamide gel electrophoresis", "TREATMENT", 103, 137], ["renaturation", "TREATMENT", 153, 165], ["dialysis", "TREATMENT", 169, 177], ["polyclonal antibody", "TREATMENT", 244, 263], ["VP6", "TEST", 267, 270], ["polyclonal antiserum", "TREATMENT", 296, 316], ["Pro-VP6", "TREATMENT", 320, 327]]], ["A New Zealand rabbit was immunized with 2 mL of gel-purified Pro-VP6 (1 mg/mL) emulsified with equal amounts of Freund\u2019s complete adjuvant via subcutaneous injection.", [["subcutaneous", "ANATOMY", 143, 155], ["Pro-VP6", "CHEMICAL", 61, 68], ["rabbit", "ORGANISM", 14, 20], ["VP6", "ORGANISM", 65, 68], ["rabbit", "SPECIES", 14, 20], ["rabbit", "SPECIES", 14, 20], ["A New Zealand rabbit", "TREATMENT", 0, 20], ["gel-purified Pro-VP6", "TREATMENT", 48, 68], ["Freund", "TREATMENT", 112, 118], ["subcutaneous injection", "TREATMENT", 143, 165], ["New", "OBSERVATION_MODIFIER", 2, 5]]], ["After ten days, 2 mL of the same antigen mixed with Freund\u2019s incomplete adjuvant were injected into the rabbit weekly at two intervals.", [["rabbit", "ORGANISM", 104, 110], ["rabbit", "SPECIES", 104, 110], ["rabbit", "SPECIES", 104, 110], ["the same antigen", "TREATMENT", 24, 40], ["Freund\u2019s incomplete adjuvant", "TREATMENT", 52, 80]]], ["Antiserum was collected from the peripheral blood of the rabbit.Generation of polyclonal antibody to VP6 ::: MethodsThe titration of the antiserum and its reaction with VP6 protein was determined using ELISA: Purified VP6 was coated onto ELISA plates at a final concentration of 5 \u03bcg/well at 4\u00b0C overnight.", [["peripheral blood", "ANATOMY", 33, 49], ["Antiserum", "ORGANISM_SUBSTANCE", 0, 9], ["peripheral blood", "ORGANISM_SUBSTANCE", 33, 49], ["rabbit", "ORGANISM", 57, 63], ["VP6", "GENE_OR_GENE_PRODUCT", 101, 104], ["antiserum", "ORGANISM_SUBSTANCE", 137, 146], ["VP6", "GENE_OR_GENE_PRODUCT", 169, 172], ["VP6", "GENE_OR_GENE_PRODUCT", 218, 221], ["polyclonal antibody", "PROTEIN", 78, 97], ["VP6", "PROTEIN", 101, 104], ["VP6 protein", "PROTEIN", 169, 180], ["Purified VP6", "PROTEIN", 209, 221], ["rabbit", "SPECIES", 57, 63], ["rabbit", "SPECIES", 57, 63], ["Antiserum", "TREATMENT", 0, 9], ["polyclonal antibody", "TEST", 78, 97], ["Methods", "TREATMENT", 109, 116], ["the antiserum", "TREATMENT", 133, 146], ["its reaction", "PROBLEM", 151, 163], ["VP6 protein", "TEST", 169, 180], ["Purified VP6", "TREATMENT", 209, 221], ["a final concentration", "TREATMENT", 254, 275], ["peripheral", "ANATOMY_MODIFIER", 33, 43], ["blood", "ANATOMY", 44, 49], ["rabbit", "ANATOMY", 57, 63], ["polyclonal antibody", "OBSERVATION", 78, 97]]], ["The next day, the wells were incubated with blocking buffer at 37\u00b0C for 2 h, after three washes with PBS-0.1% Tween20 (PBST).", [["Tween20", "CHEMICAL", 110, 117], ["Tween20", "SIMPLE_CHEMICAL", 110, 117], ["blocking buffer", "TREATMENT", 44, 59], ["PBS", "TEST", 101, 104]]], ["The wells were incubated with serially diluted polyclonal antibodies at 37\u00b0C for 1 h.", [["polyclonal antibodies", "PROTEIN", 47, 68], ["serially diluted polyclonal antibodies", "TREATMENT", 30, 68]]], ["Then the plates were incubated with goat anti-rabbit IgG conjugated with peroxidase (1:5000 dilution in PBS) at 37\u00b0C for 1 h, after three washes with PBST.", [["goat", "ORGANISM", 36, 40], ["peroxidase", "GENE_OR_GENE_PRODUCT", 73, 83], ["goat anti-rabbit IgG", "PROTEIN", 36, 56], ["peroxidase", "PROTEIN", 73, 83], ["goat", "SPECIES", 36, 40], ["anti-rabbit", "SPECIES", 41, 52], ["goat", "SPECIES", 36, 40], ["anti-rabbit", "SPECIES", 41, 52], ["the plates", "TREATMENT", 5, 15], ["goat anti-rabbit IgG", "TREATMENT", 36, 56], ["peroxidase (1:5000 dilution in PBS", "TREATMENT", 73, 107], ["PBST", "TREATMENT", 150, 154]]], ["OPD (o-Phenylenediamine dihydrochloride) substrate (100 \u03bcL/well) was added and incubated for 15 min followed by stopping reaction with 2 M H2SO4.", [["o-Phenylenediamine dihydrochloride", "CHEMICAL", 5, 39], ["OPD", "CHEMICAL", 0, 3], ["o-Phenylenediamine dihydrochloride", "CHEMICAL", 5, 39], ["H2SO4", "CHEMICAL", 139, 144], ["OPD", "SIMPLE_CHEMICAL", 0, 3], ["o-Phenylenediamine dihydrochloride", "SIMPLE_CHEMICAL", 5, 39], ["OPD (o-Phenylenediamine dihydrochloride) substrate", "TREATMENT", 0, 50], ["2 M H2SO4", "TREATMENT", 135, 144]]], ["The OD490 values were determined an ELISA reader.", [["OD490", "DNA", 4, 9], ["The OD490 values", "TEST", 0, 16]]], ["In addition, the reactivity of the anti-VP6 antibody to PRV was also tested.", [["anti-VP6 antibody", "GENE_OR_GENE_PRODUCT", 35, 52], ["PRV", "ORGANISM", 56, 59], ["anti-VP6 antibody", "PROTEIN", 35, 52], ["PRV", "SPECIES", 56, 59], ["the anti-VP6 antibody", "TREATMENT", 31, 52]]], ["Briefly, the purified PRV (104 PFU/mL) were coated onto ELISA plates (100 \u03bcL/well) and the dilution of antiserum to Pro-VP6 or the control serum was 1:24, 1:25, 1:26, 1:27, 1:28, 1:29, 1:210, 1:211 or 1:212.", [["serum", "ANATOMY", 139, 144], ["PRV", "ORGANISM", 22, 25], ["antiserum", "ORGANISM_SUBSTANCE", 103, 112], ["Pro-VP6", "SIMPLE_CHEMICAL", 116, 123], ["serum", "ORGANISM_SUBSTANCE", 139, 144], ["Pro-VP6", "PROTEIN", 116, 123], ["PRV", "SPECIES", 22, 25], ["the purified PRV", "TREATMENT", 9, 25], ["ELISA plates", "TEST", 56, 68], ["the dilution of antiserum", "TREATMENT", 87, 112], ["the control serum", "TEST", 127, 144]]], ["The other experimental steps were performed as above.Western blot ::: MethodsPro-VP6-containing bacterial protein and empty vector-transforming bacterial protein (negative control) were subjected to SDS-PAGE and transferred to a nitrocellulose (NC) membrane.", [["NC) membrane", "ANATOMY", 245, 257], ["MethodsPro-VP6", "CHEMICAL", 70, 84], ["nitrocellulose", "CHEMICAL", 229, 243], ["MethodsPro-VP6", "SIMPLE_CHEMICAL", 70, 84], ["membrane", "CELLULAR_COMPONENT", 249, 257], ["MethodsPro-VP6", "PROTEIN", 70, 84], ["bacterial protein", "PROTEIN", 96, 113], ["empty vector-transforming bacterial protein", "PROTEIN", 118, 161], ["MethodsPro-VP6", "TEST", 70, 84], ["bacterial protein", "TEST", 96, 113], ["empty vector", "TREATMENT", 118, 130], ["transforming bacterial protein", "PROBLEM", 131, 161], ["a nitrocellulose (NC) membrane", "TREATMENT", 227, 257], ["experimental steps", "OBSERVATION", 10, 28], ["bacterial protein", "OBSERVATION", 96, 113], ["empty vector", "OBSERVATION", 118, 130]]], ["Rabbit antiserum to Pro-VP6 was diluted 1:2,000 in PBS and was used to incubate the membrane at room temperature for 1.5 h followed by incubation with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:5000 dilution, Boster, China) for 1.5 h.", [["membrane", "ANATOMY", 84, 92], ["Rabbit", "ORGANISM", 0, 6], ["antiserum", "ORGANISM_SUBSTANCE", 7, 16], ["Pro-VP6", "GENE_OR_GENE_PRODUCT", 20, 27], ["membrane", "CELLULAR_COMPONENT", 84, 92], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 151, 173], ["HRP", "SIMPLE_CHEMICAL", 175, 178], ["goat", "ORGANISM", 191, 195], ["anti-rabbit IgG", "SIMPLE_CHEMICAL", 196, 211], ["Pro-VP6", "PROTEIN", 20, 27], ["horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG", "PROTEIN", 151, 211], ["Rabbit", "SPECIES", 0, 6], ["horseradish", "SPECIES", 151, 162], ["goat", "SPECIES", 191, 195], ["anti-rabbit", "SPECIES", 196, 207], ["Rabbit", "SPECIES", 0, 6], ["goat", "SPECIES", 191, 195], ["anti-rabbit", "SPECIES", 196, 207], ["Rabbit antiserum", "TREATMENT", 0, 16], ["Pro-VP6", "TREATMENT", 20, 27], ["horseradish peroxidase (HRP", "TREATMENT", 151, 178], ["conjugated goat anti-rabbit IgG", "TREATMENT", 180, 211]]], ["The protein bands were visualized using OPD.Indirect immunofluorescence assay (IFA) ::: MethodsBaby hamster kidney (BHK) cells seeded onto 24-well plates were transfected with pVAX-VP6 using polyethylenimine (PEI) transfection agent (Sigma, China) according to the manufacturer\u2019s instructions.", [["hamster kidney (BHK) cells", "ANATOMY", 100, 126], ["pVAX-VP6", "CHEMICAL", 176, 184], ["polyethylenimine", "CHEMICAL", 191, 207], ["PEI", "CHEMICAL", 209, 212], ["polyethylenimine", "CHEMICAL", 191, 207], ["PEI", "CHEMICAL", 209, 212], ["MethodsBaby hamster kidney (BHK) cells", "CELL", 88, 126], ["pVAX-VP6", "GENE_OR_GENE_PRODUCT", 176, 184], ["polyethylenimine", "SIMPLE_CHEMICAL", 191, 207], ["PEI", "SIMPLE_CHEMICAL", 209, 212], ["MethodsBaby hamster kidney (BHK) cells", "CELL_LINE", 88, 126], ["pVAX", "PROTEIN", 176, 180], ["VP6", "DNA", 181, 184], ["hamster", "SPECIES", 100, 107], ["BHK", "SPECIES", 116, 119], ["The protein bands", "TEST", 0, 17], ["Indirect immunofluorescence assay", "TEST", 44, 77], ["MethodsBaby hamster kidney (BHK) cells", "TREATMENT", 88, 126], ["pVAX", "TREATMENT", 176, 180], ["VP6 using polyethylenimine (PEI) transfection agent", "TREATMENT", 181, 232], ["protein bands", "OBSERVATION", 4, 17], ["kidney", "ANATOMY", 108, 114]]], ["Empty vector-transfected cells were used as control.", [["cells", "ANATOMY", 25, 30], ["cells", "CELL", 25, 30], ["Empty vector-transfected cells", "CELL_LINE", 0, 30], ["Empty vector-transfected cells", "TREATMENT", 0, 30], ["transfected cells", "OBSERVATION", 13, 30]]], ["The cells were fixed with 4% PFA (polyformaldehyde) in PBS at room temperature for 20 min and quenched with 0.1 M glycine in PBS.", [["cells", "ANATOMY", 4, 9], ["PFA", "CHEMICAL", 29, 32], ["polyformaldehyde", "CHEMICAL", 34, 50], ["glycine", "CHEMICAL", 114, 121], ["PFA", "CHEMICAL", 29, 32], ["polyformaldehyde", "CHEMICAL", 34, 50], ["glycine", "CHEMICAL", 114, 121], ["cells", "CELL", 4, 9], ["PFA", "SIMPLE_CHEMICAL", 29, 32], ["polyformaldehyde", "SIMPLE_CHEMICAL", 34, 50], ["glycine", "SIMPLE_CHEMICAL", 114, 121], ["4% PFA (polyformaldehyde)", "TREATMENT", 26, 51], ["0.1 M glycine in PBS", "TREATMENT", 108, 128]]], ["Then, the cells were washed three times with PBST and treated with or without 1% Triton X-100 for 10 min followed by incubation with anti-VP6 serum (1:200 dilution in PBS containing 0.1% BSA) for 1 h.", [["cells", "ANATOMY", 10, 15], ["serum", "ANATOMY", 142, 147], ["Triton X-100", "CHEMICAL", 81, 93], ["anti-VP6", "CHEMICAL", 133, 141], ["cells", "CELL", 10, 15], ["Triton X-100", "SIMPLE_CHEMICAL", 81, 93], ["anti-VP6", "ORGANISM", 133, 141], ["serum", "ORGANISM_SUBSTANCE", 142, 147], ["BSA", "SIMPLE_CHEMICAL", 187, 190], ["the cells", "TREATMENT", 6, 15], ["PBST", "TREATMENT", 45, 49], ["1% Triton", "TREATMENT", 78, 87], ["anti-VP6 serum", "TREATMENT", 133, 147]]], ["After three washes with PBST, the cells were incubated with fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (1:200 in PBS containing 1% BSA) for 1 h at 37\u00b0C. After washing with PBST, the fluorescence signals were analyzed using fluorescence microscopy.Immunoreactivity of the anti-VP6 antibody to other control viruses ::: MethodsTo evaluate the immunoreactivity of the anti-VP6 antibody, a discrimination ELISA was established.", [["cells", "ANATOMY", 34, 39], ["fluorescein isothiocyanate", "CHEMICAL", 60, 86], ["fluorescein isothiocyanate", "CHEMICAL", 60, 86], ["FITC", "CHEMICAL", 88, 92], ["cells", "CELL", 34, 39], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 60, 86], ["FITC", "SIMPLE_CHEMICAL", 88, 92], ["goat", "ORGANISM", 105, 109], ["anti-rabbit IgG", "SIMPLE_CHEMICAL", 110, 125], ["BSA", "SIMPLE_CHEMICAL", 154, 157], ["anti-VP6", "GENE_OR_GENE_PRODUCT", 294, 302], ["anti-VP6", "GENE_OR_GENE_PRODUCT", 388, 396], ["fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG", "PROTEIN", 60, 125], ["anti-VP6 antibody", "PROTEIN", 294, 311], ["anti-VP6 antibody", "PROTEIN", 388, 405], ["goat", "SPECIES", 105, 109], ["anti-rabbit", "SPECIES", 110, 121], ["goat", "SPECIES", 105, 109], ["PBST", "TREATMENT", 24, 28], ["fluorescein isothiocyanate (FITC)", "TREATMENT", 60, 93], ["conjugated goat anti-rabbit IgG", "TREATMENT", 94, 125], ["PBST", "TREATMENT", 195, 199], ["the fluorescence signals", "TEST", 201, 225], ["fluorescence microscopy", "TEST", 246, 269], ["the anti-VP6 antibody", "TREATMENT", 290, 311], ["Methods", "TREATMENT", 341, 348], ["the anti-VP6 antibody", "TEST", 384, 405], ["a discrimination ELISA", "TEST", 407, 429]]], ["PRV, Porcine transmissible gastroenteritis virus (TGEV) strain HR/DN1, Porcine epidemic diarrhea virus (PEDV) strain HLJBY, Porcine circovirus type II (PCV2) strain PCV2-LJR, Porcine reproductive and respiratory syndrome virus (PRRSV) strain JilinTN1, Porcine pseudorabies virus (PrV) strain Kaplan and Porcine parvovirus (PPV) strain PPV2010 were treated with lysis buffer (0.1% SDS, 10 mmol/liter Tris\u2013HCl [pH 7.4], and 1 mmol/liter EDTA) followed by dilution in carbonate\u2013bicarbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and the pathogens were coated into ELISA plates (8 \u03bcg/well) at 4\u00b0C overnight.", [["transmissible gastroenteritis", "DISEASE", 13, 42], ["Porcine epidemic diarrhea", "DISEASE", 71, 96], ["Porcine circovirus type II", "DISEASE", 124, 150], ["Porcine reproductive and respiratory syndrome", "DISEASE", 175, 220], ["Porcine parvovirus", "DISEASE", 303, 321], ["PPV2010", "CHEMICAL", 335, 342], ["carbonate\u2013bicarbonate", "CHEMICAL", 465, 486], ["Na2CO3", "CHEMICAL", 501, 507], ["Tris\u2013HCl", "CHEMICAL", 399, 407], ["EDTA", "CHEMICAL", 435, 439], ["carbonate\u2013bicarbonate", "CHEMICAL", 465, 486], ["Na2CO3", "CHEMICAL", 501, 507], ["NaHCO3", "CHEMICAL", 515, 521], ["PRV", "ORGANISM", 0, 3], ["Porcine transmissible gastroenteritis virus", "ORGANISM", 5, 48], ["TGEV", "ORGANISM", 50, 54], ["strain HR/DN1", "ORGANISM", 56, 69], ["Porcine epidemic diarrhea virus", "ORGANISM", 71, 102], ["PEDV) strain HLJBY", "ORGANISM", 104, 122], ["Porcine circovirus type II", "ORGANISM", 124, 150], ["PCV2", "ORGANISM", 152, 156], ["PCV2-LJR,", "ORGANISM", 165, 174], ["Porcine reproductive and respiratory syndrome virus", "ORGANISM", 175, 226], ["PRRSV", "ORGANISM", 228, 233], ["Porcine pseudorabies virus", "ORGANISM", 252, 278], ["PrV) strain", "ORGANISM", 280, 291], ["Kaplan", "ORGANISM", 292, 298], ["Porcine parvovirus", "ORGANISM", 303, 321], ["EDTA", "SIMPLE_CHEMICAL", 435, 439], ["carbonate\u2013bicarbonate", "SIMPLE_CHEMICAL", 465, 486], ["Porcine", "SPECIES", 5, 12], ["transmissible gastroenteritis virus", "SPECIES", 13, 48], ["TGEV", "SPECIES", 50, 54], ["Porcine epidemic diarrhea virus", "SPECIES", 71, 102], ["Porcine circovirus", "SPECIES", 124, 142], ["Porcine", "SPECIES", 175, 182], ["PRRSV", "SPECIES", 228, 233], ["Porcine pseudorabies virus", "SPECIES", 252, 278], ["Porcine parvovirus", "SPECIES", 303, 321], ["PRV", "SPECIES", 0, 3], ["Porcine transmissible gastroenteritis virus", "SPECIES", 5, 48], ["TGEV", "SPECIES", 50, 54], ["Porcine epidemic diarrhea virus", "SPECIES", 71, 102], ["PEDV", "SPECIES", 104, 108], ["Porcine circovirus type II (PCV2) strain PCV2-LJR", "SPECIES", 124, 173], ["Porcine reproductive and respiratory syndrome virus", "SPECIES", 175, 226], ["PRRSV", "SPECIES", 228, 233], ["Porcine pseudorabies virus", "SPECIES", 252, 278], ["PrV", "SPECIES", 280, 283], ["Porcine parvovirus (PPV) strain PPV2010", "SPECIES", 303, 342], ["PRV", "PROBLEM", 0, 3], ["Porcine transmissible gastroenteritis virus", "PROBLEM", 5, 48], ["strain HR", "TEST", 56, 65], ["DN1", "PROBLEM", 66, 69], ["Porcine epidemic diarrhea virus (PEDV) strain HLJBY", "PROBLEM", 71, 122], ["Porcine circovirus type II (PCV2) strain PCV2", "PROBLEM", 124, 169], ["LJR", "PROBLEM", 170, 173], ["Porcine reproductive", "PROBLEM", 175, 195], ["respiratory syndrome virus", "PROBLEM", 200, 226], ["strain JilinTN1", "PROBLEM", 235, 250], ["Porcine pseudorabies virus (PrV) strain Kaplan", "TREATMENT", 252, 298], ["Porcine parvovirus (PPV) strain PPV2010", "TREATMENT", 303, 342], ["lysis buffer", "TREATMENT", 361, 373], ["pH", "TEST", 409, 411], ["1 mmol/liter EDTA", "TREATMENT", 422, 439], ["dilution in carbonate\u2013bicarbonate buffer", "TREATMENT", 453, 493], ["35 mM NaHCO3", "TREATMENT", 509, 521], ["pH", "TEST", 523, 525], ["the pathogens", "PROBLEM", 535, 548], ["ELISA plates", "TEST", 566, 578], ["Porcine circovirus", "OBSERVATION", 124, 142], ["respiratory syndrome", "OBSERVATION", 200, 220], ["pseudorabies virus", "OBSERVATION", 260, 278]]], ["Wells coated with DMEM or lysis buffer were used as control.", [["DMEM", "TREATMENT", 18, 22], ["lysis buffer", "TREATMENT", 26, 38]]], ["The anti-PRV antibody was used as primary antibody in the above-mentioned ELISA to detect the pathogens.", [["anti-PRV antibody", "GENE_OR_GENE_PRODUCT", 4, 21], ["anti-PRV antibody", "PROTEIN", 4, 21], ["primary antibody", "PROTEIN", 34, 50], ["anti-PRV", "SPECIES", 4, 12], ["The anti-PRV antibody", "TEST", 0, 21], ["primary antibody", "TEST", 34, 50], ["the pathogens", "PROBLEM", 90, 103], ["pathogens", "OBSERVATION", 94, 103]]], ["The OD490 value of tested samples (P)/the OD490 value of negative control, coating buffer (N)>2 was judged as positive.", [["samples", "ANATOMY", 26, 33], ["OD490", "SIMPLE_CHEMICAL", 4, 9], ["tested samples", "TEST", 19, 33], ["coating buffer (N)", "TEST", 75, 93], ["positive", "OBSERVATION", 110, 118]]], ["Statistical analysis of the data was processed with SPSS 11.5 software; p<0.05 and p<0.01 were defined as statistically significant and statistically very significant, respectively.Competing interestsThe authors have no competing interests.Authors' contributionsXR, JZ, QY, LC, XD, WZ, REB and YR carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript.", [["Statistical analysis", "TEST", 0, 20], ["the data", "TEST", 24, 32], ["SPSS", "TEST", 52, 56], ["software", "TEST", 62, 70], ["p", "TEST", 72, 73], ["the molecular genetic studies", "TEST", 309, 338], ["the sequence alignment", "TEST", 356, 378], ["LC", "ANATOMY", 274, 276]]], ["JZ, JZ, FD, GL and XR carried out the immunoassays.", [["XR", "TEST", 19, 21], ["the immunoassays", "TEST", 34, 50]]], ["JZ, LC, GL, YR, SS and XR participated in the design of the study.", [["XR", "CHEMICAL", 23, 25], ["JZ", "TEST", 0, 2], ["the study", "TEST", 56, 65], ["LC", "ANATOMY", 4, 6], ["GL", "ANATOMY", 8, 10]]], ["XR conceived of the study and participated in its design and coordination and helped to draft the manuscript.", [["XR", "TEST", 0, 2], ["the study", "TEST", 16, 25]]]], "8e67618920b0226e661e20a2c36b4436857d9590": [["children under 5 years of age [6] .", [["children", "ORGANISM", 0, 8], ["children", "SPECIES", 0, 8]]], ["As of February 19 th 2010, there have been 37,713 confirmed cases of pandemic (H1N1) 2009 in Australia, including 191 pandemic influenza-associated deaths [7] .", [["pandemic", "DISEASE", 69, 77], ["influenza", "DISEASE", 127, 136], ["deaths", "DISEASE", 148, 154], ["pandemic", "PROBLEM", 69, 77]]]], "PMC7274691": [], "1b5d310d0656503b1d2fbc612625496a3266ae16": [["BackgroundThe most common mammalian model used for influenza virus research, the mouse, is not susceptible to infection with many unadapted human influenza A viruses of the H3N2 serotype and does not shed virus from the respiratory tract.", [["respiratory tract", "ANATOMY", 220, 237], ["influenza virus", "DISEASE", 51, 66], ["infection", "DISEASE", 110, 119], ["influenza A viruses", "DISEASE", 146, 165], ["influenza virus", "ORGANISM", 51, 66], ["mouse", "ORGANISM", 81, 86], ["human influenza A viruses", "ORGANISM", 140, 165], ["H3N2 serotype", "ORGANISM", 173, 186], ["respiratory tract", "ORGANISM_SUBDIVISION", 220, 237], ["influenza virus", "SPECIES", 51, 66], ["mouse", "SPECIES", 81, 86], ["human", "SPECIES", 140, 145], ["H3N2 serotype", "SPECIES", 173, 186], ["influenza virus", "SPECIES", 51, 66], ["mouse", "SPECIES", 81, 86], ["human influenza A viruses", "SPECIES", 140, 165], ["influenza virus research", "PROBLEM", 51, 75], ["infection", "PROBLEM", 110, 119], ["the H3N2 serotype", "PROBLEM", 169, 186], ["not susceptible to", "UNCERTAINTY", 91, 109], ["infection", "OBSERVATION", 110, 119], ["respiratory tract", "ANATOMY", 220, 237]]], ["Ferrets and macaques have increased tropisms to many primary influenza isolates but both are expensive to maintain and difficult to house.", [["influenza", "DISEASE", 61, 70], ["macaques", "ORGANISM", 12, 20], ["macaques", "SPECIES", 12, 20], ["increased tropisms", "PROBLEM", 26, 44], ["many primary influenza isolates", "PROBLEM", 48, 79], ["increased", "OBSERVATION_MODIFIER", 26, 35]]], ["Based largely on their recapitulation of human disease signs, ferrets have also been used to derive serotyping reagents for assessing antigenic distance between isolates and potential vaccine strains.", [["human", "ORGANISM", 41, 46], ["ferrets", "ORGANISM", 62, 69], ["human", "SPECIES", 41, 46], ["ferrets", "SPECIES", 62, 69], ["human", "SPECIES", 41, 46], ["ferrets", "SPECIES", 62, 69], ["human disease signs", "PROBLEM", 41, 60], ["serotyping reagents", "TREATMENT", 100, 119], ["antigenic distance between isolates", "TREATMENT", 134, 169], ["potential vaccine strains", "TREATMENT", 174, 199]]], ["However, recent reports suggest that ferrets may not faithfully mimic human immune responses, and that serological tests using ferret sera may not accurately assess vaccine strain efficacy [1, 2] .", [["sera", "ANATOMY", 134, 138], ["ferrets", "ORGANISM", 37, 44], ["human", "ORGANISM", 70, 75], ["ferret", "ORGANISM", 127, 133], ["sera", "ORGANISM_SUBSTANCE", 134, 138], ["ferrets", "SPECIES", 37, 44], ["human", "SPECIES", 70, 75], ["ferret", "SPECIES", 127, 133], ["ferrets", "SPECIES", 37, 44], ["human", "SPECIES", 70, 75], ["ferret", "SPECIES", 127, 133], ["serological tests", "TEST", 103, 120], ["ferret sera", "TEST", 127, 138]]], ["Therefore, there is a need to develop additional permissive small animal models of influenza virus infection that exhibit virus shedding.", [["influenza virus infection", "DISEASE", 83, 108], ["influenza virus", "ORGANISM", 83, 98], ["influenza virus", "SPECIES", 83, 98], ["influenza virus", "SPECIES", 83, 98], ["influenza virus infection", "PROBLEM", 83, 108], ["virus shedding", "PROBLEM", 122, 136], ["permissive", "OBSERVATION_MODIFIER", 49, 59], ["small", "OBSERVATION_MODIFIER", 60, 65], ["animal models", "OBSERVATION_MODIFIER", 66, 79], ["influenza virus infection", "OBSERVATION", 83, 108], ["virus", "OBSERVATION", 122, 127]]], ["Serial samples collected from such animal models allow the investigator to determine both the titer and duration of virus shedding from individual animals at multiple times without euthanasia.", [["samples", "ANATOMY", 7, 14], ["Serial samples", "TEST", 0, 14], ["virus shedding", "PROBLEM", 116, 130], ["euthanasia", "PROBLEM", 181, 191], ["euthanasia", "OBSERVATION", 181, 191]]], ["Further characterization of animal models capable of replicating and transmitting unadapted human, avian, and/or swine influenza viruses can be valuable for studying and testing new and improved vaccines, immunobiotics and anti-virals.", [["human", "ORGANISM", 92, 97], ["avian", "ORGANISM", 99, 104], ["swine influenza viruses", "ORGANISM", 113, 136], ["anti-virals", "SIMPLE_CHEMICAL", 223, 234], ["human", "SPECIES", 92, 97], ["swine influenza viruses", "SPECIES", 113, 136], ["human", "SPECIES", 92, 97], ["swine influenza viruses", "SPECIES", 113, 136], ["Further characterization", "TEST", 0, 24], ["swine influenza viruses", "PROBLEM", 113, 136], ["studying and testing", "TEST", 157, 177], ["improved vaccines", "TREATMENT", 186, 203], ["immunobiotics", "TREATMENT", 205, 218], ["anti-virals", "TREATMENT", 223, 234]]], ["Two promising alternative animal models, guinea pigs and cotton rats, have recently been investigated for the analysis of human influenza virus and influenza vaccine [3, 4] .", [["influenza virus", "DISEASE", 128, 143], ["influenza", "DISEASE", 148, 157], ["guinea pigs", "ORGANISM", 41, 52], ["cotton rats", "ORGANISM", 57, 68], ["human", "ORGANISM", 122, 127], ["influenza virus", "ORGANISM", 128, 143], ["guinea pigs", "SPECIES", 41, 52], ["rats", "SPECIES", 64, 68], ["human", "SPECIES", 122, 127], ["influenza virus", "SPECIES", 128, 143], ["pigs", "SPECIES", 48, 52], ["cotton", "SPECIES", 57, 63], ["human influenza virus", "SPECIES", 122, 143], ["guinea pigs and cotton rats", "TREATMENT", 41, 68], ["the analysis", "TEST", 106, 118], ["human influenza virus", "PROBLEM", 122, 143], ["influenza vaccine", "TREATMENT", 148, 165]]], ["These studies focus on the guinea pig as a model for influenza.BackgroundGuinea pigs have many attractive features for use as an animal model for influenza immunization and infection.", [["influenza", "DISEASE", 53, 62], ["influenza", "DISEASE", 146, 155], ["infection", "DISEASE", 173, 182], ["guinea pig", "ORGANISM", 27, 37], ["Guinea pigs", "ORGANISM", 73, 84], ["guinea pig", "SPECIES", 27, 37], ["Guinea pigs", "SPECIES", 73, 84], ["guinea pig", "SPECIES", 27, 37], ["pigs", "SPECIES", 80, 84], ["These studies", "TEST", 0, 13], ["the guinea pig", "TREATMENT", 23, 37], ["influenza", "PROBLEM", 53, 62], ["BackgroundGuinea pigs", "PROBLEM", 63, 84], ["an animal model", "TREATMENT", 126, 141], ["influenza immunization", "TREATMENT", 146, 168], ["infection", "PROBLEM", 173, 182], ["influenza", "OBSERVATION", 53, 62], ["infection", "OBSERVATION", 173, 182]]], ["Guinea pigs are relatively inexpensive and easy to maintain for larger studies compared to ferrets and simians.", [["Guinea pigs", "ORGANISM", 0, 11], ["ferrets", "ORGANISM", 91, 98], ["Guinea pigs", "SPECIES", 0, 11], ["ferrets", "SPECIES", 91, 98], ["ferrets", "SPECIES", 91, 98], ["larger studies", "TEST", 64, 78]]], ["They are readily infected with primary isolates of human influenza strains, and have potential uses for virus evolutionary, prophylactic and therapeutic studies [3] .", [["influenza", "DISEASE", 57, 66], ["human", "ORGANISM", 51, 56], ["influenza strains", "ORGANISM", 57, 74], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["human influenza strains", "PROBLEM", 51, 74], ["virus evolutionary", "TREATMENT", 104, 122], ["therapeutic studies", "TEST", 141, 160], ["infected", "OBSERVATION", 17, 25]]], ["A small number of reports describing experimental infection of guinea pigs with human influenza viruses were published in the 1970 s and 80 s [5] [6] [7] [8] .", [["infection", "DISEASE", 50, 59], ["influenza viruses", "DISEASE", 86, 103], ["guinea pigs", "ORGANISM", 63, 74], ["human", "ORGANISM", 80, 85], ["influenza viruses", "ORGANISM", 86, 103], ["guinea pigs", "SPECIES", 63, 74], ["human", "SPECIES", 80, 85], ["guinea pigs", "SPECIES", 63, 74], ["human influenza viruses", "SPECIES", 80, 103], ["experimental infection of guinea pigs", "PROBLEM", 37, 74], ["human influenza viruses", "PROBLEM", 80, 103], ["small", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["infection", "OBSERVATION", 50, 59]]], ["More recently, we and others have advanced the guinea pig model for the study of virus infection and spread and as a vaccine-challenge model [3] .", [["infection", "DISEASE", 87, 96], ["guinea pig", "ORGANISM", 47, 57], ["guinea pig", "SPECIES", 47, 57], ["pig", "SPECIES", 54, 57], ["the guinea pig model", "TREATMENT", 43, 63], ["the study", "TEST", 68, 77], ["virus infection", "PROBLEM", 81, 96], ["a vaccine", "TREATMENT", 115, 124]]], ["Guinea pigs can be readily infected with human influenza isolates without prior tissue culture or animal adaptation.", [["tissue", "ANATOMY", 80, 86], ["influenza", "DISEASE", 47, 56], ["pigs", "ORGANISM", 7, 11], ["human", "ORGANISM", 41, 46], ["tissue", "TISSUE", 80, 86], ["Guinea pigs", "SPECIES", 0, 11], ["human", "SPECIES", 41, 46], ["pigs", "SPECIES", 7, 11], ["human", "SPECIES", 41, 46], ["Guinea pigs", "TREATMENT", 0, 11], ["human influenza isolates", "TREATMENT", 41, 65], ["prior tissue culture", "TEST", 74, 94]]], ["The infection in guinea pigs appears to be centered largely in the upper naso-respiratory tract and the animals can pass the virus to others via aerosol transmission [9] .", [["upper naso-respiratory tract", "ANATOMY", 67, 95], ["infection", "DISEASE", 4, 13], ["guinea pigs", "ORGANISM", 17, 28], ["upper naso", "ORGANISM_SUBDIVISION", 67, 77], ["respiratory tract", "ORGANISM_SUBDIVISION", 78, 95], ["guinea pigs", "SPECIES", 17, 28], ["guinea pigs", "SPECIES", 17, 28], ["The infection in guinea pigs", "PROBLEM", 0, 28], ["infection", "OBSERVATION", 4, 13], ["guinea pigs", "OBSERVATION", 17, 28], ["appears to be", "UNCERTAINTY", 29, 42], ["upper", "ANATOMY_MODIFIER", 67, 72], ["naso", "ANATOMY_MODIFIER", 73, 77], ["respiratory tract", "ANATOMY", 78, 95]]], ["A recent study demonstrated acute viral replication and moderate virulence of the highly pathogenic 1918 pandemic and H5N1 viruses in addition to low-pathogenicity avian and human H1N1 viruses in guinea pigs [10] .BackgroundThe overall purpose of the current study was to characterize the immunological responses of guinea pigs infected with H3N2 virus or immunized with HA protein so as to assess the value of a guinea pig model in future immunological assays such as vaccine-challenge studies.", [["pandemic", "DISEASE", 105, 113], ["H5N1 viruses", "DISEASE", 118, 130], ["H5N1 viruses", "ORGANISM", 118, 130], ["avian", "ORGANISM", 164, 169], ["human", "ORGANISM", 174, 179], ["H1N1 viruses", "ORGANISM", 180, 192], ["guinea pigs", "ORGANISM", 196, 207], ["guinea pigs", "ORGANISM", 316, 327], ["H3N2 virus", "ORGANISM", 342, 352], ["guinea pig", "ORGANISM", 413, 423], ["HA protein", "PROTEIN", 371, 381], ["avian", "SPECIES", 164, 169], ["human", "SPECIES", 174, 179], ["H1N1 viruses", "SPECIES", 180, 192], ["guinea pigs", "SPECIES", 196, 207], ["guinea pigs", "SPECIES", 316, 327], ["H3N2 virus", "SPECIES", 342, 352], ["guinea pig", "SPECIES", 413, 423], ["H5N1 viruses", "SPECIES", 118, 130], ["human H1N1 viruses", "SPECIES", 174, 192], ["guinea pigs", "SPECIES", 196, 207], ["guinea pigs", "SPECIES", 316, 327], ["H3N2 virus", "SPECIES", 342, 352], ["pig", "SPECIES", 420, 423], ["A recent study", "TEST", 0, 14], ["acute viral replication", "PROBLEM", 28, 51], ["moderate virulence", "PROBLEM", 56, 74], ["H5N1 viruses", "PROBLEM", 118, 130], ["low-pathogenicity avian", "PROBLEM", 146, 169], ["human H1N1 viruses", "PROBLEM", 174, 192], ["the current study", "TEST", 247, 264], ["guinea pigs", "TREATMENT", 316, 327], ["H3N2 virus", "PROBLEM", 342, 352], ["HA protein", "PROBLEM", 371, 381], ["a guinea pig model", "TREATMENT", 411, 429], ["immunological assays", "TEST", 440, 460], ["vaccine", "TREATMENT", 469, 476], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["viral replication", "OBSERVATION", 34, 51], ["moderate", "OBSERVATION_MODIFIER", 56, 64]]], ["Because of the prophylactic properties of HA-derived vaccines, and their relative ease of production, immune responses of this subunit were studied in the guinea pig model.", [["HA", "SIMPLE_CHEMICAL", 42, 44], ["guinea pig", "ORGANISM", 155, 165], ["guinea pig", "SPECIES", 155, 165], ["guinea pig", "SPECIES", 155, 165], ["HA-derived vaccines", "TREATMENT", 42, 61], ["this subunit", "TREATMENT", 122, 134], ["the guinea pig model", "TREATMENT", 151, 171]]], ["The results support the utility of the guinea pig as a useful animal model of influenza infection and immunization.Infection of Guinea PigsFour groups of guinea pigs were chosen, (1) a negative control with no infection, (2) a positive control that received an infection only, (3) a group that was immunized with low dose of recombinant HA protein, and (4) another with high dose.", [["influenza infection", "DISEASE", 78, 97], ["infection", "DISEASE", 210, 219], ["infection", "DISEASE", 261, 270], ["guinea pig", "ORGANISM", 39, 49], ["influenza", "ORGANISM", 78, 87], ["guinea pigs", "ORGANISM", 154, 165], ["recombinant HA protein", "PROTEIN", 325, 347], ["guinea pig", "SPECIES", 39, 49], ["guinea pigs", "SPECIES", 154, 165], ["pig", "SPECIES", 46, 49], ["guinea pigs", "SPECIES", 154, 165], ["the guinea pig", "TREATMENT", 35, 49], ["influenza infection", "PROBLEM", 78, 97], ["immunization", "TREATMENT", 102, 114], ["Infection", "PROBLEM", 115, 124], ["guinea pigs", "TREATMENT", 154, 165], ["infection", "PROBLEM", 210, 219], ["a positive control", "PROBLEM", 225, 243], ["an infection", "PROBLEM", 258, 270], ["recombinant HA protein", "TREATMENT", 325, 347], ["influenza infection", "OBSERVATION", 78, 97], ["no", "UNCERTAINTY", 207, 209], ["infection", "OBSERVATION", 210, 219], ["infection", "OBSERVATION", 261, 270]]], ["ELISA extinction titers of Group 1, the control group for this serological study, remained negative and unchanged throughout the study.Infection of Guinea PigsTwo guinea pigs (Group 2) were inoculated intranasally with 3 \u00d7 10 4 plaque-forming units of A/Wyoming/ 03/2003 virus, allowed to recover from infection for 5 weeks, and then re-inoculated with the same dose of virus.", [["intranasally", "ANATOMY", 201, 213], ["infection", "DISEASE", 302, 311], ["Guinea", "ORGANISM", 148, 154], ["PigsTwo guinea pigs", "ORGANISM", 155, 174], ["03/2003", "ORGANISM", 263, 270], ["Guinea", "SPECIES", 148, 154], ["PigsTwo guinea pigs", "SPECIES", 155, 174], ["Guinea PigsTwo guinea pigs", "SPECIES", 148, 174], ["A/Wyoming/ 03/2003 virus", "SPECIES", 252, 276], ["ELISA extinction", "TEST", 0, 16], ["this serological study", "TEST", 58, 80], ["the study", "TEST", 125, 134], ["Infection", "PROBLEM", 135, 144], ["Guinea PigsTwo guinea pigs", "TREATMENT", 148, 174], ["A/Wyoming/ 03/2003 virus", "TREATMENT", 252, 276], ["infection", "PROBLEM", 302, 311], ["virus", "TREATMENT", 370, 375], ["negative", "OBSERVATION", 91, 99], ["unchanged", "OBSERVATION_MODIFIER", 104, 113], ["infection", "OBSERVATION", 302, 311]]], ["Nasal wash samples were collected at 2, 3, 6 and 9 days post infection (dpi).", [["Nasal", "ANATOMY", 0, 5], ["samples", "ANATOMY", 11, 18], ["infection", "DISEASE", 61, 70], ["Nasal wash samples", "TEST", 0, 18], ["infection", "PROBLEM", 61, 70], ["infection", "OBSERVATION", 61, 70]]], ["The guinea pigs exhibited no outward clinical signs of infection and virus was recovered from nasal washes of each animal between 2 and 6 dpi [3] .", [["nasal", "ANATOMY", 94, 99], ["infection", "DISEASE", 55, 64], ["guinea pigs", "ORGANISM", 4, 15], ["nasal", "ORGANISM_SUBDIVISION", 94, 99], ["guinea pigs", "SPECIES", 4, 15], ["outward clinical signs of infection", "PROBLEM", 29, 64], ["virus", "PROBLEM", 69, 74], ["nasal washes", "TREATMENT", 94, 106], ["infection", "OBSERVATION", 55, 64]]], ["Peak titers of progeny virus in this study occurred on day 3 and were in the range of 5 \u00d7 10 4 and 2 \u00d7 10 5 pfu/mL of nasal wash fluid (Long et al, in preparation).", [["nasal", "ANATOMY", 118, 123], ["progeny virus", "ORGANISM", 15, 28], ["Peak titers", "TEST", 0, 11], ["progeny virus", "PROBLEM", 15, 28], ["this study", "TEST", 32, 42], ["nasal wash fluid", "TREATMENT", 118, 134], ["Long et al, in preparation", "TREATMENT", 136, 162], ["progeny virus", "OBSERVATION", 15, 28], ["nasal", "ANATOMY", 118, 123]]], ["Serological samples were prepared over the course of the regimen for analysis of total anti-HA antibodies by HA ELISA, antiviral antibodies by HI assay, and identification of linear HA epitopes by PepScan ELISA.", [["samples", "ANATOMY", 12, 19], ["anti-HA antibodies", "PROTEIN", 87, 105], ["antiviral antibodies", "PROTEIN", 119, 139], ["linear HA epitopes", "PROTEIN", 175, 193], ["Serological samples", "TEST", 0, 19], ["the regimen", "TREATMENT", 53, 64], ["analysis", "TEST", 69, 77], ["total anti-HA antibodies", "TREATMENT", 81, 105], ["HA ELISA", "TEST", 109, 117], ["antiviral antibodies", "TEST", 119, 139], ["HI assay", "TEST", 143, 151], ["linear HA epitopes", "PROBLEM", 175, 193]]], ["Equal volumes of sera from each individual were used to produce pools for each time point in each group.", [["sera", "ANATOMY", 17, 21], ["sera", "ORGANISM_SUBSTANCE", 17, 21]]], ["To assess the levels of total HA-specific antibodies, serological samples were assayed by ELISA using plates coated with commercially prepared full-length Wyoming HA glycoprotein ( Figure 1 ).", [["samples", "ANATOMY", 66, 73], ["HA", "GENE_OR_GENE_PRODUCT", 30, 32], ["HA", "PROTEIN", 30, 32], ["specific antibodies", "PROTEIN", 33, 52], ["full-length Wyoming HA glycoprotein", "PROTEIN", 143, 178], ["Figure 1", "PROTEIN", 181, 189], ["total HA", "PROBLEM", 24, 32], ["specific antibodies", "TEST", 33, 52], ["serological samples", "TEST", 54, 73], ["full-length Wyoming HA glycoprotein", "TREATMENT", 143, 178]]], ["Inoculation with virus and subsequent infection of these guinea pigs resulted in a rise in ELISA titer to the HA protein by the 2 nd week which continued to increase through Week 4.Infection of Guinea PigsThe guinea pigs received a second inoculation of virus on Week 5.", [["infection", "DISEASE", 38, 47], ["guinea pigs", "ORGANISM", 57, 68], ["guinea pigs", "ORGANISM", 209, 220], ["HA protein", "PROTEIN", 110, 120], ["guinea pigs", "SPECIES", 57, 68], ["Pigs", "SPECIES", 201, 205], ["guinea pigs", "SPECIES", 209, 220], ["guinea pigs", "SPECIES", 57, 68], ["Guinea Pigs", "SPECIES", 194, 205], ["Inoculation", "PROBLEM", 0, 11], ["virus", "PROBLEM", 17, 22], ["subsequent infection", "PROBLEM", 27, 47], ["these guinea pigs", "PROBLEM", 51, 68], ["a rise in ELISA titer", "PROBLEM", 81, 102], ["the HA protein", "TREATMENT", 106, 120], ["Infection", "PROBLEM", 181, 190], ["Guinea Pigs", "TREATMENT", 194, 205], ["The guinea pigs", "TREATMENT", 205, 220], ["a second inoculation of virus", "TREATMENT", 230, 259], ["virus", "OBSERVATION", 17, 22], ["infection", "OBSERVATION", 38, 47], ["rise", "OBSERVATION_MODIFIER", 83, 87], ["increase", "OBSERVATION_MODIFIER", 157, 165], ["Guinea Pigs", "OBSERVATION", 194, 205]]], ["Peak virus titers from nasal wash samples occurred again on Day 3 and were determined to be 2 \u00d7 10 4 and 3 \u00d7 10 5 pfu/mL for the two animals.", [["nasal", "ANATOMY", 23, 28], ["samples", "ANATOMY", 34, 41], ["Peak virus titers", "TEST", 0, 17], ["nasal wash samples", "TEST", 23, 41]]], ["Anti-HA ELISA titers rose from 1:100 to 1:10,000 after the second infection with live virus.", [["infection", "DISEASE", 66, 75], ["Anti-HA ELISA titers", "TEST", 0, 20], ["the second infection", "PROBLEM", 55, 75], ["live virus", "PROBLEM", 81, 91], ["infection", "OBSERVATION", 66, 75]]], ["Antiviral activities in the sera were measured by HI assay (Figure 1 ).", [["sera", "ANATOMY", 28, 32], ["sera", "ORGANISM_SUBSTANCE", 28, 32], ["Antiviral activities in the sera", "TEST", 0, 32]]], ["In contrast to the ELISA results, Group 2 HI titers were not detectable 5 weeks after initial infection, and rose only after the re-infection.", [["infection", "DISEASE", 94, 103], ["Group 2 HI titers", "TEST", 34, 51], ["initial infection", "PROBLEM", 86, 103], ["the re-infection", "PROBLEM", 125, 141], ["infection", "OBSERVATION", 94, 103], ["re-infection", "OBSERVATION", 129, 141]]], ["By Week 9, a significant increase in titer, 64-fold over pre-infected sera, was detectable.", [["sera", "ANATOMY", 70, 74], ["sera", "ORGANISM_SUBSTANCE", 70, 74], ["a significant increase in titer", "PROBLEM", 11, 42], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["increase", "OBSERVATION_MODIFIER", 25, 33]]], ["In the following three weeks, this peak titer decreased slightly.", [["this peak titer", "TEST", 30, 45]]], ["Figure 1 Analysis of serum pools from infected guinea pigs.", [["serum", "ANATOMY", 21, 26], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["guinea pigs", "ORGANISM", 47, 58], ["guinea pigs", "SPECIES", 47, 58], ["guinea pigs", "SPECIES", 47, 58], ["serum pools", "PROBLEM", 21, 32], ["infected guinea pigs", "TREATMENT", 38, 58], ["infected", "OBSERVATION_MODIFIER", 38, 46], ["guinea pigs", "OBSERVATION", 47, 58]]], ["Serum pools were tested for total HA-binding antibodies by reactivity to full-length HA protein in a standard ELISA (solid), and antiviral titers using HI assay (dashed).", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["HA", "PROTEIN", 34, 36], ["binding antibodies", "PROTEIN", 37, 55], ["full-length HA protein", "PROTEIN", 73, 95], ["Serum pools", "TEST", 0, 11], ["total HA-binding antibodies", "PROBLEM", 28, 55], ["antiviral titers", "TEST", 129, 145]]], ["Error bars for the ELISA extinction titers are shown, but are not readily seen due to their small size.Immunization of Guinea PigsThe two immunized guinea pig groups (Groups 3 and 4) demonstrated similar patterns of increasing antibody titers over the course of the four recombinant HA protein inoculations.", [["Guinea Pigs", "ORGANISM", 119, 130], ["guinea pig", "ORGANISM", 148, 158], ["Pigs", "SPECIES", 126, 130], ["guinea pig", "SPECIES", 148, 158], ["pig", "SPECIES", 155, 158], ["Error bars", "TEST", 0, 10], ["the ELISA extinction titers", "TEST", 15, 42], ["Immunization", "TREATMENT", 103, 115], ["Guinea Pigs", "TREATMENT", 119, 130], ["The two immunized guinea pig groups (Groups", "TREATMENT", 130, 173], ["increasing antibody titers", "PROBLEM", 216, 242], ["the four recombinant HA protein inoculations", "TREATMENT", 262, 306], ["small", "OBSERVATION_MODIFIER", 92, 97], ["size", "OBSERVATION_MODIFIER", 98, 102], ["increasing", "OBSERVATION_MODIFIER", 216, 226], ["antibody titers", "OBSERVATION", 227, 242]]], ["Two doses of antigen were initially used to determine the sensitivity of immune reactivity to the HA antigen prior to vaccine-challenge studies with similar subunit antigens.", [["HA antigen", "GENE_OR_GENE_PRODUCT", 98, 108], ["HA antigen", "PROTEIN", 98, 108], ["subunit antigens", "PROTEIN", 157, 173], ["antigen", "TREATMENT", 13, 20], ["immune reactivity", "PROBLEM", 73, 90], ["the HA antigen", "TREATMENT", 94, 108], ["vaccine", "TREATMENT", 118, 125], ["challenge studies", "TEST", 126, 143], ["similar subunit antigens", "PROBLEM", 149, 173]]], ["Group 3 (lower antigen dose) ELISA titers initially lagged behind those of Group 4 (higher antigen dose), but caught up after the final boost with equivalent amounts of HA (40 micrograms) in both groups ( Figure 2) .", [["Group 3 (lower antigen dose", "TREATMENT", 0, 27], ["ELISA titers", "TEST", 29, 41], ["HA", "PROBLEM", 169, 171]]], ["Interestingly, the ELISA titers persisted at high levels for 4 months following the final immunization and showed little sign of decay.", [["the ELISA titers", "TEST", 15, 31], ["the final immunization", "TEST", 80, 102]]], ["No significant difference was found between the ELISA titers of Groups 3 and 4, with a confidence level of p = 0.33 (ANOVA).", [["the ELISA titers", "TEST", 44, 60], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["Antiviral HI titers for both groups of HA-immunized animals increased after the second, third, and fourth inoculation ( Figure 2 ).", [["HA", "ORGANISM", 39, 41], ["animals", "ORGANISM", 52, 59], ["Antiviral HI titers", "TREATMENT", 0, 19], ["HA", "PROBLEM", 39, 41], ["immunized animals", "PROBLEM", 42, 59]]], ["The inflections of the HI titer graphs roughly paralleled the anti-HA ELISA titers throughout the study.", [["anti-HA", "GENE_OR_GENE_PRODUCT", 62, 69], ["the HI titer graphs", "TEST", 19, 38], ["the anti-HA ELISA titers", "TEST", 58, 82], ["the study", "TEST", 94, 103]]], ["After the final boost at week 10, HI titers continued to rise (91-to 128-fold increase over the negative control) and persisted for 16 weeks following the last immunization, with only a 2-to 4-fold drop in magnitude.", [["HI titers", "TEST", 34, 43], ["the last immunization", "TREATMENT", 151, 172]]], ["Sera from Group 1 (negative control) remained negative throughout the study.Immunization of Guinea PigsThe specificity of the immune response to HA protein was assessed using Western blot analysis ( Figure 3 ).", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["HA", "GENE_OR_GENE_PRODUCT", 145, 147], ["HA protein", "PROTEIN", 145, 155], ["Pigs", "SPECIES", 99, 103], ["Guinea Pigs", "SPECIES", 92, 103], ["Sera", "TEST", 0, 4], ["the study", "TEST", 66, 75], ["Immunization", "TREATMENT", 76, 88], ["Guinea Pigs", "TREATMENT", 92, 103], ["HA protein", "PROBLEM", 145, 155], ["Western blot analysis", "TEST", 175, 196], ["negative", "OBSERVATION", 46, 54]]], ["Full-length recombinant HA protein was electrophoresed in a denaturing polyacrylamide gel and transferred to nitrocellulose.", [["polyacrylamide", "CHEMICAL", 71, 85], ["nitrocellulose", "CHEMICAL", 109, 123], ["HA", "GENE_OR_GENE_PRODUCT", 24, 26], ["Full-length recombinant HA protein", "PROTEIN", 0, 34], ["Full-length recombinant HA protein", "TREATMENT", 0, 34], ["a denaturing polyacrylamide gel", "TREATMENT", 58, 89], ["nitrocellulose", "TREATMENT", 109, 123]]], ["The membrane was cut into strips and probed with guinea pig sera.", [["membrane", "ANATOMY", 4, 12], ["sera", "ANATOMY", 60, 64], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["guinea", "ORGANISM", 49, 55], ["pig", "ORGANISM", 56, 59], ["sera", "ORGANISM_SUBSTANCE", 60, 64], ["guinea pig", "SPECIES", 49, 59], ["guinea pig", "SPECIES", 49, 59], ["guinea pig sera", "TREATMENT", 49, 64]]], ["Lane 1 shows negative reactivity observed using sera from mock-immunized animals.", [["sera", "ANATOMY", 48, 52], ["Lane 1", "GENE_OR_GENE_PRODUCT", 0, 6], ["sera", "ORGANISM_SUBSTANCE", 48, 52], ["sera from mock", "TEST", 48, 62], ["negative reactivity", "OBSERVATION_MODIFIER", 13, 32]]], ["Lanes 2, 3, and 4 demonstrate serological recognition of HA antigen by animals infected with influenza virus or immunized with purified HA protein.Immunization of Guinea PigsAlthough the samples were boiled in SDS-buffer containing 2-mercaptoethanol, putative dimeric and trimeric forms of the HA protein are apparent as slower-migrating species.PepScan AssaysTo characterize reactivity to linear epitopes, serum pools from sequential bleeds of the infected guinea pigs (Group 2) were tested for binding to a library of overlapping Wyoming HA peptides ( Figure 4 ).", [["samples", "ANATOMY", 187, 194], ["serum", "ANATOMY", 407, 412], ["HA antigen", "CHEMICAL", 57, 67], ["influenza virus", "DISEASE", 93, 108], ["2-mercaptoethanol", "CHEMICAL", 232, 249], ["2-mercaptoethanol", "CHEMICAL", 232, 249], ["Lanes 2", "GENE_OR_GENE_PRODUCT", 0, 7], ["3", "GENE_OR_GENE_PRODUCT", 9, 10], ["HA antigen", "GENE_OR_GENE_PRODUCT", 57, 67], ["influenza virus", "ORGANISM", 93, 108], ["HA", "GENE_OR_GENE_PRODUCT", 136, 138], ["Guinea", "ORGANISM", 163, 169], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 232, 249], ["serum", "ORGANISM_SUBSTANCE", 407, 412], ["guinea pigs", "ORGANISM", 458, 469], ["HA antigen", "PROTEIN", 57, 67], ["HA protein", "PROTEIN", 136, 146], ["HA protein", "PROTEIN", 294, 304], ["influenza virus", "SPECIES", 93, 108], ["guinea pigs", "SPECIES", 458, 469], ["influenza virus", "SPECIES", 93, 108], ["guinea pigs", "SPECIES", 458, 469], ["HA antigen", "PROBLEM", 57, 67], ["influenza virus", "PROBLEM", 93, 108], ["purified HA protein", "TREATMENT", 127, 146], ["Immunization of Guinea", "TREATMENT", 147, 169], ["the samples", "TEST", 183, 194], ["SDS", "TEST", 210, 213], ["mercaptoethanol", "TREATMENT", 234, 249], ["the HA protein", "TEST", 290, 304], ["linear epitopes", "PROBLEM", 390, 405], ["serum pools", "PROBLEM", 407, 418], ["sequential bleeds", "PROBLEM", 424, 441], ["the infected guinea pigs", "TREATMENT", 445, 469], ["overlapping Wyoming HA peptides", "TREATMENT", 520, 551], ["migrating species", "OBSERVATION", 328, 345], ["infected", "OBSERVATION_MODIFIER", 449, 457]]], ["Prior to inoculation with virus, the sera showed potential reactivity to Peptides 141, 285, and 327 (Panel A).", [["sera", "ANATOMY", 37, 41], ["sera", "ORGANISM_SUBSTANCE", 37, 41], ["virus", "PROBLEM", 26, 31], ["the sera", "TEST", 33, 41], ["Peptides", "TEST", 73, 81]]], ["Peptide 141 is within the A epitope, 285 overlaps the C epitope, and 327 is outside of defined epitopes.", [["C epitope", "PROTEIN", 54, 63], ["epitopes", "PROTEIN", 95, 103], ["Peptide", "TEST", 0, 7], ["the C epitope", "TEST", 50, 63]]], ["Although it was unclear why the pre-infection sera recognized these peptides, reactivity against 141 and 327 remained throughout the study, while reactivity against 285 waned by the second week post-infection.", [["sera", "ANATOMY", 46, 50], ["sera", "ORGANISM_SUBSTANCE", 46, 50], ["the pre-infection sera", "TEST", 28, 50], ["these peptides", "TEST", 62, 76], ["reactivity", "TEST", 78, 88], ["the study", "TEST", 129, 138]]], ["Reactivity against Peptides 9 and 453, both outside of defined epitopes, increased by Week 11 post-infection and was also observed with sera from Figure 2 Analysis of serum pools from immunized guinea pigs.", [["sera", "ANATOMY", 136, 140], ["serum", "ANATOMY", 167, 172], ["Peptides 9 and 453", "CHEMICAL", 19, 37], ["infection", "DISEASE", 99, 108], ["sera", "ORGANISM_SUBSTANCE", 136, 140], ["serum", "ORGANISM_SUBSTANCE", 167, 172], ["guinea pigs", "ORGANISM", 194, 205], ["epitopes", "PROTEIN", 63, 71], ["guinea pigs", "SPECIES", 194, 205], ["guinea pigs", "SPECIES", 194, 205], ["Peptides", "TEST", 19, 27], ["infection", "PROBLEM", 99, 108], ["sera", "TEST", 136, 140], ["serum pools", "PROBLEM", 167, 178], ["immunized guinea pigs", "TREATMENT", 184, 205], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["infection", "OBSERVATION", 99, 108]]], ["Sera pools were tested for antibodies that bind to non-denatured full-length HA protein by ELISA and are denoted with solid lines.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["HA", "GENE_OR_GENE_PRODUCT", 77, 79], ["solid lines", "CELL", 118, 129], ["antibodies", "PROTEIN", 27, 37], ["non-denatured full-length HA protein", "PROTEIN", 51, 87], ["solid lines", "CELL_LINE", 118, 129], ["Sera pools", "TEST", 0, 10], ["antibodies", "PROBLEM", 27, 37], ["ELISA", "TEST", 91, 96], ["solid lines", "TREATMENT", 118, 129], ["solid lines", "OBSERVATION", 118, 129]]], ["Sera pools were also tested for antiviral activity by HI, shown with dashed lines.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["lines", "CELL", 76, 81], ["dashed lines", "CELL_LINE", 69, 81], ["Sera pools", "TREATMENT", 0, 10], ["antiviral activity", "TREATMENT", 32, 50], ["dashed lines", "TREATMENT", 69, 81]]], ["Negative control animals in Group 1 were discontinued after 13 weeks.", [["control", "OBSERVATION_MODIFIER", 9, 16], ["animals", "OBSERVATION_MODIFIER", 17, 24]]], ["Arrows along X-axis indicate immunization boost dates.", [["immunization boost", "TREATMENT", 29, 47]]], ["Error bars for the extinction titers are shown, but due to their small size, are not visible.Figure 3Western Blot Analysis of sera from immunized and infected Guinea Pigs.", [["sera", "ANATOMY", 126, 130], ["sera", "ORGANISM_SUBSTANCE", 126, 130], ["Guinea Pigs", "ORGANISM", 159, 170], ["Pigs", "SPECIES", 166, 170], ["the extinction titers", "TEST", 15, 36], ["sera", "PROBLEM", 126, 130], ["infected Guinea Pigs", "TREATMENT", 150, 170], ["extinction titers", "OBSERVATION", 19, 36], ["small", "OBSERVATION_MODIFIER", 65, 70], ["size", "OBSERVATION_MODIFIER", 71, 75], ["not", "UNCERTAINTY", 81, 84], ["visible", "OBSERVATION_MODIFIER", 85, 92], ["infected", "OBSERVATION_MODIFIER", 150, 158], ["Guinea Pigs", "OBSERVATION", 159, 170]]], ["Full-length recombinant HA sera (Protein Sciences, Inc.) was electrophoresed in a denaturing polyacrylamide gel and transferred to membranes.", [["sera", "ANATOMY", 27, 31], ["membranes", "ANATOMY", 131, 140], ["polyacrylamide", "CHEMICAL", 93, 107], ["sera", "ORGANISM_SUBSTANCE", 27, 31], ["membranes", "CELLULAR_COMPONENT", 131, 140], ["a denaturing polyacrylamide gel", "TREATMENT", 80, 111]]], ["The lanes were cut into strips and probed with Guinea pig sera to confirm the specificity of reactivity.", [["sera", "ANATOMY", 58, 62], ["pig", "ORGANISM", 54, 57], ["sera", "ORGANISM_SUBSTANCE", 58, 62], ["Guinea pig", "SPECIES", 47, 57], ["Guinea pig", "SPECIES", 47, 57], ["Guinea pig sera", "TREATMENT", 47, 62]]], ["Lane 1: Groups 1 (mock infected) sera, 1:1500; lane 2: Group 2 (influenza infected) sera 1:1500, Lane 3: is Group 3 (immunized with lower concentration of HA protein) sera 1:3000, and Lane 4: Group 4 (immunized with higher concentration of HA protein) sera 1:3000.Figure 3Week 12 (Panels E and F).", [["sera", "ANATOMY", 33, 37], ["sera", "ANATOMY", 84, 88], ["sera", "ANATOMY", 167, 171], ["influenza infected", "DISEASE", 64, 82], ["sera", "ORGANISM_SUBSTANCE", 33, 37], ["sera", "ORGANISM", 84, 88], ["sera", "ORGANISM_SUBSTANCE", 252, 256], ["HA protein", "PROTEIN", 155, 165], ["HA protein", "PROTEIN", 240, 250], ["sera", "TEST", 33, 37], ["sera", "TEST", 84, 88], ["lower concentration of HA protein", "TREATMENT", 132, 165], ["sera", "TEST", 167, 171], ["higher concentration of HA protein", "TREATMENT", 216, 250], ["Figure", "TEST", 264, 270]]], ["Signal strength against 141 and 327 increased in sera from Week 5 post-infection (Panel C), but returned to pre-immune levels by Week 9 (Panel D).Figure 3Immune reactivities of sera from HA-immunized guinea pigs were compared with influenza-infected guinea pigs ( Figure 5 ).", [["sera", "ANATOMY", 49, 53], ["sera", "ANATOMY", 177, 181], ["infection", "DISEASE", 71, 80], ["influenza-infected", "DISEASE", 231, 249], ["sera", "ORGANISM_SUBSTANCE", 49, 53], ["sera", "ORGANISM_SUBSTANCE", 177, 181], ["HA", "ORGANISM", 187, 189], ["guinea pigs", "ORGANISM", 200, 211], ["guinea pigs", "ORGANISM", 250, 261], ["guinea pigs", "SPECIES", 200, 211], ["guinea pigs", "SPECIES", 250, 261], ["pigs", "SPECIES", 207, 211], ["Signal strength", "TEST", 0, 15], ["sera", "TEST", 49, 53], ["infection", "PROBLEM", 71, 80], ["Panel C", "TEST", 82, 89], ["sera", "PROBLEM", 177, 181], ["HA", "PROBLEM", 187, 189], ["immunized guinea pigs", "TREATMENT", 190, 211], ["influenza", "PROBLEM", 231, 240], ["infected guinea pigs", "TREATMENT", 241, 261], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["infection", "OBSERVATION", 71, 80]]], ["Sera from mock-immunized animals (Group 1, Panels A1, B1, C1, and D1 of Figure 5 ) reacted with Peptides 141 and 327, as previously seen with sera from pre-infected guinea pigs ( Figure 4A ).", [["Sera", "ANATOMY", 0, 4], ["sera", "ANATOMY", 142, 146], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["mock-immunized animals", "ORGANISM", 10, 32], ["Figure 5", "ORGANISM", 72, 80], ["sera", "ORGANISM_SUBSTANCE", 142, 146], ["guinea pigs", "ORGANISM", 165, 176], ["B1", "PROTEIN", 54, 56], ["D1", "PROTEIN", 66, 68], ["guinea pigs", "SPECIES", 165, 176], ["Sera from mock", "TEST", 0, 14], ["Peptides", "TEST", 96, 104], ["sera", "TEST", 142, 146], ["C1", "ANATOMY", 58, 60]]], ["As the mock-immunized guinea pigs aged, they developed measurable reactivity to Peptide 81, which overlaps the E epitope.Figure 3After immunization with lower dose HA antigen, sera from Group 3 animals initially increased overall reactivity against most of the representative peptides in the panel with enhanced reactivity against Peptides 81, 141, 165, and 327 (Panel B2).", [["sera", "ANATOMY", 176, 180], ["guinea pigs", "ORGANISM", 22, 33], ["sera", "ORGANISM_SUBSTANCE", 176, 180], ["E epitope", "PROTEIN", 111, 120], ["HA antigen", "PROTEIN", 164, 174], ["guinea pigs", "SPECIES", 22, 33], ["pigs", "SPECIES", 29, 33], ["Peptide", "TEST", 80, 87], ["Figure 3After immunization", "TREATMENT", 121, 147], ["lower dose HA antigen", "TEST", 153, 174], ["Peptides", "TEST", 331, 339], ["Panel B2", "TEST", 363, 371], ["increased", "OBSERVATION_MODIFIER", 212, 221]]], ["Immediately prior to the second boost, reactivity against many of the peptides decreased and reactivity primarily against 81, 141 and 327 was seen (Panel C2), which persisted through the study.", [["the peptides", "TEST", 66, 78], ["the study", "TEST", 183, 192], ["decreased", "OBSERVATION_MODIFIER", 79, 88]]], ["In addition, after boosting, weak reactivity against Peptide 45, in the C epitope, and strong activity against Peptide 483, outside defined epitopes, were observed (Panel D2).Figure 3Prior to inoculations, sera from the higher dose immunization group (Group 4) showed similar low levels of reactivity as seen with the other two immunization groups (Panel A3).", [["sera", "ANATOMY", 206, 210], ["Peptide 45", "SIMPLE_CHEMICAL", 53, 63], ["Peptide 483", "SIMPLE_CHEMICAL", 111, 122], ["sera", "ORGANISM_SUBSTANCE", 206, 210], ["Peptide 45", "PROTEIN", 53, 63], ["C epitope", "PROTEIN", 72, 81], ["epitopes", "PROTEIN", 140, 148], ["Peptide", "TEST", 53, 60], ["the C epitope", "TREATMENT", 68, 81], ["sera", "TEST", 206, 210], ["the higher dose immunization group", "TREATMENT", 216, 250], ["similar low levels of reactivity", "PROBLEM", 268, 300], ["low levels", "OBSERVATION_MODIFIER", 276, 286]]], ["At Weeks 3, 5, and 12, sera from Group 4 animals recognized Peptides 81 and 327 with moderate levels of reactivity (Panel B3).", [["sera", "ANATOMY", 23, 27], ["sera", "ORGANISM_SUBSTANCE", 23, 27], ["Peptides", "TEST", 60, 68], ["moderate levels of reactivity", "PROBLEM", 85, 114], ["moderate", "OBSERVATION_MODIFIER", 85, 93]]], ["Reactivity against Epitope A Peptides 135 and 141 increased in Week 3, peaked in Week 5, and then decreased in Week 12.", [["Epitope A Peptides", "TEST", 19, 37]]], ["Similar to what was seen for Group 3, reactivity against Peptides 45 and 483 were observed in later bleeds.", [["Peptides", "TEST", 57, 65]]], ["PepScan data from serum samples of all groups collected after Week 12 demonstrated patterns of peptide binding similar to those at Week 12 (data not shown).", [["serum samples", "ANATOMY", 18, 31], ["serum samples", "ORGANISM_SUBSTANCE", 18, 31], ["PepScan data", "TEST", 0, 12], ["serum samples", "TEST", 18, 31], ["peptide binding", "PROBLEM", 95, 110]]], ["Table 1 contains a summary of the most highly reactive peptides recognized by the guinea pig sera.Mapping reactive peptides to 3-D structureThe position of reactive peptides located on the threedimensional structure of the related H3N2 strain X-31HA was studied ( Figure 6 , Panels A-D, 1HGG.pdb, [11] ).", [["sera", "ANATOMY", 93, 97], ["X-31HA", "CHEMICAL", 243, 249], ["3-D", "CHEMICAL", 127, 130], ["guinea pig", "ORGANISM", 82, 92], ["sera", "ORGANISM_SUBSTANCE", 93, 97], ["3-D", "SIMPLE_CHEMICAL", 127, 130], ["H3N2 strain", "ORGANISM", 231, 242], ["X-31HA", "SIMPLE_CHEMICAL", 243, 249], ["Panels A-D", "SIMPLE_CHEMICAL", 275, 285], ["guinea pig", "SPECIES", 82, 92], ["guinea pig", "SPECIES", 82, 92], ["the guinea pig sera", "TREATMENT", 78, 97], ["Mapping reactive peptides", "TREATMENT", 98, 123], ["reactive peptides", "PROBLEM", 156, 173], ["the related H3N2 strain", "PROBLEM", 219, 242], ["reactive peptides", "OBSERVATION", 46, 63], ["reactive", "OBSERVATION_MODIFIER", 106, 114], ["peptides", "OBSERVATION", 115, 123], ["3-D structure", "OBSERVATION_MODIFIER", 127, 140], ["position", "OBSERVATION_MODIFIER", 144, 152], ["reactive peptides", "OBSERVATION", 156, 173], ["H3N2", "OBSERVATION", 231, 235]]], ["Figure 6A shows a ribbon diagram of the monomeric ectodomain of HA in which residues in epitopes A-E have been colorized.", [["monomeric ectodomain", "PROTEIN", 40, 60], ["HA", "PROTEIN", 64, 66], ["epitopes A-E", "PROTEIN", 88, 100], ["a ribbon diagram", "PROBLEM", 16, 32], ["HA", "PROBLEM", 64, 66], ["epitopes A-E", "OBSERVATION", 88, 100]]], ["Figure 6B identifies the locations of peptides 141 and 327, which were seen in preinfected and mock immunized sera.", [["sera", "ANATOMY", 110, 114], ["sera", "ORGANISM_SUBSTANCE", 110, 114], ["peptides", "TEST", 38, 46]]], ["Peptide 141 contains amino acid residues previously mapped to epitope A (142-146, 150, 152) [12] while peptide 327 is located in a membrane-proximal position, a previously undefined as an area of antigenic interest.", [["membrane", "ANATOMY", 131, 139], ["Peptide 141", "CHEMICAL", 0, 11], ["amino acid", "CHEMICAL", 21, 31], ["amino acid", "CHEMICAL", 21, 31], ["amino acid", "AMINO_ACID", 21, 31], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["Peptide", "TEST", 0, 7], ["amino acid residues", "TREATMENT", 21, 40], ["amino acid", "OBSERVATION", 21, 31], ["proximal", "OBSERVATION_MODIFIER", 140, 148], ["position", "OBSERVATION_MODIFIER", 149, 157], ["antigenic interest", "OBSERVATION", 196, 214]]], ["Figure 6C shows the location of the two peptides identified in PepScans from influenza infected guinea pigs, Peptides 9 and 453.", [["influenza infected", "DISEASE", 77, 95], ["Peptides 9 and 453", "CHEMICAL", 109, 127], ["PepScans", "GENE_OR_GENE_PRODUCT", 63, 71], ["guinea pigs", "ORGANISM", 96, 107], ["guinea pigs", "SPECIES", 96, 107], ["Figure 6C", "TEST", 0, 9], ["the two peptides", "PROBLEM", 32, 48], ["influenza", "PROBLEM", 77, 86], ["Peptides", "TEST", 109, 117]]], ["Figure 6D identifies the positions of Peptides 135 (also contained in epitope A) and 483 that were recognized by sera from immunized animals.", [["sera", "ANATOMY", 113, 117], ["sera", "ORGANISM_SUBSTANCE", 113, 117], ["Peptides 135", "PROTEIN", 38, 50], ["epitope A", "PROTEIN", 70, 79], ["Peptides", "TEST", 38, 46]]], ["As can be seen in Figure 6, Peptides 9, 453, and 483 are located in the membrane-proximal stem of the HA glycoprotein in a region previously not noted for containing epitopes.DiscussionA major aim of our research group is the development of broadly protective vaccines that stimulate cross-protective immunity against multiple strains of human influenza viruses [13, 14] .", [["membrane", "ANATOMY", 72, 80], ["influenza viruses", "DISEASE", 344, 361], ["membrane", "CELLULAR_COMPONENT", 72, 80], ["HA glycoprotein", "GENE_OR_GENE_PRODUCT", 102, 117], ["human", "ORGANISM", 338, 343], ["influenza viruses", "ORGANISM", 344, 361], ["HA glycoprotein", "PROTEIN", 102, 117], ["epitopes", "PROTEIN", 166, 174], ["human", "SPECIES", 338, 343], ["human influenza viruses", "SPECIES", 338, 361], ["Peptides", "TEST", 28, 36], ["the HA glycoprotein", "PROBLEM", 98, 117], ["epitopes", "PROBLEM", 166, 174], ["broadly protective vaccines", "TREATMENT", 241, 268], ["cross-protective immunity", "TREATMENT", 284, 309], ["human influenza viruses", "PROBLEM", 338, 361], ["membrane", "ANATOMY_MODIFIER", 72, 80], ["proximal", "ANATOMY_MODIFIER", 81, 89], ["stem", "ANATOMY_MODIFIER", 90, 94], ["HA", "OBSERVATION_MODIFIER", 102, 104], ["glycoprotein", "OBSERVATION", 105, 117]]], ["In the process of developing and testing vaccines for the stimulation of broadened immunity, it is necessary to raise sera in multiple species of animals for analysis of cross-strain antiviral responses.", [["sera", "ANATOMY", 118, 122], ["sera", "ORGANISM_SUBSTANCE", 118, 122], ["testing vaccines", "TREATMENT", 33, 49], ["the stimulation of broadened immunity", "TREATMENT", 54, 91]]], ["In addition, it would be helpful to assess protection from cross-strain challenge in multiple animal models.", [["cross-strain challenge", "TREATMENT", 59, 81]]], ["Because of the attractiveness of the guinea pig model for infection with influenza, we have characterized the immune responses after infection or immunization of guinea pigs.", [["infection", "DISEASE", 58, 67], ["influenza", "DISEASE", 73, 82], ["infection", "DISEASE", 133, 142], ["guinea pig", "ORGANISM", 37, 47], ["guinea pigs", "ORGANISM", 162, 173], ["guinea pig", "SPECIES", 37, 47], ["guinea pigs", "SPECIES", 162, 173], ["pig", "SPECIES", 44, 47], ["guinea pigs", "SPECIES", 162, 173], ["the guinea pig model", "TREATMENT", 33, 53], ["infection", "PROBLEM", 58, 67], ["influenza", "PROBLEM", 73, 82], ["infection", "PROBLEM", 133, 142], ["immunization of guinea pigs", "TREATMENT", 146, 173], ["infection", "OBSERVATION", 58, 67]]], ["Here we present an immunological Figure 4 PepScan ELISA of serum pools from guinea pig infected with influenza virus.", [["serum", "ANATOMY", 59, 64], ["influenza virus", "DISEASE", 101, 116], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["guinea pig", "ORGANISM", 76, 86], ["influenza virus", "ORGANISM", 101, 116], ["guinea pig", "SPECIES", 76, 86], ["influenza virus", "SPECIES", 101, 116], ["guinea pig", "SPECIES", 76, 86], ["influenza virus", "SPECIES", 101, 116], ["an immunological Figure", "TEST", 16, 39], ["serum pools", "PROBLEM", 59, 70], ["guinea pig", "TREATMENT", 76, 86], ["influenza virus", "PROBLEM", 101, 116], ["influenza virus", "OBSERVATION", 101, 116]]], ["Serum pools (1:750) from Group 2 animals were analyzed for recognition of linear epitopes by reactivity to overlapping peptides bound to microtiter plates.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["linear epitopes", "PROTEIN", 74, 89], ["Serum pools", "TEST", 0, 11], ["linear epitopes", "PROBLEM", 74, 89], ["overlapping peptides bound", "PROBLEM", 107, 133], ["microtiter plates", "TEST", 137, 154]]], ["Sequential bleeds were tested from the prebleed (A) and 2 (B), 5 (C), 9(D), 11 (E) and 12 (F) weeks after the initial infection.", [["bleeds", "ANATOMY", 11, 17], ["infection", "DISEASE", 118, 127], ["Sequential bleeds", "PROBLEM", 0, 17], ["the initial infection", "PROBLEM", 106, 127], ["bleeds", "OBSERVATION", 11, 17], ["infection", "OBSERVATION", 118, 127]]], ["Reactivity to peptides from sera after infection was compared to the results from the pre-infected sera to identify virus-specific epitopes induced during infection.Discussioncomparison between guinea pigs infected intranasally with an H3N2 virus and those immunized with the homologous HA glycoprotein, an attractive potential subunit vaccine candidate.DiscussionContrasting the serological results of infected and immunized animals provided interesting insights.", [["sera", "ANATOMY", 28, 32], ["sera", "ANATOMY", 99, 103], ["intranasally", "ANATOMY", 215, 227], ["infection", "DISEASE", 39, 48], ["infection", "DISEASE", 155, 164], ["sera", "ORGANISM_SUBSTANCE", 28, 32], ["sera", "ORGANISM_SUBSTANCE", 99, 103], ["guinea pigs", "ORGANISM", 194, 205], ["H3N2 virus", "ORGANISM", 236, 246], ["HA glycoprotein", "GENE_OR_GENE_PRODUCT", 287, 302], ["epitopes", "PROTEIN", 131, 139], ["HA glycoprotein", "PROTEIN", 287, 302], ["guinea pigs", "SPECIES", 194, 205], ["intranasally", "SPECIES", 215, 227], ["H3N2 virus", "SPECIES", 236, 246], ["guinea pigs", "SPECIES", 194, 205], ["H3N2 virus", "SPECIES", 236, 246], ["infection", "PROBLEM", 39, 48], ["the pre-infected sera", "TEST", 82, 103], ["virus", "PROBLEM", 116, 121], ["infection", "PROBLEM", 155, 164], ["guinea pigs", "TREATMENT", 194, 205], ["an H3N2 virus", "PROBLEM", 233, 246], ["the homologous HA glycoprotein", "TREATMENT", 272, 302], ["infected", "PROBLEM", 403, 411], ["immunized animals", "TREATMENT", 416, 433], ["infection", "OBSERVATION", 155, 164], ["infected", "OBSERVATION", 403, 411]]], ["The data demonstrated that guinea pigs readily seroconvert in response to both intranasal inoculations of virus and immunizations with the same recombinant HA glycoprotein.", [["guinea pigs", "ORGANISM", 27, 38], ["HA glycoprotein", "GENE_OR_GENE_PRODUCT", 156, 171], ["recombinant HA glycoprotein", "PROTEIN", 144, 171], ["guinea pigs", "SPECIES", 27, 38], ["pigs", "SPECIES", 34, 38], ["The data", "TEST", 0, 8], ["guinea pigs", "TREATMENT", 27, 38], ["both intranasal inoculations of virus", "TREATMENT", 74, 111], ["immunizations", "TREATMENT", 116, 129], ["the same recombinant HA glycoprotein", "TREATMENT", 135, 171]]], ["A rise in binding antibodies (ELISA positive) preceded the development of antiviral antibodies as determined by hemagglutinin-inhibition (HI positive) for both infected and immunized groups of guinea pigs.", [["hemagglutinin", "GENE_OR_GENE_PRODUCT", 112, 125], ["guinea pigs", "ORGANISM", 193, 204], ["binding antibodies", "PROTEIN", 10, 28], ["antiviral antibodies", "PROTEIN", 74, 94], ["hemagglutinin", "PROTEIN", 112, 125], ["guinea pigs", "SPECIES", 193, 204], ["guinea pigs", "SPECIES", 193, 204], ["A rise in binding antibodies (ELISA positive", "PROBLEM", 0, 44], ["antiviral antibodies", "TREATMENT", 74, 94], ["hemagglutinin", "TEST", 112, 125], ["guinea pigs", "TREATMENT", 193, 204], ["rise", "OBSERVATION_MODIFIER", 2, 6], ["binding antibodies", "OBSERVATION", 10, 28], ["antiviral antibodies", "OBSERVATION", 74, 94], ["infected", "OBSERVATION", 160, 168], ["guinea pigs", "OBSERVATION", 193, 204]]], ["The initial lag period was followed by strong correlation between the continued elevation of binding and antiviral (HI) antibodies.", [["antiviral (HI) antibodies", "PROTEIN", 105, 130], ["the continued elevation of binding", "PROBLEM", 66, 100], ["antiviral (HI) antibodies", "TREATMENT", 105, 130], ["elevation", "OBSERVATION", 80, 89]]], ["ELISA titers rose to approximately 1:100 titers after single inoculations with either infectious virus or purified HA antigen.", [["HA antigen", "GENE_OR_GENE_PRODUCT", 115, 125], ["purified HA antigen", "PROTEIN", 106, 125], ["ELISA titers", "TEST", 0, 12], ["single inoculations", "PROBLEM", 54, 73], ["either infectious virus", "PROBLEM", 79, 102], ["purified HA antigen", "PROBLEM", 106, 125]]], ["Peak ELISA titers of infected animals reached 1:10,000, while those of immunized animals reached 1:100,000.", [["Peak ELISA titers", "TEST", 0, 17], ["infected animals", "PROBLEM", 21, 37], ["infected", "OBSERVATION_MODIFIER", 21, 29]]], ["Measurable antiviral titer required a second dose of virus or immunogen.", [["Measurable antiviral titer", "TREATMENT", 0, 26], ["a second dose of virus", "TREATMENT", 36, 58], ["immunogen", "TREATMENT", 62, 71], ["antiviral titer", "OBSERVATION", 11, 26]]], ["HI titers of both infected and immunized animals reached approximately 1:1000 and decayed slightly over time.", [["HI titers", "TEST", 0, 9], ["both", "OBSERVATION_MODIFIER", 13, 17], ["infected", "OBSERVATION", 18, 26]]], ["The lack of measurable antiviral immune responses observed before the second inoculation of any of the experimental groups may be due to the lower sensitivity of the HI assay, and is not necessarily an indication that the first infection or immunization did not elicit HI responses.", [["infection", "DISEASE", 228, 237], ["measurable antiviral immune responses", "PROBLEM", 12, 49], ["the HI assay", "TEST", 162, 174], ["the first infection", "PROBLEM", 218, 237], ["immunization", "TREATMENT", 241, 253], ["measurable", "OBSERVATION_MODIFIER", 12, 22], ["antiviral immune", "OBSERVATION", 23, 39], ["infection", "OBSERVATION", 228, 237]]], ["Both ELISA and antiviral antibody titers persisted for many weeks following the final infectious innocula or boost with HA protein.", [["HA protein", "PROTEIN", 120, 130], ["Both ELISA", "TEST", 0, 10], ["antiviral antibody titers", "TEST", 15, 40], ["HA protein", "TREATMENT", 120, 130], ["antiviral antibody", "OBSERVATION", 15, 33]]], ["Little, if any, decay of ELISA or HI titers were observed throughDiscussionWeek 26 following the final HA immunization at Week 10.DiscussionA better understanding of the epitopes recognized by the anti-HA antibody responses in this experimental animal model, and how these epitopes compare to the human immune response, could facilitate more rapid advancements in vaccine design.", [["anti-HA", "GENE_OR_GENE_PRODUCT", 197, 204], ["human", "ORGANISM", 297, 302], ["epitopes", "PROTEIN", 170, 178], ["anti-HA antibody", "PROTEIN", 197, 213], ["epitopes", "PROTEIN", 273, 281], ["human", "SPECIES", 297, 302], ["human", "SPECIES", 297, 302], ["ELISA", "TEST", 25, 30], ["HI titers", "PROBLEM", 34, 43], ["the final HA immunization", "TREATMENT", 93, 118], ["the epitopes", "PROBLEM", 166, 178]]], ["Five dominant epitopes (A-E) of the HA glycoprotein have been previously characterized by both immunological reactivity in humans and animals, and by evolutionary variability in naturally infected humans.", [["A-E", "GENE_OR_GENE_PRODUCT", 24, 27], ["HA glycoprotein", "GENE_OR_GENE_PRODUCT", 36, 51], ["humans", "ORGANISM", 123, 129], ["humans", "ORGANISM", 197, 203], ["A", "PROTEIN", 24, 25], ["HA glycoprotein", "PROTEIN", 36, 51], ["humans", "SPECIES", 123, 129], ["humans", "SPECIES", 197, 203], ["humans", "SPECIES", 123, 129], ["humans", "SPECIES", 197, 203], ["the HA glycoprotein", "PROBLEM", 32, 51], ["dominant", "OBSERVATION_MODIFIER", 5, 13], ["epitopes", "OBSERVATION", 14, 22], ["both", "OBSERVATION_MODIFIER", 90, 94], ["immunological reactivity", "OBSERVATION", 95, 119], ["variability", "OBSERVATION_MODIFIER", 163, 174], ["naturally", "OBSERVATION_MODIFIER", 178, 187], ["infected", "OBSERVATION", 188, 196]]], ["A PepScan analysis was conducted to map the linear B cell epitopes and was intended to (peptides colorized in cyan).", [["B cell", "ANATOMY", 51, 57], ["B cell", "CELL", 51, 57], ["PepScan", "PROTEIN", 2, 9], ["linear B cell epitopes", "PROTEIN", 44, 66], ["A PepScan analysis", "TEST", 0, 18], ["the linear B cell epitopes", "TREATMENT", 40, 66], ["cell epitopes", "OBSERVATION", 53, 66]]], ["The structure was drawn from 1HGG.pbd [11] using PyMOL [30] .Discussioncorrelate immunological reactivity with previous data derived in other animals and in humans.", [["1HGG", "SIMPLE_CHEMICAL", 29, 33], ["humans", "ORGANISM", 157, 163], ["humans", "SPECIES", 157, 163], ["humans", "SPECIES", 157, 163], ["pbd", "TEST", 34, 37], ["previous data", "TEST", 111, 124]]], ["Analysis of conformational epitopes recognized by infected and immunized guinea pigs will be the subject of a future study.", [["guinea pigs", "ORGANISM", 73, 84], ["conformational epitopes", "PROTEIN", 12, 35], ["guinea pigs", "SPECIES", 73, 84], ["guinea pigs", "SPECIES", 73, 84], ["conformational epitopes", "PROBLEM", 12, 35], ["immunized guinea pigs", "TREATMENT", 63, 84], ["a future study", "TEST", 108, 122], ["infected", "OBSERVATION_MODIFIER", 50, 58]]], ["Previous immunological studies using overlapping peptides to characterize linear epitopes in influenza and other pathogens have had mixed results [14] [15] [16] [17] [18] [19] .DiscussionAlthough PepScans have identified epitopes in HIV, Measles, SARs, and Borna virus, most prior studies with this type of analysis failed to detect linear epitopes within the HA glycoprotein [20] [21] [22] .", [["influenza", "DISEASE", 93, 102], ["HIV, Measles, SARs", "DISEASE", 233, 251], ["Borna virus", "DISEASE", 257, 268], ["[14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 146, 175], ["HIV", "ORGANISM", 233, 236], ["Borna virus", "ORGANISM", 257, 268], ["PepScans", "PROTEIN", 196, 204], ["epitopes", "PROTEIN", 221, 229], ["HA glycoprotein", "PROTEIN", 360, 375], ["HIV", "SPECIES", 233, 236], ["Borna virus", "SPECIES", 257, 268], ["HIV", "SPECIES", 233, 236], ["Borna virus", "SPECIES", 257, 268], ["Previous immunological studies", "TEST", 0, 30], ["overlapping peptides", "TREATMENT", 37, 57], ["linear epitopes", "PROBLEM", 74, 89], ["influenza", "PROBLEM", 93, 102], ["other pathogens", "PROBLEM", 107, 122], ["epitopes in HIV", "PROBLEM", 221, 236], ["Measles", "PROBLEM", 238, 245], ["SARs", "PROBLEM", 247, 251], ["Borna virus", "PROBLEM", 257, 268], ["linear epitopes", "PROBLEM", 333, 348]]], ["However, the continued improvements in peptide synthesis suggested that the approach should be revisited and expanded to encompass the entire HA protein.", [["HA", "GENE_OR_GENE_PRODUCT", 142, 144], ["HA protein", "PROTEIN", 142, 152], ["peptide synthesis", "TREATMENT", 39, 56]]], ["Interestingly, the data from this study identified two immunodominant epitopes, represented by peptides with N-terminal amino acids 141 and 327, which are recognized by both preimmune and immune sera.", [["sera", "ANATOMY", 195, 199], ["N-terminal amino acids", "CHEMICAL", 109, 131], ["N", "CHEMICAL", 109, 110], ["amino acids", "CHEMICAL", 120, 131], ["amino acids", "AMINO_ACID", 120, 131], ["141", "AMINO_ACID", 132, 135], ["327", "AMINO_ACID", 140, 143], ["preimmune", "GENE_OR_GENE_PRODUCT", 174, 183], ["sera", "ORGANISM_SUBSTANCE", 195, 199], ["immunodominant epitopes", "PROTEIN", 55, 78], ["N-terminal amino acids 141 and 327", "PROTEIN", 109, 143], ["this study", "TEST", 29, 39], ["two immunodominant epitopes", "PROBLEM", 51, 78], ["N-terminal amino acids", "TEST", 109, 131], ["immunodominant epitopes", "OBSERVATION", 55, 78]]], ["While the interpretation of reactivity by pre-immune sera remains open, these results suggest that recognition of viral epitopes is present in the innate repertoire.", [["sera", "ANATOMY", 53, 57], ["sera", "ORGANISM_SUBSTANCE", 53, 57], ["viral epitopes", "PROTEIN", 114, 128], ["pre-immune sera", "TEST", 42, 57], ["viral epitopes", "PROBLEM", 114, 128], ["viral epitopes", "OBSERVATION", 114, 128]]], ["If so, it is possible that pre-infection recognition plays a role in skewing the immune system towards a more oligoclonal rather than polyclonal response.", [["immune system", "ANATOMY", 81, 94], ["pre-infection recognition", "PROBLEM", 27, 52], ["skewing the immune system", "PROBLEM", 69, 94]]], ["Induction of an immune response limited to a small set of epitopes may accentuate recognition of immunodominant epitopes that are often present in regions of high genetic variability in Class II pathogens [13] .", [["epitopes", "PROTEIN", 58, 66], ["immunodominant epitopes", "PROTEIN", 97, 120], ["an immune response", "TEST", 13, 31], ["a small set of epitopes", "PROBLEM", 43, 66], ["immunodominant epitopes", "PROBLEM", 97, 120], ["high genetic variability in Class II pathogens", "PROBLEM", 158, 204], ["immunodominant epitopes", "OBSERVATION", 97, 120], ["high genetic variability", "OBSERVATION", 158, 182]]], ["The ability to take advantage of the propensity of host immune systems to mount strain-specific immune responses largely limited to variable immunodominant epitopes may be a pathogenesis trait that influenza and other viruses have evolved so as to increase fitness on a landscape made more rugged by host immunity.", [["influenza", "DISEASE", 198, 207], ["host immune systems", "TREATMENT", 51, 70], ["mount strain", "PROBLEM", 74, 86], ["variable immunodominant epitopes", "PROBLEM", 132, 164], ["a pathogenesis trait", "PROBLEM", 172, 192], ["influenza", "PROBLEM", 198, 207], ["other viruses", "PROBLEM", 212, 225]]], ["Serum from the high dose immunization group (Group 4) showed increased reactivity to peptides 141 and 135 ( Figure 6 ) which both represent a highly variable and immunogenic loop of Epitope A [23] .", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum", "TEST", 0, 5], ["the high dose immunization", "TREATMENT", 11, 37], ["increased reactivity to peptides", "PROBLEM", 61, 93], ["immunogenic loop", "OBSERVATION", 162, 178]]], ["Unexpectedly, reactivities to additional peptides (9, 327, 453, and 483) derived from regions outside of previously defined epitopes, and near the transmembrane domain, were observed after multiple immunizations and two infectious innocula.", [["transmembrane", "ANATOMY", 147, 160], ["epitopes", "PROTEIN", 124, 132], ["transmembrane domain", "PROTEIN", 147, 167], ["additional peptides", "TEST", 30, 49], ["previously defined epitopes", "PROBLEM", 105, 132], ["multiple immunizations", "TREATMENT", 189, 211], ["two infectious innocula", "PROBLEM", 216, 239], ["epitopes", "OBSERVATION", 124, 132], ["infectious", "OBSERVATION_MODIFIER", 220, 230]]], ["The amino acid sequences at the cores of these peptides are highly conserved among influenza A strains.", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["influenza A strains", "ORGANISM", 83, 102], ["influenza A", "SPECIES", 83, 94], ["The amino acid sequences", "TEST", 0, 24], ["influenza A strains", "PROBLEM", 83, 102]]], ["The observation of linear epitopes does not preclude the reactivity of the sera to more dominant conformational epitopes that were not detected by this method.", [["sera", "ANATOMY", 75, 79], ["sera", "ORGANISM_SUBSTANCE", 75, 79], ["linear epitopes", "PROBLEM", 19, 34], ["more dominant conformational epitopes", "PROBLEM", 83, 120], ["linear", "OBSERVATION_MODIFIER", 19, 25], ["epitopes", "OBSERVATION", 26, 34]]], ["However, in a recent study of cross-reactive epitopes in avian influenza serotypes, Meuller et al. identified several linear epitopes in the HA of H4, H5, and H12 through a similar use of overlapping peptide ELISA [24] .", [["influenza", "DISEASE", 63, 72], ["avian influenza serotypes", "ORGANISM", 57, 82], ["H4", "GENE_OR_GENE_PRODUCT", 147, 149], ["cross-reactive epitopes", "PROTEIN", 30, 53], ["H4", "PROTEIN", 147, 149], ["H5", "PROTEIN", 151, 153], ["H12", "PROTEIN", 159, 162], ["avian influenza", "SPECIES", 57, 72], ["a recent study", "TEST", 12, 26], ["cross-reactive epitopes in avian influenza serotypes", "PROBLEM", 30, 82], ["several linear epitopes", "PROBLEM", 110, 133], ["H4", "PROBLEM", 147, 149], ["H5", "PROBLEM", 151, 153], ["influenza serotypes", "OBSERVATION", 63, 82], ["several", "OBSERVATION_MODIFIER", 110, 117], ["linear", "OBSERVATION_MODIFIER", 118, 124], ["epitopes", "OBSERVATION", 125, 133], ["HA", "OBSERVATION_MODIFIER", 141, 143], ["H12", "ANATOMY", 159, 162]]], ["We have aligned the sets of peptides used in both studies to determine analogous peptides so that the results can be compared more easily (data not shown).", [["both studies", "TEST", 45, 57]]], ["Interestingly, analogues of many of the H3N2 peptides that were recognized in the present study were also recognized by sera against the avian HA glycoproteins.", [["sera", "ANATOMY", 120, 124], ["H3N2", "ORGANISM", 40, 44], ["sera", "ORGANISM_SUBSTANCE", 120, 124], ["HA glycoproteins", "GENE_OR_GENE_PRODUCT", 143, 159], ["avian HA glycoproteins", "PROTEIN", 137, 159], ["avian", "SPECIES", 137, 142], ["the H3N2 peptides", "PROBLEM", 36, 53], ["the avian HA glycoproteins", "PROBLEM", 133, 159], ["H3N2", "OBSERVATION", 40, 44]]], ["Avian sera recognized analogues to peptides 141 and 327, which were recognized by preimmune Guinea pig sera.", [["sera", "ANATOMY", 6, 10], ["sera", "ANATOMY", 103, 107], ["Avian", "ORGANISM", 0, 5], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["pig", "ORGANISM", 99, 102], ["sera", "ORGANISM_SUBSTANCE", 103, 107], ["Avian", "SPECIES", 0, 5], ["Guinea pig", "SPECIES", 92, 102], ["Guinea pig", "SPECIES", 92, 102], ["Avian sera", "TEST", 0, 10], ["peptides", "TEST", 35, 43], ["preimmune Guinea pig sera", "TREATMENT", 82, 107]]], ["In addition, avian sera also recognized analogues to peptides 9, 453, and 483.", [["sera", "ANATOMY", 19, 23], ["avian", "ORGANISM", 13, 18], ["sera", "ORGANISM_SUBSTANCE", 19, 23], ["avian sera", "TEST", 13, 23], ["peptides", "TEST", 53, 61]]], ["The contribution of reactivity to these peptides towards antiviral activities will require further investigation.", [["these peptides", "TREATMENT", 34, 48], ["antiviral activities", "TREATMENT", 57, 77], ["further investigation", "TEST", 91, 112]]], ["Future studies have been planned to characterize the PepScan reactivities of sera from humans infected or immunized with influenza A/Wyoming/03/2003.DiscussionOverall, the current study has provided valuable immunogenicity data to further characterize immune responses in a relatively new animal model for human influenza infection and vaccination.ConclusionsWe present an immunological comparison between guinea pigs infected intranasally with an H3N2 virus, A/ Wyoming/03/2003, and those immunized with recombinant HA subunit from the homologous strain.", [["sera", "ANATOMY", 77, 81], ["influenza infection", "DISEASE", 312, 331], ["sera", "ORGANISM_SUBSTANCE", 77, 81], ["humans", "ORGANISM", 87, 93], ["human", "ORGANISM", 306, 311], ["guinea pigs", "ORGANISM", 406, 417], ["H3N2 virus", "ORGANISM", 448, 458], ["HA subunit", "GENE_OR_GENE_PRODUCT", 517, 527], ["recombinant HA subunit", "PROTEIN", 505, 527], ["humans", "SPECIES", 87, 93], ["human", "SPECIES", 306, 311], ["guinea pigs", "SPECIES", 406, 417], ["H3N2 virus", "SPECIES", 448, 458], ["humans", "SPECIES", 87, 93], ["influenza A/Wyoming/03/2003", "SPECIES", 121, 148], ["human", "SPECIES", 306, 311], ["guinea pigs", "SPECIES", 406, 417], ["H3N2 virus", "SPECIES", 448, 458], ["A/ Wyoming/03/2003", "SPECIES", 460, 478], ["Future studies", "TEST", 0, 14], ["influenza", "PROBLEM", 121, 130], ["the current study", "TEST", 168, 185], ["valuable immunogenicity data", "TEST", 199, 227], ["immune responses", "PROBLEM", 252, 268], ["human influenza infection", "PROBLEM", 306, 331], ["vaccination", "TREATMENT", 336, 347], ["guinea pigs", "TREATMENT", 406, 417], ["an H3N2 virus", "PROBLEM", 445, 458], ["the homologous strain", "PROBLEM", 533, 554], ["H3N2 virus", "OBSERVATION", 448, 458], ["homologous strain", "OBSERVATION", 537, 554]]], ["Sera from guinea pig treatment groups, collected over a six month period, were compared serologically for changes induced by each treatment: total antibodies were measured by ELISA, antiviral responses by HI assay, and recognized linear epitopes identified by PepScan ELISA.ConclusionsResults of this study re-enforce and extend previous reports characterizing the infection of guinea pigs following inoculation with unadapted human influenza strains.", [["Sera", "ANATOMY", 0, 4], ["infection", "DISEASE", 365, 374], ["influenza", "DISEASE", 433, 442], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["guinea pig", "ORGANISM", 10, 20], ["guinea pigs", "ORGANISM", 378, 389], ["human", "ORGANISM", 427, 432], ["PepScan", "PROTEIN", 260, 267], ["guinea pig", "SPECIES", 10, 20], ["guinea pigs", "SPECIES", 378, 389], ["human", "SPECIES", 427, 432], ["pig", "SPECIES", 17, 20], ["guinea pigs", "SPECIES", 378, 389], ["human", "SPECIES", 427, 432], ["Sera", "TREATMENT", 0, 4], ["guinea pig treatment groups", "TREATMENT", 10, 37], ["total antibodies", "TEST", 141, 157], ["ELISA", "TEST", 175, 180], ["this study", "TEST", 296, 306], ["the infection of guinea pigs", "PROBLEM", 361, 389], ["unadapted human influenza strains", "PROBLEM", 417, 450], ["infection", "OBSERVATION", 365, 374]]], ["The infected guinea pigs mounted vigorous immune responses that had antiviral activities as measured by HI assay.", [["guinea pigs", "ORGANISM", 13, 24], ["guinea pigs", "SPECIES", 13, 24], ["pigs", "SPECIES", 20, 24], ["The infected guinea pigs", "TREATMENT", 0, 24], ["antiviral activities", "TREATMENT", 68, 88], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["guinea pigs", "OBSERVATION", 13, 24], ["vigorous", "OBSERVATION_MODIFIER", 33, 41]]], ["Guinea pigs immunized with purified HA protein developed similar antiviral activities.", [["Guinea pigs", "ORGANISM", 0, 11], ["HA", "GENE_OR_GENE_PRODUCT", 36, 38], ["HA protein", "PROTEIN", 36, 46], ["Guinea pigs", "SPECIES", 0, 11], ["Guinea pigs", "TREATMENT", 0, 11], ["purified HA protein", "TREATMENT", 27, 46], ["antiviral activities", "OBSERVATION", 65, 85]]], ["Pepscan data determined that sera from na\u00efve animals recognize a linear epitope in the defined A epitope and another epitope near the fusion or HA cleavage sites.", [["sera", "ANATOMY", 29, 33], ["sera", "ORGANISM_SUBSTANCE", 29, 33], ["A epitope", "PROTEIN", 95, 104], ["HA cleavage sites", "PROTEIN", 144, 161], ["Pepscan data", "TEST", 0, 12], ["sera from na\u00efve animals", "PROBLEM", 29, 52], ["a linear epitope", "PROBLEM", 63, 79], ["A epitope", "TREATMENT", 95, 104], ["another epitope near the fusion", "TREATMENT", 109, 140], ["HA cleavage sites", "PROBLEM", 144, 161], ["linear", "OBSERVATION_MODIFIER", 65, 71], ["epitope", "OBSERVATION", 72, 79], ["fusion", "OBSERVATION", 134, 140]]], ["Further studies will be required to determine whether these innate reactivities are also found in sera from na\u00efve humans.", [["sera", "ANATOMY", 98, 102], ["sera", "ORGANISM_SUBSTANCE", 98, 102], ["humans", "ORGANISM", 114, 120], ["humans", "SPECIES", 114, 120], ["humans", "SPECIES", 114, 120], ["Further studies", "TEST", 0, 15]]], ["If so, it will be important to assess whether these antibodies offer any protective immunity, or are dysregulatory in nature.", [["antibodies", "PROTEIN", 52, 62], ["these antibodies", "TEST", 46, 62]]], ["Pepscan data also demonstrated the reactivity of sera from infected and immunized animals to linear determinants located both within and outside of previously defined major epitopes.", [["sera", "ANATOMY", 49, 53], ["sera", "ORGANISM_SUBSTANCE", 49, 53], ["epitopes", "PROTEIN", 173, 181], ["Pepscan data", "TEST", 0, 12], ["the reactivity of sera", "PROBLEM", 31, 53], ["infected", "OBSERVATION_MODIFIER", 59, 67], ["linear", "OBSERVATION_MODIFIER", 93, 99], ["major", "OBSERVATION_MODIFIER", 167, 172], ["epitopes", "OBSERVATION", 173, 181]]], ["The change in PepScan profiles over the course of the immunization and infection regimens appeared to reflect maturation of the humoral immune responses to linear epitopes.", [["infection", "DISEASE", 71, 80], ["PepScan", "PROTEIN", 14, 21], ["linear epitopes", "PROTEIN", 156, 171], ["The change in PepScan profiles", "PROBLEM", 0, 30], ["the immunization", "TREATMENT", 50, 66], ["infection regimens", "TREATMENT", 71, 89], ["linear epitopes", "PROBLEM", 156, 171], ["change", "OBSERVATION_MODIFIER", 4, 10], ["infection", "OBSERVATION", 71, 80]]], ["By altering the immunogenicity of the most dominant, yet variable, epitopes, it may be possible to refocus the immune response towards more highly conserved epitopes to derive a more broadly cross-protective influenza vaccine [13, 14] .", [["influenza", "DISEASE", 208, 217], ["epitopes", "PROTEIN", 67, 75], ["a more broadly cross-protective influenza vaccine", "TREATMENT", 176, 225], ["most dominant", "OBSERVATION_MODIFIER", 38, 51]]], ["Subunit vaccines, along with well-defined animal models for influenza research, have the potential to more rapidly, and accurately guide the development of future vaccines for both seasonal and pandemic influenza outbreaks.Cells and VirusInfluenza A/Wyoming/03/2003 (H3N2) was obtained from the Center for Disease Control and Prevention.", [["Cells", "ANATOMY", 223, 228], ["influenza", "DISEASE", 60, 69], ["influenza", "DISEASE", 203, 212], ["Cells", "CELL", 223, 228], ["VirusInfluenza A/Wyoming/03/2003", "ORGANISM", 233, 265], ["H3N2", "ORGANISM", 267, 271], ["VirusInfluenza A/Wyoming/03/2003 (H3N2", "SPECIES", 233, 271], ["Subunit vaccines", "TREATMENT", 0, 16], ["influenza", "PROBLEM", 60, 69], ["future vaccines", "TREATMENT", 156, 171], ["both seasonal and pandemic influenza outbreaks", "PROBLEM", 176, 222], ["Cells", "TEST", 223, 228], ["VirusInfluenza", "TEST", 233, 247], ["H3N2", "PROBLEM", 267, 271], ["Disease Control", "TREATMENT", 306, 321], ["influenza", "OBSERVATION", 60, 69]]], ["The virus was originally derived by reassortment and contains genes encoding HA and neuraminidase of Wyoming, with all other genes from A/Puerto Rico/8 H1N1 virus [25] .", [["HA", "GENE_OR_GENE_PRODUCT", 77, 79], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 84, 97], ["Puerto Rico/8 H1N1 virus", "ORGANISM", 138, 162], ["HA", "PROTEIN", 77, 79], ["neuraminidase", "PROTEIN", 84, 97], ["H1N1 virus", "SPECIES", 152, 162], ["A/Puerto Rico/8 H1N1 virus", "SPECIES", 136, 162], ["The virus", "PROBLEM", 0, 9], ["genes encoding HA", "PROBLEM", 62, 79], ["virus", "OBSERVATION", 4, 9]]], ["The virus was propagated in monolayer cultures of Madin-Darby canine kidney (MDCK) cells (ATCC #CCL-34) using Dulbecco's Modified Eagle Medium (Lonza), supplemented with 7% fetal bovine serum (Lonza).", [["monolayer cultures", "ANATOMY", 28, 46], ["canine kidney (MDCK) cells", "ANATOMY", 62, 88], ["ATCC #CCL-34", "ANATOMY", 90, 102], ["fetal bovine serum", "ANATOMY", 173, 191], ["monolayer cultures", "CELL", 28, 46], ["Madin-Darby canine kidney (MDCK) cells", "CELL", 50, 88], ["ATCC #CCL-34", "CELL", 90, 102], ["Lonza", "CELL", 144, 149], ["bovine", "ORGANISM", 179, 185], ["serum", "ORGANISM_SUBSTANCE", 186, 191], ["Lonza", "CELL", 193, 198], ["monolayer cultures", "CELL_LINE", 28, 46], ["Madin-Darby canine kidney (MDCK) cells", "CELL_LINE", 50, 88], ["ATCC #CCL-34", "CELL_LINE", 90, 102], ["bovine", "SPECIES", 179, 185], ["ATCC #CCL-34", "SPECIES", 90, 102], ["bovine", "SPECIES", 179, 185], ["The virus", "PROBLEM", 0, 9], ["monolayer cultures", "TEST", 28, 46], ["Madin", "TEST", 50, 55], ["ATCC", "TEST", 90, 94], ["CCL", "TEST", 96, 99], ["Dulbecco's Modified Eagle Medium (Lonza)", "TREATMENT", 110, 150], ["7% fetal bovine serum (Lonza)", "TREATMENT", 170, 199], ["virus", "OBSERVATION", 4, 9], ["kidney", "ANATOMY", 69, 75]]], ["For plaque assays, virus samples were serially diluted into 1 mL of phosphate buffered saline (PBS) and placed into 6-well plates confluent with MDCK cells.", [["plaque", "ANATOMY", 4, 10], ["samples", "ANATOMY", 25, 32], ["MDCK cells", "ANATOMY", 145, 155], ["phosphate", "CHEMICAL", 68, 77], ["phosphate", "CHEMICAL", 68, 77], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 68, 93], ["MDCK cells", "CELL", 145, 155], ["MDCK cells", "CELL_LINE", 145, 155], ["plaque assays", "TEST", 4, 17], ["virus samples", "TEST", 19, 32], ["phosphate buffered saline (PBS", "TREATMENT", 68, 98], ["plaque", "OBSERVATION", 4, 10], ["MDCK cells", "OBSERVATION", 145, 155]]], ["After an 1-hour (h) incubation, the innocula were replaced by a mixture of 1% molten agar in complete growth media.", [["innocula", "ANATOMY", 36, 44], ["incubation", "TREATMENT", 20, 30], ["the innocula", "TREATMENT", 32, 44], ["1% molten agar", "TREATMENT", 75, 89], ["growth media", "OBSERVATION", 102, 114]]], ["Upon solidification of the agar, the plates were inverted and incubated in a humidified 37\u00b0C incubator.", [["the agar", "TREATMENT", 23, 31], ["a humidified 37\u00b0C incubator", "TREATMENT", 75, 102], ["solidification", "OBSERVATION_MODIFIER", 5, 19]]], ["Plaques were typically visible for enumeration or isolation 3-4 days after inoculation.", [["Plaques", "ANATOMY", 0, 7], ["Plaques", "PROBLEM", 0, 7], ["enumeration", "PROBLEM", 35, 46], ["inoculation", "PROBLEM", 75, 86]]], ["Prior to introduction into animals, MDCK propagated virus stocks were titered using a plaque assay and adjusted to 3 \u00d7 10 5 plaqueforming units/mL (pfu/mL) with sterile saline.HA Protein Expression and PurificationRecombinant influenza A/Wyoming/03/2003 hemagglutinin (HA) was produced in stably transformed S2 drosophila cells [26, 27] .", [["MDCK", "ANATOMY", 36, 40], ["plaque", "ANATOMY", 86, 92], ["S2 drosophila cells", "ANATOMY", 308, 327], ["MDCK", "CELL", 36, 40], ["saline", "SIMPLE_CHEMICAL", 169, 175], ["Wyoming/03/2003 hemagglutinin", "GENE_OR_GENE_PRODUCT", 238, 267], ["HA", "GENE_OR_GENE_PRODUCT", 269, 271], ["S2 drosophila cells", "CELL", 308, 327], ["HA", "PROTEIN", 269, 271], ["stably transformed S2 drosophila cells", "CELL_LINE", 289, 327], ["influenza A/Wyoming/03/2003 hemagglutinin", "SPECIES", 226, 267], ["introduction into animals", "TREATMENT", 9, 34], ["MDCK propagated virus stocks", "TREATMENT", 36, 64], ["a plaque assay", "TEST", 84, 98], ["sterile saline", "TREATMENT", 161, 175], ["HA Protein Expression", "TEST", 176, 197], ["PurificationRecombinant influenza A", "PROBLEM", 202, 237], ["hemagglutinin (HA)", "PROBLEM", 254, 272], ["virus stocks", "OBSERVATION", 52, 64], ["Protein Expression", "OBSERVATION", 179, 197], ["PurificationRecombinant influenza", "OBSERVATION", 202, 235], ["S2 drosophila cells", "OBSERVATION", 308, 327]]], ["Briefly, the A/Wyoming/03/2003 gene was subcloned from a parental plasmid vector (a kind gift of Dr. Kanta Subbarao, NIAID, NIH) into pMT-BiP-V5-His (Invitrogen, Inc.) such that the mature ectodomain (amino acids 17-513) was in-frame with the BiP insect cell promoter, and sequences encoding a hexahistadine tract were inserted immediately upstream of a stop codon.", [["plasmid", "ANATOMY", 66, 73], ["cell", "ANATOMY", 254, 258], ["amino acids 17-513", "CHEMICAL", 201, 219], ["hexahistadine", "CHEMICAL", 294, 307], ["amino acids", "CHEMICAL", 201, 212], ["hexahistadine", "CHEMICAL", 294, 307], ["A", "GENE_OR_GENE_PRODUCT", 13, 14], ["03/2003", "GENE_OR_GENE_PRODUCT", 23, 30], ["pMT", "GENE_OR_GENE_PRODUCT", 134, 137], ["BiP", "GENE_OR_GENE_PRODUCT", 138, 141], ["amino acids 17-513", "AMINO_ACID", 201, 219], ["BiP", "GENE_OR_GENE_PRODUCT", 243, 246], ["hexahistadine", "GENE_OR_GENE_PRODUCT", 294, 307], ["A/Wyoming/03/2003 gene", "DNA", 13, 35], ["parental plasmid vector", "DNA", 57, 80], ["pMT", "DNA", 134, 137], ["BiP", "PROTEIN", 138, 141], ["V5", "PROTEIN", 142, 144], ["mature ectodomain", "PROTEIN", 182, 199], ["amino acids 17-513", "PROTEIN", 201, 219], ["BiP insect cell promoter", "DNA", 243, 267], ["hexahistadine tract", "DNA", 294, 313], ["stop codon", "DNA", 354, 364], ["A/Wyoming/03/2003", "SPECIES", 13, 30], ["a parental plasmid vector", "TREATMENT", 55, 80], ["BiP", "TEST", 138, 141], ["the mature ectodomain (amino acids", "TEST", 178, 212], ["the BiP insect cell promoter", "TREATMENT", 239, 267], ["a hexahistadine tract", "TREATMENT", 292, 313], ["cell promoter", "OBSERVATION", 254, 267]]], ["S2 drosophila cells were co-transfected with the HA expression plasmid and pCoBLAST (Invitrogen, Inc), and stable transformants selected with blastocidin (30 micrograms/mL, Thermo Fisher Scientific).", [["cells", "ANATOMY", 14, 19], ["transformants", "ANATOMY", 114, 127], ["blastocidin", "CHEMICAL", 142, 153], ["blastocidin", "CHEMICAL", 142, 153], ["S2 drosophila cells", "CELL", 0, 19], ["Inc", "GENE_OR_GENE_PRODUCT", 97, 100], ["transformants", "CELL", 114, 127], ["blastocidin", "SIMPLE_CHEMICAL", 142, 153], ["S2 drosophila cells", "CELL_TYPE", 0, 19], ["HA expression plasmid", "DNA", 49, 70], ["pCoBLAST", "DNA", 75, 83], ["S2 drosophila cells", "PROBLEM", 0, 19], ["the HA expression plasmid", "TREATMENT", 45, 70], ["pCoBLAST (Invitrogen", "TREATMENT", 75, 95], ["blastocidin", "TREATMENT", 142, 153], ["drosophila cells", "OBSERVATION", 3, 19], ["stable", "OBSERVATION_MODIFIER", 107, 113]]], ["Expression of recombinant HA protein was induced for four days by the addition of 1 mM cupric sulfate to the culture media.", [["cupric sulfate", "CHEMICAL", 87, 101], ["cupric sulfate", "CHEMICAL", 87, 101], ["HA", "GENE_OR_GENE_PRODUCT", 26, 28], ["cupric sulfate", "SIMPLE_CHEMICAL", 87, 101], ["recombinant HA protein", "PROTEIN", 14, 36], ["recombinant HA protein", "PROBLEM", 14, 36], ["1 mM cupric sulfate", "TREATMENT", 82, 101], ["the culture media", "TREATMENT", 105, 122]]], ["After expression, conditioned supernatants containing the secreted HA protein were clarified at 2,000 \u00d7 g for 20 min.", [["supernatants", "ANATOMY", 30, 42], ["HA", "GENE_OR_GENE_PRODUCT", 67, 69], ["HA protein", "PROTEIN", 67, 77], ["conditioned supernatants", "TREATMENT", 18, 42], ["the secreted HA protein", "TREATMENT", 54, 77]]], ["The HA protein was purified through a multi-step process including chromatographies on copper-charged Fast Flow Sepharose (GE Bio) using elution with 50 mM imidazole, lentil lectin agarose (Vector Labs) using elution with 0.5 M alpha-methly-D-mannoside, and, finally, anion exchange in DE53 resin (Whatman) at pH 8.8 with elution in 50-100 mM NaCl.", [["imidazole", "CHEMICAL", 156, 165], ["alpha-methly-D-mannoside", "CHEMICAL", 228, 252], ["NaCl", "CHEMICAL", 343, 347], ["imidazole", "CHEMICAL", 156, 165], ["alpha-methly-D-mannoside", "CHEMICAL", 228, 252], ["NaCl", "CHEMICAL", 343, 347], ["HA", "GENE_OR_GENE_PRODUCT", 4, 6], ["imidazole", "SIMPLE_CHEMICAL", 156, 165], ["agarose", "SIMPLE_CHEMICAL", 181, 188], ["alpha-methly-D-mannoside", "SIMPLE_CHEMICAL", 228, 252], ["anion", "SIMPLE_CHEMICAL", 268, 273], ["HA protein", "PROTEIN", 4, 14], ["The HA protein", "PROBLEM", 0, 14], ["a multi-step process", "TREATMENT", 36, 56], ["chromatographies", "TREATMENT", 67, 83], ["Fast Flow Sepharose (GE Bio", "TREATMENT", 102, 129], ["50 mM imidazole", "TREATMENT", 150, 165], ["lentil lectin agarose", "TREATMENT", 167, 188], ["mannoside", "TREATMENT", 243, 252], ["anion exchange in DE53 resin", "TREATMENT", 268, 296], ["pH", "TEST", 310, 312], ["elution", "TEST", 322, 329]]], ["The eluted samples were concentrated and buffers exchanged after each chromatography step using filtration spin-cartridges with 30,000 molecular weight cut-off membranes (Amicon Ultra Centrifugal Filter Devices, Millipore).", [["samples", "ANATOMY", 11, 18], ["membranes", "ANATOMY", 160, 169], ["The eluted samples", "TREATMENT", 0, 18], ["each chromatography step", "TEST", 65, 89], ["filtration spin-cartridges", "TREATMENT", 96, 122], ["membranes (Amicon Ultra Centrifugal Filter Devices", "TREATMENT", 160, 210]]], ["Protein yield and purity were determined using the Pierce Coomassie Protein assay reagent with a bovine serum albumin standard, and Western blotting with comparison to commercially prepared standards of full-length A/Wyoming/ 03/2003 HA glycoprotein (a kind gift of Dr. Joseph A. Rininger, Protein Science Corporation).", [["serum", "ANATOMY", 104, 109], ["Coomassie", "CHEMICAL", 58, 67], ["Coomassie", "SIMPLE_CHEMICAL", 58, 67], ["bovine", "ORGANISM", 97, 103], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["albumin", "SIMPLE_CHEMICAL", 110, 117], ["HA glycoprotein", "GENE_OR_GENE_PRODUCT", 234, 249], ["HA glycoprotein", "PROTEIN", 234, 249], ["bovine", "SPECIES", 97, 103], ["bovine", "SPECIES", 97, 103], ["Protein yield", "TEST", 0, 13], ["the Pierce Coomassie Protein assay reagent", "TREATMENT", 47, 89], ["a bovine serum albumin standard", "TEST", 95, 126]]], ["A mock preparation of the HA ectodomain protein was produced using the above expression and purification methods, and stably transformed S2 cells containing the empty pMT-BiP vector lacking the HA gene for use as a negative control in immunization experiments.Guinea Pig Infections and ImmunizationsSix to eight weeks of age guinea pigs were obtained from Harlan-Spraque-Dowley Inc., and animal studies performed at BioCon Inc, Rockville, MD followed appropriate AAALAC-approved guidelines for the humane treatment of animals in research.", [["S2 cells", "ANATOMY", 137, 145], ["HA ectodomain", "GENE_OR_GENE_PRODUCT", 26, 39], ["S2 cells", "CELL", 137, 145], ["pMT", "GENE_OR_GENE_PRODUCT", 167, 170], ["BiP", "GENE_OR_GENE_PRODUCT", 171, 174], ["HA", "GENE_OR_GENE_PRODUCT", 194, 196], ["guinea", "ORGANISM", 325, 331], ["pigs", "ORGANISM", 332, 336], ["HA ectodomain protein", "PROTEIN", 26, 47], ["stably transformed S2 cells", "CELL_LINE", 118, 145], ["pMT", "PROTEIN", 167, 170], ["BiP vector", "DNA", 171, 181], ["HA gene", "DNA", 194, 201], ["guinea pigs", "SPECIES", 325, 336], ["pigs", "SPECIES", 332, 336], ["Harlan-Spraque-Dowley", "SPECIES", 356, 377], ["A mock preparation", "TREATMENT", 0, 18], ["the HA ectodomain protein", "TREATMENT", 22, 47], ["the above expression", "TREATMENT", 67, 87], ["purification methods", "TEST", 92, 112], ["the empty pMT", "TREATMENT", 157, 170], ["BiP vector", "TREATMENT", 171, 181], ["the HA gene", "TREATMENT", 190, 201], ["immunization experiments", "TREATMENT", 235, 259], ["Guinea Pig Infections", "PROBLEM", 260, 281], ["ImmunizationsSix", "TREATMENT", 286, 302], ["age guinea pigs", "TREATMENT", 321, 336], ["animal studies", "TEST", 388, 402], ["the humane treatment", "TREATMENT", 494, 514], ["Pig Infections", "OBSERVATION", 267, 281]]], ["Guinea pigs were divided into four groups ( Table 2 ) and test bleeds were collected prior to the study.", [["pigs", "ORGANISM", 7, 11], ["Guinea pigs", "SPECIES", 0, 11], ["Guinea pigs", "TREATMENT", 0, 11], ["test bleeds", "PROBLEM", 58, 69], ["the study", "TEST", 94, 103], ["bleeds", "OBSERVATION", 63, 69]]], ["Group 1 (n = 4, each) guinea pigs were immunized subcutaneously with the mock prepared negative control protein, and served as a negative control.", [["subcutaneously", "ANATOMY", 49, 63], ["guinea", "ORGANISM", 22, 28], ["pigs", "ORGANISM", 29, 33], ["mock prepared negative control protein", "PROTEIN", 73, 111], ["guinea pigs", "SPECIES", 22, 33], ["pigs", "SPECIES", 29, 33], ["Group 1 (n = 4, each) guinea pigs", "TREATMENT", 0, 33]]], ["Group 2 (n = 2), were lightly anesthetized and intranasally inoculated with 1 mL of A/Wyoming/03/2003 influenza virus (3 \u00d7 10 4 pfu/mL).", [["03/2003 influenza virus", "ORGANISM", 94, 117], ["influenza virus", "SPECIES", 102, 117], ["A/Wyoming/03/2003 influenza virus", "SPECIES", 84, 117], ["influenza virus", "PROBLEM", 102, 117]]], ["Animals were re-infected at five weeks after the first inoculation with the same dose of virus.", [["Animals", "ORGANISM", 0, 7], ["the first inoculation", "TREATMENT", 45, 66], ["virus", "PROBLEM", 89, 94]]], ["Guinea pigs in Groups 3 and 4 (n = 4) were subcutaneously immunized with recombinant HA protein in Complete Freund's Adjuvant (Thermo Fisher Scientific) and boosted at weeks 3, 5, and 10 with HA protein in Incomplete Freund's Adjuvant (Thermo Fisher Scientific) to characterize the boosting effects of the HA antigen.", [["Guinea pigs", "ORGANISM", 0, 11], ["HA antigen", "GENE_OR_GENE_PRODUCT", 306, 316], ["recombinant HA protein", "PROTEIN", 73, 95], ["HA protein", "PROTEIN", 192, 202], ["HA antigen", "PROTEIN", 306, 316], ["Guinea pigs", "SPECIES", 0, 11], ["Guinea pigs in Groups", "TREATMENT", 0, 21], ["recombinant HA protein", "TREATMENT", 73, 95], ["Complete Freund's Adjuvant", "TREATMENT", 99, 125], ["HA protein", "TREATMENT", 192, 202], ["Incomplete Freund's Adjuvant", "TREATMENT", 206, 234], ["the HA antigen", "PROBLEM", 302, 316]]], ["Initial experimental design also included a comparison of increasing antigen load to study how the animals responded to increasing concentrations of antigen.", [["animals", "ORGANISM", 99, 106], ["increasing antigen load", "PROBLEM", 58, 81], ["increasing concentrations of antigen", "TREATMENT", 120, 156]]], ["This was an attempt to scale the amount of recombinant HA protein to that which would be presented by natural infection.", [["infection", "DISEASE", 110, 119], ["HA", "GENE_OR_GENE_PRODUCT", 55, 57], ["recombinant HA protein", "PROTEIN", 43, 65], ["recombinant HA protein", "TREATMENT", 43, 65], ["natural infection", "PROBLEM", 102, 119], ["natural", "OBSERVATION_MODIFIER", 102, 109], ["infection", "OBSERVATION", 110, 119]]], ["Group 4 animals were immunized three times with 30 micrograms of recombinant HA, with a final boost of 40 micrograms.", [["animals", "ORGANISM", 8, 15], ["recombinant HA", "TREATMENT", 65, 79]]], ["At the same intervals, Group 1 control guinea pigs were immunized with the mock protein preparation derived from the insect cell system used to propagate the HA recombinant antigen.ELISA and Immunoblot Analysis of Guinea Pig SeraGuinea pig serum samples were assessed for induction of specific HA antibody responses using a standard ELISA method.", [["cell", "ANATOMY", 124, 128], ["serum samples", "ANATOMY", 240, 253], ["guinea pigs", "ORGANISM", 39, 50], ["insect cell", "CELL", 117, 128], ["pig", "ORGANISM", 236, 239], ["serum samples", "ORGANISM_SUBSTANCE", 240, 253], ["HA recombinant antigen", "PROTEIN", 158, 180], ["HA antibody", "PROTEIN", 294, 305], ["guinea pigs", "SPECIES", 39, 50], ["Pig SeraGuinea pig", "SPECIES", 221, 239], ["pigs", "SPECIES", 46, 50], ["pig", "SPECIES", 236, 239], ["Group 1 control guinea pigs", "TREATMENT", 23, 50], ["the mock protein preparation", "TREATMENT", 71, 99], ["the insect cell system", "TREATMENT", 113, 135], ["the HA recombinant antigen", "PROBLEM", 154, 180], ["ELISA", "TEST", 181, 186], ["Immunoblot Analysis", "TEST", 191, 210], ["Guinea Pig SeraGuinea pig serum samples", "TEST", 214, 253], ["specific HA antibody responses", "TEST", 285, 315], ["a standard ELISA method", "TREATMENT", 322, 345], ["insect cell", "OBSERVATION", 117, 128]]], ["Briefly, Nunc Maxisorb flat-bottom 96-well plates were coated overnight with 0.1 mL/well containing 1.5 micrograms of full-length A/Wyoming/ 03/2003 HA protein (Protein Science Corporation).", [["HA protein", "PROTEIN", 149, 159]]], ["Plates were blocked with 10% nonfat dried milk in PBS for 2 h at 37\u00b0C. Serum samples were serially diluted in 1% milk solution and 100 microliter aliquots were tested for binding to antigen in triplicate.", [["milk", "ANATOMY", 42, 46], ["Serum samples", "ANATOMY", 71, 84], ["milk", "ANATOMY", 113, 117], ["milk", "ORGANISM_SUBSTANCE", 42, 46], ["Serum samples", "ORGANISM_SUBSTANCE", 71, 84], ["milk", "ORGANISM_SUBSTANCE", 113, 117], ["10% nonfat dried milk in PBS", "TREATMENT", 25, 53], ["Serum samples", "TEST", 71, 84], ["microliter aliquots", "TREATMENT", 135, 154]]], ["After 1 h incubation at 37\u00b0C, the plates were washed in PBS containing 0.1% Tween-20 (PBS-T) and probed with a peroxidaseconjugated goat anti-guinea pig total IgG antibody (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD, KPL, 1:1000) for 1 h.", [["Tween-20", "CHEMICAL", 76, 84], ["Tween-20", "CHEMICAL", 76, 84], ["Tween-20", "SIMPLE_CHEMICAL", 76, 84], ["PBS-T", "SIMPLE_CHEMICAL", 86, 91], ["goat", "ORGANISM", 132, 136], ["pig", "ORGANISM", 149, 152], ["peroxidaseconjugated goat anti-guinea pig total IgG antibody", "PROTEIN", 111, 171], ["goat", "SPECIES", 132, 136], ["pig", "SPECIES", 149, 152], ["goat", "SPECIES", 132, 136], ["pig", "SPECIES", 149, 152], ["the plates", "TREATMENT", 30, 40], ["PBS", "TREATMENT", 56, 59], ["a peroxidaseconjugated goat anti-guinea", "TREATMENT", 109, 148]]], ["After additional washes, bound conjugates were quantitated by the addition of tetramethylbenzidine (TMB) substrate (KPL) for 90 sec, followed by an equal volume of 0.1N sulphuric acid.", [["tetramethylbenzidine", "CHEMICAL", 78, 98], ["TMB", "CHEMICAL", 100, 103], ["KPL", "CHEMICAL", 116, 119], ["sulphuric acid", "CHEMICAL", 169, 183], ["tetramethylbenzidine", "CHEMICAL", 78, 98], ["TMB", "CHEMICAL", 100, 103], ["N sulphuric acid", "CHEMICAL", 167, 183], ["tetramethylbenzidine", "SIMPLE_CHEMICAL", 78, 98], ["TMB", "SIMPLE_CHEMICAL", 100, 103], ["KPL", "SIMPLE_CHEMICAL", 116, 119], ["sulphuric acid", "SIMPLE_CHEMICAL", 169, 183], ["additional washes", "TREATMENT", 6, 23], ["bound conjugates", "TREATMENT", 25, 41], ["tetramethylbenzidine (TMB) substrate (KPL)", "TREATMENT", 78, 120], ["an equal volume", "TEST", 145, 160], ["sulphuric acid", "TREATMENT", 169, 183]]], ["Plates were read at 450 nm and mean values of triplicate wells were calculated.", [["Plates", "TEST", 0, 6], ["mean values", "TEST", 31, 42], ["triplicate wells", "TEST", 46, 62]]], ["Plate backgrounds were determined from antigen-coated wells detected with secondary antibody only.", [["antigen", "GENE_OR_GENE_PRODUCT", 39, 46], ["secondary antibody", "PROTEIN", 74, 92], ["Plate backgrounds", "TEST", 0, 17], ["antigen-coated wells", "PROBLEM", 39, 59], ["secondary antibody", "PROBLEM", 74, 92]]], ["ELISA extinction titers were calculated as the maximum serum dilutions that resulted in a signal that exceeded a value that was three times plate background (approximately 0.15 OD units).ELISA and Immunoblot Analysis of Guinea Pig SeraMean values with error bars equal to one standard deviation of the triplicate were graphed as a function of time over the course of the study.ELISA and Immunoblot Analysis of Guinea Pig SeraThe specificity of immune responses to HA protein was assessed by Western blot analysis.", [["serum", "ANATOMY", 55, 60], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["HA", "GENE_OR_GENE_PRODUCT", 464, 466], ["HA protein", "PROTEIN", 464, 474], ["ELISA extinction titers", "TEST", 0, 23], ["the maximum serum dilutions", "TEST", 43, 70], ["ELISA", "TEST", 187, 192], ["Immunoblot Analysis", "TEST", 197, 216], ["Guinea Pig SeraMean values", "TREATMENT", 220, 246], ["error bars", "TREATMENT", 252, 262], ["the study", "TEST", 367, 376], ["ELISA", "TEST", 377, 382], ["Immunoblot Analysis", "TEST", 387, 406], ["Guinea Pig", "TREATMENT", 410, 420], ["immune responses", "PROBLEM", 444, 460], ["HA protein", "TEST", 464, 474], ["blot analysis", "TEST", 499, 512]]], ["Samples containing 30-50 ng of full-length recombinant A/Wyoming/ 03/2003 HA protein (Protein Sciences, Inc.) were electrophoresed in 4-20% Tris-Glycine gels (Invitrogen) and transferred to nitrocellulose membrane.", [["Samples", "ANATOMY", 0, 7], ["membrane", "ANATOMY", 205, 213], ["Tris-Glycine", "CHEMICAL", 140, 152], ["Tris-Glycine", "CHEMICAL", 140, 152], ["nitrocellulose", "CHEMICAL", 190, 204], ["Tris-Glycine gels", "SIMPLE_CHEMICAL", 140, 157], ["Invitrogen", "SIMPLE_CHEMICAL", 159, 169], ["membrane", "CELLULAR_COMPONENT", 205, 213], ["03/2003 HA protein", "PROTEIN", 66, 84], ["Samples", "TEST", 0, 7], ["HA protein", "TEST", 74, 84], ["Protein Sciences", "TEST", 86, 102], ["Tris-Glycine gels", "TREATMENT", 140, 157], ["nitrocellulose membrane", "TREATMENT", 190, 213]]], ["The membrane was cut such that each replicate lane was in a single strip, blocked in a solution of 10% nonfat dried milk in PBS, and probed with sera from immunized and infected guinea pigs.", [["membrane", "ANATOMY", 4, 12], ["milk", "ANATOMY", 116, 120], ["sera", "ANATOMY", 145, 149], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["milk", "ORGANISM_SUBSTANCE", 116, 120], ["sera", "ORGANISM_SUBSTANCE", 145, 149], ["guinea pigs", "ORGANISM", 178, 189], ["guinea pigs", "SPECIES", 178, 189], ["guinea pigs", "SPECIES", 178, 189], ["a single strip", "TREATMENT", 58, 72], ["a solution of 10% nonfat dried milk in PBS", "TREATMENT", 85, 127], ["sera", "TREATMENT", 145, 149], ["infected guinea pigs", "TREATMENT", 169, 189], ["membrane", "OBSERVATION_MODIFIER", 4, 12], ["guinea pigs", "OBSERVATION", 178, 189]]], ["After washing in PBS-T, the strips were detected with peroxidase-conjugated goat anti-Guinea pig antibody, washed again, developed with West Pico Chemiluminescent Substrate (Pierce).", [["peroxidase", "GENE_OR_GENE_PRODUCT", 54, 64], ["pig", "ORGANISM", 93, 96], ["peroxidase", "PROTEIN", 54, 64], ["conjugated goat anti-Guinea pig antibody", "PROTEIN", 65, 105], ["goat", "SPECIES", 76, 80], ["pig", "SPECIES", 93, 96], ["pig", "SPECIES", 93, 96], ["PBS", "TEST", 17, 20], ["the strips", "TEST", 24, 34], ["peroxidase-conjugated goat anti-Guinea pig antibody", "TREATMENT", 54, 105], ["West Pico Chemiluminescent Substrate (Pierce)", "TREATMENT", 136, 181]]], ["The blot was exposed to X-ray film and images of the strips assembled for comparison.Hemagglutination Inhibition Assay (HI)A standard HI assay was performed in blinded fashion to assess Wyoming/03-specific neutralizing antibody levels [28] .", [["X-ray film", "TEST", 24, 34], ["images of the strips", "TEST", 39, 59], ["Hemagglutination Inhibition Assay", "TEST", 85, 118], ["A standard HI assay", "TEST", 123, 142], ["Wyoming/03", "TEST", 186, 196], ["specific neutralizing antibody levels", "TEST", 197, 234]]], ["Prior to assay, serum samples were treated with Receptor Destroying Enzyme (RDE, Denka Seiken CO LTD., Tokyo, Japan) overnight at 37\u00b0C followed by heat inactivation for 1 hour at 56\u00b0C. Two-fold dilutions of serum samples were mixed with A/Wyoming/03/2003 virus (at a concentration of 4 hemagglutination units per well) and incubated for 15 min at room temperature.", [["serum samples", "ANATOMY", 16, 29], ["serum samples", "ANATOMY", 207, 220], ["serum samples", "ORGANISM_SUBSTANCE", 16, 29], ["serum samples", "ORGANISM_SUBSTANCE", 207, 220], ["03/2003 virus", "ORGANISM", 247, 260], ["A/Wyoming/03/2003 virus", "SPECIES", 237, 260], ["assay", "TEST", 9, 14], ["serum samples", "TEST", 16, 29], ["Two-fold dilutions", "TEST", 185, 203], ["serum samples", "TEST", 207, 220], ["A/Wyoming/03/2003 virus", "PROBLEM", 237, 260], ["a concentration of 4 hemagglutination units", "TREATMENT", 265, 308]]], ["0.05 mL of a 0.5% suspension of chicken red blood cells was added and hemagglutination was assessed after 1 h, as described.Peptide Synthesis and Peptide Scanning (PepScan) AssayTo map linear antibody responses, a set of overlapping peptides (Figure 7) representing amino acids -16 through 513 of the Wyoming HA glycoprotein was synthesized by Mimotopes, Inc. (Melbourne, Australia) [29] .", [["red blood cells", "ANATOMY", 40, 55], ["amino acids", "CHEMICAL", 266, 277], ["amino acids", "CHEMICAL", 266, 277], ["chicken", "ORGANISM", 32, 39], ["red blood cells", "CELL", 40, 55], ["amino acids", "AMINO_ACID", 266, 277], ["chicken red blood cells", "CELL_TYPE", 32, 55], ["Wyoming HA glycoprotein", "PROTEIN", 301, 324], ["chicken", "SPECIES", 32, 39], ["chicken", "SPECIES", 32, 39], ["a 0.5% suspension of chicken red blood cells", "TREATMENT", 11, 55], ["hemagglutination", "TEST", 70, 86], ["Peptide Synthesis", "TREATMENT", 124, 141], ["Peptide Scanning", "TEST", 146, 162], ["AssayTo map linear antibody responses", "TEST", 173, 210], ["overlapping peptides", "PROBLEM", 221, 241], ["amino acids", "TEST", 266, 277], ["the Wyoming HA glycoprotein", "TREATMENT", 297, 324]]], ["Peptide 1 represented the amino terminus of the precursor protein, including the signal leader sequence, and was synthesized with a C-terminal linker of four residues followed by a biotin label.", [["biotin", "CHEMICAL", 181, 187], ["amino", "CHEMICAL", 26, 31], ["C", "CHEMICAL", 132, 133], ["biotin", "CHEMICAL", 181, 187], ["Peptide 1", "GENE_OR_GENE_PRODUCT", 0, 9], ["amino", "AMINO_ACID", 26, 31], ["biotin", "SIMPLE_CHEMICAL", 181, 187], ["amino terminus", "PROTEIN", 26, 40], ["precursor protein", "PROTEIN", 48, 65], ["signal leader sequence", "PROTEIN", 81, 103], ["C-terminal linker", "PROTEIN", 132, 149], ["the signal leader sequence", "TEST", 77, 103], ["a C-terminal linker of four residues", "TREATMENT", 130, 166], ["a biotin label", "TREATMENT", 179, 193], ["precursor protein", "OBSERVATION", 48, 65]]], ["All other peptides were synthesized with an N-terminal linker and an N-terminal biotin.", [["N", "CHEMICAL", 44, 45], ["N", "CHEMICAL", 69, 70], ["biotin", "CHEMICAL", 80, 86], ["biotin", "SIMPLE_CHEMICAL", 80, 86], ["N-terminal linker", "PROTEIN", 44, 61], ["N-terminal biotin", "PROTEIN", 69, 86], ["an N-terminal linker", "TREATMENT", 41, 61], ["an N-terminal biotin", "TREATMENT", 66, 86]]], ["The peptides contained 18 residues and overlapped in sequence with each neighbouring peptide by 10 residues.", [["The peptides", "TREATMENT", 0, 12], ["each neighbouring peptide", "TREATMENT", 67, 92], ["18 residues", "OBSERVATION_MODIFIER", 23, 34]]], ["Peptides were synthesized with a biotin conjugate to facilitate binding to streptavidincoated microtiter plates.", [["biotin", "CHEMICAL", 33, 39], ["biotin", "CHEMICAL", 33, 39], ["biotin", "SIMPLE_CHEMICAL", 33, 39], ["a biotin conjugate", "TREATMENT", 31, 49], ["streptavidincoated microtiter plates", "TREATMENT", 75, 111]]], ["Figure 7 shows the overlap design of the peptides and the N-terminus number assigned to each individual peptide.Peptide Synthesis and Peptide Scanning (PepScan) AssayTo assess immune recognition of linear epitopes, peptides were bound to plates and tested for reactivity to serum samples.", [["serum samples", "ANATOMY", 274, 287], ["N", "CHEMICAL", 58, 59], ["serum samples", "ORGANISM_SUBSTANCE", 274, 287], ["N-terminus", "PROTEIN", 58, 68], ["the peptides", "TREATMENT", 37, 49], ["Peptide Synthesis", "TREATMENT", 112, 129], ["Peptide Scanning", "TEST", 134, 150], ["linear epitopes", "PROBLEM", 198, 213], ["serum samples", "TEST", 274, 287]]], ["Briefly, 0.1 mL of a 4 microgram/mL solution of streptavidin (Promega) was introduced into each well of Nunc Maxisorp plates and allowed to evaporate overnight at 25\u00b0C. The plates were washed ten times with PBS-T, blocked for 2 h with PBS-T and evacuated.", [["streptavidin", "SIMPLE_CHEMICAL", 48, 60], ["Promega", "ORGANISM", 62, 69], ["a 4 microgram/mL solution of streptavidin (Promega)", "TREATMENT", 19, 70], ["Nunc Maxisorp plates", "TREATMENT", 104, 124], ["The plates", "TREATMENT", 169, 179], ["PBS", "TREATMENT", 207, 210], ["PBS", "TEST", 235, 238], ["plates", "OBSERVATION_MODIFIER", 173, 179]]], ["For each peptide, 0.1 mL of a solution, adjusted to 20 microgram/mL, was placed into a well and allowed to bind overnight at 25\u00b0C, and rinsed with PBS-T.", [["a solution", "TREATMENT", 28, 38]]], ["The plates were blocked overnight with 10% nonfat dried milk, at 4\u00b0C, and rinsed with PBS-T.", [["milk", "ANATOMY", 56, 60], ["milk", "ORGANISM_SUBSTANCE", 56, 60], ["The plates", "TREATMENT", 0, 10], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["Guinea pig serum samples were diluted in 1% milk and incubated in the wells for 2 h at 37\u00b0C. Plates were washed with PBS-T, probed with an 1 micrograms/mL solution of peroxidase-conjugated goat anti-guinea pig IgG for 1 h at 37\u00b0C, washed again, and developed with TMB solution.", [["serum samples", "ANATOMY", 11, 24], ["milk", "ANATOMY", 44, 48], ["TMB", "CHEMICAL", 264, 267], ["pig", "ORGANISM", 7, 10], ["serum samples", "ORGANISM_SUBSTANCE", 11, 24], ["milk", "ORGANISM_SUBSTANCE", 44, 48], ["peroxidase", "SIMPLE_CHEMICAL", 167, 177], ["goat", "ORGANISM", 189, 193], ["pig", "ORGANISM", 206, 209], ["IgG", "ORGANISM_SUBSTANCE", 210, 213], ["TMB", "SIMPLE_CHEMICAL", 264, 267], ["peroxidase", "PROTEIN", 167, 177], ["conjugated goat anti-guinea pig IgG", "PROTEIN", 178, 213], ["Guinea pig", "SPECIES", 0, 10], ["goat", "SPECIES", 189, 193], ["pig", "SPECIES", 206, 209], ["pig", "SPECIES", 7, 10], ["goat", "SPECIES", 189, 193], ["pig", "SPECIES", 206, 209], ["Guinea pig serum samples", "TEST", 0, 24], ["PBS", "TREATMENT", 117, 120], ["an 1 micrograms/mL solution of peroxidase", "TREATMENT", 136, 177], ["conjugated goat anti-guinea pig IgG", "TREATMENT", 178, 213], ["TMB solution", "TREATMENT", 264, 276]]], ["Bound antibody was detected in a standard plate reader using the same methods as described above for ELISA detection.", [["Bound antibody", "TEST", 0, 14], ["ELISA detection", "TEST", 101, 116], ["antibody", "OBSERVATION", 6, 14]]]]}